UROLITHIASIS A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2003 by ICON Group International, Inc. Copyright 2003 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Urolithiasis: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-83645-0 1. Urolithiasis-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on urolithiasis. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes & Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON UROLITHIASIS ........................................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Urolithiasis.................................................................................. 13 E-Journals: PubMed Central ....................................................................................................... 26 The National Library of Medicine: PubMed ................................................................................ 27 CHAPTER 2. NUTRITION AND UROLITHIASIS ............................................................................... 131 Overview.................................................................................................................................... 131 Finding Nutrition Studies on Urolithiasis ................................................................................ 131 Federal Resources on Nutrition ................................................................................................. 139 Additional Web Resources ......................................................................................................... 139 CHAPTER 3. ALTERNATIVE MEDICINE AND UROLITHIASIS ......................................................... 145 Overview.................................................................................................................................... 145 National Center for Complementary and Alternative Medicine................................................ 145 Additional Web Resources ......................................................................................................... 152 General References ..................................................................................................................... 158 CHAPTER 4. PATENTS ON UROLITHIASIS ...................................................................................... 159 Overview.................................................................................................................................... 159 Patents on Urolithiasis .............................................................................................................. 159 Patent Applications on Urolithiasis........................................................................................... 166 Keeping Current ........................................................................................................................ 168 CHAPTER 5. BOOKS ON UROLITHIASIS.......................................................................................... 169 Overview.................................................................................................................................... 169 Book Summaries: Federal Agencies............................................................................................ 169 Book Summaries: Online Booksellers......................................................................................... 172 The National Library of Medicine Book Index ........................................................................... 173 Chapters on Urolithiasis ............................................................................................................ 174 CHAPTER 6. MULTIMEDIA ON UROLITHIASIS ............................................................................... 177 Overview.................................................................................................................................... 177 Video Recordings ....................................................................................................................... 177 Bibliography: Multimedia on Urolithiasis ................................................................................. 178 CHAPTER 7. PERIODICALS AND NEWS ON UROLITHIASIS ............................................................ 179 Overview.................................................................................................................................... 179 News Services and Press Releases.............................................................................................. 179 Newsletter Articles .................................................................................................................... 181 Academic Periodicals covering Urolithiasis............................................................................... 182 CHAPTER 9. RESEARCHING MEDICATIONS .................................................................................. 183 Overview.................................................................................................................................... 183 U.S. Pharmacopeia..................................................................................................................... 183 Commercial Databases ............................................................................................................... 185 Researching Orphan Drugs ....................................................................................................... 186 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 189 Overview.................................................................................................................................... 189 NIH Guidelines.......................................................................................................................... 189 NIH Databases........................................................................................................................... 191 Other Commercial Databases..................................................................................................... 193 The Genome Project and Urolithiasis ........................................................................................ 193 APPENDIX B. PATIENT RESOURCES ............................................................................................... 197 Overview.................................................................................................................................... 197 Patient Guideline Sources.......................................................................................................... 197
viii Contents
Finding Associations.................................................................................................................. 203 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 205 Overview.................................................................................................................................... 205 Preparation................................................................................................................................. 205 Finding a Local Medical Library................................................................................................ 205 Medical Libraries in the U.S. and Canada ................................................................................. 205 ONLINE GLOSSARIES................................................................................................................ 211 Online Dictionary Directories ................................................................................................... 214 UROLITHIASIS DICTIONARY ................................................................................................. 215 INDEX .............................................................................................................................................. 269
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with urolithiasis is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about urolithiasis, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to urolithiasis, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on urolithiasis. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to urolithiasis, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on urolithiasis. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON UROLITHIASIS Overview In this chapter, we will show you how to locate peer-reviewed references and studies on urolithiasis.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and urolithiasis, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “urolithiasis” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Etiology of Urolithiasis in HIV Infected Patients Source: Journal of Urology. 169(2): 475-477. February 2003. Contact: Available from Lippincott Williams and Wilkins. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030 or (301) 714-2334. Fax (301) 824-7290. Summary: It is commonly thought that urinary stones (lithiasis) in HIV infected patients on protease inhibitor therapy is composed primarily of the protease inhibitor itself. Since many HIV infected patients on protease inhibitors presenting to the authors' institution had nonprotease inhibitor stones, the authors of this article investigated potential underlying metabolic abnormalities that may account for the stone development (lithogenesis). A total of 24 patients were identified, and all were or had been on protease inhibitors (indinavir 14, ritonavir 3, nelfnavir 2, and unspecified 5). Of
4
Urolithiasis
the 14 patients on indinavir, only 4 (28.6 percent) had indinavir containing stones. The remaining stones in this group and in those not on indinavir contained various amounts of calcium oxalate monohydrate and dihydrate, ammonium acid urate, and uric acid. Of 10 patients who underwent 24 hour urine collection for metabolic evaluation, 8 (80 percent) had abnormalities. The authors conclude that HIV infected patients form many types of stones, which probably are attributable to underlying metabolic abnormalities rather than the use of protease inhibitors. A complete metabolic evaluation is warranted in these patients, as a means of guiding treatment to prevent future stone episodes, while avoiding the need to alter antiretroviral regimens. 1 figure. 11 references. •
Effective Management of Pediatric Urolithiasis Source: Contemporary Urology. 14(1): 47-52. January 2002. Contact: Available from Medical Economics Publishing Inc. Montvale, NJ 07645. (800) 432-4570. Summary: This continuing education article addresses the effective management of pediatric urolithiasis (urinary tract stones in children). The authors compare the incidence of stone disease and the clinical presentation of the pediatric stone patient with that of the adult stone patient. The authors describe how to formulate a metabolic evaluation and subsequent treatment plan for the pediatric stone patient. Other topics covered include the technique of ESWL (extracorporeal shock wave lithotripsy) in the treatment of pediatric urolithiasis, the role of ureteroscopy and percutaneous nephrostolithotomy (stone removal) in the management of the pediatric stone patient, and the care of bladder stones. The authors stress that while the etiology (cause) of stones in children may be similar to that in adults, children should not be approached simply as 'small adults.' Besides being anatomically smaller, they differ with respect to life-years at risk, anesthetic requirements, emotional response, and tolerance of pain. Early diagnosis of obstruction and metabolic abnormalities aids in treatment of the primary stone and in prevention of recurrence. 1 table. 29 references.
•
Prevention of Spinal Bone Loss by Potassium Citrate in Cases of Calcium Urolithiasis Source: Journal of Urology. 168(7): 31-34. July 2002. Contact: Available from Lippincott Williams and Wilkins. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030 or (301) 714-2334. Fax (301) 824-7290. Summary: This article reports on a study undertaken to determine if potassium citrate treatment stabilizes spinal bone density among patients with recurrent calcium oxalate nephrolithiasis (kidney stones consisting of calcium oxalate). The authors studied a group of 16 men and 5 women with stones taking potassium citrate from 11 to 120 months. This group represented all patients from the authors' Stone Clinic who took potassium citrate alone for at least 11 months. L2-L4 bone mineral density data before and after potassium citrate treatment were retrieved retrospectively and analyzed. In the combined group L2-L4 bone mineral density increased significantly by 3.1 percent over a mean duration of 44 months. Urinary pH, citrate and potassium increased significantly during treatment, but urinary calcium did not change. The authors conclude that potassium citrate, a commonly used drug for the prevention of recurrent nephrolithiasis, may avert age dependent bone loss. Spinal bone density increased in most patients when it normally decreases. 1 figure. 3 tables. 22 references.
Studies
•
5
Indinavir Urolithiasis Source: Current Opinion in Urology. 10(6): 557-561. November 2000. Contact: Available from Lippincott Williams and Wilkins. 241 Borough High Street, London, SE1 1GB, UK. +44 (0) 171940-7500. E-mail:
[email protected]. Summary: Indinavir sulfate (Crixivan) is an antiviral agent (a protease inhibitor) that has been found to be extremely effective in increasing CD4 cell counts and in decreasing HIV RNA titers in patients with HIV and AIDS. However, patients receiving indinavir also have been noted to have a significant risk for developing urolithiasis (urinary stones). This article reviews recent literature related to indinavir urolithiasis. Published reports on indinavir urolithiasis estimate its incidence at between 4 and 13 percent. Indinavir has a high urinary excretion with poor solubility in a physiologic pH solution. Consequently, patients develop urinary stones that are principally composed of indinavir or of a mixture of indinavir and other substances, such as calcium oxalate. Similar to other forms of urinary stones, acute flank pain and hematuria (blood in the urine) are the typical symptoms of indinavir urolithiasis. Indinavir uroliathisis is unique in that computed tomography (CT scan), which was once thought to be effective in identifying all urinary calculi, is not useful in imaging stones that are composed of pure indinavir. Indinavir urolithiasis generally responds to a conservative regimen of hydration, pain control, and the temporary discontinuation of the medication. Only a minority of patients need surgical intervention. Approximately 10 percent of patients ultimately need to discontinue indinavir therapy altogether. However, indinavir is a significant therapeutic tool in the treatment of AIDS, so physicians need to know more about indinavir urolithiasis to help their patients cope with its potential complications. 26 references (3 annotated).
•
Indinavir Urolithiasis: An Emerging Cause of Renal Colic in Patients with Human Immunodeficiency Virus Source: Journal of Urology. 161(6): 1765-1768. June 1999. Summary: This article reports on a study that evaluated the clinical, diagnostic, and radiographic findings in patients on indinavir therapy who presented with renal colic; the authors also propose appropriate treatment options for indinavir urolithiasis. A total of 16 patients positive for human immunodeficiency virus (HIV) on indinavir (a protease inhibitor) were evaluated for 18 episodes of severe renal colic requiring hospitalization. Laboratory evaluation was performed in all patients followed by an imaging study. Conservative treatment included intravenous hydration, narcotic analgesics, and temporary cessation of indinavir. Intervention was elected only in patients with persistent fever or intractable pain. A month after hospital discharge, an excretory urogram and metabolic stone evaluation were performed. All patients presented with nausea or vomiting and hematuria. Imaging studies confirmed obstruction in all patients with 13 radiolucent (indinavir) and 3 radiopaque (calcium oxalate) stones. Patients with radiolucent and radiopaque stones demonstrated significant differences in urinary pH and serum creatinine. Conservative therapy was successful in 11 patients (68.8 percent) within 48 hours, and 4 patients (25 percent) with radiolucent calculi required endoscopic stenting for persistent fever. Metabolic stone evaluation demonstrated significant hypocitraturia in all patients with radiolucent calculi. The authors conclude that urologists should be familiar with this growing cause of renal colic in patients on indinavir therapy. Pure indinavir stones are radiolucent and have a soft, gelatinous, endoscopic appearance. Conservative treatment is successful in
6
Urolithiasis
most patients; if intervention is deemed medically necessary, endoscopic stent placement should be the procedure of choice. 1 figure. 3 tables. 20 references. (AA-M). •
Urolithiasis: New Tools for Diagnosis and Treatment Source: Patient Care. 33(15): 28-31, 34, 37-38, 41-42. September 30, 1999. Contact: Available from Medical Economics. 5 Paragon Drive, Montvale, NJ 07645. (800) 432-4570. Fax (201) 573-4956. Summary: Pain and recurrence still plague patients with urinary tract stones (urolithiasis), although a significant amount of new research is changing the management and prevention of this condition. This article reviews these new tools for diagnosis and treatment. The authors contend that diagnosis can be speeded up with the use of unenhanced spiral CT scan, which provides fast, accurate data for choosing between spontaneous passage of the stone or intervention. The authors suggest that physicians consider using nonsteroidal antiinflammatory drugs (NSAIDs) in addition to opioids for pain. New guidelines from the American Urological Association are available for when to recommend extracorporeal shock wave lithotripsy (ESWL) or ureteroscopy for interventional treatment. And advances in dietary research and medical therapy (drug therapy) can be used to prevent recurrence. The authors briefly review the signs and symptoms of acute urolithiasis, the different types of stones, pain relief, the use of KUB (kidney, ureter, bladder) radiography, open surgical stone removal (now used as a last resort), stones during pregnancy, recommended patient followup, dietary changes (including increase of fluid intake), and drug therapy that may be used to prevent recurrence. The article is accompanied by a patient education handout that describes what to expect when passing a kidney stone. 1 figure. 1 table. 14 references.
•
Frequency of Urolithiasis in Individuals Seropositive for Human Immunodeficiency Virus Treated with Indinavir Is Higher Than Previously Assumed Source: Journal of Urology. 161(4): 1082-1084. April 1999. Contact: Available from Lippincott Williams and Wilkins. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030 or (301) 714-2334. Fax (301) 824-7290. Summary: Indinavir was approved by the Food and Drug Administration in 1996 as a human immunodeficiency type 1 protease inhibitor to treat HIV infection. This article reports on a study in which, prompted by the high number of patients receiving indinavir who present with renal colic (kidney pain) at their institution, the authors performed a detailed investigation of the true frequency of urolithiasis (kidney stones) during indinavir treatment. The authors evaluated 105 patients with a mean age of 38.1 years who were treated with indinavir from 1996 to 1997. Before indinavir treatment was initiated, all patients underwent renal ultrasonography, urinalysis, and determination of serum sodium, potassium, calcium, uric acid, and creatinine. It was recommended that all patients drink 2 liters of fluid daily, and all remained under continuous surveillance. Metabolic evaluation and ultrasonography showed no abnormality in any case. A stone episode occurred in 13 men (12.4 percent) as renal colic during observation. Colic recurred in 1 patient after 2 and 5 months, and in 1 patient after 2 months. Median duration of indinavir treatment until an acute stone episode was 21.5 weeks (range 6 to 50). A total of 12 stones passed spontaneously. Three patients underwent ureteroscopic calculus removal and 1 was treated with extracorporeal shock wave lithotripsy (ESWL). Despite adequate patient information and compliance, the rate of nephrolithiasis during indinavir therapy was 12.4 percent. 2 tables. 18 references.
Studies
•
7
Medical Therapy: Calcium Oxalate Urolithiasis Source: Urologic Clinics of North America. 24(1): 117-133. February 1997. Contact: Available from W.B. Saunders Company. Periodicals Fulfillment, 6277 Sea Harbor Drive, Orlando, FL 32887. (800) 654-2452. Summary: This article covers patient management strategies that can prevent calcium oxalate stone formation in patients at risk for these calculi. The authors describe diagnostic protocols that identify specific risk factors for calcium oxalate nephrolithiasis (kidney stones). These protocols are aimed at correcting underlying metabolic disturbances. Initiation of these treatment programs has reduced markedly the rate of stone formation in the majority of patients who form stones. The authors discuss the rationale underlying the choice of medical therapy for the various pathophysiologic causes of calcium oxalate nephrolithiasis, particularly the appropriate use of available medications. Pathophysiologic causes discussed include hypercalciuria, hyperuricosuria, hypocitraturia, low urinary pH, hyperoxaluria, and anatomic abnormalities. 2 figures. 1 table. 148 references. (AA-M).
•
Pediatric Urolithiasis Source: Urologic Clinics of North America. 24(1): 173-184. February 1997. Contact: Available from W.B. Saunders Company. Periodicals Fulfillment, 6277 Sea Harbor Drive, Orlando, FL 32887. (800) 654-2452. Summary: This article covers pediatric urolithiasis (urinary tract stones). Urolithiasis in childhood is of diverse causes that require carefully planned individualized diagnostic and management protocols. The efficiency in the diagnosis and management of urolithiasis in childhood follows a learning curve, especially when using the more recent technical innovations for management of urinary calculi. The author discusses the clinical presentation of pediatric urolithiasis, general management considerations, and specific treatment techniques. With current technical sophistication of transurethral and percutaneous techniques and extracorporeal shock wave lithotripsy (ESWL), management of urolithiasis during childhood should be relatively straightforward. One section briefly covers the use of chemical dissolution of urinary calculi in children. The author recommends monotherapy using a single modality or a combined approach with one or more techniques, saving open surgical intervention for situations where the new technology is either unavailable or inappropriate, or when surgical reconstruction of the urinary tract is necessary to forestall recurrent calculus formation. Postoperative morbidity after management of urinary calculi during childhood appears insignificant; calculus recurrence is uncommon. 63 references. (AA-M).
•
Protease Inhibitors and Urolithiasis Source: Journal of Urology. 158(1): 31-33. July 1997. Summary: In this case report, the authors discuss the specific urologic abnormalities associated with protease inhibitor therapy. They report on an HIV positive patient who was on protease inhibitor therapy and presented with renal colic. The stone passed spontaneously. Stone analysis was not consistent with any known composition of urinary calculus; the stone was consistent with possible drug precipitation. Protease inhibitors work by arresting the maturation of HIV particles, resulting in a decrease in the infectious virus. Recognizing the increased risk of urinary stone formation during indinavir (the most widely used protease inhibitor) therapy, the drug manufacturer has made a standard recommendation for prophylactic hydration in all patients with at least
8
Urolithiasis
48 ounces fluid per 24-hour period. The authors conclude that the widespread use of protease inhibitor therapy will mandate that the clinician become familiar with this complication in the HIV positive patient population. Indeed, the authors note that, due to its efficacy in such cases, patients with HIV positive disease will probably accept the risk of urolithiasis to benefit from continued protease inhibitor therapy. 1 figure. 25 references. (AA-M). •
Retroperitoneal Laparoscopic Management of Urolithiasis Source: Journal of Laparoendoscopic and Advanced Surgical Techniques. 7(2): 95-98. April 1997. Contact: Available from Mary Ann Liebert, Inc. 2 Madison Avenue, Larchmont NY 10538. (914) 834-3100. Fax (914) 834-3582. E-Mail:
[email protected]. Summary: This article reports on the use of retroperitoneal laparoscopy for the management of urolithiasis (urinary tract stones). The authors report on a series of 20 patients undergoing laparoscopic retroperitoneal pyelolithotomy (Lap PL) and 24 patients undergoing ureterolithotomy (Lap UL). The average operating time was 61.4 minutes for Lap UL and 80.2 minutes for Lap PL. The conversion rate for Lap PL was 4 patients (20 percent), and none of the Lap ULs required conversion. There were no major postoperative complications, except prolonged tube drainage in 2 patients, and the average hospital stay was 3.6 days. The authors conclude that laparoscopic urolithotomy management can be selected as an optional substitute for open management; in impacted, large ureteric calculi; when PCNL (percutaneous nephrolithotomy), ESWL (extracorporeal shock wave lithotripsy), or ureteroscopy fails; and in those patients in whom it is expected that PCNL or ESWL would probably be a repeated effort. 2 tables. 11 references. (AA-M).
•
Treatment of Renal Colic and the Medical and Dietary Management of Urolithiasis Source: Current Opinion in Urology. 7(7): 226-230. July 1997. Contact: Available from Rapid Science Publishers. 400 Market Street, Suite 750, Philadelphia, PA 19106. (800) 552-5866 or (215) 574-2210. Fax (215) 574-3533. Summary: This review article addresses recent research into the treatment of renal colic and the medical and dietary management of urolithiasis (urinary tract calculi). The author notes that it is now established that renal tract prostaglandins are the prime hormonal and chemical mediators of the pathophysiological events associated with partial and complete acute and chronic ureteral obstruction. Thus, nonsteroidal antiinflammatory drugs (NSAIDs) are the drugs of choice for the treatment of renal colic and have replaced narcotic analgesics and spasmolytics. The role of substance P and nitric oxide have yet to be defined. The importance of dietary calcium, protein, fat, and fluid intake as predisposing risk factors for stone formation is receiving prominence. The author calls for long-term controlled clinical trials to evaluate drug therapy and dietary modifications for the prevention and treatment of stone disease. 27 references. (AA-M).
•
Macromolecular Substances: Their Role in Urolithiasis Source: Current Opinion in Urology. 7(7): 234-239. July 1997. Contact: Available from Rapid Science Publishers. 400 Market Street, Suite 750, Philadelphia, PA 19106. (800) 552-5866 or (215) 574-2210. Fax (215) 574-3533.
Studies
9
Summary: This review article examines the role of macromolecular substances in urolithiasis (urinary tract calculi). The author notes that macromolecules can interfere with the formation and retention of calcium oxalate and calcium phosphate crystals in urine and might be important determinants for the risk of forming calcium stones. With modern analytical techniques, it has been possible to identify several macromolecules in urine and stone matrix that might be important in this respect. Prothrombin fragment 1, osteopontin or uropontin, heparan sulphate, Tamm-Horsfall protein, and nephrocalcin are examples of macromolecules that presently are highly interesting in terms of calcium stone formation. The author cautions that the interpretation of the influence that each compound might have on the different steps of the crystallization process is highly dependent on the sample preparation and the analytical techniques used. As a result, a sometimes confusing picture can emerge in which the same macromolecule demonstrates promotive as well as inhibitory properties. This reflects the complexity of the crystallization process involved and underscores the need for further studies under standardized and well controlled conditions. 53 references. (AA-M). •
Dietary and Behavioral Risk Factors for Urolithiasis: Potential Implications for Prevention Source: American Journal of Kidney Diseases. 28(2): 195-201. August 1996. Contact: Available from W.B. Saunders Company. Periodicals Fulfillment, 6277 Sea Harbor Drive, Orlando, FL 32887. (800) 654-2452. Summary: Few studies have examined urolithiasis (urinary tract calculi, or stones) in primary care populations, and limited data are available on non-drug interventions to reduce the risk for urinary calculi. This article reports on a case-control study of 240 men experiencing initial episodes of urolithiasis, ascertained by reviewing radiology procedure logs and medical records. The 392 controls were age-matched men with no history of urolithiasis. Data were collected using standardized telephone interviews. The risk for urinary tract calculi was related to both consumption variables (such as a low-fat or weight-reduction diet) and beer drinking, and to demographic variables, such as African-American ethnicity and a positive family history. These findings suggest the need to evaluate appropriate behavioral interventions to reduce the morbidity associated with urolithiasis. The authors conclude that prospective studies should evaluate the possibilities that beer drinking, even in modest amounts, and a low-fat or weight reduction diet are associated with substantial reductions in risk. 2 tables. 32 references. (AA-M).
•
Clinical Approach to Children With Urolithiasis Source: Seminars in Nephrology. 16(5): 389-397. September 1996. Contact: Available from W.B. Saunders Company. Periodicals Department, 6277 Sea Harbor Drive, Orlando, FL 32887-4800. (800) 654-2452. Summary: This article presents a general overview of urolithiasis (urinary stones) in children and a practical approach to the medical evaluation of such children. The author notes that urinary stones are being recognized more frequently in children. As a result of major advancements in the urological therapies available to children with obstructed uropathy, infection-related stones no longer dominate the clinical manifestations of urinary stones in children. The symptoms of urolithiasis in children differ somewhat from adults and change during childhood. Causes of urolithiasis in children are remarkably similar to those of adults, although diagnostic criteria frequently vary throughout childhood. Hypercalciuria is the most common metabolic cause of pediatric
10 Urolithiasis
urinary stones. The author concludes that a high fluid intake is critical in preventing supersaturation of the urine regardless of the cause of urolithiasis. In addition, a reduced sodium and low oxalate diet is recommended for children with hypercalciuria, oxaluria, and idiopathic stones because of the well-known calciuric effect of high dietary sodium intake. 8 tables. 65 references. (AA-M). •
Summary of the National Institutes of Arthritis, Diabetes, Digestive and Kidney Diseases Conference on Urolithiasis: State of the Art and Future Research Needs Source: Journal of Urology. 153(1): 4-9. January 1995. Contact: Available from Williams and Wilkins. 351 West Camden Street, Baltimore, MD 21201-2436. (800) 638-6423; in Maryland (800) 638-4007. Summary: This article summarizes the National Institutes of Arthritis, Diabetes, Digestive and Kidney Diseases conference on urolithiasis, focusing on the state of the art and future research needs. Topics covered include the Special Centers for Oriented Research program; the 1988 NIH Consensus Development Conference on treatment of kidney stones; the epidemiology of urolithiasis; patient care; basic research, including basic research needs; state of the art clinical research (medical and surgical); economics; funding; research grants; and training programs. General recommendations to enhance urolithiasis research include recruitment of new investigators in various disciplines to urolithiasis research, expansion of training grants in urolithiasis, new support of organized groups for urolithiasis research, an improved NIH review process of urolithiasis research proposals, and development of a request for application for urolithiasis. The article concludes with a list of areas of investigation to emphasize. 2 tables.
•
Urolithiasis in Children Source: Current Opinion in Urology. 2(6): 426-427. December 1992. Summary: Urolithiasis is an uncommon but not rare condition in childhood. Stones are often the end-result of another underlying pathophysiologic condition such as infection, anatomic abnormality resulting in residual urine, or metabolic disorders. This article discusses the newest theories in the pathogenesis and therapeutic options for urolithiasis. Topics include epidemiology, etiology, and treatment with techniques including extracorporeal shock-wave lithotripsy and percutaneous nephrostomy. The author concludes that prematurity, idiopathic hypercalciuria, infection, and anatomic abnormalities resulting in residual urine are the biggest risk factors in stone formation in children. 12 annotated references. (AA-M).
•
Diet and Hyperoxaluria in the Syndrome of Idiopathic Calcium Oxalate Urolithiasis Source: American Journal of Kidney Diseases. 17(4): 370-375. April 1991. Summary: This article discusses diet and hyperoxaluria in the syndrome of idiopathic calcium oxalate urolithiasis. Diet and the availability of calcium and oxalate from the diet within the intestine are important factors in the hyperoxaluria that is present in some of those patients with idiopathic calcium oxalate urolithiasis. Other abnormalities in endogenous metabolism or transport of oxalate may play a role in the hyperoxaluria in some of these patients. 3 figures. 5 tables. 25 references. (AA-M).
•
Urolithiasis in Tennessee: An Occupational Window into a Regional Problem Source: American Journal of Public Health. 81(5): 587-591. May 1991.
Studies 11
Summary: Urinary tract stones are believed to be unusually common in the southeastern U.S., but neither the incidence of nor the risk factors for stones are known. This article reports on a study that assessed the prevalence, incidence, and cumulative incidence of stones and measured biochemical risk factors for lithogenesis. The authors found that risk factors were age, a family history, and urinary saturation with calcium-oxalate. Persons with a positive family history and the highest measure calcium-oxalate index had a predicted lifetime risk of 88.8 percent. Biochemical factors affecting lithogenesis were hypercalcuria, hyperoxaluria, and low urine volume. 1 figure. 4 tables. 25 references. (AA-M). •
Etiology and Treatment of Urolithiasis Source: American Journal of Kidney Diseases. 18(6): 624-637. December 1991. Contact: Available from National Kidney Foundation. 30 East 33rd Street, New York, NY 10016. (212) 889-2210 or (800) 622-9010. Summary: This article discusses the etiology and treatment of urolithiasis. The author contends that many practicing physicians lack sufficient skills to apply an appropriate stone prevention program. This review is designed to provide them with background knowledge that would be useful in the management of patients with stones. A detailed discussion of the pathophysiology of nephrolithiasis is given, since its understanding is critical for the selection of appropriate therapy. Practical guidelines in the diagnostic categorization of different causes of stones are provided. In addition, various therapeutic options for the prevention of stone formation are discussed. 2 figures. 3 tables. 51 references.
•
Pathophysiology and Medical Treatment of Urolithiasis Source: Seminars in Nephrology. 10(1): 31-52. January 1990. Summary: The formation of a stone within the urinary tract is not a disease, but rather a potential complication of many varied disorders. This article discusses the pathophysiology and medical treatment of urolithiasis. The author stresses that to develop rational and effective approaches to treatment, one must consider the abnormalities that allow the stones to form. The first part of the article covers the pathophysiology of urolithiasis in four sections: the state of saturation; modifiers of crystal formation; heterogenous nucleation; and secondary factors. The remainder of the article considers the medical evaluation and treatment of urolithiasis, including patient background; enzyme disorders; renal tubular syndromes; enteric urolithiasis; hypercalcemic states; secondary urolithiasis; and foreign chemicals and compounds. 183 references. 10 tables.
•
Diagnosis and Initial Management of Kidney Stones Source: American Family Physician. 63(7): 1329-1338. April 1, 2001. Contact: Available from American Academy of Family Physicians. 11400 Tomahawk Creek Parkway, Leawood, KS 66211-2672. (800) 274-2237. Website: www.aafp.org. Summary: This article discusses the diagnosis and initial management of urinary stones (urolithiasis), which have undergone considerable evolution in recent years. The application of nonconstrast helical computed tomography (CT scan) in patients with suspected renal colic (kidney pain) is one major advance. The superior sensitivity and specificity of helical CT allow urolithiasis to be diagnosed or excluded definitively and expeditiously without the potential harmful effects of contrast media. Initial
12 Urolithiasis
management is based on three key concepts: the recognition of urgent and emergency requirements for urologic consultation, the provision of effective pain control using a combination of narcotics and nonsteroidal antiinflammatory drugs (NSAIDs) in appropriate patients, and an understanding of the impact of stone location and size on natural history and definitive urologic management. The authors discuss these concepts with reference to contemporary literature, with the goal of providing tools that family physicians can use in the emergency department or clinic. A patient care algorithm is also provided. 2 figures. 5 tables. 32 references. •
Single 24-Hour Urine Collection is Inadequate for the Medical Evaluation of Nephrolithiasis Source: Journal of Urology. 167(4): 1607-1612. April 2002. Contact: Available from Lippincott Williams and Wilkins. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030 or (301) 714-2334. Fax (301) 824-7290. Summary: This study determined the adequacy of a single 24 hour urine sample for evaluating patients for medical renal (kidney) stone prevention. A total of 459 patients from a private urology practice specializing in the treatment of urolithiasis (urinary tract stones) and 683 from a university stone research clinic provided two and three 24 hour urine samples, respectively. The authors used samples 1 and 2 from private practice patients, and 1 and 3 from university clinic patients for analysis, and compared each to the others. Although the correlation of urine values 1 and 2 was excellent for all stone risk factors, standard deviation values for the differences were large enough to misdiagnose common metabolic disorders. Principle stone risk factors and dietary and environmental factors vary enough in 24 hour urine samples that a single urine specimen is not an ideal predictor of the final mean of two urine samples. The authors conclude that a single 24 hour sample is not sufficient for evaluating patients before metabolic treatment for stone prevention because misdiagnosis is common, leading to inappropriate treatment. 1 figure. 5 tables. 17 references.
•
Blood Pressure Changes Following Extracorporeal Shock Wave Lithotripsy and Other Forms of Treatment for Nephrolithiasis Source: Journal of the American Medical Association. 263(13): 1789-1794. April 4, 1990. Summary: This paper reports the design and results of a study that assessed the possible risk of hypertension from extracorporeal shock wave lithotripsy (ESWL) and other nonESWL treatment options for urolithiasis (percutaneous nephrostolithotomy (PCNL), combined PCNL-ESWL, ureteroscopy, and spontaneous stone passage). Detailed blood pressures were measured in 961 patients at least 1 year after treatment using randomzero blood pressure devices. Patients included: 731 who received ESWL only, 171 who received ureteroscopy or spontaneous stone passage (control subjects), 25 who received PCNL only, and 34 who received both ESWL and PCNL. The annualized incidence of patients who received ESWL only (2.4 percent) did not differ significantly from the control group (4.0 percent). Among patients who received ESWL, no correlation was found between hypertension incidence and unilateral bs. bilateral treatments, the number of shock waves administered, the kilovoltage applied, or the poser (shock wave number times kilovoltage). However, a significant increase in diastolic blood pressure after ESWL treatment (0.78 mm Hg), but not in the control group. This validity and long-term significance of this finding is unknown and requires further study. 36 references.
Studies 13
Federally Funded Research on Urolithiasis The U.S. Government supports a variety of research studies relating to urolithiasis. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to urolithiasis. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore urolithiasis. The following is typical of the type of information found when searching the CRISP database for urolithiasis: •
Project Title: BIOCHEMICAL STUDIES OF OXALATE DECARBOXYLASE Principal Investigator & Institution: Richards, Nigel G. Professor; Chemistry; University of Florida Gainesville, FL 32611 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-JAN-2007 Summary: (provided by applicant): Oxalic acid, a compound that is toxic to almost all organisms, is produced in large quantities by cellular metabolism. A number of pathological conditions can arise if oxalate accumulates in Man, including hyperoxaluria, the formation of calcium oxalate stones in the kidney (urolithiasis), renal failure, cardiomyopathy and cardiac conductance disorders. In addition, high levels of oxalate appear correlated with vulvodynia, a painful disease in women for which no treatment is currently available. Evidence has emerged to support the clinical application of oxalate-metabolizing enzymes in new, and intriguing, therapeutic strategies for lowering oxalate levels in biological fluids. The Yvrk gene found in Bacillus subtilis encodes oxalate decarboxylase (OxDC), an enzyme that converts oxalate to formate and CO2 in a Mn-dependent reaction for which the catalytic mechanism is not known. As part of our long-term aim to facilitate the use of OxDC in the treatment of oxalate-related illness, this project seeks to characterize Bacillus subtilis OxDC using the techniques of bioinorganic chemistry, molecular spectroscopy, enzyme kinetics and protein engineering. These studies are also likely to impact general understanding of radical mediated enzyme catalysis and to give new insights into (i) the role of protein environment in modulating metal reactivity and (ii) metalloenzyme evolution. Specific aims of this project are: 1) To investigate the catalytic mechanism of bacterial oxalate decarboxylase using steady-state kinetics, site-directed mutagenesis and isotope effects, 2) To determine the metal-dependence of OxDC, 3) To evaluate the effect of protein environment in controlling the chemical properties of the metal center(s) in OxDC, and 4) To identify steady-state radicals formed during steady-state turnover of oxalate decarboxylase. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
14 Urolithiasis
•
Project Title: BIOENGINEERING OF BLADDER TISSUES Principal Investigator & Institution: Atala, Anthony; Associate Professor; Children's Hospital (Boston) Boston, MA 021155737 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2004 Summary: The bladder is exposed to a variety of possible injuries from the time the fetus develops. Aside from congenital abnormalities, individuals may also suffer from other disorders such as cancer, trauma, infection, inflammation, iatrogenic injuries r other conditions which may lead to painful bladder damage or loss, requiring eventual bladder replacement or repair. Currently, gastrointestinal segments are commonly used as tissues for bladder replacement or repair. However, when gastrointestinal tissues are in contact with the urinary tract, multiple complications may ensure, such as infection, metabolic disturbances, urolithiasis perforation, increased mucous production, and malignancy. Even though the use of bowel for bladder tissue replacement was first proposed over 100 years ago, it still remains the gold standard today, despite its known associated problems and due to a lack of a better alternative. It is evident that urothelial to urothelial anastomoses are preferable functionally. However, the limited amount of autologous urologic associated tissues fro reconstruction generally precludes this option. There is a critical need for tissues to replace lost and functionally- deficient bladder tissues. Bioengineering bladder tissues using selective cell transplantation may provide a means to create functional new genitourinary tissues. The approach which we have followed to bioengineer tissues in our laboratory involves the eventual use of autologous cells, thus avoid rejection, wherein a biopsy of tissue is obtained from the host, the cells are dissociated and expanded in vitro, reattached to a biodegradable matrix, and implanted into the same host. The proposed application is based on several proven concepts derived from our previous work, performed over the last 9 years, which have lead to the development of large portions of bioengineered bladder tissue for augmentation and subtotal replacement. However, before patients who require complete bladder replacement can benefit from this technology, further studies need to be performed wherein total bladder cystectomies are performed. This would not entail the partial replacement of bladder tissue, as had been demonstrated experimentally, but rather, complete bladder replacement with ureteral reimplantation. Therefore, the overall goal of this proposal is to achieve complete bladder replacement using bioengineered tissues in an experimental model, thus avoiding the problems associated with the currently used gastrointestinal segments. Like other types of orthotopic bladders created with gastrointestinal segments, it is expected that the neobladders created with bioengineered tissues could empty mostly by intermittent catheterization, but these should be able to provide low pressure and high compliance reservoirs with native autologous tissues. The specific aims of this proposal: Specific Aim 1: To determine the feasibility of reimplanting ureters long term in tissue engineered bladders. In these experiments we will test the hypotheses that ureters can be hyperimplanted into engineered bladder tissue, that the ureters will not obstruct, and the ureters will not reflux. Specific Aim 2: To determine the feasibility of attaining complete bladder replacement using tissue engineering techniques. In these experiments we will test to the hypothesis that bioengineered bladder tissues can be anastomosed to native urethras, that complete bladder replacement is feasible using bioengineered bladder tissues that ureteral replacement in a model of total bladder replacement is feasible, without ureteral obstruction or vesicoureteral reflux, and that bioengineered bladders can be emptied efficiently in an intermittent fashion. Specific Aim 3: To determine the short term and long term phenotypic and functional characteristics of bladder tissues engineered for subtotal and complete replacement. In this aim we will attempt to
Studies 15
determine the phenotypic and functional characteristics, over time, of the bioengineered bladder tissues, as compared to controls. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DEVELOPMENT OF A UREA BIOSENSOR USING THE URER PROTEIN Principal Investigator & Institution: Mobley, Harry L. Professor; Microbiology and Immunology; University of Maryland Balt Prof School Baltimore, MD 21201 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2005 Summary: (provided by applicant): Individuals in the U.S. with kidney conditions including infection, kidney stones, cancer, or missing kidney exceed 2.5 million annually. Most renal diseases affect serum urea concentration which provides a sensitive indicator of such disease. The blood urea nitrogen (BUN) test, a routine but critical clinical laboratory assay used to evaluate renal function, quantifies serum urea that is produced in the liver as an endpoint of protein degradation. Studies are proposed that will lead to the development of a fluorescence-based biosensor capable of quantifying urea in a sample in real time. The sensor will employ the UreR protein encoded by the urease operon of the uropathogenic bacterial species Proteus mirabilis. UreR, to date, is the only documented urea-binding protein. When UreR binds urea, the protein undergoes a conformational change that is detectable using fluorescence technology. Three approaches to biosensor design will include fluorescent labeling of genetically modified UreR, fluorescence resonance energy transfer of UreR-Yellowfluorescent-protein fusions, and an anisotropy approach using the binding of its target DNA by UreR. The proposed UreR biosensor will directly measure urea in real time without the necessity of hydrolyzing urea with urease, which is required in current sensor technology. Primary applications may include routine blood urea nitrogen determination and monitoring of blood urea nitrogen directly in the blood of patients undergoing kidney dialysis. In addition, the biosensor will be useful in basic science investigations including urea transport in the liver and kidney, the role of urea hydrolysis in urolithiasis, and urea metabolism in the gastric mucosa infected by urease-positive Helicobacter pylori. This biosensor also offers the prospect of imaging urea concentration and fluxes in tissue using fluorescence and confocal microscopy. Our experimental approaches are organized into three Specific Aims: 1) To define the urea binding domain of the UreR protein 2) to develop a urea sensor using UreR; and 3) to construct a prototype UreR-based urea sensor and validate it in specific applications. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GORDON RESEARCH CONFERENCE ON BIOMINERALIZATION Principal Investigator & Institution: Weiner, Stephen; Gordon Research Conferences Gordon Res Ctr C/O Univ of Rhode Island Kingston, RI 02881 Timing: Fiscal Year 2001; Project Start 01-AUG-2000; Project End 31-JUL-2003 Summary: This proposal is submitted to seek support to help organize and conduct the Gordon Research Conference on Biomineralization. This International conference will be held August 13-18, 2000 and in 2002 at the Colby-Sawyer College, New London, New Hampshire. This meeting is a continuation of the Gordon Research Conference on Calcium Phosphates (previously held on alternate years since 1979), organized in a new direction. The biomineralization conference will emphasize the physical chemistry of mineralization in both biological and industrial systems and the relevant properties of mineralized tissues and synthetic prototypes. This conference will also address
16 Urolithiasis
fundamental aspects of research in areas where such knowledge can be used to produce new and useful synthetic biomaterials for orthopedic and dental applications. This conference is specifically designed to bring together chemists, physicists, biologists, mineralogists, dentists, and physicians, to facilitate further advances in these important areas of study. The biomineralization conference will address the current state of knowledge regarding the mechanism of controlled nucleation and growth of calcium phosphates and related biomaterials in both biological systems and in industrial applications, addressing fundamental research in biomineralization, urolithiasis, and implantology. Session topics will include: 1) regulation of crystal nucleation; 2) regulation of crystal growth in biological systems: bone and cartilage; 3) regulation of crystal growth in biological systems: invertabrates; 4) regulation of crystal growth in biological systems: dental tissues; 5) mineralization at non-skeletal sites (oxalates and calcium phosphates); 6) improving on nature: biomimetics; 7) improving on nature: engineering new implant materials; 8) new strategies for mapping biomineralization; 9) strategies for capturing information in mineralized tissues. Unlike other conferences, this conference will provide a unique forum where investigators in the physical sciences will actively interact with their counterparts in biological research. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GOUTY DIATHESIS--PATHOPHYSIOLOGY AND MOLECULAR GENETIC BASIS Principal Investigator & Institution: Sakhaee, Khashayar; University of Texas Sw Med Ctr/Dallas Dallas, TX 753909105 Timing: Fiscal Year 2001 Summary: (Taken directly from the application) A disturbance in urate metabolism has been shown to lead to the development of both uric acid and calcium stones. In addition, primary gout is frequently observed with uric acid lithiasis, where undue urinary pH from defective ammonium production is believed to promote uric acid crystallization. We have used the term gouty diathesis to describe stone formation associate with primary gout, and that it is comprised of acquired and primary (genetic) variants. This hypothesis will be tested by (1) assessing whether defective ammonium production in gouty diathesis is evident by controlling acid intake and imposing phosphate restriction and that, in the acquired form of the disease, insulin resistance is responsible for undue acidity and other biochemical features of this disease, and (2) identifying the molecular defect in the "primary" genetic form of the disease. These studies will help elucidate the pathophysiology of gouty diathesis and may lead to improvements in the diagnosis and treatment of this form of urolithiasis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HYPEROXALURIA AND TUBULE INJURY AND KIDNEY STONE DISEASE Principal Investigator & Institution: Mandel, Neil S. Professor; Medicine; Medical College of Wisconsin Po Box26509 Milwaukee, WI 532264801 Timing: Fiscal Year 2003; Project Start 01-MAR-2003; Project End 28-FEB-2005 Summary: (provided by applicant): Kidney stone disease is a substantial health problem associated with significant pain, suffering, and economic costs. 5% to 15% of the population will have a symptomatic episode of a stone by the age of 70 and at least 50% of these individuals will have recurrent disease. To date, urolithiasis researchers have been limited to cell culure studies or a rat model where hyperoxaluria is induced by
Studies 17
either ethylene glycol oral administration that is toxic to multiple organs or by high dose intraperitoneal sodium oxalate injection. The levels of induced urinary oxalate excretion in the rat needed to produce oxalate crystalluria and tisssue or cell response are criticized as being supraphysiologic compared to man. We propose that the pig is ideal for the development of an animal model of calcium oxalate crystalluria and calcium oxalate stone disease. The anatomy and physiology of the pig kidney is very similar to man. The anerobic bacteria Oxalobacter formigenes degrades oxalate to formate in the pig gut and normally stops the pig from becoming hyperoxaluric. We have successfully obtained Oxalobacter formigenes free pigs and report here for the first time that these pigs demonstrated a significant increase in urinary oxalate excretion as the result of an oral oxalate load similar to that experienced by man ingesting an oxalate rich diet. We propose to induce hyperoxaluria in the pig by feeding them an oxalate rich diet. We propose to study the effect of hyperoxaluria on pig kidney physiology and its impact on calcium oxalate crystal attachment and stone maturation. We hypothesize that pigs fed oxalate will form calcium oxalate crystalluria and calcium oxalate stones in their urinary tract in a manner very similar to man. We also hypothesize that these hyperoxaluric pigs are ideally suited for the extension of studies on the effect of hyperoxaluria on renal epithelial cell physiology, crystal attachment and stone maturation. This grant proposal contains three Specific Aims that test our hypotheses:Specific Aim I: To develop a new hyperoxaluric pig animal model.Specific Aim II: To initiate calcium oxalate crystalluria in the pig and to identify the site of crystal attachment along the nephron.Specific Aim III: To induce calcium oxalate stone disease in the pig and to characterize the process of stone maturation. These Specific Aims and their associated questions will allow us to fully describe the development of hyperoxaluria in the pig and the development of calcium oxalate crystalluria and calcium oxalate stones. The hyperoxaluric pig will have great potential in the advancement of many areas of urolithiasis research and in the design of new therapeutic modalities for the treatment of stone disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INNOVATIONS IN SHOCK WAVE LITHOTRIPSY TECHNOLOGY Principal Investigator & Institution: Zhong, Pei; Associate Research Professor; Mech Engr & Materials Science; Duke University Durham, NC 27706 Timing: Fiscal Year 2001; Project Start 10-SEP-1997; Project End 31-AUG-2006 Summary: (provided by applicant): Although shock wave lithotripsy (SWL) is used routinely for the comminution of kidney and upper urinary stones, treatment efficiency has not been improved in the past twenty years. Further, renal injuries such as hemorrhage and kidney edema are often observed following lithotripsy, and the longterm clinical consequences of SWL (especially in pediatric and elderly patients) are still under investigation. Hence, it is imperative to improve the treatment efficiency of SWL while reducing its deleterious effects on renal tissues. The overall hypothesis of this project is that cavitation, the formation and subsequent violent expansion and collapse of small gas/vapor bubbles in a lithotripter field, is an important physical phenomenon relating to both stone comminution and tissue injury. However, the underlying mechanisms by which cavitation contributes to stone comminution and to tissue injury are different, making it possible to manipulate selectively bubble dynamics to enhance stone comminution while reducing tissue injury. In the current funding period, we have demonstrated that 1) controlled, forced collapse of cavitation bubbles can significantly improve stone comminution in vitro, and 2) SWL-induced rapid, large intraluminal bubble expansion can rupture capillary and small blood vessels if cavitation nuclei greater than 10 nm in diameter exist in vivo. Based on these observations, we propose
18 Urolithiasis
four new specific aims to better understand the mechanisms of stone comminution and to develop novel cavitation control techniques to improve the efficiency and safety of SWL under clinically relevant conditions. A systematic approach will be undertaken to 1) assess the relative contribution of spalling vs. cavitation in stone comminution, 2) develop a piezoelectric annular array (PEAA) shock wave generator that can be retrofitted on a Domier HM-3 lithotripter to achieve in situ cavitation control, 3) explore novel techniques to suppress large intraluminal bubble expansion in SWL in order to reduce vascular injury, and 4) optimize the design of clinical lithotripters to maximize stone comminution while minimizing tissue injury. Since these techniques under development can be upgraded on existing clinical lithotripters, once successful, they could produce immediate clinical and economic benefits to the overall management of urolithiasis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR CRYSTALLIZATION
MODULATION
OF
CALCIUM
OXALATE
Principal Investigator & Institution: De Yoreo, James J. Senior Scientist; Materials Science & Technology; University of Calif-Lawrnc Lvrmr Nat Lab Lawrence Livermore National Lab Livermore, CA 94550 Timing: Fiscal Year 2002; Project Start 15-AUG-2002; Project End 31-JUL-2006 Summary: (provided by applicant): Urinary tract stone disease (urolithiasis) is a common clinical disorder that frequently leads to hospitalization. The objective of this proposal is to advance the understanding of the pathogenesis of urolithiasis by determining the physical mechanisms through which important inhibitors that include small urinary molecules, such as magnesium and citrate that are currently used in the treatment of urinary tract stone disease and urinary macromolecules, such as osteopontin control the nucleation, growth, aggregation, and phase transformations of calcium oxalate (CaOx) precipitates. This objective will be accomplished by investigations focusing on 1). the mechanisms of modulation of CaOx nucleation and growth by small urinary molecules and urinary macromolecules, 2). the mechanisms by which urinary modulators affect the sequence of events during phase transformations of CaOx crystals and 3). the surface interactions and events underlying urinary protein modulation of CaOx aggregation. The proposed research will use in situ atomic force microscopy to follow the evolution of CaOx crystal surfaces and quantify the impact of growth modulators on the thermodynamic and kinetic factors controlling the dynamics of atomic steps on those surfaces. This work will lead to new insights that integrates an understanding of the specific stereochemical interactions on the crystal surface with the quantitative impact on kinetics and morphology. The atomic force microscopy measurements will be correlated with concurrently performed constant composition measurements of growth kinetics and contact angle measurements of interfacial energies. The knowledge derived from our studies will assist in the design of inhibitory molecules that are potentially useful in therapy of stone disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: OXALATE & CRYSTAL RENAL PHENOTYPES: A MICROARRAY STUDY Principal Investigator & Institution: Marengo, Susan R. Associate Professor; Urology; Case Western Reserve University 10900 Euclid Ave Cleveland, OH 44106 Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-JUL-2004
Studies 19
Summary: (provided by applicant): Despite the fact that hyperoxaluria is an established risk factor for calcium oxalate (CaOx) urolithiasis, except for extreme cases, oxalate's exact role in urolithiasis is not well understood. There has been little progress in determining the genetic defects involved in idiopathic hyperoxaluria or urolithiasis, in part because oxalate's effects on the nephron are not well understood. In vivo models allow study of oxalate's effects on the renal epithelium with the intercellular associations and regulatory cascades intact. We will use a graded series of hyperoxaluric rat models 1) vehicle control; 2) hyperoxaluria, 3) hyperoxaluria+crystalluria and 4) hyperoxaluria+crystalluria+crystals deposited in the kidneys) and microarray analysis to develop a solid data base to be used as a springboard for future studies. In Specific Aim I we will develop a new model for the study of hyperoxaluric rats by using osmotic minipumps to deliver the oxalate subcutaneously. Specific Aim 2 will validate the microarray analysis by determining the number of rats needed for each pool of tissue, the number of pools/treatment group and the number of chips on which a pool must be run to control for technical and biological variability. It will also determine the limits of sensitivity for detecting changes between control and treated rats, by comparing the results obtained by microarray analysis vs RT-PCR. Specific Aim 3 will use microarray analysis and the models developed above to determine how the pattern of gene expression changes as hyperoxaluria progresses into urolithiasis, with particular emphasis on those genes regulated by oxalate in the absence of crystals. Data will be analyzed by SAM(statistical analysis) and the data mining programs SpotFire & GeneSpring. Kidney function will be monitored by creatinine clearance and fraction sodium excretion. Renal morphology will be evaluated by light and electron microscopy. Markers of tubular function will be evaluated in the urine and kidney to determine those segments of the nephron that are the most sensitive to damage by oxalate. Depending on the marker, expression will be measured at the level of the message (RT-PCR, Northern blot) and protein (Western blot, immunohistochemistry or enzymatic assays). The long term objective of this work is to establish the mechanism of oxalate induced damage in the kidney. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: OXALOBACTER FORMIGENES AND OTHER FACTORS IN UROLITHIASIS Principal Investigator & Institution: Kaufman, David W. Slone Epidemiology Unit; Boston University Medical Campus 715 Albany St, 560 Boston, MA 02118 Timing: Fiscal Year 2003; Project Start 15-AUG-2003; Project End 31-JUL-2006 Summary: (provided by applicant): Oxalobacter formigenes (Oxf) is a gram-negative, anaerobic bacterium that is able to metabolize dietary oxalate in the intestinal tract of humans. It is present in approximately 70% of the normal adult population. The absence of Oxf could permit higher absorption of dietary oxalate, leading to higher urinary oxalate, and thus, greater predisposition to calcium oxalate renal calculus formation. Preliminary data support this possibility; to evaluate the hypothesis more definitively, we propose a case-control study of 275 prospectively enrolled patients presenting to urologists at two Boston hospitals with recurrent episodes of calcium oxalate urolithiasis. One age and sex-matched control will be enrolled for each case, selected from among the spouses or cohabitees of other stone formers from the same hospitals. Oxf will be detected by potymerase chain reaction (PCR) testing of fecal smears, conducted on two samples for each subject. Information on factors that might affect Oxf such as consumption of oxalate and calcium-containing foods and antibiotic use, and on known risk factors for renal calculus formation, including fluid intake and personal and
20 Urolithiasis
family history of calculi, will be obtained by telephone interview. A modified version of the food frequency questionnaire from the Nurses' Health Study will be used to obtain the dietary information. The sample size will be large enough to detect a 40% or larger reduction in the risk of calcium oxalate renal calculi among subjects who are positive for Oxf relative to those who are not. The interaction between Oxf and other risk factors will also be examined, to develop a new risk profile for the development of calcium oxalate calculi. A subset of 140 cases and 140 controls will have 24 hour urinary volume, oxalate, and other factors measured twice under their usual dietary conditions, and correlated with the presence or absence of Oxf, and its quantitative level. The sample size will be sufficient to detect, separately in men and women, a 20% difference in oxalate excretion between those who are negative for the bacterium and those who are positive. Urolithiasis is common in the U.S. population and the severe pain with which it is often associated has a substantial impact on quality of life. The condition also accounts for considerable utilization of medical care resources. The large majority of calculi are predominantly calcium oxalate. If the absence of Oxf is shown to be relevant to the etiology of oxalate stone formation, the possibility is raised for future intervention strategies which might eventually lead to a significant reduction in the recurrence of renal calculi. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: OXALOBACTER FORMIGENES DIAGNOSTIC KIT DEVELOPMENT Principal Investigator & Institution: Sidhu, Harmeet; Ixion Biotechnology, Inc. Box 13, 13709 Progress Blvd Alachua, FL 32615 Timing: Fiscal Year 2002; Project Start 01-SEP-2000; Project End 31-AUG-2004 Summary: (provided by applicant): Absence of Oxalobacter formigenes (Oxf) from the GI-tract is a risk factor for development of hyperoxaluria and calcium oxalate kidney stones. Recent data now indicate that patients with recurrent urolithiasis have a lower prevalence rate of Oxf in their stools than non-stone forming individuals. In addition, urinary oxalate levels are higher in non-colonized individuals as compared to colonized individuals. This indicates a clinical need for a test that can identify non-colonized individuals. Phase I of this grant resulted in the development of a reliable and rapid PCR ELISA-based microtiter plate assay for the detection of Oxf in human fecal samples. Pre-clinical performance data for the test (Le. its analytical sensitivity, analytical specificity, precision and reproducibility) were obtained as per the NCCLS guidelines. In Phase II of this project, we propose to complete the development of a production prototype of the XEntrix(TM) O. formigenes Monitor Kit. Analytical and clinical performance of the prototypic test kit will be determined in a multicentre clinical trial. The clinical studies have been designed not only to validate the test kit but also to strengthen the utility of Oxf determination as a diagnostic tool for the assessment of risk for calcium oxalate urolithiasis. By end of the proposed Phase II studies, we will have sufficient analytical and clinical performance data on this diagnostic kit to seek a premarket approval under section 510K of the Food Drugs and Cosmetic Act, from the Center for Devices and Radiological Health. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PATHOGENESIS OF UROLITHIASIS Principal Investigator & Institution: Hoyer, John R. Professor; Children's Hospital of Philadelphia 34Th St and Civic Ctr Blvd Philadelphia, PA 19104 Timing: Fiscal Year 2001; Project Start 01-AUG-1983; Project End 30-JUN-2005
Studies 21
Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF ENTERIC HYPEROXALURI BY OXALOBACTER Principal Investigator & Institution: Peck, Ammon B. Professor; Pathology, Immunol & Lab Med; University of Florida Gainesville, FL 32611 Timing: Fiscal Year 2001; Project Start 27-MAR-1998; Project End 28-FEB-2003 Summary: Oxalobacter formigenes, a recently identified bacterium that colonizes the gastrointestinal (GI) tracts of all vertebrates, has gained considerable attention due to its important symbiotic relationship with its hosts in regulating oxalic acid absorption in the intestines as well as oxalic acid levels in plasma two factors associated with the risk to develop calcium-oxalate kidney stones. Oxalic acid is a by-product of metabolism and a common constituent of most diets; however, if permitted to accumulate, it can cause numerous pathological conditions, including hyperoxaluria, cardiac conductance disorders, calcium oxalate stones, renal failure, death and possibly inflammatory bowel disease and vulvovestibulitis. Despite the potential significance of O. formigenes in controlling enteric hyperoxaluria, and thus oxalate-related disorders, research has been limited due to inherent difficulties in culturing and identifying this bacterium. Nevertheless, preliminary studies already suggest a correlation between the number of colony forming units of Oxalobacter sp. per gram feces and the frequency of recurrent urolithiasis, inflammatory bowel disease and hyperoxaluria/nephrocalcinosis in cystic fibrosis. With the development of a rapid and sensitive DNA-based detection system highly specific for O. formigenes, we are now able to investigate the correlation between an increased risk for urolithiasis and the absence of O. formigenes from the GI tract. Using the laboratory rat as a model, we propose to: 1) study the colonization of noncolonized rats with various sub-strains of O. formigenes to determine if variations exist in the efficacy of different strains of O. formigenes to colonize and if primary colonization precludes secondary colonizations, 2) determine whether O. formigenes can prevent hyperoxaluria and subsequent formation of calcium-oxalate crystals in rats colonized with various sub-strains of the bacterium and challenged with high oxalatecontaining diets, and 3) examine the relationship between diet and/or antibiotic treatment with subsequent decolonization of the GI tract by O. formigenes known to occur in human populations and whether decolonization of the GI tract is irreversible. Results from these studies should provide insight into the role O. formigenes plays in regulating oxalate homeostasis in vertebrates, including humans, and should offer new modalities in prevention therapy for oxalate-associated disorders, such as recurrent kidney stone formation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: RISK FACTORS FOR HIP FRACTURES AMONG THE ELDERLY Principal Investigator & Institution: Melton, Joseph L.; Mayo Clinic Rochester 200 1St St Sw Rochester, MN 55905 Timing: Fiscal Year 2001 Summary: This project complements studies of pathophysiology by addressing fractures, the principle clinical manifestation of osteoporosis. Through the unique data resources of the Rochester Epidemiology Project, we can identify large inception cohorts of Rochester and/or Olmsted County, Minnesota., residents with specific medical and surgical conditions and conduct a series of retrospective (=historical) cohort studies to estimate the long-term risk of age-related fractures associated with secondary
22 Urolithiasis
osteoporosis, an important contributor to bone loss in the elderly. Secondary, osteoporosis is an important area of research because new therapies are being developed for affected men and older women who are not candidates for estrogen replacement. We previously determined the risk of fracture among cohorts with diabetes mellitus, hyperparathryoidism, thyroidectomy, gastrectomy, pernicious anemia, oophorectomy, urolithiasis, anticoagulant therapy, anorexia nervosa, dementia, parkinsonism, epilepsy, poliomyelitis, rheumatoid arthritis, ankylosing spondylitis and breast cancer. We now proposed to extend this work by quantifying the fracture risk associated with conditions that might impair peak bone mass (endometriosis, infertility), induce hypogonadism (orchiectomy), disturb extraskeletal bone metabolism in the kidney (chronic renal failure) and gut (inflammatory bowel disease) or cause a generalized increase in bone resorbing cytokine (multiple myeloma). Each condition represents a natural experiment with respect to the pathogenesis of osteoporosis, several of which parallel the concerns of other projects. These will be the first assessments of fracture risk among cohorts of unselected patients from the community, and the results should be more valid and more precise than any previous estimates. Our overall goal is to develop new information that will lead to effective strategies for preventing osteoporosis-related fractures among the elderly. This project contributes by demonstrating the public health importance of specific risk factors and, by identifying high risk groups within each cohort, allowing future control programs to be designed and conducted more efficiently. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE OF BIOPOLYMERS AND LIPIDS IN KIDNEY STONE FORMATION Principal Investigator & Institution: Gower, Laurie A. Assistant Professor; Materials Science and Engr; University of Florida Gainesville, FL 32611 Timing: Fiscal Year 2001; Project Start 15-JUL-2001; Project End 30-JUN-2005 Summary: The objective of the proposed bioengineering research partnership (BRP), located at the University of Florida, is to examine two key issues relevant to urolithiasis; 1) the effects of acidic biopolymers and lipid membranes on nucleation, growth and aggregation of calcium oxalate (CaOx) crystals in an artificial urinary environment; and 2) the injurious effects of a liquid-phase mineral precursor on tubular epithelial cells grown in culture. With regard to 1), many investigators have examined the promotory and inhibitory effects of acidic glycoproteins on crystal growth and aggregation. Our work differs in that a primary focus will be to investigate the relevance of a recently discovered polymer-induced liquid-precursor (PILP) process to pathological biomineralization. The PILP process generates non- equilibrium crystal morphologies which exhibit features similar to crystals found in kidney stones, such as for example, stratified spherulites. Mineral films and coatings are also deposited by the process, and repetitive depositions might lead to concentrically laminated structures, such as those commonly observed in composite stones. In addition, the interfacial aspects of this liquid-liquid phase separation process lead to a pronounced aggregation tendency of crystals. Lastly, we hypothesize that the presence of this cementatious mineral precursor in the urinary tract could influence the attachment and retention of crystals to renal epithelial cells; or the highly ionic precursor phase could cause cell injury or death, leading to the release of modulatory factors or membrane fragments, which could promote heterogeneous nucleation and/or aggregation of crystals. The proposed work consists of ten Specific Aims which fall under four topical areas: crystal-macromolecule, crystal- crystal, crystal-lipid, and crystal-cell interactions. The bioengineering techniques to be used include measurement of interparticle forces by Atomic Force Microscopy,
Studies 23
measurement of long-range interactions between submicron CaOx particles and mimetic lipid membranes with an optical trap force transducer, and nucleation of crystals and PILP phase on mimetic lipid membranes using Langmuir monolayers. This 5-year project will enable us to assess the relevance of the PILP process to pathological calcification, as well as to perform a comparative analysis with the more traditional concepts pertaining to the role of lipids and acidic biopolymers in stone formation, and will contribute to the development of bioengineering techniques that are new to the field of stone research. The long-range clinical goal of this BRP is to provide a more effective means of diagnosis, treatment, and long-term prevention of renal calculi. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SLOW RELEASE HYPERCALCIURIA CORRECTION
NEUTRAL
PHOSPHATE--ABSORPTIVE
Principal Investigator & Institution: Pak, Charles Y.; University of Texas Sw Med Ctr/Dallas Dallas, TX 753909105 Timing: Fiscal Year 2001 Summary: Absorptive hypercalciuria is a major cause of urolithiasis, encountered in approximately 50% of patients with recurrent formation of kidney stones. The objective of this project is to test the hypothesis that UroPhos-K , a slow-release neutral potassium phosphate, safely corrects the physiological and physicochemical abnormalities found in stone- formers with absorptive hypercalciuria. We have completed and published a 3 month placebo-controlled study that demonstrateds that UroPhos-K improves the physicochemical and physiological abnormalities in these patients (Breslau JBMR 1995, Breslau JCEM submitted). Unlike thiazide treatment in which the hypocalciuric effect declines over the long term, we have found in 20 patients completing 2 years that the effect is maintained (Heller Urolithiasis 1996, abs JBMR). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TISSUE-CRYSTAL NEPHROLITHIASIS
INTERACTION
CA
OXALATE
Principal Investigator & Institution: Khan, Saeed R. Professor; Pathology, Immunol & Lab Med; University of Florida Gainesville, FL 32611 Timing: Fiscal Year 2001; Project Start 01-MAR-2000; Project End 31-JAN-2004 Summary: Urolithiasis is a significant urological disease afflicting a large percentage of US population costing approximately 2.39 billion dollars/year. Nearly two-thirds of the urinary stones contain calcium oxalate. Chances of stone recurrence within 10 years of the first episode are over 60 percent. To reduce the likelihood of recurrence it is necessary to understand the mechanisms involved in stone formation and to determine urinary markers of stone initiation. This project is aimed towards developing an understanding of the processes involved and identification of urinary markers which can be utilized to determine the onset of nephrolithiasis. It is our hypothesis that calcium oxalate stone formation involves a cascade of events which starts with hyperoxaluria. A moderate hyperoxaluric challenge induces increased production of crystallization modulators such as osteopontin which interact with calcium as well as the calcific crystals and facilitate their removal from the renal tubules. Significantly high level of oxalate however, injures the renal epithelial cells. The injury results in promotion of crystal formation and their retention within the renal tubules by providing substrates for crystal nucleation, agents for crystal aggregation and by creating sites for crystal adherence to the renal epithelial cells. Crystallization modulators produced by
24 Urolithiasis
the injured cells maybe abnormal and/or functionally inadequate. Production of such atypical modulators can indicate initiation of the stone forming cascade. We want to test this hypothesis using, 1. an animal model of calcium oxalate nephrolithiasis and, 2. cell culture experiments. In the animal model hyperoxaluria is induced in male rats. In cell culture experiments renal epithelial cell; MDCK and LLC-PK1 are exposed to oxalate and calcium oxalate crystals. We can follow various events of nephrolithiasis in the animal model and cats explore the outcome of renal epithelial cell exposure to oxalate and calcium oxalate crystals in the cell cultures. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: UROLITHIASIS AND PEROXIDATIVE INJURY Principal Investigator & Institution: Thamilselvan, Sivagnanam; Urology; Case Western Reserve Univ-Henry Ford Hsc Research Administraion Cfp-046 Detroit, MI 48202 Timing: Fiscal Year 2001; Project Start 01-SEP-1999; Project End 31-JUL-2004 Summary: Urolithiasis is a major health problem in the United States, and the incidence and frequency of stone formation appears to be increasing in this country. The current cost to the nation for treating kidney stones is approximaately 2.39 billion dollars/year. About two thirds of the stones contain calcium oxalate. Chances of recurrences within 10 years are nearly 60 percent. Treatment program includes medications, open surgery, percutaneous techniques and extra corporeal shock wave lithotripsy. Despite recent advances in treatment, stone recurrence can be reduced by only 50 percent. To reduce the likelihood of stone recurrence it is necessary to determine and understand the mechanisms involved in stone formation. Our working hypothesis is that cell injury is central to the process of urolithiasis and that prevention of cell injury will prevent calcium oxalate formation, retention and deposition. Hyperoxaluria and calcium oxalate crystalluria are often associated with increased excretion of tubular marker enzymes, a finding consistent with damage to renal tubular cells. Moreover, these changes are observed even in the absence of crystalluria, suggesting that oxalate induced membrane damage is not due solely to injury produced by calcium oxalate crystals. Our studies have suggested that oxalate induces peroxidative injury to the kidney tubules which can alter membrane permeability, and result in the deterioration of ability of the cells to maintain normal ionic environment. The oxidant and antioxidant balance is therefore likely to be a critical determinant of cell sensitivity to free radical injury and a major impact on the magnitude of stone crystal nucleation on the injured renal tubular epithelium and the development of stone nidus. We propose to test this hypothesis in an animal model and renal epithelial cell culture (LLC-PK1 and MDCK). In an animal model hyperoxaluria is induced in male rats. In cell culture experiments, renal epithelial cells in culture are exposed to oxalate and calcium oxalate monohydrate crystals. The effect of antioxidants on these experimental models will be tested. These studies will provide valuable information on the importance of antioxidants in decreasing oxalate synthesis and deposition and, whether antioxidants offer promise as a therapeutic agent for recurrent stone formation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: UROLITHIASIS: OXALATE INTERACTIONS WITH RENAL CELLS Principal Investigator & Institution: Koul, Hari K. Director of Research; Urology; Case Western Reserve Univ-Henry Ford Hsc Research Administraion Cfp-046 Detroit, MI 48202 Timing: Fiscal Year 2003; Project Start 20-SEP-1997; Project End 31-JAN-2008
Studies 25
Summary: (provided by applicant): Urolithiasis is a multi-factorial disease and it is unlikely that a single factor will be responsible for the entire spectrum of this disorder. Nonetheless, one important factor is an abnormality in the oxalate metabolism. The manner by which increase in urinary oxalate influences stone formation is not completely understood and has been the focus of our investigation. We have demonstrated that oxalate exposure to renal epithelial cells, results in re-initiation of the DNA synthesis, altered gene expression and cell death, and- promotes crystal retention. However, the specific signal transduction pathways involved in these diverse effects of oxalate are not understood. The proposed studies will evaluate the hypothesis that p38 Mitogen-activated Protein kinase (p38 MAPK) and Jun N-terminal kinase (JNK) signal transduction pathways play a central role in mediating the toxic effects of oxalate and in modulating the cellular responses to oxalate toxicity. This hypothesis is driven by our observations that oxalate exposure selectively caused a rapid and robust activation of p38 MAPK and a mild activation of JNK but had no effect on ERK1/ERK2 MAP kinase pathway. Moreover, the precise sequence/s through which oxalate causes selective activation of p38 MAPK and JNK pathways is/are not understood. The present studies have three objectives: (1) to elucidate the molecular mechanisms involved in oxalate induced activation of p38 Mitogen-activated Protein kinase and Jun N-terminal kinase pathways; (2) to investigate the roles played by p38 Mitogen-activated Protein kinase pathway and Jun N-terminal kinase pathway in mediating the effects of oxalate; and (3) to evaluate the activation of p38 Mitogen-activated Protein kinase and Jun N-terminal kinase pathways, in vivo, in response to hyperoxaluria. Understanding the specific signaling processes that mediate the effects of oxalate in renal epithelial cells will help us develop strategies to inhibit the toxic effects of oxalate and prevent crystal retention and renal stone formation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: UROLITHIASIS--ROLE OF NEPHRON DYSFUNCTION/INJURY Principal Investigator & Institution: Jonassen, Julie J. Physiology; Univ of Massachusetts Med Sch Worcester Office of Research Funding Worcester, MA 01655 Timing: Fiscal Year 2003; Project Start 01-JAN-1991; Project End 30-JUN-2004 Summary: Our working hypothesis is that oxalate-induced injury to renal epithelial cells plays a central role in the development of calcium oxalate stone disease, with oxalateinduced injury promoting the nucleation, growth and retention of calcium oxalate crystals within the kidney. Recent studies in our laboratory support this hypothesis and indicate that oxalate-induced injury to renal tubular cells may be secondary to increased free radical production. This working hypothesis serves as the focus of the present proposal and its 3 interrelated aims. Aim 1 will determine the mechanism(s) of oxalate toxicity, defining a) the role of oxalate crystals and/or the oxalate anion in oxalate injury, b) cellular processes that could mediate oxalate actions c) relevant sites of free radical production within the cells and d) targets of free radical actions (plasma membrane, mitochondria, etc.) e) the effects of prior "sensitizing" stimuli on oxalate toxicity. Aim 2 will characterize oxalate-induced changes in gene expression in renal epithelial cells, defining a) the pattern of oxalate induced changes in gene expression, b) the cellular events leading to the observed changes in gene expression, and c) the therapeutic benefits of genetic manipulations which increase free radical "buffering" or facilitate oxalate degradation. Aim 3 will determine whether hyperoxaluria in experimental animals will evoke changes in renal cell function which are comparable to those observed in response to hyperoxaluria in cultured renal epithelial cells. The proposed in vitro studies will utilize LLC-PK1 cells for the majority of the studies
26 Urolithiasis
confirming key findings in distal tubular cells (MDCK cells) and in human renal epithelial cells (RPTEC cells). These studies will define oxalate actions in vitro and evaluate the effectiveness of various pharmacological and genetic manipulations to limit oxalate toxicity. Results from these in vitro studies will inform and guide the design of in vivo studies to assess the consequences of hyperoxaluria in experimental animals and to define the role of oxidant stress in the development/progression of stone disease. This combination of in vitro and in vivo studies should provide important insights as to processes involved in calcium oxalate stone disease and suggest possible therapeutic strategies for management of this disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “urolithiasis” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for urolithiasis in the PubMed Central database: •
Adenine Phosphoribosyltransferase-Deficient Mice Develop 2,8-Dihydroxyadenine Nephrolithiasis. by Engle SJ, Stockelman MG, Chen J, Boivin G, Yum M, Davies PM, Ying MY, Sahota A, Simmonds HA, Stambrook PJ, Tischfield JA. 1996 May 28; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=39241
•
Circadian pattern in occurrence of renal colic in an emergency department: analysis of patients' notes. by Manfredini R, Gallerani M, Cecilia OL, Boari B, Fersini C, Portaluppi F. 2002 Mar 30; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=100317
•
Nephrolithiasis: site of the initial solid phase. by Bushinsky DA. 2003 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151909
•
Nephrology: 1. Investigation and treatment of recurrent kidney stones. by Morton AR, Iliescu EA, Wilson JW. 2002 Jan 22; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=99277
•
Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. by Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, Sommer AJ, Paterson RF, Kuo RL, Grynpas M. 2003 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151900
3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
Studies 27
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with urolithiasis, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “urolithiasis” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for urolithiasis (hyperlinks lead to article summaries): •
2,8-Dihydroxyadenine crystalluria vs urolithiasis. Author(s): Laxdal T. Source: Lancet. 1992 July 18; 340(8812): 184. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1352601&dopt=Abstract
•
2,8-Dihydroxyadenine urolithiasis due to partial deficit in adenine phosphoribosyltransferase: a case report. Author(s): Katsuoka Y, Miyakita H, Shiramizu M, Iwagaki H, Ikeda T. Source: Hinyokika Kiyo. 1992 May; 38(5): 573-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1609669&dopt=Abstract
•
2,8-Dihydroxyadenine urolithiasis in a patient with considerable residual adenine phosphoribosyltransferase activity in cell extracts but with mutations in both copies of APRT. Author(s): Deng L, Yang M, Frund S, Wessel T, De Abreu RA, Tischfield JA, Sahota A. Source: Molecular Genetics and Metabolism. 2001 March; 72(3): 260-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11243733&dopt=Abstract
•
2,8-Dihydroxyadenine urolithiasis, an underdiagnosed disease. Author(s): Ceballos-Picot I, Perignon JL, Hamet M, Daudon M, Kamoun P. Source: Lancet. 1992 April 25; 339(8800): 1050-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1349069&dopt=Abstract
6
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
28 Urolithiasis
•
2,8-Dihydroxyadenine urolithiasis. Author(s): Ward ID, Addison GM. Source: Lancet. 1992 May 23; 339(8804): 1296. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1349690&dopt=Abstract
•
2,8-Dihydroxyadenine urolithiasis. Author(s): Maddocks JL. Source: Lancet. 1992 May 23; 339(8804): 1296. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1349689&dopt=Abstract
•
2,8-Dihydroxyadenine urolithiasis. Author(s): Simmonds H, Van Acker KJ, Sahota AS. Source: Lancet. 1992 May 23; 339(8804): 1295-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1349687&dopt=Abstract
•
2,8-dihydroxyadenine urolithiasis: report of a case first diagnosed after renal transplant. Author(s): Glicklich D, Gruber HE, Matas AJ, Tellis VA, Karwa G, Finley K, Salem C, Soberman R, Seegmiller JE. Source: The Quarterly Journal of Medicine. 1988 October; 68(258): 785-93. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3077470&dopt=Abstract
•
2,8-Dihydroxyadenine urolithiasis: report of a case in a woman in the United States. Author(s): Lamontagne AE Jr. Source: The Journal of Urology. 1989 August; 142(2 Pt 1): 369-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2746754&dopt=Abstract
•
2,8-Dihydroxyadenine urolithiasis: report of an adult case in the United States. Author(s): Manyak MJ, Frensilli FJ, Miller HC. Source: The Journal of Urology. 1987 February; 137(2): 312-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3806829&dopt=Abstract
•
2,8-dihydroxyadenine urolithiasis: review of the literature and report of a case in the United States. Author(s): Witten FR, Morgan JW, Foster JG, Glenn JF. Source: The Journal of Urology. 1983 November; 130(5): 938-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6632104&dopt=Abstract
•
A biochemical basis for grouping of patients with urolithiasis. Author(s): Tiselius HG, Almgard LE, Larsson L, Sorbo B. Source: European Urology. 1978; 4(4): 241-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=668734&dopt=Abstract
Studies 29
•
A case of a compound heterozygote for adenine phosphoribosyltransferase deficiency (APRT*J/APRT*Q0) leading to 2,8-dihydroxyadenine urolithiasis: review of the reported cases with 2,8-dihydroxyadenine stones in Japan. Author(s): Takeuchi H, Kaneko Y, Fujita J, Yoshida O. Source: The Journal of Urology. 1993 April; 149(4): 824-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8455250&dopt=Abstract
•
A comparative study between etiological factors of calcium oxalate monohydrate and calcium oxalate dihydrate urolithiasis. Author(s): Galan JA, Conte A, Llobera A, Costa-Bauza A, Grases F. Source: Urologia Internationalis. 1996; 56(2): 79-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8659015&dopt=Abstract
•
A family-based study of metabolic phenotypes in calcium urolithiasis. Author(s): Tessier J, Petrucci M, Trouve ML, Valiquette L, Guay G, Ouimet D, Bonnardeaux A. Source: Kidney International. 2001 September; 60(3): 1141-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11532110&dopt=Abstract
•
A fast and simple screening method for detection of 2,8-dihydroxyadenine urolithiasis by capillary zone electrophoresis. Author(s): Sevcik J, Adam T, Mazacova H. Source: Clinica Chimica Acta; International Journal of Clinical Chemistry. 1996 February 9; 245(1): 85-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8646818&dopt=Abstract
•
A high incidence of urolithiasis in male marathon runners. Author(s): Milvy P, Colt E, Thornton J. Source: The Journal of Sports Medicine and Physical Fitness. 1981 September; 21(3): 2958. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7321562&dopt=Abstract
•
A method for description and classification of patients with urolithiasis. Author(s): Tiselius HG. Source: Scandinavian Journal of Urology and Nephrology. 1987; 21(2): 131-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3616505&dopt=Abstract
•
A mutant adenine phosphoribosyltransferase in 2,8-dihydroxyadenine urolithiasis. Author(s): Nishida Y, Hirano S, Miyamoto T. Source: Archives of Internal Medicine. 1986 October; 146(10): 2068-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3767554&dopt=Abstract
30 Urolithiasis
•
A new factor in urolithiasis: long-term effects of severe respiratory poliomyelitis. Author(s): Poole-Wilson PA. Source: British Journal of Urology. 1973 August; 45(4): 335-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4517123&dopt=Abstract
•
A patient with sarcoidosis associated with recurrent urolithiasis and tubular injury caused by calcium deposition. Author(s): Mimura Y, Maeshima Y, Ogura T, Kashihara N, Kawabata K, Hayakawa N, Nagake Y, Hironaka K, Makino H, Ota Z, Kageyama J. Source: Nippon Jinzo Gakkai Shi. 1996 March; 38(3): 141-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8721336&dopt=Abstract
•
A possible role of fish preparation 'Hentak' in urolithiasis in Manipur--an experimental study. Author(s): Singh PP, Rathore V, Singh LB. Source: Indian J Exp Biol. 1986 February; 24(2): 88-90. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3733171&dopt=Abstract
•
A proposal for a standard reference artificial urine in in vitro urolithiasis experiments. Author(s): Burns JR, Finlayson B. Source: Invest Urol. 1980 September; 18(2): 167-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7410032&dopt=Abstract
•
A review of possible roles of urates in calcium oxalate urolithiasis. Author(s): Brockis JG, Bowyer RC, McCulloch RK. Source: Scand J Urol Nephrol Suppl. 1980; 53: 179-85. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6937994&dopt=Abstract
•
A study of the etiology of idiopathic calcium urolithiasis in children: hypocitruria is the most important risk factor. Author(s): Tekin A, Tekgul S, Atsu N, Sahin A, Ozen H, Bakkaloglu M. Source: The Journal of Urology. 2000 July; 164(1): 162-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10840454&dopt=Abstract
•
A study of urolithiasis in North West Frontier Province of Pakistan. Author(s): Rab F, Qazi FM, Ahmad R, Zahoorullah, Khan I, Akhtar T. Source: J Pak Med Assoc. 1990 October; 40(10): 241-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2123261&dopt=Abstract
Studies 31
•
A study on the prevalence of urolithiasis among Turkish medical doctors. Author(s): Bakkaloglu MA, Erkan I, Ozen HA, Remzi D. Source: Turk J Pediatr. 1984; 26(1-4): 5-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6537086&dopt=Abstract
•
A study on the urolithiasis incidence in Turkish school-age children. Author(s): Remzi D, Cakmak F, Erkan I. Source: The Journal of Urology. 1980 April; 123(4): 608. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7365921&dopt=Abstract
•
A survey of calcium urolithiasis in normocalcemic hypercalciuria: possible role of nutrients and diet-mediated factors. Author(s): Schwille PO. Source: Urological Research. 1979 September; 7(3): 149-55. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=388796&dopt=Abstract
•
A survey of the incidence of urolithiasis in Norway from 1853 to 1960. Author(s): Andersen DA. Source: J Oslo City Hosp. 1966 May-June; 16(5): 101-47. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5327590&dopt=Abstract
•
A telemedicine consultative service for the evaluation of patients with urolithiasis. Author(s): Hayes WS, Tohme WG, Komo D, Dai H, Persad SG, Benavides A, Juttner HU, Fleming MP, Wonsetler B, Mun SK, Pahira JJ. Source: Urology. 1998 January; 51(1): 39-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9457286&dopt=Abstract
•
A thermodynamic equilibrium model for calcium salt urolithiasis: clinical application. Author(s): Ashby R, Gyory AZ. Source: Experimental Nephrology. 1997 May-June; 5(3): 246-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9208285&dopt=Abstract
•
A urinary detergent and urolithiasis. Author(s): Charlton CA. Source: British Journal of Urology. 1989 June; 63(6): 561-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2665900&dopt=Abstract
32 Urolithiasis
•
Absent hematuria and expensive computerized tomography: case characteristics of emergency urolithiasis. Author(s): Li J, Kennedy D, Levine M, Kumar A, Mullen J. Source: The Journal of Urology. 2001 March; 165(3): 782-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11176467&dopt=Abstract
•
Acetazolamide and urolithiasis. Author(s): Kass MA, Kolker AE, Gordon M, Goldberg I, Gieser DK, Krupin T, Becker B. Source: Ophthalmology. 1981 March; 88(3): 261-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7231915&dopt=Abstract
•
Adenine phosphoribosyltransferase deficiency: 2,8-dihydroxyadenine urolithiasis in a 48-year-old woman. Author(s): Usenius JP, Ruopuro ML, Usenius R. Source: British Journal of Urology. 1988 December; 62(6): 521-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3219508&dopt=Abstract
•
Adequacy of a single stone risk analysis in the medical evaluation of urolithiasis. Author(s): Pak CY, Peterson R, Poindexter JR. Source: The Journal of Urology. 2001 February; 165(2): 378-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11176377&dopt=Abstract
•
Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis--a prospective randomized study. Author(s): Hofbauer J, Hobarth K, Szabo N, Marberger M. Source: British Journal of Urology. 1994 April; 73(4): 362-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8199822&dopt=Abstract
•
Allopurinol and urolithiasis. Author(s): Smith MJ, Boyce WH. Source: The Journal of Urology. 1969 December; 102(6): 750-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5372029&dopt=Abstract
•
Amino acids in urine and plasma of urolithiasis patients. Author(s): Kohri K, Takada M, Katoh Y, Kataoka K, Iguchi M, Kurita T. Source: International Urology and Nephrology. 1989; 21(1): 9-16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2714953&dopt=Abstract
Studies 33
•
An acromegalic patient with recurrent urolithiasis. Author(s): Tsuchiya H, Onishi T, Takamoto S, Morimoto S, Fukuo K, Imanaka S, Yamamoto H, Yukawa S, Koh E, Sonoda T, et al. Source: Endocrinol Jpn. 1985 December; 32(6): 851-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3841720&dopt=Abstract
•
An algorithm for diagnosis and therapy of management and complications of urolithiasis during pregnancy. Author(s): Hendricks SK, Ross SO, Krieger JN. Source: Surg Gynecol Obstet. 1991 January; 172(1): 49-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1985341&dopt=Abstract
•
An interesting case of a small child with urolithiasis. Author(s): Smith DP, Malagon M, Raper CA. Source: Tenn Med. 1997 September; 90(9): 362-3. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9308390&dopt=Abstract
•
Analysis of osteopontin DNA in patients with urolithiasis. Author(s): Yamate T, Tsuji H, Amasaki N, Iguchi M, Kurita T, Kohri K. Source: Urological Research. 2000 June; 28(3): 159-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10929424&dopt=Abstract
•
Analysis of urinary proteins in urolithiasis by isoelectric focusing using ultra-thinlayer gel. Author(s): Nadvi IN, Talati J, Ali TZ, Waqar MA. Source: Biochemical Society Transactions. 1990 April; 18(2): 261. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2379703&dopt=Abstract
•
Analysis of urinary proteins in urolithiasis by ultra-thin-layer SDS/polyacrylamidegradient-gel electrophoresis. Author(s): Nadvi IN, Talati J, Ali TZ, Waqar MA. Source: Biochemical Society Transactions. 1990 April; 18(2): 263. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2379705&dopt=Abstract
•
Anterior transperitoneal approach for treatment of urolithiasis. Author(s): Linke CA, Linke CL, Davis RS, Barbaric ZL, Khuri FJ. Source: The Journal of Urology. 1978 April; 119(4): 453-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=650742&dopt=Abstract
34 Urolithiasis
•
Anuria due to bilateral cystine urolithiasis in an infant. Author(s): Martini A, Ravelli A, Viola S, Beluffi G, Verga G. Source: Helv Paediatr Acta. 1986 March; 41(6): 545-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3583776&dopt=Abstract
•
Anuria in childhood due to bilateral urolithiasis. A report of four cases. Author(s): Aladjem M, Many M, Boichis H, Scapa E, Orda S, Hertz M. Source: Clinical Pediatrics. 1979 August; 18(8): 501-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=455883&dopt=Abstract
•
Apparent change in the male:female ratio of incidence of urolithiasis in California. Author(s): Kizer KW, Moran ME, Vassar M. Source: The Medical Journal of Australia. 1994 April 4; 160(7): 448. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8007873&dopt=Abstract
•
Are metabolic studies of urolithiasis necessary? Author(s): Resnick MI, Pak CY. Source: The Journal of Urology. 1987 May; 137(5): 960-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3573196&dopt=Abstract
•
Arterial blood pressure following different types of urinary stone therapy. Presented at the 8th European Symposium on Urolithiasis, Parma, Italy, 1999. Author(s): Strohmaier WL, Schmidt J, Lahme S, Bichler KH. Source: European Urology. 2000 December; 38(6): 753-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11111196&dopt=Abstract
•
Ascorbic acid in idiopathic recurrent calcium urolithiasis in humans--does it have an abettor role in oxalate, and calcium oxalate crystallization? Author(s): Schwille PO, Schmiedl A, Herrmann U, Manoharan M, Fan J, Sharma V, Gottlieb D. Source: Urological Research. 2000 June; 28(3): 167-77. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10929425&dopt=Abstract
•
Association of vitamin D receptor gene polymorphism with urolithiasis. Author(s): Nishijima S, Sugaya K, Naito A, Morozumi M, Hatano T, Ogawa Y. Source: The Journal of Urology. 2002 May; 167(5): 2188-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11956476&dopt=Abstract
•
Basic studies on the cause of urolithiasis. 3. Role of urinary citrate in urolithiasis. Author(s): Matsuo M. Source: Hinyokika Kiyo. 1966 September; 12(9): 869-80 Concl. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6009217&dopt=Abstract
Studies 35
•
Biochemical distinction between hyperuricosuric calcium urolithiasis and gouty diathesis. Author(s): Pak CY, Poindexter JR, Peterson RD, Koska J, Sakhaee K. Source: Urology. 2002 November; 60(5): 789-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12429297&dopt=Abstract
•
Biochemical evaluation of patients with urolithiasis. Author(s): Tiselius HG, Larsson L. Source: European Urology. 1981; 7(1): 31-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7460993&dopt=Abstract
•
Biochemical evaluation of succinic acid therapy in urolithiasis. Author(s): Thind SK, Nath R, Verma G, Rao DM, Bapna BC. Source: Int J Clin Pharmacol Biopharm. 1978 November; 16(11): 516-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=730417&dopt=Abstract
•
Biological control to diminish dangers of urolithiasis. Author(s): Sarig S, Azoury R, Garti N. Source: Urologia Internationalis. 1985; 40(5): 274-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2866620&dopt=Abstract
•
Blind ending branch of duplicate ureter associated with urolithiasis of contra-lateral kidney: case report and review of literature. Author(s): Mosli HA, Rawas MM, Farsi HM, Rimawi MH. Source: East Afr Med J. 1990 October; 67(10): 737-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2282898&dopt=Abstract
•
Blood coagulation proteins and urolithiasis are linked: crystal matrix protein is the F1 activation peptide of human prothrombin. Author(s): Stapleton AM, Ryall RL. Source: British Journal of Urology. 1995 June; 75(6): 712-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7613825&dopt=Abstract
•
Blood levels of glucometabolic hormones and urinary saturation with stone forming phases after an oral test meal in male patients with recurrent idiopathic calcium urolithiasis and in healthy controls. Author(s): Schwille PO, Rumenapf G, Kohler R. Source: Journal of the American College of Nutrition. 1989 December; 8(6): 557-66. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2576028&dopt=Abstract
36 Urolithiasis
•
Blood pressure changes following extracorporeal shock wave lithotripsy for urolithiasis. Author(s): Yokoyama M, Shoji F, Yanagizawa R, Kanemura M, Kitahara K, Takahasi S, Kawai K, Oda H, Osaka M, Handa H. Source: The Journal of Urology. 1992 March; 147(3): 553-7; Discussion 557-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1538427&dopt=Abstract
•
Bone mineral content in patients with calcium urolithiasis. Author(s): Lawoyin S, Sismilich S, Browne R, Pak CY. Source: Metabolism: Clinical and Experimental. 1979 December; 28(12): 1250-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=514087&dopt=Abstract
•
Bone mineral density in patients with urolithiasis. A preliminary report. Author(s): Alhava EM, Juuti M, Karjalainen P. Source: Scandinavian Journal of Urology and Nephrology. 1976; 10(2): 154-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=948725&dopt=Abstract
•
Bone mineral density loss in patients with urolithiasis: a follow-up study. Author(s): Cvijetic S, Furedi-Milhofer H, Babic-Ivancic V, Tucak A, Galic J, DekanicOzegovic D. Source: Archives of Medical Research. 2002 March-April; 33(2): 152-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11886714&dopt=Abstract
•
Calcium excretion by each kidney separately in urolithiasis. Author(s): Sotornik I, Adamicka V, Kocvara S, Schuck O. Source: Nephron. 1972; 9(5): 318-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4661674&dopt=Abstract
•
Calcium salt urolithiasis. Review of theory for diagnosis and management. Author(s): Gyory AZ, Ashby R. Source: Clinical Nephrology. 1999 April; 51(4): 197-208. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10230552&dopt=Abstract
•
Calcium urolithiasis: is it analogous to bone formation? Author(s): Pak CY. Source: Calcif Tissue Res. 1978 December 8; 26(3): 195-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=750062&dopt=Abstract
Studies 37
•
Calcium-45 uptake in blood and urine in experimental urolithiasis and idiopathic stoneformers. Author(s): Thind SK, Nath R, Aggarwal SK, Rao MS, Bapna BC. Source: The Indian Journal of Medical Research. 1979 April; 69: 639-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=457206&dopt=Abstract
•
Calcium-47 absorption in urolithiasis. Author(s): Blacklock NJ, Macleod MA. Source: British Journal of Urology. 1974 August; 46(4): 377-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4412281&dopt=Abstract
•
Calcium-loading test and bone disease in patients with urolithiasis. Author(s): Lindergard B, Colleen S, Mansson W, Rademark C, Rogland B. Source: Proc Eur Dial Transplant Assoc. 1983; 20: 460-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6657669&dopt=Abstract
•
Can a relationship reflect the risk of calcium oxalate urolithiasis? Author(s): Roca P, Conte A, Riera T, Grases F. Source: International Urology and Nephrology. 1990; 22(3): 215-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2210974&dopt=Abstract
•
Can conventional examinations contribute to the diagnostic power of unenhanced helical computed tomography in urolithiasis? Author(s): Unal D, Yeni E, Karaoglanoglu M, Verit A, Karatas OF. Source: Urologia Internationalis. 2003; 70(1): 31-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12566812&dopt=Abstract
•
Canine calcium oxalate urolithiasis. Case-based applications of therapeutic principles. Author(s): Lulich JP, Osborne CA, Lekcharoensuk C, Allen TA, Nakagawa Y. Source: The Veterinary Clinics of North America. Small Animal Practice. 1999 January; 29(1): 123-39. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10028155&dopt=Abstract
•
Cation exchange resin preparation in recurrent calcium urolithiasis. Author(s): Rugendorff EW, Schneider HJ. Source: Urology. 1983 August; 22(2): 143-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6879885&dopt=Abstract
38 Urolithiasis
•
Changing treatments for primary urolithiasis: impact on services and renal preservation in 16,679 patients in Western Australia. Author(s): Holman CD, Wisniewski ZS, Semmens JB, Bass AJ. Source: Bju International. 2002 July; 90(1): 7-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12081761&dopt=Abstract
•
Characteristics of pediatric urolithiasis in south-east Anatolia. Author(s): Ece A, Ozdemir E, Gurkan F, Dokucu AI, Akdeniz O. Source: International Journal of Urology : Official Journal of the Japanese Urological Association. 2000 September; 7(9): 330-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11020057&dopt=Abstract
•
Chemical measurement of calcium oxalate crystalluria: results in various causes of calcium urolithiasis. Author(s): Hallson PC, Rose GA. Source: Urologia Internationalis. 1990; 45(6): 332-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2288049&dopt=Abstract
•
Chemical urolithiasis 2. Thermodynamic aspects of bladder stone induction by terephthalic acid and dimethyl terephthalate in weanling Fischer-344 rats. Author(s): Heck HD. Source: Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology. 1981 July-August; 1(4): 299-308. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7185577&dopt=Abstract
•
Chemically induced urolithiasis in weanling rats. Author(s): Wolkowski-Tyl R, Chin TY, Popp JA, Heck HD. Source: American Journal of Pathology. 1982 June; 107(3): 419-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7081391&dopt=Abstract
•
Childhood urolithiasis in Britain. Author(s): Ghazali S, Barratt TM, Williams DI. Source: Archives of Disease in Childhood. 1973 April; 48(4): 291-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4574640&dopt=Abstract
•
Childhood urolithiasis in Iran with special reference to staghorn calculi. Author(s): Kheradpir MH, Bodaghi E. Source: Urologia Internationalis. 1990; 45(2): 99-103. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2330666&dopt=Abstract
Studies 39
•
Childhood urolithiasis in Iran: a comparative study on the calculi composition of 121 cases. Author(s): Kheradpir MH, Armbruster T. Source: Z Kinderchir. 1985 June; 40(3): 163-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4036368&dopt=Abstract
•
Childhood urolithiasis in northern Israel. Author(s): Stark H. Source: Isr J Med Sci. 1970 May-June; 6(3): 341-5. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5473860&dopt=Abstract
•
Childhood urolithiasis in the United Kingdom and Eire. Author(s): Ghazali S. Source: British Journal of Urology. 1975; 47(7): 739-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1222339&dopt=Abstract
•
Childhood urolithiasis. Author(s): Rainer D, Leumann EP, Stauffer U. Source: Helv Paediatr Acta. 1980 September; 35(4): 301-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7451234&dopt=Abstract
•
Childhood urolithiasis. Author(s): Sinno K, Boyce WH, Resnick MI. Source: The Journal of Urology. 1979 May; 121(5): 662-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=439265&dopt=Abstract
•
Childhood urolithiasis: experiences and advances. Author(s): Gearhart JP, Herzberg GZ, Jeffs RD. Source: Pediatrics. 1991 April; 87(4): 445-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2011420&dopt=Abstract
•
Childhood urolithiasis: urological management of upper tract calculi in the era of extracorporeal shock-wave lithotripsy. Author(s): Robert M, Drianno N, Guiter J, Averous M, Grasset D. Source: Urologia Internationalis. 1996; 57(2): 72-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8873360&dopt=Abstract
•
Cholelithiasis and urolithiasis in Crohn's disease. Author(s): Andersson H, Bosaeus I, Fasth S, Hellberg R, Hulten L. Source: Scandinavian Journal of Gastroenterology. 1987 March; 22(2): 253-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3576131&dopt=Abstract
40 Urolithiasis
•
Cholelithiasis and urolithiasis in ileostomy patients. Author(s): Giunchi F, Balbi B, Giulianini G, Cacciaguerra G. Source: Ital J Surg Sci. 1989; 19(1): 37-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2745042&dopt=Abstract
•
Chronic renal insufficiency (CRI) in urolithiasis. Author(s): Revusova V, Zvara Z, Kridl J, Borosova E, Pribylincova V, Reznicek J, Gratzlova J. Source: International Urology and Nephrology. 1980; 12(4): 325-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7052364&dopt=Abstract
•
Chronopharmacological studies on potassium citrate treatment of oxalocalcic urolithiasis. Author(s): Grases F, Conte A, March JG, Garcia-Ferragut L, Villalonga N. Source: International Urology and Nephrology. 1997; 29(3): 263-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9285296&dopt=Abstract
•
Circulating adhesion molecules and neutral endopeptidase enzymuria in patients with urolithiasis and hydronephrosis. Author(s): Huang H, Chen J, Chen C. Source: Urology. 2000 June; 55(6): 961-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10840126&dopt=Abstract
•
Citrate and recurrent idiopathic calcium urolithiasis. A longitudinal pilot study on the metabolic effects of oral potassium citrate administered over the short-, mediumand long-term medication of male stone patients. Author(s): Schwille PO, Herrmann U, Wolf C, Berger I, Meister R. Source: Urological Research. 1992; 20(2): 145-55. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1553790&dopt=Abstract
•
Citrate and recurrent idiopathic calcium urolithiasis. A longitudinal pilot study on the metabolic effects of oral potassium sodium citrate administered as short-, medium- and long-term to male stone patients. Author(s): Herrmann U, Schwille PO, Schwarzlaender H, Berger I, Hoffmann G. Source: Urological Research. 1992; 20(5): 347-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1455567&dopt=Abstract
•
Citrate in daily and fasting urine: results of controls, patients with recurrent idiopathic calcium urolithiasis, and primary hyperparathyroidism. Author(s): Schwille PO, Scholz D, Paulus M, Engelhardt W, Sigel A. Source: Invest Urol. 1979 May; 16(6): 457-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=447479&dopt=Abstract
Studies 41
•
Citrate in the management of urolithiasis. Author(s): Pattaras JG, Moore RG. Source: Journal of Endourology / Endourological Society. 1999 November; 13(9): 687-92. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10608522&dopt=Abstract
•
Citrate in urine and serum and associated variables in subgroups of urolithiasis. Results from an outpatient stone clinic. Author(s): Schwille PO, Scholz D, Schwille K, Leutschaft R, Goldberg I, Sigel A. Source: Nephron. 1982; 31(3): 194-202. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7121665&dopt=Abstract
•
Clinical and urinary characteristics of urolithiasis in ulcerative colitis. Author(s): Fukushima T, Ishiguro N, Matsuda Y, Takemura H, Tsuchiya S. Source: The American Journal of Gastroenterology. 1982 April; 77(4): 238-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6122377&dopt=Abstract
•
Clinical approach to children with urolithiasis. Author(s): Stapleton FB. Source: Semin Nephrol. 1996 September; 16(5): 389-97. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8890395&dopt=Abstract
•
Clinical aspects of urolithiasis in the Sudan. Author(s): Ibrahim A, Zein M, Beleil O. Source: Journal of the Royal College of Surgeons of Edinburgh. 1979 January; 24(1): 34-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=448659&dopt=Abstract
•
Clinical association with urinary glycosaminoglycans and urolithiasis. Author(s): Erturk E, Kiernan M, Schoen SR. Source: Urology. 2002 April; 59(4): 495-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11927298&dopt=Abstract
•
Clinical experience with hyperparathyroidism in sixty patients, fifty-one of them having urolithiasis. Author(s): Frank M, Nathan P, Lazebnik J, De Vries A. Source: Urologia Internationalis. 1968; 23(4): 315-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5674560&dopt=Abstract
•
Clinical experience with pediatric urolithiasis. Author(s): Noe HN, Stapleton FB, Jerkins GR, Roy S 3rd. Source: The Journal of Urology. 1983 June; 129(6): 1166-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6854792&dopt=Abstract
42 Urolithiasis
•
Clinical manifestations of calcium oxalate monohydrate and dihydrate urolithiasis. Author(s): Koide T, Itatani H, Yoshioka T, Ito H, Namiki M, Nakano E, Okuyama A, Takemoto M, Sonoda T. Source: The Journal of Urology. 1982 June; 127(6): 1067-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7087010&dopt=Abstract
•
Clinical patterns of paediatric urolithiasis. Author(s): Diamond DA. Source: British Journal of Urology. 1991 August; 68(2): 195-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1884149&dopt=Abstract
•
Coexistence of VATER association and recurrent urolithiasis: a case report. Author(s): Unuvar E, Oguz F, Sahin K, Nayir A, Ozbey H, Sidal M. Source: Pediatric Nephrology (Berlin, Germany). 1998 February; 12(2): 141-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9543375&dopt=Abstract
•
Combination of chemolysis and extracorporeal shock wave lithotripsy in cystine urolithiasis. Author(s): Vandeursen H, Baert L. Source: British Journal of Urology. 1991 April; 67(4): 435-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2032086&dopt=Abstract
•
Common characteristics of mutant adenine phosphoribosyltransferases from four separate Japanese families with 2,8-dihydroxyadenine urolithiasis associated with partial enzyme deficiencies. Author(s): Fujimori S, Akaoka I, Sakamoto K, Yamanaka H, Nishioka K, Kamatani N. Source: Human Genetics. 1985; 71(2): 171-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3876264&dopt=Abstract
•
Comparison of comprehensive and limited metabolic evaluations in the treatment of patients with recurrent calcium urolithiasis. Author(s): Yagisawa T, Chandhoke PS, Fan J. Source: The Journal of Urology. 1999 May; 161(5): 1449-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10210370&dopt=Abstract
•
Comparison of metabolic risk factors in patients with recurrent urolithiasis stratified according to age and gender. Author(s): Yagisawa T, Hayashi T, Yoshida A, Kobayashi C, Okuda H, Ishikawa N, Toma H. Source: European Urology. 2000 September; 38(3): 297-301. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10940703&dopt=Abstract
Studies 43
•
Comparison of urinary oxalate excretion in urolithiasis patients with and without hypercalciuria. Author(s): Koide T, Bowyer RC, Brockis JG. Source: British Journal of Urology. 1985 October; 57(5): 505-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4063729&dopt=Abstract
•
Compliance with use of the Hydrate 1 system by patients with treated urolithiasis. Author(s): Dilworth JP, Segura JW. Source: Journal of Endourology / Endourological Society. 1993 June; 7(3): 197-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8358414&dopt=Abstract
•
Complication of short bowel syndrome: an infant with short bowel syndrome developing ammonium acid urate urolithiasis. Author(s): Buyukgebiz B, Arslan N, Ozturk Y, Soylu A, Kavukcu S. Source: Pediatrics International : Official Journal of the Japan Pediatric Society. 2003 April; 45(2): 208-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12709153&dopt=Abstract
•
Computed tomography versus intravenous urography in diagnosis of acute flank pain from urolithiasis: a randomized study comparing imaging costs and radiation dose. Author(s): Thomson JM, Glocer J, Abbott C, Maling TM, Mark S. Source: Australasian Radiology. 2001 August; 45(3): 291-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11531751&dopt=Abstract
•
Correlation of unilateral urolithiasis with sleep posture. Author(s): Shekarriz B, Lu HF, Stoller ML. Source: The Journal of Urology. 2001 April; 165(4): 1085-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11257643&dopt=Abstract
•
Corynebacterium group D2 and urolithiasis in a boy with megacalycosis. Author(s): Nadal D, Schwobel M, von Graevenitz A. Source: Infection. 1988 July-August; 16(4): 245-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3053458&dopt=Abstract
•
Cost analysis of extracorporeal shock wave lithotripsy relative to other surgical and nonsurgical treatment alternatives for urolithiasis. Author(s): Lingeman JE, Saywell RM Jr, Woods JR, Newman DM. Source: Medical Care. 1986 December; 24(12): 1151-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3796081&dopt=Abstract
44 Urolithiasis
•
Crystalluria and urolithiasis in a relatively stone-free population. Author(s): Rodgers AL, De Klerk DP. Source: Scan Electron Microsc. 1986; (Pt 3): 1157-67. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3798018&dopt=Abstract
•
Crystalluria determined by polarization microscopy. Technique and results in healthy control subjects and patients with idiopathic recurrent calcium urolithiasis classified in accordance with calciuria. Author(s): Herrmann U, Schwille PO, Kuch P. Source: Urological Research. 1991; 19(3): 151-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1887522&dopt=Abstract
•
Crystalluria in idiopathic recurrent calcium urolithiasis. Dependence on stone composition. Author(s): Herrmann U, Schwille PO. Source: Urological Research. 1992; 20(2): 157-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1553791&dopt=Abstract
•
CT diagnosis of acute flank pain from urolithiasis. Author(s): Chen MY, Scharling ES, Zagoria RJ, Bechtold RE, Dixon RL, Dyer RB. Source: Semin Ultrasound Ct Mr. 2000 February; 21(1): 2-19. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10688064&dopt=Abstract
•
Current management of urolithiasis in the spinal cord injury patient. Author(s): Culkin DJ, Wheeler JS Jr. Source: J Am Paraplegia Soc. 1987 July-October; 10(2): 23-7. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3330125&dopt=Abstract
•
Current management of urolithiasis: progress or regress? Author(s): Kerbl K, Rehman J, Landman J, Lee D, Sundaram C, Clayman RV. Source: Journal of Endourology / Endourological Society. 2002 June; 16(5): 281-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12184077&dopt=Abstract
•
Current trends in urolithiasis. Author(s): Wilkiemeyer RM. Source: J Med Assoc Ga. 1982 May; 71(5): 325-8. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7086302&dopt=Abstract
Studies 45
•
Cystine urolithiasis in Finland. Author(s): Ala-Opas M. Source: Ann Chir Gynaecol. 1989; 78(2): 136-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2802494&dopt=Abstract
•
Cystinuria and cystine urolithiasis in childhood. Author(s): Pruzanski W. Source: Acta Paediatr Scand. 1966 January; 55(1): 97-106. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5919477&dopt=Abstract
•
Determination of urine saturation with computer program EQUIL 2 as a method for estimation of the risk of urolithiasis. Author(s): Milosevic D, Batinic D, Blau N, Konjevoda P, Stambuk N, Votava-Raic A, Barbaric V, Fumic K, Rumenjak V, Stavljenic-Rukavina A, Nizic L, Vrljicak K. Source: Journal of Chemical Information and Computer Sciences. 1998 July-August; 38(4): 646-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9691474&dopt=Abstract
•
Development of metaphylaxis in calcium urolithiasis: a restriction of conventional drug therapy. Author(s): Kocvara R, Louzensky G, Tuikova J. Source: International Urology and Nephrology. 1994; 26(3): 269-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7960537&dopt=Abstract
•
Diagnosis and management of urolithiasis. Author(s): Fox GN, Troncale JA, Bui TN. Source: The Journal of Family Practice. 1989 August; 29(2): 139-41, 145-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2754402&dopt=Abstract
•
Diagnosis of hyperparathyroidism in patients with urolithiasis using measurement of serum immunoreactive parathyroid hormone and serum calcium. Author(s): Kvarstein B, Gautvik K, Steinsvik E, Mathisen W. Source: Scandinavian Journal of Urology and Nephrology. 1983; 17(1): 105-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6867614&dopt=Abstract
•
Diet and hyperoxaluria in the syndrome of idiopathic calcium oxalate urolithiasis. Author(s): Smith LH. Source: American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 1991 April; 17(4): 370-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2008901&dopt=Abstract
46 Urolithiasis
•
Dietary and behavioral risk factors for urolithiasis: potential implications for prevention. Author(s): Krieger JN, Kronmal RA, Coxon V, Wortley P, Thompson L, Sherrard DJ. Source: American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 1996 August; 28(2): 195-201. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8768913&dopt=Abstract
•
Dietary and biochemical aspects of patients with urolithiasis in and around Coimbatore. Author(s): Bakthavathsalam G, Pai MG, Natarajan S, Balasundaram A. Source: J Indian Med Assoc. 1985 April; 83(4): 105-8. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4078321&dopt=Abstract
•
Dietary management of idiopathic calcium urolithiasis. Author(s): Pak CY, Smith LH, Resnick MI, Weinerth JL. Source: The Journal of Urology. 1984 May; 131(5): 850-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6708211&dopt=Abstract
•
Dietary management of urolithiasis. Author(s): Smith LH. Source: Current Opinion in Nephrology and Hypertension. 1994 March; 3(2): 189-94. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7842268&dopt=Abstract
•
Dietary treatment of idiopathic calcium urolithiasis. Author(s): Hill JM, Harvey PW, Fleming SJ. Source: The Medical Journal of Australia. 1993 September 20; 159(6): 366-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8377683&dopt=Abstract
•
Dihydroxyadenine urolithiasis in children with partial deficiency of adenine phosphoribosyltransferase. Author(s): Sakamoto K, Fujisawa Y, Ohmori A, Minoda K, Yamanaka H, Nishioka K. Source: Urologia Internationalis. 1981; 36(4): 274-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7331059&dopt=Abstract
•
Distribution of blood groups of the ABO system in patients with urolithiasis. Author(s): Rozanski W, Miekos E, Monita W, Pietraszun R. Source: International Urology and Nephrology. 1983; 15(4): 303-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6662648&dopt=Abstract
Studies 47
•
Distribution of patients with 2,8-dihydroxyadenine urolithiasis and adenine phosphoribosyltransferase deficiency in Japan. Author(s): Kamatani N, Sonoda T, Nishioka K. Source: The Journal of Urology. 1988 December; 140(6): 1470-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3193517&dopt=Abstract
•
Does replacing intravenous pyelography with noncontrast helical computed tomography benefit patients with suspected acute urolithiasis? Author(s): Worster A, Haines T. Source: Canadian Association of Radiologists Journal = Journal L'association Canadienne Des Radiologistes. 2002 June; 53(3): 144-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12101535&dopt=Abstract
•
Donor-gifted allograft urolithiasis: early percutaneous management. Author(s): Lu HF, Shekarriz B, Stoller ML. Source: Urology. 2002 January; 59(1): 25-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11796274&dopt=Abstract
•
Drinking water hardness and urolithiasis. Author(s): Churchill D, Bryant D, Fodor G, Gault MH. Source: Annals of Internal Medicine. 1978 April; 88(4): 513-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=637432&dopt=Abstract
•
Drug-seeking behavior in urolithiasis in the noncontrast computed tomography era: 2 cases. Author(s): Gray CL, Kane CJ. Source: Urology. 1999 October; 54(4): 744. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10754147&dopt=Abstract
•
Early cystinuria, a risk factor for metabolic urolithiasis. Author(s): Mogos T, Tanase I, Mogos C, Panus C, Mincu I. Source: Rom J Intern Med. 1994 October-December; 32(4): 299-303. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7613503&dopt=Abstract
•
Economic evaluation of extracorporeal shock wave lithotripsy, percutaneous ultrasonic lithotripsy, and standard surgical treatment of urolithiasis--a Canadian perspective. Author(s): Labelle RJ, Churchill DN, Martin S, Isbister E, Orovan W. Source: Clinical and Investigative Medicine. Medecine Clinique Et Experimentale. 1987 March; 10(2): 86-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3107861&dopt=Abstract
48 Urolithiasis
•
Economic impact of urolithiasis in the United States. Author(s): Clark JY, Thompson IM, Optenberg SA. Source: The Journal of Urology. 1995 December; 154(6): 2020-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7500448&dopt=Abstract
•
Economics of urolithiasis: cost-effectiveness of therapies. Author(s): Chandhoke PS. Source: Current Opinion in Urology. 2001 July; 11(4): 391-3. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11429499&dopt=Abstract
•
Editorial: Acquired hyperoxaluria, urolithiasis, and intestinal disease: a new digestive disorder? Author(s): Smith LH, Hofman AF. Source: Gastroenterology. 1974 June; 66(6): 1257-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4829127&dopt=Abstract
•
Effect of cola consumption on urinary biochemical and physicochemical risk factors associated with calcium oxalate urolithiasis. Author(s): Rodgers A. Source: Urological Research. 1999; 27(1): 77-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10092157&dopt=Abstract
•
Effect of combined therapy in patients with urolithiasis of lower urinary pH. Author(s): Wei XY. Source: Hinyokika Kiyo. 1987 November; 33(11): 1778-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2833086&dopt=Abstract
•
Effect of extracorporeal shockwave lithotripsy for urolithiasis on concentrations of creatine kinase isozymes in patient serum and urine. Author(s): Hasegawa S, Kato K, Takashi M, Zhu Y, Yokoi K, Kobayashi H, Ando T, Obata K, Kondo A, Miyake K. Source: Urologia Internationalis. 1992; 48(4): 420-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1413305&dopt=Abstract
•
Effect of high oral doses of xylitol versus sucrose on urinary risk factors of urolithiasis in man. Author(s): Bar A. Source: Int J Vitam Nutr Res Suppl. 1985; 28: 91-118. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3938808&dopt=Abstract
Studies 49
•
Effect of less invasive treatment modalities on handling urolithiasis in Belgium. Author(s): Verbaeys A. Source: European Urology. 1996; 29(1): 55-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8821691&dopt=Abstract
•
Effect of mineral water containing calcium and magnesium on calcium oxalate urolithiasis risk factors. Author(s): Rodgers AL. Source: Urologia Internationalis. 1997; 58(2): 93-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9096270&dopt=Abstract
•
Effect of oral purine load and allopurinol on the crystallization of calcium salts in urine of patients with hyperuricosuric calcium urolithiasis. Author(s): Pak CY, Barilla DE, Holt K, Brinkley L, Tolentino R, Zerwekh JE. Source: The American Journal of Medicine. 1978 October; 65(4): 593-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=707519&dopt=Abstract
•
Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. Author(s): Soygur T, Akbay A, Kupeli S. Source: Journal of Endourology / Endourological Society. 2002 April; 16(3): 149-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12028622&dopt=Abstract
•
Effect of unprocessed wheat bran on calciuria and oxaluria in patients with urolithiasis. Author(s): Gleeson MJ, Thompson AS, Mehta S, Griffith DP. Source: Urology. 1990 March; 35(3): 231-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2156368&dopt=Abstract
•
Effect of urate on calcium oxalate crystallization in human urine: evidence for a promotory role of hyperuricosuria in urolithiasis. Author(s): Grover PK, Ryall RL, Marshall VR. Source: Clinical Science (London, England : 1979). 1990 July; 79(1): 9-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2167797&dopt=Abstract
•
Effect of urinary intestinal diversion on urinary risk factors for urolithiasis. Author(s): Terai A, Arai Y, Kawakita M, Okada Y, Yoshida O. Source: The Journal of Urology. 1995 January; 153(1): 37-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7966785&dopt=Abstract
50 Urolithiasis
•
Effects of a 'common sense diet' on urinary composition and supersaturation in patients with idiopathic calcium urolithiasis. Author(s): Hess B, Mauron H, Ackermann D, Jaeger P. Source: European Urology. 1999 August; 36(2): 136-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10420035&dopt=Abstract
•
Effects of bacteria involved with the pathogenesis of infection-induced urolithiasis on the urokinase and sialidase (neuraminidase) activity. Author(s): du Toit PJ, van Aswegen CH, Steyn PL, Pols A, du Plessis DJ. Source: Urological Research. 1992; 20(6): 393-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1462476&dopt=Abstract
•
Effects of weight and glucose ingestion on urinary calcium and phosphate excretion: implications for calcium urolithiasis. Author(s): Ulmann A, Aubert J, Bourdeau A, Cheynel C, Bader C. Source: The Journal of Clinical Endocrinology and Metabolism. 1982 May; 54(5): 1063-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7061697&dopt=Abstract
•
Endoscopic management of urolithiasis in the morbidly obese patient. Author(s): Nguyen TA, Belis JA. Source: Journal of Endourology / Endourological Society. 1998 February; 12(1): 33-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9531148&dopt=Abstract
•
Endoscopic treatment of pediatric urolithiasis. Author(s): Kurzrock EA, Huffman JL, Hardy BE, Fugelso P. Source: Journal of Pediatric Surgery. 1996 October; 31(10): 1413-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8906675&dopt=Abstract
•
Enteric hyperoxaluria and urolithiasis. Author(s): Brown JM, Chalmers AH, Cowley DM, McWhinney BC. Source: The New England Journal of Medicine. 1986 October 9; 315(15): 970-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3762602&dopt=Abstract
•
Environmental factors in the development of urolithiasis. Author(s): Ljunghall S. Source: Contrib Nephrol. 1984; 37: 9-12. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6713884&dopt=Abstract
Studies 51
•
Environmental factors in the pathophysiology of recurrent idiopathic calcium urolithiasis (RCU), with emphasis on nutrition. Author(s): Schwille PO, Herrmann U. Source: Urological Research. 1992; 20(1): 72-83. Review. Erratum In: Urol Res 1992; 20(2): 164. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1736491&dopt=Abstract
•
Epidemiologic features of urolithiasis among industrial employees. The Israeli CORDIS Study. Author(s): Kristal-Boneh E, Goffer D, Green MS. Source: J Occup Med. 1994 October; 36(10): 1115-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7830170&dopt=Abstract
•
Epidemiological and clinical significances of urolithiasis in childhood. Author(s): Zvara V, Revusova V, Hornak M, Landsmannova L, Payer J, Badalik L. Source: Urologia Internationalis. 1979; 34(1): 36-45. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=425217&dopt=Abstract
•
Epidemiological profile, mineral metabolic pattern and crystallographic analysis of urolithiasis in Kuwait. Author(s): el-Reshaid K, Mughal H, Kapoor M. Source: European Journal of Epidemiology. 1997 February; 13(2): 229-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9085010&dopt=Abstract
•
Epidemiology and socioeconomic aspects of urolithiasis. Author(s): Asper R. Source: Urological Research. 1984; 12(1): 1-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6372194&dopt=Abstract
•
Epidemiology of urolithiasis in Japan: a chronological and geographical study. Author(s): Yoshida O, Okada Y. Source: Urologia Internationalis. 1990; 45(2): 104-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2330656&dopt=Abstract
•
Epidemiology of urolithiasis in the elderly. Author(s): Kohri K, Ishikawa Y, Katoh Y, Kataoka K, Iguchi M, Yachiku S, Kurita T. Source: International Urology and Nephrology. 1991; 23(5): 413-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1938239&dopt=Abstract
52 Urolithiasis
•
Epidemiology of urolithiasis. Author(s): Trinchieri A. Source: Arch Ital Urol Androl. 1996 September; 68(4): 203-49. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8936716&dopt=Abstract
•
Epidemiology, Pathogenesis and diagnosis of calcium oxalate urolithiasis. Author(s): Vahlensieck EW, Bach D, Hesse A, Strenge A. Source: International Urology and Nephrology. 1982; 14(4): 333-47. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7182367&dopt=Abstract
•
EQUIL93: a tool for experimental and clinical urolithiasis. Author(s): Brown CM, Ackermann DK, Purich DL. Source: Urological Research. 1994; 22(2): 119-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7974915&dopt=Abstract
•
Erythrocyte membrane protein phosphorylation in urolithiasis. Author(s): Baggio B, Clari G, Marzaro G, Gambaro G, Borsatti A, Moret V. Source: Contrib Nephrol. 1987; 58: 156-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2961512&dopt=Abstract
•
Estrogen replacement increased the citrate and calcium excretion rates in postmenopausal women with recurrent urolithiasis. Author(s): Dey J, Creighton A, Lindberg JS, Fuselier HA, Kok DJ, Cole FE, Hamm LL. Source: The Journal of Urology. 2002 January; 167(1): 169-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11743298&dopt=Abstract
•
Etiologic factors involved in urolithiasis: a review of recent research. Author(s): King JS Jr. Source: The Journal of Urology. 1967 April; 97(4): 583-91. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5337221&dopt=Abstract
•
Etiological and clinical patterns of urolithiasis in Turkish children. Author(s): Oner A, Demircin G, Ipekcioglu H, Bulbul M, Ecin N. Source: European Urology. 1997; 31(4): 453-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9187907&dopt=Abstract
•
Etiology and treatment of urolithiasis. Author(s): Pak CY. Source: American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 1991 December; 18(6): 624-37. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1962646&dopt=Abstract
Studies 53
•
Evaluation of calcium urolithiasis in ambulatory patients: comparison of results with those of inpatient evaluation. Author(s): Pak CY, Fetner C, Townsend J, Brinkley L, Northcutt C, Barilla DE, Kadesky M, Peters P. Source: The American Journal of Medicine. 1978 June; 64(6): 979-87. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=207183&dopt=Abstract
•
Evaluation of the risk of stone formation: study on crystalluria in patients with recurrent calcium oxalate urolithiasis. Author(s): Robert M, Boularan AM, Delbos O, Monnier L, Grasset D. Source: European Urology. 1996; 29(4): 456-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8791054&dopt=Abstract
•
Evidence for a reduced urinary magnesium/creatinine ratio in patients with calcium urolithiasis. Author(s): Vagelli G, Mazzotta A, Ferraris V, Pratesi G, Calabrese G, Gonella M. Source: Contrib Nephrol. 1987; 58: 111-4. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3691113&dopt=Abstract
•
Examination of intrarenal blood flow by Doppler ultrasound before and after extracorporeal shock wave lithotripsy for urolithiasis. Author(s): Johansson M, Sorensen V, Jonsson O, Pettersson S, Volkmann R. Source: Scandinavian Journal of Urology and Nephrology. 1997 February; 31(1): 27-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9060079&dopt=Abstract
•
Exclusion mapping of major crystallization inhibitors in idiopathic calcium urolithiasis. Author(s): Cailhier JF, Petrucci M, Valiquette L, Guay G, Ouimet D, Bonnardeaux A. Source: The Journal of Urology. 2001 October; 166(4): 1484-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11547117&dopt=Abstract
•
Excretion of urinary calcium and oxalate on three diets in patients with urolithiasis. Author(s): Juuti M, Alhava EM. Source: Ann Clin Res. 1980 December; 12(6): 320-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7235608&dopt=Abstract
•
Excretion of urinary phosphate and magnesium on three diets in patients with urolithiasis. Author(s): Juuti M, Alhava EM, Lammi S. Source: Ann Clin Res. 1981 February; 13(1): 1-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7247320&dopt=Abstract
54 Urolithiasis
•
Experience with childhood urolithiasis. Report of 196 cases. Author(s): Basaklar AC, Kale N. Source: British Journal of Urology. 1991 February; 67(2): 203-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2004237&dopt=Abstract
•
Extracorporeal lithotripsy for urolithiasis in myelomeningocoele. Author(s): Corbally M, Ryan J, FitzPatrick J, Fitzgerald RJ. Source: Z Kinderchir. 1990 December; 45 Suppl 1: 37. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2293537&dopt=Abstract
•
Extracorporeal shock wave lithotripsy for urolithiasis. Experience with 3000 patients. Author(s): Bhatia V, Biyani CS. Source: Int Surg. 1994 January-March; 79(1): 80-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8063562&dopt=Abstract
•
Extracorporeal shock-wave lithotripsy (ESWL) for treatment of urolithiasis. Author(s): Chaussy C, Schuller J, Schmiedt E, Brandl H, Jocham D, Liedl B. Source: Urology. 1984 May; 23(5 Spec No): 59-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6719681&dopt=Abstract
•
Extracorporeal shockwave therapy for urolithiasis with renal insufficiency. Author(s): Bhatia V, Biyani CS, al-Awadi K. Source: Urologia Internationalis. 1995; 55(1): 11-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7571175&dopt=Abstract
•
Factitious uric acid urolithiasis as a feature of the Munchausen syndrome. Author(s): Sharon E, Diamond HS. Source: The Mount Sinai Journal of Medicine, New York. 1974 September-October; 41(5): 696-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4547206&dopt=Abstract
•
Failure of dissolution of xanthine urolithiasis by local lavage. Author(s): Frayha RA, Salti IS. Source: British Journal of Urology. 1980 August; 52(4): 322. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7426998&dopt=Abstract
•
Fasting and post-calcium load serum calcium, parathyroid hormone, calcitonin, in male idiopathic calcium urolithiasis--evidence for a basic disturbance in calcium metabolism. Author(s): Schwille PO, Rumenapf G, Schmidtler J, Kohler R. Source: Exp Clin Endocrinol. 1987 August; 90(1): 71-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3666061&dopt=Abstract
Studies 55
•
Felbamate urolithiasis. Author(s): Sparagana SP, Strand WR, Adams RC. Source: Epilepsia. 2001 May; 42(5): 682-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11380578&dopt=Abstract
•
Fibrinolysis and urolithiasis. Author(s): Charlton CA. Source: Lancet. 1967 June 3; 1(7501): 1199-200. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4165137&dopt=Abstract
•
Fibroepithelial ureteral polyps and urolithiasis. Author(s): Bolton D, Stoller ML, Irby P 3rd. Source: Urology. 1994 October; 44(4): 582-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7941202&dopt=Abstract
•
Fibronectin as a potent inhibitor of calcium oxalate urolithiasis. Author(s): Tsujihata M, Miyake O, Yoshimura K, Kakimoto KI, Takahara S, Okuyama A. Source: The Journal of Urology. 2000 November; 164(5): 1718-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11025758&dopt=Abstract
•
Fracture risk among patients with urolithiasis: a population-based cohort study. Author(s): Melton LJ 3rd, Crowson CS, Khosla S, Wilson DM, O'Fallon WM. Source: Kidney International. 1998 February; 53(2): 459-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9461107&dopt=Abstract
•
Frequency of blood groups of the ABC and Rho(D) system in patients with viral hepatitis, cirrhosis of the liver, bile stones, pancreatitis, urolithiasis and ulcerative colitis. Author(s): Vesely KT. Source: Rev Czech Med. 1970; 16(2): 60-71. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4987703&dopt=Abstract
•
Frequency of urolithiasis in a prepaid medical care program. Author(s): Hiatt RA, Dales LG, Friedman GD, Hunkeler EM. Source: American Journal of Epidemiology. 1982 February; 115(2): 255-65. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7058784&dopt=Abstract
56 Urolithiasis
•
Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. Author(s): Reiter WJ, Schon-Pernerstorfer H, Dorfinger K, Hofbauer J, Marberger M. Source: The Journal of Urology. 1999 April; 161(4): 1082-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10081842&dopt=Abstract
•
Further evidence linking urolithiasis and blood coagulation: urinary prothrombin fragment 1 is present in stone matrix. Author(s): Stapleton AM, Dawson CJ, Grover PK, Hohmann A, Comacchio R, Boswarva V, Tang Y, Ryall RL. Source: Kidney International. 1996 March; 49(3): 880-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8648933&dopt=Abstract
•
Further research on glycine content in urine in cases of oxalic urolithiasis (considering urolithiasis in seamen). Author(s): Renke W, Kasztelan Z, Winnicka A. Source: Biul Inst Med Morsk Gdansk. 1973; 24(1): 73-8. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4518553&dopt=Abstract
•
Genetic disorders and urolithiasis. Author(s): Danpure CJ. Source: The Urologic Clinics of North America. 2000 May; 27(2): 287-99, Viii. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10778471&dopt=Abstract
•
Geriatric urolithiasis. Author(s): Gentle DL, Stoller ML, Bruce JE, Leslie SW. Source: The Journal of Urology. 1997 December; 158(6): 2221-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9366348&dopt=Abstract
•
Getting ready for advanced practice certification: urolithiasis, Part II. Author(s): Greene C. Source: Urologic Nursing : Official Journal of the American Urological Association Allied. 1998 December; 18(4): 315-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9873359&dopt=Abstract
•
Getting ready for advanced practice certification: urolithiasis. Author(s): Becker J. Source: Urologic Nursing : Official Journal of the American Urological Association Allied. 1998 March; 18(1): 53-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9582896&dopt=Abstract
Studies 57
•
Getting ready for certification: urolithiasis. Author(s): Wilkinson G. Source: Urologic Nursing : Official Journal of the American Urological Association Allied. 2002 October; 22(5): 346, 345. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12432721&dopt=Abstract
•
Getting ready for certification: urolithiasis. Author(s): Wilkinson G. Source: Urologic Nursing : Official Journal of the American Urological Association Allied. 2002 June; 22(3): 196, 194. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12087795&dopt=Abstract
•
Glycosaminoglycans and oxalocalcic urolithiasis. Author(s): Grases F, Llompart I, Conte A, Coll R, March JG. Source: Nephron. 1994; 68(4): 449-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7870230&dopt=Abstract
•
Glycosaminoglycans and semisynthetic sulfated polysaccharides: an overview of their potential application in treatment of patients with urolithiasis. Author(s): Cao LC, Boeve ER, de Bruijn WC, Kok DJ, de Water R, Deng G, Schroder FH. Source: Urology. 1997 August; 50(2): 173-83. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9255284&dopt=Abstract
•
Glycosaminoglycans in urolithiasis. Author(s): Nesse A, Garbossa G, Romero MC, Bogado CE, Zanchetta JR. Source: Nephron. 1992; 62(1): 36-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1436289&dopt=Abstract
•
Glycosaminoglycans, uric acid and calcium oxalate urolithiasis. Author(s): Grases F, Costa-Bauza A, March JG, Masarova L. Source: Urological Research. 1991; 19(6): 375-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1759332&dopt=Abstract
•
Guidelines on urolithiasis. Author(s): Tiselius HG, Ackermann D, Alken P, Buck C, Conort P, Gallucci M; Working Party on Lithiasis, European Association of Urology. Source: European Urology. 2001 October; 40(4): 362-71. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11713390&dopt=Abstract
58 Urolithiasis
•
Haematuria and urolithiasis in patients with haemophilia. Author(s): Ghosh K, Jijina F, Mohanty D. Source: European Journal of Haematology. 2003 June; 70(6): 410-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12756025&dopt=Abstract
•
Hematuria due to urolithiasis in a child with chronic immune thrombocytopenic purpura. Author(s): Ramdas J, Warrier S, Warrier R. Source: Pediatric Emergency Care. 2002 December; 18(6): 436-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12488838&dopt=Abstract
•
Hereditary hypercalciuric urolithiasis. A study of a family. Author(s): Weinberger A, Schechter J, Pinkhas J, Sperling O. Source: British Journal of Urology. 1981 August; 53(4): 285-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7260536&dopt=Abstract
•
Hereditary renal hypouricemia with hyperuricosuria and variably absorptive hypercalciuria and urolithiasis--a new syndrome. Author(s): Sperling O, de Vries A. Source: Advances in Experimental Medicine and Biology. 1980; 122A: 149-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7424628&dopt=Abstract
•
Hereditary xanthinuria and xanthine urolithiasis: an additional 3 cases. Author(s): Frayha RA, Salti IS, Abu Haidar GI, al-Khalidi U, Hemady K. Source: The Journal of Urology. 1973 May; 109(5): 871-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4699688&dopt=Abstract
•
Hereditary xanthinuria with severe urolithiasis occurring in infancy as renal tubular acidosis and hypercalciuria. Author(s): Fildes RD. Source: The Journal of Pediatrics. 1989 August; 115(2): 277-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2754557&dopt=Abstract
•
Heterozygous cystinuria and calcium oxalate urolithiasis. Author(s): Carpentier PJ, Kurth KH, Blom W, Huijmans JG. Source: The Journal of Urology. 1983 August; 130(2): 302-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6876277&dopt=Abstract
•
Heterozygous cystinuria and calcium oxalate urolithiasis. Author(s): Resnick MI, Goodman HO, Boyce WH. Source: The Journal of Urology. 1979 July; 122(1): 52-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=458988&dopt=Abstract
Studies 59
•
High urinary excretion level of citrate and magnesium in children: potential etiology for the reduced incidence of pediatric urolithiasis. Author(s): Miyake O, Yoshimura K, Yoshioka T, Koide T, Okuyama A. Source: Urological Research. 1998; 26(3): 209-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9694604&dopt=Abstract
•
HLA and urolithiasis. Author(s): Bear JC, Churchill DN, Morgan J, Marshall WH, Gault MH. Source: Tissue Antigens. 1984 March; 23(3): 181-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6729807&dopt=Abstract
•
Holmium:YAG laser and its use in the treatment of urolithiasis: our first 160 cases. Author(s): Gould DL. Source: Journal of Endourology / Endourological Society. 1998 February; 12(1): 23-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9531146&dopt=Abstract
•
Horseshoe kidney and urolithiasis. Author(s): Evans WP, Resnick MI. Source: The Journal of Urology. 1981 May; 125(5): 620-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7230330&dopt=Abstract
•
Hydration feature of urinary compounds. Evidence for molecular abnormality in calcium oxalate urolithiasis. Author(s): Azoury R, Ramon J, Abrashkin S, Shalev J, Goldwasser B. Source: Urological Research. 1990; 18(1): 7-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2316076&dopt=Abstract
•
Hydroxyapatite--the forgotten crystal in calcium urolithiasis. Author(s): Smith LH, Werness PG. Source: Trans Am Clin Climatol Assoc. 1983; 95: 183-90. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6679136&dopt=Abstract
•
Hypercalciuria and urolithiasis in a case of Costello syndrome. Author(s): Assadi FK, Scott CI Jr, McKay CP, Nicholson L, Cafone M, Hopp L, Fattori DA. Source: Pediatric Nephrology (Berlin, Germany). 1999 January; 13(1): 57-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10100291&dopt=Abstract
60 Urolithiasis
•
Hypercalciuria during administration of calcium aminosalicylate as a causitive factor in urolithiasis. Author(s): Schone D, Hauschild G, Wasser S. Source: Ger Med Mon. 1969 November; 14(11): 557-8 Passim. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5369518&dopt=Abstract
•
Hypercalciuria in children with urolithiasis. Author(s): Stapleton FB, Noe HN, Roy S 3rd, Jerkins G. Source: Am J Dis Child. 1982 August; 136(8): 675-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7102617&dopt=Abstract
•
Hyperoxaluria and urolithiasis in young children: an atypical presentation. Author(s): Monico CG, Milliner DS. Source: Journal of Endourology / Endourological Society. 1999 November; 13(9): 633-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10608514&dopt=Abstract
•
Hyperparathyroidism and obstructive urolithiasis. Combined surgical approach. Author(s): Giuliani L, Belgrano E, Puppo P, Repetto U, Pittaluga P. Source: Acta Urol Belg. 1983; 51(4): 489-95. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6650297&dopt=Abstract
•
Hyperparathyroidism with hypercalciuria and urolithiasis: long-term effects of parathyroid surgery and postoperative thiazide therapy. Author(s): Elomaa I, Sivula A, Kahri A, Puutula-Rasanen L, Pelkonen R. Source: World Journal of Surgery. 1983 March; 7(2): 186-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6868632&dopt=Abstract
•
Hypocitraturia in patients with urolithiasis. Author(s): Hoppe B, Langman CB. Source: Archives of Disease in Childhood. 1997 February; 76(2): 174-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9068316&dopt=Abstract
•
Hypocitraturia in patients with urolithiasis. Author(s): Akcay T, Konukoglu D, Celik C. Source: Archives of Disease in Childhood. 1996 April; 74(4): 350-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8669940&dopt=Abstract
•
Iatrogenic injuries of renal pelvis and ureter following open surgery for urolithiasis. Author(s): Naeem M, Anwar K. Source: J Pak Med Assoc. 2001 August; 51(8): 282-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11715890&dopt=Abstract
Studies 61
•
Identification of a 7-basepair deletion in the adenine phosphoribosyltransferase gene as a cause of 2,8-dihydroxyadenine urolithiasis. Author(s): Bye S, Mallmann R, Duley J, Simmonds HA, Chen J, Tischfield JA, Sahota A. Source: Clin Investig. 1994 July; 72(7): 550-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7981585&dopt=Abstract
•
Identification of a compound heterozygote for adenine phosphoribosyltransferase deficiency (APRT*J/APART*Q0) leading to 2,8-dihydroxyadenine urolithiasis. Author(s): Kamatani N, Kuroshima S, Yamanaka H, Nakashe S, Take H, Hakoda M. Source: Human Genetics. 1990 October; 85(5): 500-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2227934&dopt=Abstract
•
Identifying patients who are suitable for stentless ureteroscopy following treatment of urolithiasis. Author(s): Hollenbeck BK, Schuster TG, Seifman BD, Faerber GJ, Wolf JS Jr. Source: The Journal of Urology. 2003 July; 170(1): 103-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12796656&dopt=Abstract
•
Idiopathic calcium oxalate urolithiasis and endogenous oxalate production. Author(s): Baker PW, Rofe AM, Bais R. Source: Critical Reviews in Clinical Laboratory Sciences. 1996 January; 33(1): 39-82. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8833627&dopt=Abstract
•
Idiopathic calcium oxalate urolithiasis. Author(s): Smith LH. Source: Endocrinology and Metabolism Clinics of North America. 1990 December; 19(4): 937-47. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2081520&dopt=Abstract
•
Idiopathic calcium urolithiasis: genetic aspects. Author(s): Caudarella R, Malavolta N, Rizzoli E, Stefani F, D'Antuono G. Source: Annales De Medecine Interne. 1986; 137(3): 200-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3767183&dopt=Abstract
•
Idiopathic hypercalciuria of childhood: response to oral calcium loading in children with and without urolithiasis. Author(s): Hymes LC. Source: The Journal of Urology. 1985 March; 133(3): 436-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3973992&dopt=Abstract
62 Urolithiasis
•
Idiopathic hypercalciuria: association with isolated hematuria and risk for urolithiasis in children. The Southwest Pediatric Nephrology Study Group. Author(s): Stapleton FB. Source: Kidney International. 1990 February; 37(2): 807-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2407891&dopt=Abstract
•
Images in clinical radiology. Obstructive distal urolithiasis managed by endorectal ultrasound: real or fortuitous? Author(s): Coulier B, Navez JF. Source: Jbr-Btr. 2001 August; 84(4): 166. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11688731&dopt=Abstract
•
Immediate in situ ESWL as monotherapy in acute obstructive urolithiasis: useful or not? Author(s): Baert L, Willemen P. Source: J Lithotr Stone Dis. 1990 January; 2(1): 46-8; Discussion 49. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10148927&dopt=Abstract
•
Immunochemical studies of serum, urine and calculus proteins in urolithiasis. Author(s): Ibrahim AM, Shaker YM, el-Hawary MF, Fayek KI, Zahran MM, el-Shawarby NK. Source: Clin Physiol Biochem. 1985; 3(1): 16-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3995870&dopt=Abstract
•
Immunohistochemical detection of renal carbonic anhydrase of patients with recurrent urolithiasis. Author(s): Jonas L, Klein B, Hoffmann L, Kumpulainen T. Source: Clinical Nephrology. 1991 May; 35(5): 190-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1906789&dopt=Abstract
•
Impact of urometabolic evaluation on prevention of urolithiasis: a retrospective study. Author(s): van Drongelen J, Kiemeney LA, Debruyne FM, de la Rosette JJ. Source: Urology. 1998 September; 52(3): 384-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9730448&dopt=Abstract
•
Importance of metabolic contributions to urolithiasis in pediatric patients. Author(s): Lieberman E. Source: Mayo Clinic Proceedings. 1993 March; 68(3): 313-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8474276&dopt=Abstract
Studies 63
•
Importance of mild hyperoxaluria in the pathogenesis of urolithiasis--new evidence from studies in the Arabian peninsula. Author(s): Robertson WG, Hughes H. Source: Scanning Microsc. 1993 March; 7(1): 391-401; Discussion 401-2. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8316808&dopt=Abstract
•
Improved renal function following aggressive treatment of urolithiasis and concurrent mild to moderate renal insufficiency. Author(s): Gupta M, Bolton DM, Gupta PN, Stoller ML. Source: The Journal of Urology. 1994 October; 152(4): 1086-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8072069&dopt=Abstract
•
Improvement in serum creatinine following definite treatment of urolithiasis in patients with concurrent renal insufficiency. Author(s): Paryani JP, Ather MH. Source: Scandinavian Journal of Urology and Nephrology. 2002; 36(2): 134-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12028687&dopt=Abstract
•
Incidence and clinical features of renal tubular acidosis-1 in urolithiasis. Author(s): Ito H, Kotake T, Suzuki F. Source: Urologia Internationalis. 1993; 50(2): 82-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8460453&dopt=Abstract
•
Incidence of pouch stones and risk factors for urolithiasis in patients with continent urinary diversion or neobladder using intestine. Author(s): Takeda M, Katayama Y, Takahashi H, Go H, Tsutsui T, Tanikawa T, Nishiyama T, Komeyama T, Sato S. Source: Urologia Internationalis. 1994; 52(1): 21-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8140675&dopt=Abstract
•
Incidence of urolithiasis and composition of household water in southern Finland. Author(s): Juuti M, Heinonen OP. Source: Scandinavian Journal of Urology and Nephrology. 1980; 14(2): 181-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7209423&dopt=Abstract
•
Incidence of urolithiasis in cystectomy patients after intestinal conduit or continent urinary diversion. Author(s): Turk TM, Koleski FC, Albala DM. Source: World Journal of Urology. 1999 October; 17(5): 305-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10552149&dopt=Abstract
64 Urolithiasis
•
Incidence of urolithiasis in northeast Thailand. Author(s): Yanagawa M, Kawamura J, Onishi T, Soga N, Kameda K, Sriboonlue P, Prasongwattana V, Borwornpadungkitti S. Source: International Journal of Urology : Official Journal of the Japanese Urological Association. 1997 November; 4(6): 537-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9477179&dopt=Abstract
•
Incidence of urolithiasis leading to hospitalization in Finland. Author(s): Juuti M, Heinonen OP. Source: Acta Med Scand. 1979; 206(5): 397-403. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=525441&dopt=Abstract
•
Incidence, etiology, diagnosis, and treatment of recurrent urolithiasis: results of a 5year study at an osteopathic referral center. Author(s): Cianciolo KD, Wadle RW, Lanesky JR, Roth SJ, Slick GL. Source: J Am Osteopath Assoc. 1983 April; 82(8): 577-83. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6853241&dopt=Abstract
•
Incidence, Prevalence and mortality of urolithiasis in the German Federal Republic. Author(s): Vahlensieck EW, Bach D, Hesse A. Source: Urological Research. 1982; 10(4): 161-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7179607&dopt=Abstract
•
Increased urolithiasis in patients with alkaptonuria in childhood. Author(s): Zibolen M, Srsnova K, Srsen S. Source: Clinical Genetics. 2000 July; 58(1): 79-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10945668&dopt=Abstract
•
Indices of lithogenic activity in patients with primitive calcium oxalate urolithiasis. Author(s): Cupisti A, Ciardella F, Morelli E, Lupetti S, Luchi S, Niosi F, Fosso A, Carlini A, Meola M, Barsotti G. Source: Contrib Nephrol. 1987; 58: 82-4. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3691153&dopt=Abstract
•
Indinavir crystallization and urolithiasis. Author(s): Grases F, Costa-Bauza A, Garcia-Gonzalez R, Payeras A, Bassa A, Torres JJ, Conte A. Source: International Urology and Nephrology. 1999; 31(1): 23-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10408298&dopt=Abstract
Studies 65
•
Indinavir urolithiasis. Author(s): Wu DS, Stoller ML. Source: Current Opinion in Urology. 2000 November; 10(6): 557-61. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11148725&dopt=Abstract
•
Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus. Author(s): Kohan AD, Armenakas NA, Fracchia JA. Source: The Journal of Urology. 1999 June; 161(6): 1765-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10332431&dopt=Abstract
•
Infection-induced struvite urolithiasis in rats. Author(s): Olson ME, Nickel JC, Costerton JW. Source: American Journal of Pathology. 1989 September; 135(3): 581-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2782383&dopt=Abstract
•
Influence of pyrophosphate on the crystallisation of uric acid and magnesium ammonium phosphate and its implications in phosphate therapy for urolithiasis. Author(s): Fleisch H, Bisaz S, Russell RG. Source: Urologia Internationalis. 1967; 22(6): 483-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4298307&dopt=Abstract
•
Influence of sex and age in the risk of urolithiasis--a biochemical evaluation in Indian subjects. Author(s): Sarada B, Satyanarayana U. Source: Annals of Clinical Biochemistry. 1991 July; 28 ( Pt 4): 365-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1892347&dopt=Abstract
•
Inhibition of calculi fragment growth by metal-bisphosphonate complexes demonstrated with a new assay measuring the surface activity of urolithiasis inhibitors. Author(s): Wolf JS Jr, Stoller ML. Source: The Journal of Urology. 1994 November; 152(5 Pt 1): 1609-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7933215&dopt=Abstract
•
Inhibition of urease by miscellaneous ions and compounds. Implications for the therapy of infection-induced urolithiasis. Author(s): Burr RG. Source: Invest Urol. 1977 September; 15(2): 180-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=903216&dopt=Abstract
66 Urolithiasis
•
Inhibitors of calcium oxalate crystallization and urolithiasis. Author(s): Grases F, Conte A, Genestar C, Costa-Bauza A. Source: Urologia Internationalis. 1992; 48(4): 409-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1413303&dopt=Abstract
•
Inhibitory effect of pyrophosphate, citrate, magnesium and chondroitin sulphate in calcium oxalate urolithiasis. Author(s): Grases F, Genestar C, Conte A, March P, Costa-Bauza A. Source: British Journal of Urology. 1989 September; 64(3): 235-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2553195&dopt=Abstract
•
Initial experience with endoscopic holmium laser lithotripsy for pediatric urolithiasis. Author(s): Reddy PP, Barrieras DJ, Bagli DJ, McLorie GA, Khoury AE, Merguerian PA. Source: The Journal of Urology. 1999 November; 162(5): 1714-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10524920&dopt=Abstract
•
Investigation of the possible role of sialic acid in calcium oxalate urolithiasis. Author(s): Yoshimura K, Yoshioka T, Miyake O, Honda M, Koide T, Okuyama A. Source: European Urology. 1998; 33(1): 111-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9471052&dopt=Abstract
•
Is hypocitraturia associated with phosphaturia--a potential cause of calcium urolithiasis in first-time stone formers. Author(s): Khand FD, Ansari AF, Khand TU, Memon JM. Source: J Pak Med Assoc. 1994 August; 44(8): 179-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7996662&dopt=Abstract
•
Is increased intestinal calcium absorption in human calcium urolithiasis a feature of a hormonal imbalance? Author(s): Schwille PO, Scholz D, Engelhardt W. Source: Hepatogastroenterology. 1981 June; 28(3): 131-4. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6114029&dopt=Abstract
•
Is there a learning curve in diagnosing urolithiasis with noncontrast helical computed tomography? Author(s): Rosser CJ, Zagoria R, Dixon R, Scurry WC, Bare RL, McCullough DL, Assimos DG. Source: Canadian Association of Radiologists Journal = Journal L'association Canadienne Des Radiologistes. 2000 June; 51(3): 177-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10914083&dopt=Abstract
Studies 67
•
Is there a role for uric acid in an animal model of calcium phosphate nephrocalcinosis and calcium phosphate crystallization in urine of patients with idiopathic calcium urolithiasis? An orientational study. Author(s): Schwille PO, Schmiedl A, Manoharan M, Wipplinger J. Source: Journal of Endourology / Endourological Society. 1999 November; 13(9): 637-45. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10608515&dopt=Abstract
•
IVP or CT for suspected urolithiasis. Author(s): Butler G, Somers S, Stolberg H, Thomson JG. Source: Canadian Association of Radiologists Journal = Journal L'association Canadienne Des Radiologistes. 2002 October; 53(4): 241. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12391931&dopt=Abstract
•
IVP or CT for suspected urolithiasis: reply. Author(s): Worster A, Haines T. Source: Canadian Association of Radiologists Journal = Journal L'association Canadienne Des Radiologistes. 2002 December; 53(5): 307-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12500385&dopt=Abstract
•
Laparoscopic management of urolithiasis in a continent urostomy. Author(s): Coleman RL, Mahoney NM, Hatch KD. Source: Gynecologic Oncology. 2002 March; 84(3): 473-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11855892&dopt=Abstract
•
Laparoscopic surgery for renal urolithiasis: pyelolithotomy, caliceal diverticulectomy, and treatment of stones in a pelvic kidney. Author(s): Ramakumar S, Segura JW. Source: Journal of Endourology / Endourological Society. 2000 December; 14(10): 82932. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11206616&dopt=Abstract
•
Letter: Urolithiasis in inflammatory bowel disease. Author(s): Maratka Z. Source: Gastroenterology. 1975 October; 69(4): 1041-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1175880&dopt=Abstract
•
Long-term functional outcome of kidneys in children with urolithiasis after ESWL treatment. Author(s): Vlajkovic M, Slavkovic A, Radovanovic M, Siric Z, Stefanovic V, Perovic S. Source: European Journal of Pediatric Surgery : Official Journal of Austrian Association of Pediatric Surgery. [et Al] = Zeitschrift Fur Kinderchirurgie. 2002 April; 12(2): 118-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12015657&dopt=Abstract
68 Urolithiasis
•
Long-term urinary acidification in phosphatic urolithiasis. Author(s): Pizzarelli F, Peacock M. Source: Contrib Nephrol. 1987; 58: 187-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3691124&dopt=Abstract
•
Low calcium diet in idiopathic urolithiasis: a risk factor for osteopenia as great as in primary hyperparathyroidism. Author(s): Fuss M, Pepersack T, Bergman P, Hurard T, Simon J, Corvilain J. Source: British Journal of Urology. 1990 June; 65(6): 560-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2372668&dopt=Abstract
•
Lower tract urolithiasis after prostatectomy. Author(s): Haddad FS. Source: The Journal of Urology. 1986 July; 136(1): 123-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3712598&dopt=Abstract
•
Magnesium deficiency in children with urolithiasis. Author(s): Revusova V, Gratzlova J, Zvara V, Kridl J. Source: International Urology and Nephrology. 1976; 8(3): 197-202. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1002396&dopt=Abstract
•
Magnesium excretion and calcium oxalate urolithiasis. Author(s): Resnick MI, Munday D, Boyce WH. Source: Urology. 1982 October; 20(4): 385-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7147507&dopt=Abstract
•
Magnesium excretion in recurrent calcium urolithiasis. Evaluation of 46 hypercalciuric patients. Author(s): Piana P, Casetta G, Giona C, Petrillo M, Tizzani A. Source: Contrib Nephrol. 1987; 58: 115-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3691114&dopt=Abstract
•
Magnesium status in idiopathic calcium urolithiasis--an orientational study in younger males. Author(s): Schmiedl A, Schwille PO. Source: Eur J Clin Chem Clin Biochem. 1996 May; 34(5): 393-400. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8790974&dopt=Abstract
Studies 69
•
Magnesium, citrate, magnesium citrate and magnesium-alkali citrate as modulators of calcium oxalate crystallization in urine: observations in patients with recurrent idiopathic calcium urolithiasis. Author(s): Schwille PO, Schmiedl A, Herrmann U, Fan J, Gottlieb D, Manoharan M, Wipplinger J. Source: Urological Research. 1999 April; 27(2): 117-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10424393&dopt=Abstract
•
Management and complications of urolithiasis during pregnancy. Author(s): Haller H, Mozetic V, Topljak-Polic D, Randic L, Fuckar Z. Source: International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 1993 February; 40(2): 135-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8094683&dopt=Abstract
•
Management of pediatric urolithiasis in Pakistan: experience with 1,440 children. Author(s): Rizvi SA, Naqvi SA, Hussain Z, Hashmi A, Hussain M, Zafar MN, Sultan S, Mehdi H. Source: The Journal of Urology. 2003 February; 169(2): 634-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12544331&dopt=Abstract
•
Management of urolithiasis during pregnancy, delivery and puerperium. Author(s): Szczerbo A, Bartoszewski A, Zwierzynski T, Zbroja-Sontag W. Source: Pol Med J. 1972; 11(1): 220-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5041001&dopt=Abstract
•
Management of urolithiasis during pregnancy. Author(s): Rodriguez PN, Klein AS. Source: Surg Gynecol Obstet. 1988 February; 166(2): 103-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3336823&dopt=Abstract
•
Management of urolithiasis: an analysis of 1,293 lithotriptor procedures. Author(s): Jantzen JP, Erdmann K, Wilbert DM, Hein HA, Klein AM. Source: Tex Med. 1986 December; 82(12): 37-43. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3810500&dopt=Abstract
•
Measurement of ascorbic acid in human plasma and urine by high-performance liquid chromatography. Results in healthy subjects and patients with idiopathic calcium urolithiasis. Author(s): Manoharan M, Schwille PO. Source: Journal of Chromatography. B, Biomedical Applications. 1994 March 18; 654(1): 134-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8004235&dopt=Abstract
70 Urolithiasis
•
Mechanism for calcium urolithiasis among patients with hyperuricosuria: supersaturation of urine with respect to monosodium urate. Author(s): Pak CY, Waters O, Arnold L, Holt K, Cox C, Barilla D. Source: The Journal of Clinical Investigation. 1977 March; 59(3): 426-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14173&dopt=Abstract
•
Medical management of urolithiasis. Author(s): Bissada NK, Redman JF. Source: American Family Physician. 1976 May; 13(5): 89-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1274811&dopt=Abstract
•
Medical therapy and new approaches to management of urolithiasis. Author(s): Pak CY, Resnick MI. Source: The Urologic Clinics of North America. 2000 May; 27(2): 243-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10778467&dopt=Abstract
•
Medical therapy, calcium oxalate urolithiasis. Author(s): Ruml LA, Pearle MS, Pak CY. Source: The Urologic Clinics of North America. 1997 February; 24(1): 117-33. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9048856&dopt=Abstract
•
Medical treatment of urolithiasis. Author(s): Wilson DM. Source: Geriatrics. 1979 August; 34(8): 65-9, 72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=447088&dopt=Abstract
•
Medical treatment to prevent recurrent calcium urolithiasis. A guide to critical appraisal. Author(s): Churchill DN. Source: Mineral and Electrolyte Metabolism. 1987; 13(4): 294-304. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3627054&dopt=Abstract
•
Medullary sponge kidney and urolithiasis. Author(s): Sage MR, Lawson AD, Marshall VR, Ryall RL. Source: Clinical Radiology. 1982 July; 33(4): 435-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7083742&dopt=Abstract
•
Metabolic and clinical disturbances in patients with calcium urolithiasis. Author(s): Smith LH, Werness PG, Wilson DM. Source: Scand J Urol Nephrol Suppl. 1980; 53: 213-20. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6937998&dopt=Abstract
Studies 71
•
Metabolic changes in various types of recurrent urolithiasis. Author(s): Hrebicek J. Source: Acta Univ Palacki Olomuc Fac Med. 1992; 133: 25-30. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1344593&dopt=Abstract
•
Metabolic disorders in patients with calcium urolithiasis. Author(s): Butz M. Source: International Urology and Nephrology. 1986; 18(2): 131-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3721772&dopt=Abstract
•
Metabolic effects of thiazide versus placebo in patients under long-term treatment for recurrent urolithiasis. Author(s): Laerum E. Source: Scandinavian Journal of Urology and Nephrology. 1984; 18(2): 143-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6463598&dopt=Abstract
•
Metabolic evaluation of children with urolithiasis: are adult references for supersaturation appropriate? Author(s): Battino BS, DeFOOR W, Coe F, Tackett L, Erhard M, Wacksman J, Sheldon CA, Minevich E. Source: The Journal of Urology. 2002 December; 168(6): 2568-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12441985&dopt=Abstract
•
Metabolic evaluation of urolithiasis. Author(s): Hwang TI, Yang CR, Chang CL, Chang CH, Wu HC. Source: J Formos Med Assoc. 1990 July; 89(7): 577-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1979600&dopt=Abstract
•
Metabolic evaluation of urolithiasis. Author(s): Seftel A, Resnick MI. Source: The Urologic Clinics of North America. 1990 February; 17(1): 159-69. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2407014&dopt=Abstract
•
Metabolic factors for urolithiasis in acromegalic patients. Author(s): Heilberg IP, Czepielewski MA, Ajzen H, Ramos OL, Schor N. Source: Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas / Sociedade Brasileira De Biofisica. [et Al.]. 1991; 24(7): 687-96. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1668402&dopt=Abstract
72 Urolithiasis
•
Metabolic factors in urolithiasis: a study in Brazil. Author(s): Giugliani R, Ferrari I. Source: The Journal of Urology. 1980 October; 124(4): 503-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7420593&dopt=Abstract
•
Metabolic response to refined carbohydrates in idiopathic urolithiasis. Author(s): Rao PN, Gordon C, Davies D, Blacklock NJ. Source: Urologia Internationalis. 1984; 39(3): 165-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6377646&dopt=Abstract
•
Methodological aspects of examination of 24 hour urinary excretions in outpatients with recurrent urolithiasis. Author(s): Laerum E, Palmer H. Source: Scandinavian Journal of Urology and Nephrology. 1983; 17(3): 321-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6648379&dopt=Abstract
•
Methods for the study of calcium oxalate crystallisation and their application to urolithiasis research. Author(s): Kavanagh JP. Source: Scanning Microsc. 1992 September; 6(3): 685-704; Discussion 704-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1439665&dopt=Abstract
•
Methylmalonic aciduria and urolithiasis in a Chinese boy with untreated phenylketonuria. Author(s): Hou JW, Wang TR. Source: Journal of Inherited Metabolic Disease. 1995; 18(1): 79-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7623449&dopt=Abstract
•
Microbial degradation of dietary oxalate in the human gut and urinary oxalate concentrations in patients with calcium oxalate urolithiasis and control persons. Author(s): Kleinschmidt K, Mahlmann A, Hautmann R. Source: Investig Urol (Berl). 1994; 5: 222-4. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7719310&dopt=Abstract
•
Microbial studies of feline urolithiasis. Author(s): Fabricant CG, Rich LJ. Source: J Am Vet Med Assoc. 1971 March 15; 158(6): Suppl 2: 976+. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4930310&dopt=Abstract
Studies 73
•
Mineralogical and chemical investigations of urolithiasis. Author(s): Ataman G. Source: Turk J Pediatr. 1984; 26(1-4): 11-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6537057&dopt=Abstract
•
Missense mutation in the adenine phosphoribosyltransferase gene causing 2,8dihydroxyadenine urolithiasis. Author(s): Sahota A, Chen J, Boyadjiev SA, Gault MH, Tischfield JA. Source: Human Molecular Genetics. 1994 May; 3(5): 817-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7915931&dopt=Abstract
•
Molecular aspects of idiopathic urolithiasis. Author(s): Nath R, Thind SK, Murthy MS, Talwar HS, Farooqui S. Source: Molecular Aspects of Medicine. 1984; 7(1-2): 1-176. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6376994&dopt=Abstract
•
Multiple urolithiasis in bilharziasis patients. Author(s): Lukacs T, Frang D, el-Seaghy AA, Pajor L. Source: International Urology and Nephrology. 1989; 21(3): 269-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2807777&dopt=Abstract
•
Munchausen syndrome presenting as urolithiasis. Author(s): Jones WA, Cooper TP, Kiviat MD. Source: The Western Journal of Medicine. 1978 February; 128(2): 185-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=629056&dopt=Abstract
•
Myocardial infarction and urolithiasis. A preliminary communication. Author(s): Linden V. Source: J Kans Med Soc. 1972 December; 73(12): 503-5. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4640970&dopt=Abstract
•
N-acetyl-beta-D-glucosaminidase excretion in healthy children and in pediatric patients with urolithiasis. Author(s): Balla AA, Salah AM, Abdalmotaal E, Hoppe B, Bongartz D, Kessler T, Hesse A. Source: World Journal of Urology. 1998; 16(6): 413-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9870291&dopt=Abstract
•
National trend of the incidence of urolithiasis in Japan from 1965 to 1995. Author(s): Yoshida O, Terai A, Ohkawa T, Okada Y. Source: Kidney International. 1999 November; 56(5): 1899-904. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10571800&dopt=Abstract
74 Urolithiasis
•
Nephrocalcinosis and urolithiasis in carbonic anhydrase II deficiency syndrome. Author(s): Ismail EA, Abul Saad S, Sabry MA. Source: European Journal of Pediatrics. 1997 December; 156(12): 957-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9453381&dopt=Abstract
•
New aspects of urolithiasis in France. GERBAP: Groupe d'Evaluation et de Recherche des Biologistes de l'Assistance Publique des Hopitaux de Paris. Author(s): Donsimoni R, Hennequin C, Fellahi S, Troupel S, Moel GL, Paris M, Lacour B, Daudon M. Source: European Urology. 1997; 31(1): 17-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9032529&dopt=Abstract
•
Nutrition and urolithiasis. Author(s): Smith LH, Van Den Berg CJ, Wilson DM. Source: The New England Journal of Medicine. 1978 January 12; 298(2): 87-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=339082&dopt=Abstract
•
Nutritional aspects of urolithiasis. Author(s): Ringsdorf WM Jr, Cheraskin E. Source: Southern Medical Journal. 1981 January; 74(1): 41-3, 46. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7006092&dopt=Abstract
•
On the therapy of urolithiasis in chronic renal failure. Author(s): Brien G, Lenk S, Althaus P, Bick C, Dutz W. Source: International Urology and Nephrology. 1978; 10(1): 7-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=649289&dopt=Abstract
•
Oral calcium tolerance and urinary cyclic AMP in urolithiasis. Author(s): Nelson JH 3rd, Rehm RA, Riemenschneider HW, Wise HA 2nd, Pflug B, Kemple K, Whitehouse WK, Winter CC. Source: Urology. 1978 November; 12(5): 519-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=214923&dopt=Abstract
•
Oral magnesium intake and its effect on various urinary constituents in the prophylaxis of urolithiasis. Author(s): Kohler FP, Uhle CA. Source: The Journal of Urology. 1966 November; 96(5): 812-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5923311&dopt=Abstract
Studies 75
•
Oral potassium citrate treatment for idiopathic hypocitruria in children with calcium urolithiasis. Author(s): Tekin A, Tekgul S, Atsu N, Bakkaloglu M, Kendi S. Source: The Journal of Urology. 2002 December; 168(6): 2572-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12441986&dopt=Abstract
•
Orthophosphate treatment in calcium urolithiasis. Author(s): Smith LH, Werness PG, VanDenBerg CJ, Wilson DM. Source: Scand J Urol Nephrol Suppl. 1980; 53: 253-63. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6938002&dopt=Abstract
•
Outpatient evaluation of patients with calcium urolithiasis. Author(s): Drach GW, Perin R, Jacobs S. Source: The Journal of Urology. 1979 May; 121(5): 564-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=439249&dopt=Abstract
•
Overview of surgical treatment of urolithiasis with special reference to lithotripsy. Author(s): Finlayson B, Ackermann D. Source: The Journal of Urology. 1989 March; 141(3 Pt 2): 778-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2918618&dopt=Abstract
•
Oxalate measurement in the picomol range by ion chromatography: values in fasting plasma and urine of controls and patients with idiopathic calcium urolithiasis. Author(s): Schwille PO, Manoharan M, Rumenapf G, Wolfel G, Berens H. Source: J Clin Chem Clin Biochem. 1989 February; 27(2): 87-96. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2746168&dopt=Abstract
•
Oxalate urolithiasis following jejunoileal bypass. Author(s): Clayman RV, Williams RD. Source: The Surgical Clinics of North America. 1979 December; 59(6): 1071-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=531740&dopt=Abstract
•
Oxalate urolithiasis: significance of serum and urinary oxalate. Author(s): Butz M, Kohlbecker G. Source: Urologia Internationalis. 1980; 35(4): 303-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7394936&dopt=Abstract
76 Urolithiasis
•
Oxypurines, protein, glucose and the functional state of blood vasculature are markers of renal calcium stone-forming processes? Observations in men with idiopathic recurrent calcium urolithiasis. Author(s): Manoharan M, Schwille PO. Source: Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 2002 March; 40(3): 266-77. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12005217&dopt=Abstract
•
Paediatric urolithiasis in a remote Australian aboriginal community. Author(s): Williams WM, Nicholas JJ, Nungurrayi PB, Napurrula CR. Source: Journal of Paediatrics and Child Health. 1996 August; 32(4): 344-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8844543&dopt=Abstract
•
Paediatric urolithiasis in Greece. Author(s): Androulakakis PA, Michael V, Polychronopoulou S, Aghioutantis C. Source: British Journal of Urology. 1991 February; 67(2): 206-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2004238&dopt=Abstract
•
Parathyroid gland function in subgroups of metabolically mediated urolithiasis as evaluated by serum parathyroid hormone, and urinary and nephrogenous cyclic nucleotides. Author(s): Schwille PO, Scholz D, Schwille K, Engelhardt W, Schreiber B, Goldberg I, Sigel A. Source: Klin Wochenschr. 1982 March 1; 60(5): 229-36. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6281515&dopt=Abstract
•
Partial and complete adenine phosphoribosyltransferase deficiency associated with 2,8-dihydroxyadenine urolithiasis: kinetic and immunochemical properties of APRT. Author(s): Abe S, Hayasaka K, Narisawa K, Tada K, Okada G, Koyama H, Kurosu S, Kudoh M, Matsushita K. Source: Enzyme. 1987; 37(4): 182-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2440671&dopt=Abstract
•
Pattern of calcium metabolism in normo- and hypercalciuric patients with calcium urolithiasis in Saudi Arabia. Author(s): Hanash KA, Bissada NK, Woodhouse NJ. Source: Urology. 1985 July; 26(1): 27-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2990080&dopt=Abstract
•
Pattern of urolithiasis in a general hospital. A prospective study. Author(s): Khalifa MS, al Shazly A, Reavey PC. Source: International Urology and Nephrology. 1989; 21(1): 17-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2714947&dopt=Abstract
Studies 77
•
Pattern of urolithiasis in Benin City, Nigeria. Author(s): Monu JU. Source: Journal of the National Medical Association. 1989 June; 81(6): 695-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2746692&dopt=Abstract
•
Pattern of urolithiasis in Brooklyn, New York. Author(s): Mooppan MM, Kim H, Wax SH. Source: Urology. 1979 November; 14(5): 482-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=505699&dopt=Abstract
•
Pediatric urolithiasis in Armenia: a study of 198 patients observed from 1991 to 1999. Author(s): Sarkissian A, Babloyan A, Arikyants N, Hesse A, Blau N, Leumann E. Source: Pediatric Nephrology (Berlin, Germany). 2001 September; 16(9): 728-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11511987&dopt=Abstract
•
Pediatric urolithiasis in Kuwait. Author(s): Al-Eisa AA, Al-Hunayyan A, Gupta R. Source: International Urology and Nephrology. 2002; 33(1): 3-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12090336&dopt=Abstract
•
Pediatric urolithiasis in southern Israel: the role of uricosuria. Author(s): Landau D, Tovbin D, Shalev H. Source: Pediatric Nephrology (Berlin, Germany). 2000 October; 14(12): 1105-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11045396&dopt=Abstract
•
Pediatric urolithiasis in sub-saharan Africa: a comparative study in two regions of Cameroon. Author(s): Angwafo FF 3rd, Daudon M, Wonkam A, Kuwong PM, Kropp KA. Source: European Urology. 2000 January; 37(1): 106-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10671795&dopt=Abstract
•
Pediatric urolithiasis in the 1970s. Author(s): Churchill DN, Maloney CM, Nolan R, Gault MH, Winsor G. Source: The Journal of Urology. 1980 February; 123(2): 237-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7354529&dopt=Abstract
•
Pediatric urolithiasis. Author(s): Minevich E. Source: Pediatric Clinics of North America. 2001 December; 48(6): 1571-85. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11732131&dopt=Abstract
78 Urolithiasis
•
Pediatric urolithiasis. Author(s): Faerber GJ. Source: Current Opinion in Urology. 2001 July; 11(4): 385-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11429498&dopt=Abstract
•
Pediatric urolithiasis. Author(s): Kroovand RL. Source: The Urologic Clinics of North America. 1997 February; 24(1): 173-84. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9048860&dopt=Abstract
•
Pediatric urolithiasis. Author(s): Remzi D, Bakkaloglu MA, Erkan I, Ozen HA. Source: Turk J Pediatr. 1984; 26(1-4): 43-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6537085&dopt=Abstract
•
Pediatric urolithiasis. Author(s): Paulson DF, Glenn JF, Hughes J, Roberts LC, Coppridge AJ. Source: The Journal of Urology. 1972 November; 108(5): 811-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5081725&dopt=Abstract
•
Pediatric urolithiasis: developing nation perspectives. Author(s): Rizvi SA, Naqvi SA, Hussain Z, Hashmi A, Hussain M, Zafar MN, Sultan S, Mehdi H. Source: The Journal of Urology. 2002 October; 168(4 Pt 1): 1522-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12352448&dopt=Abstract
•
Pediatric urolithiasis: medical and surgical management. Author(s): Cohen TD, Ehreth J, King LR, Preminger GM. Source: Urology. 1996 March; 47(3): 292-303. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8633391&dopt=Abstract
•
Pediatric urolithiasis: report of a case. Author(s): Bloom RB. Source: J Am Osteopath Assoc. 1983 May; 82(9): 681-5. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6863045&dopt=Abstract
•
Pediatric urolithiasis: review of research and current management. Author(s): Harmon EP, Neal DE, Thomas R. Source: Pediatric Nephrology (Berlin, Germany). 1994 August; 8(4): 508-12. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7947050&dopt=Abstract
Studies 79
•
Pediatric urolithiasis: to cut or not to cut. Author(s): Moazam F, Nazir Z, Jafarey AM. Source: Journal of Pediatric Surgery. 1994 June; 29(6): 761-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8078015&dopt=Abstract
•
Percutaneous and extracorporeal management of urolithiasis. Author(s): Erturk E, Lange PH, Hulbert JC. Source: Investigative Radiology. 1987 December; 22(12): 995-1004. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3326857&dopt=Abstract
•
Percutaneous chemolysis--an important tool in the treatment of urolithiasis. Author(s): Heimbach D, Baumler D, Schoeneich G, Hesse A. Source: International Urology and Nephrology. 1998; 30(6): 655-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10195856&dopt=Abstract
•
Percutaneous management of urolithiasis after kidney transplantation. Report of a case and review of the literature. Author(s): Fahlenkamp D, Oesterwitz H, Althaus P, Schopke WD, Brien G. Source: European Urology. 1988; 14(4): 330-2. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3049108&dopt=Abstract
•
Percutaneous management of urolithiasis during pregnancy. Author(s): Kavoussi LR, Albala DM, Basler JW, Apte S, Clayman RV. Source: The Journal of Urology. 1992 September; 148(3 Pt 2): 1069-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1507334&dopt=Abstract
•
Percutaneous renal surgery for urolithiasis. Author(s): Tan HM, Cheung HS. Source: Med J Malaysia. 1990 June; 45(2): 118-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2152015&dopt=Abstract
•
Physicochemical aspects of urolithiasis. Author(s): Finlayson B. Source: Kidney International. 1978 May; 13(5): 344-60. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=351263&dopt=Abstract
•
Physicochemical considerations in the development and prevention of calcium oxalate urolithiasis. Author(s): Kok DJ, Papapoulos SE. Source: Bone Miner. 1993 January; 20(1): 1-15. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8453319&dopt=Abstract
80 Urolithiasis
•
Pitfalls in parathyroid evaluation in patients with calcium urolithiasis. Author(s): Barilla DE, Pak CY. Source: Urological Research. 1979 September; 7(3): 177-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=505680&dopt=Abstract
•
Plain radiography, renography, and 99mTc-DMSA renal scintigraphy before and after extracorporeal shock wave lithotripsy for urolithiasis. Author(s): Munck O, Gerquari I, Moller JT, Jensen LI, Thomsen HS. Source: Acta Radiologica (Stockholm, Sweden : 1987). 1992 November; 33(6): 569-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1333258&dopt=Abstract
•
Possible causes for the low prevalence of pediatric urolithiasis. Author(s): Miyake O, Yoshimura K, Tsujihata M, Yoshioka T, Koide T, Takahara S, Okuyama A. Source: Urology. 1999 June; 53(6): 1229-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10367860&dopt=Abstract
•
Possible role for chondroitin sulfate in urolithiasis: in vivo studies in an experimental model. Author(s): Michelacci YM, Boim MA, Bergamaschi CT, Rovigatti RM, Schor N. Source: Clinica Chimica Acta; International Journal of Clinical Chemistry. 1992 June 15; 208(1-2): 1-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1638745&dopt=Abstract
•
Predictive value of kidney stone composition in the detection of metabolic abnormalities. Author(s): Pak CY, Poindexter JR, Adams-Huet B, Pearle MS. Source: The American Journal of Medicine. 2003 July; 115(1): 26-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12867231&dopt=Abstract
•
Predisposition towards urolithiasis associated with the NQO1 null-allele. Author(s): Schulz WA, Krummeck A, Rosinger I, Schmitz-Drager BJ, Sies H. Source: Pharmacogenetics. 1998 October; 8(5): 453-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9825838&dopt=Abstract
•
Preliminary experience with the pulsed dye laser for treatment of urolithiasis. Author(s): Loughlin KR, Sharpe JF Jr. Source: Lasers in Surgery and Medicine. 1991; 11(1): 1-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1997774&dopt=Abstract
Studies 81
•
Prevalence and epidemiologic characteristics of urolithiasis in Seoul, Korea. Author(s): Kim H, Jo MK, Kwak C, Park SK, Yoo KY, Kang D, Lee C. Source: Urology. 2002 April; 59(4): 517-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11927302&dopt=Abstract
•
Prevalence of urolithiasis in a Finnish district. An epidemiologic study of adults in Tampere. Author(s): Nikkila MT, Pasternack A. Source: Scandinavian Journal of Urology and Nephrology. 1988; 22(4): 293-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3238335&dopt=Abstract
•
Prevalence of urolithiasis in Kaizuka City, Japan--an epidemiologic study of urinary stones. Author(s): Iguchi M, Umekawa T, Katoh Y, Kohri K, Kurita T. Source: International Journal of Urology : Official Journal of the Japanese Urological Association. 1996 May; 3(3): 175-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8776612&dopt=Abstract
•
Prevention of spinal bone loss by potassium citrate in cases of calcium urolithiasis. Author(s): Pak CY, Peterson RD, Poindexter J. Source: The Journal of Urology. 2002 July; 168(1): 31-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12050486&dopt=Abstract
•
Prevention of urolithiasis. Education to adequate fluid intake in a new town situated in the Judean Desert Mountains. Author(s): Frank M, De Vries A. Source: Archives of Environmental Health. 1966 November; 13(5): 625-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5925636&dopt=Abstract
•
Primary hyperparathyroidism and urolithiasis: concomitant surgical management. Author(s): van Heerden JA, Segura JW, Grant CS. Source: Surgery. 1989 December; 106(6): 992-5; Discussion 995-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2588126&dopt=Abstract
•
Proceedings: Urinary excretion of oxalate, calcium, magnesium, and uric acid in inflammatory bowel disease and relationship to urolithiasis. Author(s): Farmer RG, Mir-Madjlessi SH, Kiser WS. Source: Gut. 1973 October; 14(10): 828. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4758698&dopt=Abstract
82 Urolithiasis
•
Prognosis of urolithiasis and nephrocalcinosis in hypomagnesemia. Author(s): Revusova V, Zvara V, Karlikova L, Suchanek B. Source: Czech Med. 1985; 8(4): 207-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3937709&dopt=Abstract
•
Promoters and inhibitors of calcium urolithiasis in children. Author(s): Lama G, Carbone MG, Marrone N, Russo P, Spagnuolo G. Source: Child Nephrol Urol. 1990; 10(2): 81-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2253256&dopt=Abstract
•
Prophylaxis in idiopathic calcium urolithiasis. Author(s): Ackermann D. Source: Urological Research. 1990; 18 Suppl 1: S37-40. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2291248&dopt=Abstract
•
Prophylaxis of oxalate urolithiasis with alkaline citrates. Author(s): Frang D, Berenyi M, Szebeni R. Source: Ther Hung. 1990; 38(2): 64-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2377983&dopt=Abstract
•
Protease inhibitor-induced urolithiasis. Author(s): Gentle DL, Stoller ML, Jarrett TW, Ward JF, Geib KS, Wood AF. Source: Urology. 1997 October; 50(4): 508-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9338723&dopt=Abstract
•
Protease inhibitors and urolithiasis. Author(s): Sutherland SE, Reigle MD, Seftel AD, Resnick MI. Source: The Journal of Urology. 1997 July; 158(1): 31-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9186316&dopt=Abstract
•
Proteoglycan core protein in human urine and its possible role on calcium oxalate urolithiasis. Author(s): Yoshimura K, Miyake O, Tsujihata M, Yoshioka T, Yamaguchi S, Koide T, Takahara S, Okuyama A. Source: International Journal of Urology : Official Journal of the Japanese Urological Association. 1999 November; 6(11): 567-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10585122&dopt=Abstract
•
Pure calcium carbonate urolithiasis in a human. Author(s): Koide T, Yokogawa K, Takemoto M, Itatani H, Sagawa S, Sonoda T. Source: European Urology. 1982; 8(5): 319-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7117348&dopt=Abstract
Studies 83
•
Quantitation of response to therapy in calcium urolithiasis. Author(s): Zerwekh JE, Lawoyin O, Pak CY. Source: Urological Research. 1979 September; 7(3): 209-13. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=388797&dopt=Abstract
•
Racial variation in gender frequency of calcium urolithiasis. Author(s): Michaels EK, Nakagawa Y, Miura N, Pursell S, Ito H. Source: The Journal of Urology. 1994 December; 152(6 Pt 2): 2228-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7966716&dopt=Abstract
•
Radiologic evaluation of urolithiasis. Author(s): Laerum E, Finnanger AM, Stiris G, Heldaas O, Larsen S. Source: Acta Radiol Diagn (Stockh). 1986 September-October; 27(5): 561-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3799229&dopt=Abstract
•
Radionuclide kidney function evaluation in the management of urolithiasis. Author(s): Bueschen AJ, Lloyd LK, Dubovsky EV, Tauxe WN. Source: The Journal of Urology. 1978 July; 120(1): 16-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=671597&dopt=Abstract
•
Rapid method for the diagnosis of partial adenine phosphoribosyltransferase deficiencies causing 2,8-dihydroxyadenine urolithiasis. Author(s): Takeuchi F, Matsuta K, Miyamoto T, Enomoto S, Fujimori S, Akaoka I, Kamatani N, Nishioka K. Source: Human Genetics. 1985; 71(2): 167-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4043967&dopt=Abstract
•
Rational prevention of calcium urolithiasis. Author(s): Butz M. Source: Urologia Internationalis. 1986; 41(5): 387-92. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3544440&dopt=Abstract
•
Re: Adenine phosphoribosyltransferase deficiency: 2,8-dihydroxyadenine urolithiasis in a 48-year-old woman. Author(s): Gleeson MJ. Source: British Journal of Urology. 1989 September; 64(3): 324. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2804578&dopt=Abstract
84 Urolithiasis
•
Re: Distribution of patients with 2,8-dihydroxyadenine urolithiasis and adenine phosphoribosyltransferase deficiency in Japan. Author(s): Gleeson MJ, Griffith DP. Source: The Journal of Urology. 1989 September; 142(3): 834. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2769881&dopt=Abstract
•
Re: Metabolic factors in urolithiasis: a study in Brazil. Author(s): Giugliani R, Ferrari I, Martins AC, Ciconelli AJ. Source: The Journal of Urology. 1987 February; 137(2): 320. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3806838&dopt=Abstract
•
Re: Percutaneous management of urolithiasis during pregnancy. Author(s): Haddad FS. Source: The Journal of Urology. 1993 July; 150(1): 199. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8141867&dopt=Abstract
•
Re: Silicate urolithiasis. Author(s): Goodwin WE. Source: The Journal of Urology. 1986 June; 135(6): 1272. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3520022&dopt=Abstract
•
Re: Specific gravity test strips used in monitoring urine concentrations of urolithiasis patients. Author(s): Haddad FS. Source: The Journal of Urology. 1989 May; 141(5): 1213. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2709513&dopt=Abstract
•
Re: Treatment options for proximal ureteral urolithiasis: review and recommendations. Author(s): Khanna S, Saxena A, Vohra BK. Source: The Journal of Urology. 1991 June; 145(6): 1277. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2033712&dopt=Abstract
•
Recurrences in primarily infected and uninfected urolithiasis. Author(s): Wencel M, Czaplicki M, Wesolowski S. Source: International Urology and Nephrology. 1978; 10(4): 275-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=365823&dopt=Abstract
•
Recurrences of urolithiasis. Author(s): Ala-Opas M, Lehtonen T. Source: Ann Chir Gynaecol. 1990; 79(1): 50-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2357056&dopt=Abstract
Studies 85
•
Recurrent calcium oxalate urolithiasis in a man with familial periodic paralysis and hypokalemia. Author(s): Zitella A, Moiso A, De Zan A, Casetta G, Piana P, Tizzani A. Source: The Journal of Urology. 1999 June; 161(6): 1899. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10332462&dopt=Abstract
•
Recurrent calcium urolithiasis and primary hyperparathyroidism: some problems of diagnosis. Author(s): Lenzi F. Source: Panminerva Medica. 1967 June; 9(6): 198-204. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6074995&dopt=Abstract
•
Recurrent suture urolithiasis 29 years after open pyelolithotomy. Author(s): Applewhite JC, Assimos DG. Source: Journal of Endourology / Endourological Society. 1999 July-August; 13(6): 4379. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10479010&dopt=Abstract
•
Recurrent urolithiasis after augmentation gastrocystoplasty. Author(s): Palmer LS, Palmer JS, Firlit BM, Firlit CF. Source: The Journal of Urology. 1998 April; 159(4): 1331-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9507878&dopt=Abstract
•
Recurrent urolithiasis following anatrophic nephrolithotomy. Author(s): Russell JM, Harrison LH, Boyce WH. Source: The Journal of Urology. 1981 April; 125(4): 471-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7218441&dopt=Abstract
•
Recurrent urolithiasis: a general-practice study of risk factors and clinical consequences. Author(s): Laerum E. Source: Scandinavian Journal of Urology and Nephrology. 1984; 18(1): 67-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6719052&dopt=Abstract
•
Reduction of the urinary risk factors of urolithiasis with magnesium and tartrate mixture: a new treatment. Author(s): Hallson PC, Rose GA. Source: British Journal of Urology. 1988 May; 61(5): 382-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3395794&dopt=Abstract
86 Urolithiasis
•
Reduction of urine oxalate during long-term thiazide therapy in patients with calcium urolithiasis. Author(s): Cohanim M, Yendt ER. Source: Invest Urol. 1980 September; 18(2): 170-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7410033&dopt=Abstract
•
Relation between hypercalciuria and vitamin D3-status in patients with urolithiasis. Author(s): Berlin T, Bjorkhem I, Collste L, Holmberg I, Wijkstrom H. Source: Scandinavian Journal of Urology and Nephrology. 1982; 16(3): 269-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6298930&dopt=Abstract
•
Relation of magnesium to osteoporosis and calcium urolithiasis. Author(s): Wallach S. Source: Magnes Trace Elem. 1991-92; 10(2-4): 281-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1844560&dopt=Abstract
•
Renal hypouricemia due to enhanced tubular secretion of urate associated with urolithiasis: successful treatment of urolithiasis by alkalization of urine K+, Na(+)citrate. Author(s): Hisatome I, Tanaka Y, Kotake H, Kosaka H, Hirata N, Fujimoto Y, Yoshida A, Shigemasa C, Mashiba H, Sato R, et al. Source: Nephron. 1993; 65(4): 578-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8302413&dopt=Abstract
•
Renal insufficiency secondary to 2,8-dihydroxyadenine urolithiasis. Author(s): Gelb AB, Fye KH, Tischfield JA, Sahota AS, Sparks JW, Hancock DC, Sibley RK. Source: Human Pathology. 1992 September; 23(9): 1081-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1516930&dopt=Abstract
•
Renal oxalate excretion in calcium urolithiasis. Author(s): Galosy R, Clarke L, Ward DL, Pak CY. Source: The Journal of Urology. 1980 March; 123(3): 320-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7359627&dopt=Abstract
•
Renal prostaglandins and calcium excretion in urolithiasis. Author(s): Buck AC. Source: J Int Med Res. 1983; 11 Suppl 2: 18-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6347754&dopt=Abstract
Studies 87
•
Renal tubular hypouricemia and calcium urolithiasis. Author(s): Kotake T, Miura N, Ito H. Source: Scanning Microsc. 1993 March; 7(1): 417-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8316811&dopt=Abstract
•
Report on the 'International Symposium on Urolithiasis Research' Davos, March 29 to April 1, 1976. Author(s): Schulman CC, Weiser M. Source: European Urology. 1976; 2(4): 203-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12981&dopt=Abstract
•
Rethinking the role of urinary magnesium in calcium urolithiasis. Author(s): Schwartz BF, Bruce J, Leslie S, Stoller ML. Source: Journal of Endourology / Endourological Society. 2001 April; 15(3): 233-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11339386&dopt=Abstract
•
Retrograde renal pelvic access sheath to facilitate flexible ureteroscopic lithotripsy for the treatment of urolithiasis in a horseshoe kidney. Author(s): Andreoni C, Portis AJ, Clayman RV. Source: The Journal of Urology. 2000 October; 164(4): 1290-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10992383&dopt=Abstract
•
Retroperitoneal laparoscopic management of urolithiasis. Author(s): Sinha R, Sharma N. Source: Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A. 1997 April; 7(2): 95-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9459808&dopt=Abstract
•
Retrospective approach to explain growth retardation and urolithiasis in a child with long-term nutritional acid loading. Author(s): Manz F, Schmidt H. Source: Zeitschrift Fur Ernahrungswissenschaft. 1992 June; 31(2): 121-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1496830&dopt=Abstract
•
Review: metabolic disorders associated with urolithiasis in children. Author(s): Wenzl JE. Source: J Okla State Med Assoc. 1968 November; 61(11): 550-5. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4881917&dopt=Abstract
88 Urolithiasis
•
Review: urolithiasis--electrohydraulic and laser lithotripsy. Author(s): Dretler SP. Source: Journal of Endourology / Endourological Society. 1993 October; 7(5): 387-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8298619&dopt=Abstract
•
Risk factors for urolithiasis in children on the ketogenic diet. Author(s): Furth SL, Casey JC, Pyzik PL, Neu AM, Docimo SG, Vining EP, Freeman JM, Fivush BA. Source: Pediatric Nephrology (Berlin, Germany). 2000 November; 15(1-2): 125-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11095028&dopt=Abstract
•
Risk formulas in calcium oxalate urolithiasis. Author(s): Tiselius HG. Source: World Journal of Urology. 1997; 15(3): 176-85. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9228725&dopt=Abstract
•
Role of diet in the therapy of urolithiasis. Author(s): Assimos DG, Holmes RP. Source: The Urologic Clinics of North America. 2000 May; 27(2): 255-68. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10778468&dopt=Abstract
•
Role of extracorporeal shock-wave lithotripsy in treatment of urolithiasis in patients with medullary sponge kidney. Author(s): Nakada SY, Erturk E, Monaghan J, Cockett AT. Source: Urology. 1993 April; 41(4): 331-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8470317&dopt=Abstract
•
Role of genital mycoplasmata and other bacteria in urolithiasis. Author(s): Kaya S, Poyraz O, Gokce G, Kilicarslan H, Kaya K, Ayan S. Source: Scandinavian Journal of Infectious Diseases. 2003; 35(5): 315-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12875517&dopt=Abstract
•
Role of inhibitor deficiency in urolithiasis. I. Rationale of urinary magnesium, citrate, pyrophosphate and glycosaminoglycan determinations. Author(s): Akinci M, Esen T, Kocak T, Ozsoy C, Tellaloglu S. Source: European Urology. 1991; 19(3): 240-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1649759&dopt=Abstract
Studies 89
•
Role of inhibitor deficiency in urolithiasis. II. Deficiency grade-adjusted and intermittent augmentation therapy for magnesium and citrate deficiency. Author(s): Esen T, Akinci M, Tellaloglu S, Kocak T. Source: European Urology. 1991; 19(3): 244-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1855531&dopt=Abstract
•
Role of the diurnal variation of urinary pH and urinary calcium in urolithiasis: a study in outpatients. Author(s): Murayama T, Sakai N, Yamada T, Takano T. Source: International Journal of Urology : Official Journal of the Japanese Urological Association. 2001 October; 8(10): 525-31; Discussion 532. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11737477&dopt=Abstract
•
Role of vitamins in urolithiasis. Author(s): Khanam A, Rahman B, Rahman MA. Source: Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 1988; 42(9): 609-13. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3071383&dopt=Abstract
•
Sarcoidosis masquerading as leprosy, pulmonary tuberculosis and urolithiasis. Author(s): Singh K, Raina V, Narulla AK, Singh R. Source: J Assoc Physicians India. 1990 September; 38(9): 657-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2266087&dopt=Abstract
•
Sclerosing cholangitis and oxalate urolithiasis in ulcerative colitis. Author(s): Mann NS, Tsai MF, Hopens T. Source: Tex Med. 1989 March; 85(3): 39-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2711349&dopt=Abstract
•
Screening of primary hyperparathyroidism among the patients with urolithiasis. Author(s): Sonoda T, Okawa T, Takeuchi M, Kusunoki T. Source: Med J Osaka Univ. 1967 December; 18(3): 281-91. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5598110&dopt=Abstract
•
Screening of primary hyperparathyroidism among the patients with urolithiasis. Author(s): Sonoda T, Ohkawa T, Kusunoki T. Source: Urologia Internationalis. 1967; 22(6): 517-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5590841&dopt=Abstract
90 Urolithiasis
•
Seasonal variation in urinary excretion of calcium, oxalate, magnesium and phosphate on free and standard mineral diet in men with urolithiasis. Author(s): Juuti M, Heinonen OP, Alhava EM. Source: Scandinavian Journal of Urology and Nephrology. 1981; 15(2): 137-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7330607&dopt=Abstract
•
Second generation extracorporeal shock wave lithotripsy for treatment of urolithiasis. Author(s): Tanikawa K, Nishizawa K, Okada K, Matsushita K, Kawamura N. Source: Tokai J Exp Clin Med. 1988 June; 13(2): 121-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3074523&dopt=Abstract
•
Secondary and miscellaneous urolithiasis. Medications, urinary diversions, and foreign bodies. Author(s): Drach GW. Source: The Urologic Clinics of North America. 2000 May; 27(2): 269-73. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10778469&dopt=Abstract
•
Secondary urolithiasis. Author(s): Muldoon LD, Resnick MI. Source: Endocrinology and Metabolism Clinics of North America. 1990 December; 19(4): 909-18. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2081518&dopt=Abstract
•
Serum and urinary magnesium levels in cases of acute glomeulonephritis, nephrotic syndrome and urolithiasis. Author(s): Bansal RK, Agrawal SN, Bhatnagar VM, Seth ON. Source: J Indian Med Assoc. 1979 September; 73(5-6): 83-5. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=541510&dopt=Abstract
•
Serum and urinary uric acid levels in healthy subjects and in patients with urolithiasis. Author(s): Sila-On A, Pavaro U, Nuchpramool W. Source: J Med Assoc Thai. 1991 August; 74(8): 352-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1791385&dopt=Abstract
•
Serum and urinary zinc levels in urolithiasis. Author(s): Rangnekar GV, Gaur MS. Source: British Journal of Urology. 1993 May; 71(5): 527-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8518857&dopt=Abstract
Studies 91
•
Significance of the calcium to creatinine concentration ratio of a single-voided urine specimen in patients with hypercalciuric urolithiasis. Author(s): Matsushita K, Tanikawa K. Source: Tokai J Exp Clin Med. 1987 September; 12(3): 167-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3454077&dopt=Abstract
•
Silica urolithiasis without magnesium trisilicate intake. Author(s): Ichiyanagi O, Sasagawa I, Adachi Y, Suzuki H, Kubota Y, Nakada T. Source: Urologia Internationalis. 1998 October; 61(1): 39-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9792982&dopt=Abstract
•
Silicate urolithiasis. Author(s): Farrer JH, Rajfer J. Source: The Journal of Urology. 1984 October; 132(4): 739-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6088815&dopt=Abstract
•
Simple method for the study of heterogeneous nucleation in calcium oxalate urolithiasis. Author(s): Grases F, Conte A, Gil JJ. Source: British Journal of Urology. 1988 June; 61(6): 468-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3401655&dopt=Abstract
•
Sodium is neither a risk nor a protective factor in urolithiasis? Author(s): Singh PP, Pendse AK, Hada P, Nagori PC, Rathore V, Dashora PK. Source: Urological Research. 1987; 15(2): 105-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3590427&dopt=Abstract
•
Some features of paediatric urolithiasis in a group of Syrian children. Author(s): Hadidy S, Shammaa MZ, Kharma A. Source: International Urology and Nephrology. 1987; 19(1): 3-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3583609&dopt=Abstract
•
Some laboratory findings in patients with urolithiasis. Author(s): Revusova V, Zvara V, Gratzlova J. Source: International Urology and Nephrology. 1971; 3(3): 251-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5154572&dopt=Abstract
•
Some new concepts on the pathogenesis and the treatment of urolithiasis. Author(s): Fleisch H. Source: Urologia Internationalis. 1965; 19(6): 372-89. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4284576&dopt=Abstract
92 Urolithiasis
•
Some observations on genetic factors in urolithiasis. Author(s): Giugliani R, Ferrari I. Source: Urology. 1981 January; 17(1): 33-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7456195&dopt=Abstract
•
Some observations on urolithiasis in Jamnagar area: incidence and etiological factors. Author(s): Roy PB, Mehta NR, Shahade MG, Mehta RT. Source: Indian Journal of Medical Sciences. 1966 March; 20(3): 200-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5948716&dopt=Abstract
•
Specific gravity test strips used in monitoring urine concentrations of urolithiasis patients. Author(s): Cadoff RE, Drach GW, LeBouton J. Source: The Journal of Urology. 1988 February; 139(2): 323-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3339731&dopt=Abstract
•
Spectrum of 2,8-dihydroxyadenine urolithiasis in complete APRT deficiency. Author(s): Simmonds HA, Barratt TM, Webster DR, Sahota A, Van Acker KJ, Cameron JS, Dillon M. Source: Advances in Experimental Medicine and Biology. 1980; 122A: 337-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7424654&dopt=Abstract
•
Spectrum of pediatric urolithiasis in western India. Author(s): Shah AM, Kalmunkar S, Punekar SV, Billimoria FR, Bapat SD, Deshmukh SS. Source: Indian J Pediatr. 1991 July-August; 58(4): 543-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1800338&dopt=Abstract
•
Spontaneous perforation of the ureter: a rare complication of urolithiasis. Author(s): Leuthardt R, Bernhardt E, Gasser T, Kummer M. Source: European Journal of Pediatric Surgery : Official Journal of Austrian Association of Pediatric Surgery. [et Al] = Zeitschrift Fur Kinderchirurgie. 1994 August; 4(4): 205-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7981166&dopt=Abstract
•
Spot urine samples for the metabolic evaluation of urolithiasis patients. Author(s): Strohmaier WL, Hoelz KJ, Bichler KH. Source: European Urology. 1997; 32(3): 294-300. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9358216&dopt=Abstract
Studies 93
•
Staphylococci in canine urolithiasis: species identification, using a commercially available tray micromethod. Author(s): Case LC, Ling GV, Biberstein EL, Ruby AL, Jang SS. Source: Am J Vet Res. 1985 January; 46(1): 238-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3882027&dopt=Abstract
•
Stone recurrence after lithotripsy in patients with recurrent idiopathic calcium urolithiasis: efficacy of treatment with fiuggi water. Author(s): Di Silverio F, Ricciuti GP, D'Angelo AR, Fraioli A, Simeoni G. Source: European Urology. 2000 February; 37(2): 145-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10705191&dopt=Abstract
•
Stress as a principal cause of calcium oxalate urolithiasis. Author(s): Walters DC. Source: International Urology and Nephrology. 1986; 18(3): 271-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3021644&dopt=Abstract
•
Strong inference in mechanistic urolithiasis: a tribute to Birdwell Finlayson's biophysical contributions. Author(s): Brown CM, Purich DL. Source: American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 1991 April; 17(4): 451-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2008915&dopt=Abstract
•
Struvite urolithiasis in animals and man: formation, detection, and dissolution. Author(s): Osborne CA, Polzin DJ, Abdullahi SU, Leininger JR, Clinton CW, Griffith DP. Source: Adv Vet Sci Comp Med. 1985; 29: 1-101. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3911756&dopt=Abstract
•
Studies in urolithiasis. I. X-ray diffraction analysis of calculi from Delhi region. Author(s): Rao MV, Agarwal JS. Source: The Indian Journal of Medical Research. 1973 July; 61(7): 1094-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4758002&dopt=Abstract
•
Studies in urolithiasis. III. Electron optical investigation on the morphology of the colloidal matrix of urinary calculi. Author(s): Rao MV, Agarwal JS, Taneja OP. Source: Invest Urol. 1978 May; 15(6): 452-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=649293&dopt=Abstract
94 Urolithiasis
•
Studies in urolithiasis: II. X-ray diffraction analysis of calculi from Delhi region. Author(s): Rao MV, Agarwal JS, Taneja OP. Source: The Indian Journal of Medical Research. 1976 January; 64(1): 102-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1270092&dopt=Abstract
•
Studies in urolithiasis: Part IV--An electron optical investigation on kinds of crystallization in urinary calculi. Author(s): Rao MV, Agarwal JS. Source: Indian J Exp Biol. 1979 April; 17(4): 366-70. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=489064&dopt=Abstract
•
Studies of bladder stone disease in Thailand. II. Hospital experience. Urolithiasis at Ubol Provincial Hospital, 1956-1962. Author(s): Chutikorn C, Valyasevi A, Halstead SB. Source: The American Journal of Clinical Nutrition. 1967 December; 20(12): 1320-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6074669&dopt=Abstract
•
Studies on aetiology of urolithiasis in Karachi. Author(s): Khan IA, Rahman MA. Source: The Biochemical Journal. 1971 March; 122(1): 22P-23P. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5124792&dopt=Abstract
•
Studies on the etiology of urolithiasis in Karachi. Author(s): Shahjehan S, Rahman MA. Source: The American Journal of Clinical Nutrition. 1971 January; 24(1): 32-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5539053&dopt=Abstract
•
Studies on the role of urinary macromolecules in urolithiasis: review of methodologies and a proposal for a standard reference crystallization system. Author(s): Rodgers AL, Jappie D. Source: Scanning Microsc. 1996; 10(2): 535-45; Discussion 545-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9813630&dopt=Abstract
•
Studies on urolithiasis in general practice. Author(s): Laerum E. Source: Scand J Urol Nephrol Suppl. 1983; 80: 1-39. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6382586&dopt=Abstract
•
Studies on urolithiasis in Israel. Author(s): Zaidman JL, Pinto N. Source: The Journal of Urology. 1976 June; 115(6): 626-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=940190&dopt=Abstract
Studies 95
•
Successful sodium thiosulphate treatment for recurrent calcium urolithiasis. Author(s): Yatzidis H. Source: Clinical Nephrology. 1985 February; 23(2): 63-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3886226&dopt=Abstract
•
Sulfadiazine-induced multiple urolithiasis and acute renal failure in a patient with AIDS and Toxoplasma encephalitis. Author(s): Diaz F, Collazos J, Mayo J, Martinez E. Source: The Annals of Pharmacotherapy. 1996 January; 30(1): 41-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8773165&dopt=Abstract
•
Sulfinpyrazone induced uric acid urolithiasis with acute renal failure. Author(s): Kovalchik MT 3rd. Source: Conn Med. 1981 July; 45(7): 423-4. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7249646&dopt=Abstract
•
Summary of the National Institutes of Arthritis, Diabetes, Digestive and Kidney Diseases conference on urolithiasis: state of the art and future research needs. Author(s): Resnick MI, Persky L. Source: The Journal of Urology. 1995 January; 153(1): 4-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7966786&dopt=Abstract
•
Surgical aspects of urolithiasis in children. Author(s): el-Damanhoury H, Burger R, Hohenfellner R. Source: Pediatric Nephrology (Berlin, Germany). 1991 May; 5(3): 339-47. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1867991&dopt=Abstract
•
Surgical management of urolithiasis at the Kenyatta National Hospital. Author(s): Ndirangu K, Ngwanyam NY. Source: East Afr Med J. 1990 October; 67(10): 689-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2282889&dopt=Abstract
•
Surgical management of urolithiasis. Author(s): Auge BK, Preminger GM. Source: Endocrinology and Metabolism Clinics of North America. 2002 December; 31(4): 1065-82. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12474646&dopt=Abstract
96 Urolithiasis
•
Surgical overview of urolithiasis. Author(s): Drach GW. Source: The Journal of Urology. 1989 March; 141(3 Pt 2): 711-3. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2645428&dopt=Abstract
•
Suspected urolithiasis in pregnant women: imaging algorithm and literature review. Author(s): Boridy IC, Maklad N, Sandler CM. Source: Ajr. American Journal of Roentgenology. 1996 October; 167(4): 869-75. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8819373&dopt=Abstract
•
Symposium on renal lithiasis. Medical evaluation of urolithiasis. Etiologic aspects and diagnostic evaluation. Author(s): Smith LH. Source: The Urologic Clinics of North America. 1974 June; 1(2): 241-60. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4372766&dopt=Abstract
•
Symptomatology and development of urolithiasis in children with frequency-dysuria syndrome associated with hypercalciuria. Author(s): Escribano J, Feliu A, Balaguer A, Espax R, Soler L. Source: Croatian Medical Journal. 1999 March; 40(1): 80-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9933901&dopt=Abstract
•
The accuracy of noncontrast helical computed tomography versus intravenous pyelography in the diagnosis of suspected acute urolithiasis: a meta-analysis. Author(s): Worster A, Preyra I, Weaver B, Haines T. Source: Annals of Emergency Medicine. 2002 September; 40(3): 280-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12192351&dopt=Abstract
•
The aetiological and clinical pattern of childhood urolithiasis in Saudi Arabia. Author(s): Al-Rasheed SA, el-Faqih SR, Husain I, Abdurrahman M, al-Mugeirin MM. Source: International Urology and Nephrology. 1995; 27(4): 349-55. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8586504&dopt=Abstract
•
The association of androgen- and oestrogen-receptor gene polymorphisms with urolithiasis in men. Author(s): Chen WC, Wu HC, Lin WC, Wu MC, Hsu CD, Tsai FJ. Source: Bju International. 2001 September; 88(4): 432-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11564035&dopt=Abstract
Studies 97
•
The characteristics of urolithiasis in east Thrace: a statistical review. Author(s): Aydin S, Inci O, Aydin AO. Source: International Urology and Nephrology. 1994; 26(5): 485-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7860193&dopt=Abstract
•
The child with urolithiasis. Practical considerations in diagnosis and management. Author(s): Herrin JT. Source: Clinical Pediatrics. 1971 June; 10(6): 306-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5578149&dopt=Abstract
•
The current management of urolithiasis during pregnancy. Author(s): Loughlin KR, Ker LA. Source: The Urologic Clinics of North America. 2002 August; 29(3): 701-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12476533&dopt=Abstract
•
The diagnosis, occurrence and clinical aspects of primary hyperparathyroidism in patients with recurrent urolithiasis as registered in general practice. Author(s): Laerum E, Borchgrevink CF, Gautvik KM, Aune S. Source: Scandinavian Journal of Primary Health Care. 1985 November; 3(4): 207-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4081402&dopt=Abstract
•
The effect of fenquizone on the urinary inhibitors of calcium oxalate urolithiasis. Author(s): Cupisti A, Ciardella F, Morelli E, Dani L, Lupetti S, Luchi S, Meola M, Barsotti G. Source: Contrib Nephrol. 1987; 58: 184-6. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3691123&dopt=Abstract
•
The effect of pumpkin seeds snack on inhibitors and promoters of urolithiasis in Thai adolescents. Author(s): Suphiphat V, Morjaroen N, Pukboonme I, Ngunboonsri P, Lowhnoo T, Dhanamitta S. Source: J Med Assoc Thai. 1993 September; 76(9): 487-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7964254&dopt=Abstract
•
The effects of the calcium-restricted diet of urolithiasis patients with absorptive hypercalciuria type II on risk factors for kidney stones and osteopenia. Author(s): van Faassen A, van der Ploeg EM, Habets HM, van der Meer R, Hermus RJ, Janknegt RA. Source: Urological Research. 1998; 26(1): 65-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9537699&dopt=Abstract
98 Urolithiasis
•
The epidemiological and clinical picture of urolithiasis at the Kenyatta National Hospital. Author(s): Ndirangu K, Ngwanyam NY. Source: East Afr Med J. 1990 October; 67(10): 685-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2282888&dopt=Abstract
•
The etiology of uric acid urolithiasis following ileostomy. Author(s): Wilmore DW, Gots RE. Source: Archives of Surgery (Chicago, Ill. : 1960). 1969 October; 99(4): 421-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4980097&dopt=Abstract
•
The etiology of urolithiasis in HIV infected patients. Author(s): Nadler RB, Rubenstein JN, Eggener SE, Loor MM, Smith ND. Source: The Journal of Urology. 2003 February; 169(2): 475-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12544290&dopt=Abstract
•
The etiology of urolithiasis in Udaipur (western part of India). Author(s): Pendse AK, Singh PP. Source: Urological Research. 1986; 14(2): 59-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3727215&dopt=Abstract
•
The frequency of urolithiasis in hospital discharge diagnoses in the United States. Author(s): Sierakowski R, Finlayson B, Landes RR, Finlayson CD, Sierakowski N. Source: Invest Urol. 1978 May; 15(6): 438-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=649290&dopt=Abstract
•
The frusemide test: simple screening test for renal acidification defect in urolithiasis. Author(s): Reynolds TM, Burgess N, Matanhelia S, Brain A, Penney MD. Source: British Journal of Urology. 1993 August; 72(2): 153-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8402016&dopt=Abstract
•
The ileal ureter in recurrent urolithiasis. Author(s): Monnig JA, Dale G, Bicknell SL. Source: The Journal of Urology. 1976 December; 116(6): 699-702. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1003634&dopt=Abstract
•
The incidence of symptomatic urolithiasis in Royal Naval submariners comparison with personnel of the surface fleet. Author(s): Raffaelli PI. Source: J R Nav Med Serv. 1988 Summer; 74(2): 86-94. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3256633&dopt=Abstract
Studies 99
•
The incidence of urolithiasis in peptic ulcer patients. Author(s): Golematis B, Melissas J, Hatzitheofilou C, Dreiling DA, Kambysi-dea S. Source: The American Journal of Gastroenterology. 1977 October; 68(4): 367-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=580163&dopt=Abstract
•
The influence of renal prostaglandins on glomerular filtration rate (GFR) and calcium excretion in urolithiasis. Author(s): Buck AC, Sampson WF, Lote CJ, Blacklock NJ. Source: British Journal of Urology. 1981 December; 53(6): 485-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6797500&dopt=Abstract
•
The long-term stone recurrence rate and renal function change in unilateral nephrectomy urolithiasis patients. Author(s): Lee YH, Huang WC, Chang LS, Chen MT, Yang YF, Huang JK. Source: The Journal of Urology. 1994 November; 152(5 Pt 1): 1386-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7933165&dopt=Abstract
•
The management of paediatric urolithiasis. Author(s): Choong S, Whitfield H, Duffy P, Kellett M, Cuckow P, Van't Hoff W, Corry D. Source: Bju International. 2000 November; 86(7): 857-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11069414&dopt=Abstract
•
The medical aspects of urolithiasis: an overview. Author(s): Smith LH. Source: The Journal of Urology. 1989 March; 141(3 Pt 2): 707-10. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2645427&dopt=Abstract
•
The natural history of asymptomatic urolithiasis. Author(s): Glowacki LS, Beecroft ML, Cook RJ, Pahl D, Churchill DN. Source: The Journal of Urology. 1992 February; 147(2): 319-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1732583&dopt=Abstract
•
The natural history of calcium urolithiasis. Author(s): Coe FL, Keck J, Norton ER. Source: Jama : the Journal of the American Medical Association. 1977 October 3; 238(14): 1519-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=578220&dopt=Abstract
100 Urolithiasis
•
The pathophysiology and medical treatment of urolithiasis. Author(s): Smith LH. Source: Semin Nephrol. 1990 January; 10(1): 31-52. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2404328&dopt=Abstract
•
The pattern of urolithiasis in the Royal Navy. Author(s): Blacklock NJ. Source: J R Nav Med Serv. 1965 Summer; 51(2): 99-111. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5825874&dopt=Abstract
•
The pattern of urolithiasis in the Sudan. Author(s): Kambal A, Wahab SM, Khattab AH. Source: British Journal of Urology. 1978 October; 50(6): 376-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=709059&dopt=Abstract
•
The proper choice of agents to diminish hypercalciuria in urolithiasis. Author(s): Gursel E, Zinsser HH. Source: Med Times. 1968 November; 96(11): 1133-48. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5704909&dopt=Abstract
•
The relation between orthophosphate and pyrophosphate in normal subjects and in patients with urolithiasis. Author(s): Conte A, Roca P, Genestar C, Grases F. Source: Urological Research. 1989; 17(3): 173-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2546315&dopt=Abstract
•
The relation of clinical catastrophes, endogenous oxalate production, and urolithiasis. Author(s): Conyers RA, Bais R, Rofe AM. Source: Clinical Chemistry. 1990 October; 36(10): 1717-30. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2208646&dopt=Abstract
•
The relationship between urinary bilharziasis and urolithiasis in the Sudan. Author(s): Ibrahim A. Source: British Journal of Urology. 1978 August; 50(5): 294-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=753482&dopt=Abstract
•
The response of atrial natriuretic peptide to oral frusemide in patients with idiopathic urolithiasis. Author(s): Reynolds T, Penney M, Hampton D, Burgess N. Source: Metabolism: Clinical and Experimental. 1993 January; 42(1): 135-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8446041&dopt=Abstract
Studies 101
•
The rise in urolithiasis in Nigeria. Author(s): Osegbe DN. Source: British Medical Journal (Clinical Research Ed.). 1987 December 19-26; 295(6613): 1654. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3121114&dopt=Abstract
•
The role of abnormal glucose tolerance, human lymphocyte antigen (HLA) typing, and urolithiasis in lichen planus. Author(s): Halevy S, Ingber A, Sandbank M. Source: Journal of the American Academy of Dermatology. 1986 January; 14(1): 134-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3950101&dopt=Abstract
•
The role of citrate complexes in preventing urolithiasis. Author(s): Ashby RA, Sleet RJ. Source: Clinica Chimica Acta; International Journal of Clinical Chemistry. 1992 September 30; 210(3): 157-65. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1468138&dopt=Abstract
•
The role of magnesium in calcium oxalate urolithiasis. Author(s): Kohri K, Garside J, Blacklock NJ. Source: British Journal of Urology. 1988 February; 61(2): 107-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3349276&dopt=Abstract
•
The role of open stone surgery in the management of urolithiasis. Author(s): Paik ML, Resnick MI. Source: Tech Urol. 1997 Summer; 3(2): 96-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9297770&dopt=Abstract
•
The role of schistosomiasis in urolithiasis. Author(s): Cutajar CL. Source: British Journal of Urology. 1983 August; 55(4): 349-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6883039&dopt=Abstract
•
The role of surgery and lithotripsy in childhood urolithiasis. Author(s): Pelzer JO, Leumann E, Schwobel MG. Source: European Journal of Pediatric Surgery : Official Journal of Austrian Association of Pediatric Surgery. [et Al] = Zeitschrift Fur Kinderchirurgie. 1994 August; 4(4): 196-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7981163&dopt=Abstract
102 Urolithiasis
•
The role of Tamm-Horsfall mucoprotein in calcium oxalate crystallization. Nacetylcysteine--a new therapy for calcium oxalate urolithiasis. Author(s): Fan J, Shen SJ. Source: British Journal of Urology. 1994 September; 74(3): 288-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7953256&dopt=Abstract
•
The role of trace metals in calcium urolithiasis. Author(s): Meyer JL, Angino EE. Source: Invest Urol. 1977 March; 14(5): 347-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=844995&dopt=Abstract
•
The role of urate in idiopathic calcium urolithiasis. Author(s): Silcock SR. Source: Advances in Experimental Medicine and Biology. 1980; 122A: 121-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7424623&dopt=Abstract
•
The scientific basis of calcium oxalate urolithiasis. Predilection and precipitation, promotion and proscription. Author(s): Ryall RL. Source: World Journal of Urology. 1993; 11(1): 59-65. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8490669&dopt=Abstract
•
The stone clinic effect in patients with idiopathic calcium urolithiasis. Author(s): Hosking DH, Erickson SB, Van den Berg CJ, Wilson DM, Smith LH. Source: The Journal of Urology. 1983 December; 130(6): 1115-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6644890&dopt=Abstract
•
The treatment of uric acid urolithiasis with particular reference to the southwestern U.S.A. Author(s): Fleming T, Banowsky LH, Lackner LH. Source: Ariz Med. 1970 January; 27(1): 68-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5412499&dopt=Abstract
•
The urinary excretion of oxalic acid and magnesium in oxalate urolithiasis. Author(s): Takasaki E, Shimano E. Source: Invest Urol. 1967 November; 5(3): 303-12. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6073639&dopt=Abstract
•
The value of standard diet in urolithiasis. Author(s): Bastian HP, Vahlensieck W. Source: European Urology. 1975; 1(5): 235-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1233189&dopt=Abstract
Studies 103
•
Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Author(s): Laerum E, Larsen S. Source: Acta Med Scand. 1984; 215(4): 383-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6375276&dopt=Abstract
•
Thiazide treatment for calcium urolithiasis in patients with idiopathic hypercalciuria. Author(s): Ohkawa M, Tokunaga S, Nakashima T, Orito M, Hisazumi H. Source: British Journal of Urology. 1992 June; 69(6): 571-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1638340&dopt=Abstract
•
Thiazides and calcium urolithiasis. Author(s): Yendt ER, Cohanim M. Source: Can Med Assoc J. 1978 April 8; 118(7): 755-8. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=638900&dopt=Abstract
•
Thyrocalcitonin deficiency and urolithiasis. Preliminary report. Author(s): Gursel EO, Zinsser HH. Source: N Y State J Med. 1972 July 1; 72(13): 1705-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4504057&dopt=Abstract
•
Total blood and urine protein of urolithiasis patients with renal calculi of different chemical composition. Author(s): Bilobrov VM, Mironov OL, Minasjants EZ. Source: Urologia Internationalis. 1993; 51(3): 142-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8249224&dopt=Abstract
•
Treatment of bilateral urolithiasis. Author(s): Matsushita K, Tanikawa K, Masuda A, Matsunaga J, Matsuzaki S. Source: Tokai J Exp Clin Med. 1992 December; 17(5-6): 167-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1343424&dopt=Abstract
•
Treatment of calcium urolithiasis with diphosphonate: efficacy and hazards. Author(s): Bone HG 3rd, Zerwekh JE, Britton F, Pak CY. Source: The Journal of Urology. 1979 May; 121(5): 568-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=220433&dopt=Abstract
•
Treatment of cystine urolithiasis by a combination of extracorporeal shock wave lithotripsy and chemolysis. Author(s): Ahlstrand C, Tiselius HG. Source: J Stone Dis. 1993 January; 5(1): 32-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10148259&dopt=Abstract
104 Urolithiasis
•
Treatment of indinavir sulfate induced urolithiasis in HIV-positive patients. Author(s): Kalaitzis C, Dimitriadis G, Tsatidis T, Kuntz R, Touloupidis S, Kelidis G. Source: International Urology and Nephrology. 2002; 34(1): 13-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12549631&dopt=Abstract
•
Treatment of paediatric urolithiasis by extracorporeal shock-wave lithotripsy. Author(s): Wilbert DM, Schofer O, Riedmiller H. Source: European Journal of Pediatrics. 1988 August; 147(6): 579-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3181197&dopt=Abstract
•
Treatment of pediatric urolithiasis between 1984 and 1994. Author(s): Lim DJ, Walker RD 3rd, Ellsworth PI, Newman RC, Cohen MS, Barraza MA, Stevens PS. Source: The Journal of Urology. 1996 August; 156(2 Pt 2): 702-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8683764&dopt=Abstract
•
Treatment of uric acid urolithiasis with allopurinol: a xanthine oxidase inhibitor. Author(s): Alexander S, Brendler H. Source: The Journal of Urology. 1967 February; 97(2): 340-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6018432&dopt=Abstract
•
Treatment options for proximal ureteral urolithiasis: review and recommendations. Author(s): Liong ML, Clayman RV, Gittes RF, Lingeman JE, Huffman JL, Lyon ES. Source: The Journal of Urology. 1989 March; 141(3): 504-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2645418&dopt=Abstract
•
Treatment update on pediatric urolithiasis. Author(s): Esen T, Krautschick A, Alken P. Source: World Journal of Urology. 1997; 15(3): 195-202. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9228727&dopt=Abstract
•
Trends in urolithiasis in various ethnic groups and by age, in Israel. Author(s): Zaidman JL, Eidelman A, Pinto N, Negelev S, Assa S. Source: Clinica Chimica Acta; International Journal of Clinical Chemistry. 1986 October 31; 160(2): 87-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3780014&dopt=Abstract
•
Triamterene urolithiasis. Author(s): Gault MH, Snedden W, Taor RE, Churchill DN, Ahmed M. Source: Can Med Assoc J. 1981 June 15; 124(12): 1556-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7248862&dopt=Abstract
Studies 105
•
Triamterene urolithiasis: solubility, pk, effect on crystal formation, and matrix binding of triamterene and its metabolites. Author(s): Werness PG, Bergert JH, Smith LH. Source: The Journal of Laboratory and Clinical Medicine. 1982 February; 99(2): 254-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7061920&dopt=Abstract
•
Ultrasound detection rate of childhood urolithiasis. Author(s): al Rasheed SA, al Mugeiren MM, al-Faquih SR, Hussein I, Muzrakchi A. Source: Annals of Tropical Paediatrics. 1992; 12(3): 317-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1280049&dopt=Abstract
•
Ultrasound findings in urolithiasis in the lower ureter. Author(s): Ohnishi K, Watanabe H, Ohe H, Saitoh M. Source: Ultrasound in Medicine & Biology. 1986 July; 12(7): 577-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3529567&dopt=Abstract
•
Ureteral fibroepithelial polyp associated with urolithiasis induced by steroid therapy in a child: a case report. Author(s): Taki T, Matuura O, Isobe Y, Kamihira O, Yamada S, Kondo A, Yamada Y, Honda N. Source: Hinyokika Kiyo. 2001 August; 47(8): 579-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11579600&dopt=Abstract
•
Ureteroscopy for the treatment of urolithiasis in children. Author(s): Schuster TG, Russell KY, Bloom DA, Koo HP, Faerber GJ. Source: The Journal of Urology. 2002 April; 167(4): 1813-; Discussion 1815-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11912438&dopt=Abstract
•
Uric acid excretion in children with urolithiasis. Author(s): Miller LA, Noe HN, Stapleton FB. Source: The Journal of Pediatrics. 1989 December; 115(6): 923-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2585228&dopt=Abstract
•
Uric acid urolithiasis and crystallization inhibitors. Author(s): Grases F, Ramis M, Villacampa AI, Costa-Bauza A. Source: Urologia Internationalis. 1999; 62(4): 201-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10567882&dopt=Abstract
106 Urolithiasis
•
Uricemia and urolithiasis. Author(s): Smith MJ, Hunt LD, King JS Jr, Boyce WH. Source: The Journal of Urology. 1969 May; 101(5): 637-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5780596&dopt=Abstract
•
Urinary cAMP and calcium excretion in the fasting state and their response to oral calcium loading in patients with calcium urolithiasis. Author(s): Lien J, Keane P. Source: The Journal of Urology. 1983 February; 129(2): 401-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6300472&dopt=Abstract
•
Urinary citrate excretion in normal persons and patients with idiopathic calcium urolithiasis. Author(s): Hosking DH, Wilson JW, Liedtke RR, Smith LH, Wilson DM. Source: The Journal of Laboratory and Clinical Medicine. 1985 December; 106(6): 682-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4067380&dopt=Abstract
•
Urinary citrate excretion in patients with urolithiasis and normal subjects. Author(s): Nikkila M, Koivula T, Jokela H. Source: European Urology. 1989; 16(5): 382-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2776809&dopt=Abstract
•
Urinary composition in men and women and the risk of urolithiasis. Author(s): Sarada B, Satyanarayana U. Source: Clinical Biochemistry. 1991 December; 24(6): 487-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1773489&dopt=Abstract
•
Urinary cytology changes in protease inhibitor induced urolithiasis. Author(s): Hamm M, Wawroschek F, Rathert P. Source: The Journal of Urology. 2000 April; 163(4): 1249-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10737512&dopt=Abstract
•
Urinary excretion substances in patients with cystic fibrosis: risk of urolithiasis? Author(s): Hoppe B, Hesse A, Bromme S, Rietschel E, Michalk D. Source: Pediatric Nephrology (Berlin, Germany). 1998 May; 12(4): 275-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9655356&dopt=Abstract
•
Urinary glycosaminoglycan excretion in urolithiasis. Author(s): Harangi F, Gyorke Z, Melech B. Source: Archives of Disease in Childhood. 2000 January; 82(1): 88. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10755995&dopt=Abstract
Studies 107
•
Urinary glycosaminoglycan excretion in urolithiasis. Author(s): Akcay T, Konukoglu D, Dincer Y. Source: Archives of Disease in Childhood. 1999 March; 80(3): 271-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10325710&dopt=Abstract
•
Urinary IL-6 is elevated in patients with urolithiasis. Author(s): Rhee E, Santiago L, Park E, Lad P, Bellman GC. Source: The Journal of Urology. 1998 December; 160(6 Pt 1): 2284-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9817385&dopt=Abstract
•
Urinary ionic calcium and binding sites in normocalciuric idiopathic calcium urolithiasis. Author(s): Jacobson AL, Singhal PC, Mandin H, Hyne JB. Source: Invest Urol. 1979 November; 17(3): 218-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=500320&dopt=Abstract
•
Urinary ionized calcium in urolithiasis. Effect of cranberry juice. Author(s): Light I, Gursel E, Zinnser HH. Source: Urology. 1973 January; 1(1): 67-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4792290&dopt=Abstract
•
Urinary magnesium and oxalic acid excretion in patients with recurrent oxalate urolithiasis. Author(s): Takasaki E. Source: Invest Urol. 1975 January; 12(4): 251-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1112654&dopt=Abstract
•
Urinary mucoprotein in pediatric urolithiasis. Author(s): Singhal GD, Singh DN, Gopal SC, Ambasta SS, Gupta RM. Source: Journal of Pediatric Surgery. 1987 March; 22(3): 218-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3559863&dopt=Abstract
•
Urinary oxalate excretion in patients with urolithiasis. Author(s): Revusova V, Zvara V, Gratzlova J. Source: Urologia Internationalis. 1971; 26(4): 277-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5128557&dopt=Abstract
•
Urinary oxalate excretion in urolithiasis and nephrocalcinosis. Author(s): Neuhaus TJ, Belzer T, Blau N, Hoppe B, Sidhu H, Leumann E. Source: Archives of Disease in Childhood. 2000 April; 82(4): 322-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10735843&dopt=Abstract
108 Urolithiasis
•
Urinary phosphate excretion in the pathophysiology of idiopathic recurrent calcium urolithiasis: hormonal interactions and lipid metabolism. Author(s): Schwille PO, Herrmann U, Schmiedl A, Kissler H, Wipplinger J, Manoharan M. Source: Urological Research. 1997; 25(6): 417-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9443652&dopt=Abstract
•
Urinary pyrophosphate in patients with recurrent calcium urolithiasis and in healthy controls: a re-evaluation. Author(s): Schwille PO, Rumenapf G, Wolfel G, Kohler R. Source: The Journal of Urology. 1988 August; 140(2): 239-45. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2840520&dopt=Abstract
•
Urinary response to oral potassium citrate therapy for urolithiasis in a private practice setting. Author(s): Nicar MJ, Hsu MC, Fetner C. Source: Clinical Therapeutics. 1986; 8(2): 219-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3698069&dopt=Abstract
•
Urinary tract infection and urolithiasis. Author(s): Klausner JS, Osborne CA. Source: The Veterinary Clinics of North America. Small Animal Practice. 1980 November; 9(4): 701-11. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6996297&dopt=Abstract
•
Urinary tract stones - urolithiasis. Author(s): Foo KT. Source: Nurs J Singapore. 1981 August-September; 21: 56-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6915472&dopt=Abstract
•
Urinary volume in children with urolithiasis. Author(s): Miller LA, Stapleton FB. Source: The Journal of Urology. 1989 April; 141(4): 918-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2926890&dopt=Abstract
•
Urinary zinc excretion in patients with urolithiasis. Author(s): Revusova V, Zvara V, Gratzlova J. Source: Urologia Internationalis. 1973; 28(2): 72-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4703931&dopt=Abstract
Studies 109
•
Urine and calculus amino acids in the different types of urolithiasis. Author(s): Shaker YM, El-Hawary MF, Zahran MM, Mostafa SO. Source: Urologia Internationalis. 1983; 38(1): 51-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6836781&dopt=Abstract
•
Urine composition in patients with urolithiasis during treatment with magnesium oxide. Author(s): Tiselius HG, Ahlstrand C, Larsson L. Source: Urological Research. 1980; 8(4): 197-206. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7222314&dopt=Abstract
•
Urine specific gravity and water hardness in relation to urolithiasis in persons with spinal cord injury. Author(s): Chen Y, Roseman JM, Funkhouser E, DeVivo MJ. Source: Spinal Cord : the Official Journal of the International Medical Society of Paraplegia. 2001 November; 39(11): 571-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11641806&dopt=Abstract
•
Urokinase gene 3'-UTR T/C polymorphism is associated with urolithiasis. Author(s): Tsai FJ, Lin CC, Lu HF, Chen HY, Chen WC. Source: Urology. 2002 March; 59(3): 458-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11880102&dopt=Abstract
•
Urolithiasis after intestinal bypass for morbid obesity. Author(s): Thomas MH, Madura JA. Source: Urology. 1977 February; 9(2): 170-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=841779&dopt=Abstract
•
Urolithiasis after intestinal bypass. Author(s): Gregory JG. Source: Urology. 1977 June; 9(6): 708-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=883081&dopt=Abstract
•
Urolithiasis after kidney transplantation--clinical and mineralogical aspects. Author(s): Brien G, Scholz D, Oesterwitz H, Schubert G, Bick C. Source: Urological Research. 1980; 8(4): 211-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7013227&dopt=Abstract
•
Urolithiasis after renal transplantation. Author(s): Hayes JM, Streem SB, Graneto D, Steinmuller DR, Novick AC. Source: Transplantation Proceedings. 1989 February; 21(1 Pt 2): 1960-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2652640&dopt=Abstract
110 Urolithiasis
•
Urolithiasis and acute renal failure in an infant. Author(s): Choudhry VP, Arya LS, Singh M. Source: Indian Pediatrics. 1978 March; 15(3): 269-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=680981&dopt=Abstract
•
Urolithiasis and coronary heart disease: a note on association. Author(s): Westlund K. Source: American Journal of Epidemiology. 1973 March; 97(3): 167-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4692992&dopt=Abstract
•
Urolithiasis and cystic fibrosis. Author(s): Matthews LA, Doershuk CF, Stern RC, Resnick MI. Source: The Journal of Urology. 1996 May; 155(5): 1563-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8627822&dopt=Abstract
•
Urolithiasis and distal renal tubular acidosis preceding primary Sjogren's syndrome: a retrospective study 5-53 years after the presentation of urolithiasis. Author(s): Eriksson P, Denneberg T, Enestrom S, Johansson B, Lindstrom F, Skogh T. Source: Journal of Internal Medicine. 1996 June; 239(6): 483-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8656141&dopt=Abstract
•
Urolithiasis and enteric hyperoxaluria in a child with steatorrhea. Author(s): Jones DP, Stapleton FB, Whitington G, Noe HN. Source: Clinical Pediatrics. 1987 June; 26(6): 304-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3581641&dopt=Abstract
•
Urolithiasis and hyperoxaluria in chronic inflammatory bowel disease. Author(s): Hylander E, Jarnum S, Frandsen I. Source: Scandinavian Journal of Gastroenterology. 1979; 14(4): 475-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=482860&dopt=Abstract
•
Urolithiasis and nephropathy in gout. Author(s): Malhotra KK, Kathpalia SC, Goulatia RK. Source: J Assoc Physicians India. 1973 October; 21(10): 807-11. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4793269&dopt=Abstract
•
Urolithiasis and prostatolithiasis in alcaptonuria with ochronosis. Author(s): Krizek V. Source: International Urology and Nephrology. 1971; 3(3): 245-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5154571&dopt=Abstract
Studies 111
•
Urolithiasis and race: another viewpoint. Author(s): Mason JC, Miles BJ, Belville WD. Source: The Journal of Urology. 1985 September; 134(3): 501-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4032547&dopt=Abstract
•
Urolithiasis and the protease inhibitor indinavir. Author(s): Hermieu J, Prevot M, Ravery V, Sauty L, Moulinier F, Delmas V, Bouvet E, Boccon-Gibod L. Source: European Urology. 1999; 35(3): 239-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10072627&dopt=Abstract
•
Urolithiasis as a complication of chronic diarrheal disease. Author(s): Grossman MS, Nugent FW. Source: Am J Dig Dis. 1967 May; 12(5): 491-8. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6026427&dopt=Abstract
•
Urolithiasis as a hazard of sulfonamide therapy. Author(s): Albala DM, Prien EL Jr, Galal HA. Source: Journal of Endourology / Endourological Society. 1994 December; 8(6): 401-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7703990&dopt=Abstract
•
Urolithiasis associated with hypercalciuria. Author(s): Weinberger A, Sperling O, Schechter J, Liberman UA, Pinkhas J, de Vries A. Source: International Urology and Nephrology. 1977; 9(3): 213-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=608817&dopt=Abstract
•
Urolithiasis associated with pregnancy. Author(s): Jones WA, Correa RJ Jr, Ansell JS. Source: The Journal of Urology. 1979 September; 122(3): 333-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=470004&dopt=Abstract
•
Urolithiasis associated with protease inhibitors. Author(s): Sundaram CP, Saltzman B. Source: Journal of Endourology / Endourological Society. 1999 May; 13(4): 309-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10405912&dopt=Abstract
•
Urolithiasis associated with the ketogenic diet. Author(s): Herzberg GZ, Fivush BA, Kinsman SL, Gearhart JP. Source: The Journal of Pediatrics. 1990 November; 117(5): 743-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2231206&dopt=Abstract
112 Urolithiasis
•
Urolithiasis associated with the protease inhibitor indinavir. Author(s): Bruce RG, Munch LC, Hoven AD, Jerauld RS, Greenburg R, Porter WH, Rutter PW. Source: Urology. 1997 October; 50(4): 513-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9338724&dopt=Abstract
•
Urolithiasis associated with urogenital tuberculosis. Clinical and mineralogical aspects. Author(s): Lenk S, Schubert G, Oesterwitz H, Brien G. Source: Urological Research. 1988; 16(3): 157-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3413906&dopt=Abstract
•
Urolithiasis complicating inflammatory bowel disease. Author(s): McLeod RS, Churchill DN. Source: The Journal of Urology. 1992 September; 148(3 Pt 2): 974-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1507354&dopt=Abstract
•
Urolithiasis due to 2,8-dihydroxyadenine in an adult. Author(s): Gault MH, Simmonds HA, Snedden W, Dow D, Churchill DN, Penney H. Source: The New England Journal of Medicine. 1981 December 24; 305(26): 1570-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7311997&dopt=Abstract
•
Urolithiasis following formation of a continent urostomy: case report and review of the literature. Author(s): Sait K, Stuart G, Nation J, Ghatage P. Source: Gynecologic Oncology. 2000 May; 77(2): 330-3. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10785490&dopt=Abstract
•
Urolithiasis from stapler anastomosis. Author(s): Bisson J, Vinson RK, Leadbetter GW Jr. Source: American Journal of Surgery. 1979 February; 137(2): 280-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=371428&dopt=Abstract
•
Urolithiasis in a child: an uncommon presentation of an uncommon disease. Author(s): Thompson B, Harwood-Nuss AL. Source: Annals of Emergency Medicine. 1995 June; 25(6): 837-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7755211&dopt=Abstract
•
Urolithiasis in a children's hospital: 1985-1990. Author(s): Nimkin K, Lebowitz RL, Share JC, Teele RL. Source: Urol Radiol. 1992; 14(3): 139-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1290199&dopt=Abstract
Studies 113
•
Urolithiasis in a patient ingesting pure silica: a scanning electron microscopy study. Author(s): Leusmann DB, Pohl J, Kleinhans G. Source: Scan Electron Microsc. 1986; (Pt 2): 757-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3026031&dopt=Abstract
•
Urolithiasis in acromegaly. Author(s): Pines A, Olchovsky D. Source: Urology. 1985 September; 26(3): 240-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4035839&dopt=Abstract
•
Urolithiasis in adolescents. Author(s): Rambar AC, MacKenzie RG. Source: Am J Dis Child. 1978 November; 132(11): 1117-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=362895&dopt=Abstract
•
Urolithiasis in allograft kidneys. Author(s): Klingler HC, Kramer G, Lodde M, Marberger M. Source: Urology. 2002 March; 59(3): 344-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11880067&dopt=Abstract
•
Urolithiasis in an African population. Author(s): Mbonu O, Attah C, Ikeakor I. Source: International Urology and Nephrology. 1984; 16(4): 291-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6535779&dopt=Abstract
•
Urolithiasis in Australian aboriginal children. Author(s): Thambi Dorai CR, Dewan PA, Boucaut HA, Ehrlich J. Source: The Australian and New Zealand Journal of Surgery. 1994 February; 64(2): 99101. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8291986&dopt=Abstract
•
Urolithiasis in black Africans. Author(s): Tshipeta N, Lufuma L. Source: Urology. 1983 November; 22(5): 517-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6649207&dopt=Abstract
•
Urolithiasis in childhood acute leukemia and nonHodgkin's lymphoma. Author(s): Pui CH, Roy S 3rd, Noe HN. Source: The Journal of Urology. 1986 November; 136(5): 1052-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3464763&dopt=Abstract
114 Urolithiasis
•
Urolithiasis in childhood. Author(s): Ozokutan BH, Kucukaydin M, Gunduz Z, Kabaklioglu M, Okur H, Turan C. Source: Pediatric Surgery International. 2000; 16(1-2): 60-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10663838&dopt=Abstract
•
Urolithiasis in childhood. Author(s): Kapadia T, Vani SN. Source: Indian J Pediatr. 1991 September-October; 58(5): 671-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1813412&dopt=Abstract
•
Urolithiasis in childhood. Author(s): Polinsky MS, Kaiser BA, Baluarte HJ. Source: Pediatric Clinics of North America. 1987 June; 34(3): 683-710. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3295722&dopt=Abstract
•
Urolithiasis in childhood. Author(s): Zvara V, Revusova V, Karlikova L, Stojkovic J. Source: Czech Med. 1985; 8(4): 196-206. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3937708&dopt=Abstract
•
Urolithiasis in childhood. Author(s): Remzi D. Source: J Med. 1980; 11(5-6): 439-47. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6962828&dopt=Abstract
•
Urolithiasis in childhood. Author(s): Scholten HG, Bakker NJ, Cornil C. Source: The Journal of Urology. 1973 April; 109(4): 744-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4695122&dopt=Abstract
•
Urolithiasis in childhood. Author(s): Beane HC, Magoss JV, Staubitz WJ, Jewett TC Jr. Source: The Journal of Urology. 1967 March; 97(3): 537-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6019614&dopt=Abstract
•
Urolithiasis in childhood. Author(s): Marquardt H, Nagel R. Source: Urology. 1977 June; 9(6): 627-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=883062&dopt=Abstract
Studies 115
•
Urolithiasis in childhood. A study of 181 cases. Author(s): Borgmann V, Nagel R. Source: Urologia Internationalis. 1982; 37(3): 198-204. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7123709&dopt=Abstract
•
Urolithiasis in childhood: current management. Author(s): Choi H, Snyder HM 3rd, Duckett JW. Source: Journal of Pediatric Surgery. 1987 February; 22(2): 158-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3820016&dopt=Abstract
•
Urolithiasis in childhood: metabolic evaluation. Author(s): Perrone HC, dos Santos DR, Santos MV, Pinheiro ME, Toporovski J, Ramos OL, Schor N. Source: Pediatric Nephrology (Berlin, Germany). 1992 January; 6(1): 54-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1536741&dopt=Abstract
•
Urolithiasis in childhood: surgery and lithotripsy. Author(s): Zupancic B, Antabak A, Bradic I, Batinica S, Luetic T, Mrazovac D, Krhen I, Marekovic Z. Source: Acta Med Croatica. 1997; 51(4-5): 221-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9473802&dopt=Abstract
•
Urolithiasis in childhood: the significance of oxaluria. Case reports. Author(s): Thompson IM, Ross G Jr, McCoy EE. Source: Mo Med. 1967 April; 64(4): 321-4 Passim. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6041540&dopt=Abstract
•
Urolithiasis in childhood: when to do what? Author(s): Carvajal Busslinger MI, Gygi C, Ackermann D, Kaiser G, Bianchetti M. Source: European Journal of Pediatric Surgery : Official Journal of Austrian Association of Pediatric Surgery. [et Al] = Zeitschrift Fur Kinderchirurgie. 1994 August; 4(4): 199200. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7981164&dopt=Abstract
•
Urolithiasis in children following augmentation cystoplasty. Author(s): Palmer LS, Franco I, Kogan SJ, Reda E, Gill B, Levitt SB. Source: The Journal of Urology. 1993 August; 150(2 Pt 2): 726-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8326634&dopt=Abstract
116 Urolithiasis
•
Urolithiasis in children with spinal cord injury. Author(s): Tori JA, Kewalramani LS. Source: Paraplegia. 1979 February; 16(4): 357-65. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=431966&dopt=Abstract
•
Urolithiasis in children. Author(s): Ni YH, Tsau YK, Chen CH, Hsu TC, Lee JD, Tsai WS. Source: Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1991 January-February; 32(1): 9-16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2063681&dopt=Abstract
•
Urolithiasis in children. Author(s): O'Regan S, Homsy Y, Mongeau JG. Source: Canadian Journal of Surgery. Journal Canadien De Chirurgie. 1982 September; 25(5): 566-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7116256&dopt=Abstract
•
Urolithiasis in children. Author(s): Bagga A. Source: Indian J Pediatr. 1992 July-August; 59(4): 549-51. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1452276&dopt=Abstract
•
Urolithiasis in children. Author(s): Maheshwari RK, Gupta BD, Karunakaran M, Panpalia SS, Bafna KC. Source: Indian Pediatrics. 1987 December; 24(12): 1073-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3450656&dopt=Abstract
•
Urolithiasis in children. Author(s): Minkov N, Konstantinov D, Gotsev G. Source: European Urology. 1981; 7(3): 132-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7202447&dopt=Abstract
•
Urolithiasis in children. Author(s): Noronha RF, Gregory JG, Duke JJ. Source: The Journal of Urology. 1979 April; 121(4): 478-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=439224&dopt=Abstract
•
Urolithiasis in children. Presenting signs, etiology, bacteriology and localisation. Author(s): Bensman A, Roubach L, Allouch G, Magny JF, Brun JG, Vazquez MP, Brueziere J. Source: Acta Paediatr Scand. 1983 November; 72(6): 879-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6673490&dopt=Abstract
Studies 117
•
Urolithiasis in children: current medical management. Author(s): Laufer J, Boichis H. Source: Pediatric Nephrology (Berlin, Germany). 1989 July; 3(3): 317-31. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2702115&dopt=Abstract
•
Urolithiasis in children: innovations in management. Author(s): Shepherd P, Thomas R, Harmon EP. Source: The Journal of Urology. 1988 October; 140(4): 790-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3418799&dopt=Abstract
•
Urolithiasis in children: the role of hypercalciuria. Author(s): Stapleton FB, McKay CP, Noe HN. Source: Pediatric Annals. 1987 December; 16(12): 980-1,984-92. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3320916&dopt=Abstract
•
Urolithiasis in chronic inflammatory bowel disease. Author(s): Knudsen L, Marcussen H, Fleckenstein P, Pedersen EB, Jarnum S. Source: Scandinavian Journal of Gastroenterology. 1978; 13(4): 433-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=675152&dopt=Abstract
•
Urolithiasis in Crohn's disease and ulcerative colitis. Author(s): Gibson JN. Source: Guys Hosp Rep. 1966; 115(4): 443-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5956011&dopt=Abstract
•
Urolithiasis in general practice. An epidemiological study from a Norwegian district. Author(s): Laerum E. Source: Scandinavian Journal of Urology and Nephrology. 1983; 17(3): 313-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6648378&dopt=Abstract
•
Urolithiasis in horseshoe kidneys: therapeutic management. Author(s): Lampel A, Hohenfellner M, Schultz-Lampel D, Lazica M, Bohnen K, Thurof JW. Source: Urology. 1996 February; 47(2): 182-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8607230&dopt=Abstract
•
Urolithiasis in hyperuricemia and gout. Author(s): Yu TF. Source: The Journal of Urology. 1981 October; 126(4): 424-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7288928&dopt=Abstract
118 Urolithiasis
•
Urolithiasis in industrial workers. Author(s): Yaqin H. Source: J Pak Med Assoc. 1975 October; 25(10): 274-8. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=815587&dopt=Abstract
•
Urolithiasis in infancy. Author(s): Remzi D. Source: Urology. 1980 March; 15(3): 248-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7361354&dopt=Abstract
•
Urolithiasis in Irish children. Author(s): Puri P, O'Donnell B, Guiney EJ. Source: Ir Med J. 1975 April 26; 68(8): 192. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1132967&dopt=Abstract
•
Urolithiasis in Irish children. Author(s): Puri P, Guiney EJ. Source: Ir Med J. 1975 February 22; 68(4): 96-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1112695&dopt=Abstract
•
Urolithiasis in Jordanian children. A report of 52 cases. Author(s): Dajani AM, Abu Khadra AL, Baghdadi FM. Source: British Journal of Urology. 1988 June; 61(6): 482-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3042081&dopt=Abstract
•
Urolithiasis in Kashmir. Author(s): Wani NA, Garyali RK, Guru AA, Bhan BL, Bhan B. Source: Int Surg. 1976 September; 61(9): 498-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=965193&dopt=Abstract
•
Urolithiasis in Kuwait. Author(s): Khalifa NS, Gabal AA, Shihab M. Source: International Urology and Nephrology. 1986; 18(2): 147-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3721774&dopt=Abstract
•
Urolithiasis in lichen planus. Author(s): Kumar B, Sethuraman G, Khandelwal N, Kaur I. Source: Dermatology (Basel, Switzerland). 1999; 199(3): 280. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10592419&dopt=Abstract
Studies 119
•
Urolithiasis in lichen planus. Author(s): Halevy S, Feuerman EJ. Source: Archives of Dermatology. 1983 May; 119(5): 364. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6847211&dopt=Abstract
•
Urolithiasis in Manipur (north eastern region of India). Incidence and chemical composition of stones. Author(s): Singh PP, Singh LB, Prasad SN, Singh MG. Source: The American Journal of Clinical Nutrition. 1978 September; 31(9): 1519-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=685868&dopt=Abstract
•
Urolithiasis in northeast Bombay: seasonal prevalence and chemical composition of stones. Author(s): Hussain F, Billimoria FR, Singh PP. Source: International Urology and Nephrology. 1990; 22(2): 119-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2354890&dopt=Abstract
•
Urolithiasis in patients with a jejunoileal bypass. Author(s): Clayman RV, Buchwald H, Varco RL, DeWolf WC, Williams RD. Source: Surg Gynecol Obstet. 1978 August; 147(2): 225-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=684575&dopt=Abstract
•
Urolithiasis in patients with end stage renal failure. Author(s): Daudon M, Lacour B, Jungers P, Drueke T, Reveillaud RJ, Chevalier A, Bader CA. Source: The Journal of Urology. 1992 April; 147(4): 977-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1552617&dopt=Abstract
•
Urolithiasis in patients with Hirschsprung's disease. Author(s): Sarioglu A, Tanyel FC, Buyukpamukcu N, Hicsonmez A. Source: European Journal of Pediatric Surgery : Official Journal of Austrian Association of Pediatric Surgery. [et Al] = Zeitschrift Fur Kinderchirurgie. 1997 June; 7(3): 149-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9241500&dopt=Abstract
•
Urolithiasis in patients with spinal cord injury. Author(s): Nikakhtar B, Vaziri ND, Khonsari F, Gordon S, Mirahmadi MD. Source: Paraplegia. 1981; 19(6): 363-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7312388&dopt=Abstract
120 Urolithiasis
•
Urolithiasis in pediatric patients with acute lymphoblastic leukemia. Author(s): Howard SC, Kaplan SD, Razzouk BI, Rivera GK, Sandlund JT, Ribeiro RC, Rubnitz JE, Gajjar AJ, Ke W, Hancock ML, Skoch JP, Roy S, Hudson M, Pui CH. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2003 March; 17(3): 541-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12646942&dopt=Abstract
•
Urolithiasis in pediatric patients. Author(s): Milliner DS, Murphy ME. Source: Mayo Clinic Proceedings. 1993 March; 68(3): 241-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8474265&dopt=Abstract
•
Urolithiasis in pregnancy. Author(s): O'Regan S, Laberge I, Homsy Y. Source: European Urology. 1984; 10(1): 40-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6698085&dopt=Abstract
•
Urolithiasis in pregnancy. A case report. Author(s): Schamroth AD. Source: South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde. 1990 January 20; 77(2): 102-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2296724&dopt=Abstract
•
Urolithiasis in pregnancy. Diagnosis, management and pregnancy outcome. Author(s): Lewis DF, Robichaux AG 3rd, Jaekle RK, Marcum NG, Stedman CM. Source: J Reprod Med. 2003 January; 48(1): 28-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12611091&dopt=Abstract
•
Urolithiasis in pregnancy. I: pathophysiology, fetal considerations and diagnosis. Author(s): Biyani CS, Joyce AD. Source: Bju International. 2002 May; 89(8): 811-8; Quiz I-Ii. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11972502&dopt=Abstract
•
Urolithiasis in pregnancy. II: management. Author(s): Biyani CS, Joyce AD. Source: Bju International. 2002 May; 89(8): 819-23. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11972503&dopt=Abstract
Studies 121
•
Urolithiasis in pregnancy--a clinical challenge. Author(s): Buchholz NP, Biyabani R, Sulaiman MN, Talati J. Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology. 1998 September; 80(1): 25-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9758255&dopt=Abstract
•
Urolithiasis in pre-term neonates associated with furosemide therapy. Author(s): Noe HN, Bryant JF, Roy S 3rd, Stapleton FB. Source: The Journal of Urology. 1984 July; 132(1): 93-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6726969&dopt=Abstract
•
Urolithiasis in primary care. Author(s): Frank SH, Resnick MI. Source: Primary Care. 1989 December; 16(4): 967-80. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2692048&dopt=Abstract
•
Urolithiasis in railroad shopmen in relation to oxalic acid exposure at work. Author(s): Laerum E, Aarseth S. Source: Scand J Work Environ Health. 1985 April; 11(2): 97-100. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4001903&dopt=Abstract
•
Urolithiasis in renal and combined pancreas/renal transplant recipients. Author(s): Rhee BK, Bretan PN Jr, Stoller ML. Source: The Journal of Urology. 1999 May; 161(5): 1458-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10210372&dopt=Abstract
•
Urolithiasis in Sahelian Africa. Author(s): Docquier J, Sako A, Thuriaux MC. Source: Trans R Soc Trop Med Hyg. 1981; 75(1): 123-4. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7268841&dopt=Abstract
•
Urolithiasis in Saudi Arabia. Author(s): Abomelha MS, al-Khader AA, Arnold J. Source: Urology. 1990 January; 35(1): 31-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2296813&dopt=Abstract
•
Urolithiasis in spina bifida. Author(s): Gros DA, Thakkar RN, Lakshmanan Y, Ruffing V, Kinsman SL, Docimo SG. Source: European Journal of Pediatric Surgery : Official Journal of Austrian Association of Pediatric Surgery. [et Al] = Zeitschrift Fur Kinderchirurgie. 1998 December; 8 Suppl 1: 68-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9926338&dopt=Abstract
122 Urolithiasis
•
Urolithiasis in Sudan. Geographical distribution and the influence of climate. Author(s): Kambal A, Wahab EM, Khattab AH. Source: Trop Geogr Med. 1979 March; 31(1): 75-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=483375&dopt=Abstract
•
Urolithiasis in Tennessee: an occupational window into a regional problem. Author(s): Thun MJ, Schober S. Source: American Journal of Public Health. 1991 May; 81(5): 587-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2014858&dopt=Abstract
•
Urolithiasis in the aboriginal and non-aboriginal children and adults of Central Australia. Author(s): Farago C. Source: Australasian Radiology. 1987 August; 31(3): 300-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3435347&dopt=Abstract
•
Urolithiasis in the aboriginal--a comment. Author(s): Bateson EM. Source: Australasian Radiology. 1989 February; 33(1): 64-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2712791&dopt=Abstract
•
Urolithiasis in the exstrophy-epispadias complex. Author(s): Silver RI, Gros DA, Jeffs RD, Gearhart JP. Source: The Journal of Urology. 1997 September; 158(3 Pt 2): 1322-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9258206&dopt=Abstract
•
Urolithiasis in the low birth weight infant: the role and efficacy of extracorporeal shock wave lithotripsy. Author(s): Shukla AR, Hoover DL, Homsy YL, Perlman S, Schurman S, Reisman EM. Source: The Journal of Urology. 2001 June; 165(6 Pt 2): 2320-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11371971&dopt=Abstract
•
Urolithiasis in the lower urinary tract. Author(s): Banner MP, Pollack HM. Source: Semin Roentgenol. 1982 April; 17(2): 140-8. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7089595&dopt=Abstract
•
Urolithiasis in the Sudan. Studies on a stone-prone and a stone-free population. Author(s): Kambal A, Wahab EM, Khattab AH, Zaki J. Source: British Journal of Urology. 1981 February; 53(1): 7-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7470805&dopt=Abstract
Studies 123
•
Urolithiasis in Tunisian children: a study of 120 cases based on stone composition. Author(s): Kamoun A, Daudon M, Abdelmoula J, Hamzaoui M, Chaouachi B, Houissa T, Zghal A, Ben Ammar S, Belkahia C, Lakhoua R. Source: Pediatric Nephrology (Berlin, Germany). 1999 November; 13(9): 920-5; Discussion 926. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10603149&dopt=Abstract
•
Urolithiasis in Udaipur (Rajasthan). Author(s): Pendse AK, Srivastava AK, Kumawat JL, Goyal A, Ghosh R, Sharma HS, Singh PP. Source: J Indian Med Assoc. 1984 May; 82(5): 151-5. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6481171&dopt=Abstract
•
Urolithiasis in Zimbabwe: yesterday, today and tomorrow. Author(s): Danso AP. Source: Cent Afr J Med. 1991 January; 37(1): 30-9. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2060006&dopt=Abstract
•
Urolithiasis inhibitors and calculus nucleation. Author(s): Grases F, Gil JJ, Conte A. Source: Urological Research. 1989; 17(3): 163-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2546313&dopt=Abstract
•
Urolithiasis on suture materials: its importance, pathogenesis and prophylaxis: an introduction to the monofilament teflon suture. Author(s): Yudofsky SC, Scott FB. Source: The Journal of Urology. 1969 December; 102(6): 745-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5392744&dopt=Abstract
•
Urolithiasis on the Byzantine throne. Author(s): Lascaratos J, Kostakopoulos A, Poulakou-Rebelakou E. Source: Urology. 2001 October; 58(4): 631-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11597558&dopt=Abstract
•
Urolithiasis related to laxative abuse. Author(s): Wu WJ, Huang CH, Chiang CP, Huang CN, Wang CN. Source: J Formos Med Assoc. 1993 November; 92(11): 1004-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7910057&dopt=Abstract
124 Urolithiasis
•
Urolithiasis research: progress and trends. Author(s): Cummings NB. Source: Advances in Experimental Medicine and Biology. 1980; 128: 473-81. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6252761&dopt=Abstract
•
Urolithiasis research--where is it going? Author(s): Schwille PO. Source: Urological Research. 1985; 13(4): 157-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4049600&dopt=Abstract
•
Urolithiasis risk factors in continent reservoir ileostomy patients. Author(s): Stern H, Cohen Z, Wilson DR, Mickle DA. Source: Diseases of the Colon and Rectum. 1980 November-December; 23(8): 556-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7460692&dopt=Abstract
•
Urolithiasis through the ages. Author(s): Shah J, Whitfield HN. Source: Bju International. 2002 May; 89(8): 801-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11972501&dopt=Abstract
•
Urolithiasis update: biophysical and radiologic advances enhance antistone therapy. Author(s): Gill WB. Source: American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 1981 September; 1(2): 66-90. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7036717&dopt=Abstract
•
Urolithiasis update: clinical experience with the Swiss LithoClast. Author(s): Schock J, Barsky RI, Pietras JR. Source: J Am Osteopath Assoc. 2001 August; 101(8): 437-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11526875&dopt=Abstract
•
Urolithiasis with blind-ending ureteral duplication and azotemia treated with shock wave therapy. Author(s): Bhatia V, Biyani CS. Source: Urologia Internationalis. 1993; 51(4): 237-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8266619&dopt=Abstract
•
Urolithiasis with congenital upper tract anomalies: a 4-year experience with extracorporeal shock wave lithotripsy. Author(s): Bhatia V, Biyani CS. Source: Journal of Endourology / Endourological Society. 1994 February; 8(1): 5-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8186785&dopt=Abstract
Studies 125
•
Urolithiasis, inhibitors and promoters. Author(s): Grases F, Conte A. Source: Urological Research. 1992; 20(1): 86-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1736493&dopt=Abstract
•
Urolithiasis. Author(s): Magoha GA. Source: East Afr Med J. 1990 October; 67(10): 681-4. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2282887&dopt=Abstract
•
Urolithiasis. Author(s): Malek RS. Source: Archives of Internal Medicine. 1982 June; 142(6): 1089. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7092422&dopt=Abstract
•
Urolithiasis. Author(s): Schenkman NS, Stoller ML. Source: The Western Journal of Medicine. 1998 August; 169(2): 110-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9735693&dopt=Abstract
•
Urolithiasis. Author(s): Andriani RT, Carson CC 3rd. Source: Clin Symp. 1986; 38(3): 3-32. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3527525&dopt=Abstract
•
Urolithiasis. Author(s): Griffith DP. Source: The Journal of Urology. 1981 October; 126(4): 431. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7026801&dopt=Abstract
•
Urolithiasis. Author(s): Goode LS. Source: J Ky Med Assoc. 1972 March; 70(3): 205-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5023656&dopt=Abstract
•
Urolithiasis. Author(s): Nordin BE, Hodgkinson A. Source: Adv Intern Med. 1967; 13: 155-82. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5334721&dopt=Abstract
126 Urolithiasis
•
Urolithiasis. A study of its frequency. Author(s): Norlin A, Lindell B, Granberg PO, Lindvall N. Source: Scandinavian Journal of Urology and Nephrology. 1976; 10(2): 150-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=948724&dopt=Abstract
•
Urolithiasis/calcinations in renal graft--a link with renal transplant bone disease treatment? Author(s): Ponikvar JB, Kmetec A, Ponikvar R. Source: Transplantation Proceedings. 2001 November-December; 33(7-8): 3672-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11750562&dopt=Abstract
•
Urolithiasis: a comparative spectrophotometric, pathological and morphological study. Author(s): Arnold W, Seemann N. Source: Ger Med Mon. 1969 July; 14(7): 341-4. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5820417&dopt=Abstract
•
Urolithiasis: a tribal scenario. Author(s): Bakane BC, Nagtilak SB, Patil B. Source: Indian J Pediatr. 1999 November-December; 66(6): 863-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10798152&dopt=Abstract
•
Urolithiasis: detection and management with unenhanced spiral CT--a urologic perspective. Author(s): Preminger GM, Vieweg J, Leder RA, Nelson RC. Source: Radiology. 1998 May; 207(2): 308-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9577473&dopt=Abstract
•
Urolithiasis: evaluation and management. Author(s): Krzyzaniak KE. Source: J S C Med Assoc. 1982 December; 78(12): 678-82. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6961253&dopt=Abstract
•
Urolithiasis: extracorporeal shock wave lithotripsy and endourologic techniques. Author(s): Winfield HN. Source: Iowa Med. 1989 November; 79(11): 537-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2599812&dopt=Abstract
•
Urolithiasis--a study of drinking water hardness and genetic factors. Author(s): Churchill DN, Maloney CM, Bear J, Bryant DG, Fodor G, Gault MH. Source: J Chronic Dis. 1980; 33(11-12): 727-31. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7430324&dopt=Abstract
Studies 127
•
Urolithiasis--historical, comparative and pathophysiological aspects: a review. Author(s): Michell AR. Source: Journal of the Royal Society of Medicine. 1989 November; 82(11): 669-72. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2687468&dopt=Abstract
•
Urolithiasis--present state and outlook. Author(s): Vahlensieck W. Source: Urological Research. 1979 September; 7(3): 137-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=505677&dopt=Abstract
•
Urolithoscintigraphy: preliminary report of a new imaging modality for urolithiasis. Author(s): Pollack HW, Alavi A. Source: Journal of Endourology / Endourological Society. 1995 June; 9(3): 287-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7550277&dopt=Abstract
•
Urolithoscintigraphy: preliminary report of a new imaging modality for urolithiasis. Author(s): Wolf JS Jr, Irby PB 3rd, Shields A, Yuen-Green MS, Hattner RS, Stoller ML. Source: Journal of Endourology / Endourological Society. 1994 April; 8(2): 133-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8061671&dopt=Abstract
•
Urologic manifestations of nonurologic disease urolithiasis. Author(s): Matlaga BR, Assimos DG. Source: The Urologic Clinics of North America. 2003 February; 30(1): 91-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12580561&dopt=Abstract
•
Validity of biochemical findings in the evaluation of patients with urolithiasis. Author(s): Tiselius HG, Larsson L. Source: European Urology. 1980; 6(2): 90-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7358065&dopt=Abstract
•
Value of repeated analyses of 24-hour urine in recurrent calcium urolithiasis. Author(s): Menon M. Source: The Journal of Urology. 1995 February; 153(2): 555. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7815641&dopt=Abstract
•
Value of repeated analyses of 24-hour urine in recurrent calcium urolithiasis. Author(s): Hobarth K, Hofbauer J, Szabo N. Source: Urology. 1994 July; 44(1): 20-4; Discussion 24-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8042263&dopt=Abstract
128 Urolithiasis
•
Value of routine citrate analysis and calcium/citrate ratio in calcium urolithiasis. Author(s): Hobarth K, Hofbauer J. Source: European Urology. 1991; 19(2): 165-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2022221&dopt=Abstract
•
Value of the urinary stone promoters/inhibitors ratios in the estimation of the risk of urolithiasis. Author(s): Batinic D, Milosevic D, Blau N, Konjevoda P, Stambuk N, Barbaric V, SubatDezulovic M, Votava-Raic A, Nizic L, Vrljicak K. Source: Journal of Chemical Information and Computer Sciences. 2000 May-June; 40(3): 607-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10850766&dopt=Abstract
•
Variations in the activity of urinary inhibitors in calcium oxalate urolithiasis. Author(s): Grases F, Genestar C, March P, Conte A. Source: British Journal of Urology. 1988 December; 62(6): 515-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2851362&dopt=Abstract
•
Vasectomy and urolithiasis. Author(s): Kronmal RA, Alderman E, Krieger JN, Killip T, Kennedy JW, Athearn MW. Source: Lancet. 1988 January 2-9; 1(8575-6): 22-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2891890&dopt=Abstract
•
Vasectomy is associated with an increased risk for urolithiasis. Author(s): Kronmal RA, Krieger JN, Coxon V, Wortley P, Thompson L, Sherrard DJ. Source: American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 1997 February; 29(2): 207-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9016891&dopt=Abstract
•
Vitamin A and urolithiasis. Author(s): Grases F, Garcia-Gonzalez R, Genestar C, Torres JJ, March JG. Source: Clinica Chimica Acta; International Journal of Clinical Chemistry. 1998 January 30; 269(2): 147-57. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9526674&dopt=Abstract
•
Wilson's disease presenting as symptomatic urolithiasis: a case report and review of the literature. Author(s): Nakada SY, Brown MR, Rabinowitz R. Source: The Journal of Urology. 1994 September; 152(3): 978-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8051776&dopt=Abstract
Studies 129
•
Xanthine urolithiasis: ultrastructure analysis of renal and bladder calculi. Author(s): Kario K, Matsuo T, Tankawa H. Source: International Urology and Nephrology. 1991; 23(4): 317-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1938226&dopt=Abstract
•
Xanthinuria : study of a large kindred with familial urolithiasis and gout. Author(s): Auscher C, Pasquier C, de Gery A, Weissenbach R, Delbarre F. Source: Biomedicine. 1977 March; 27(2): 57-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=861350&dopt=Abstract
•
Xanthogranulomatous pyelonephritis in the spinal cord injury patient: a complication of urolithiasis. Author(s): Culkin DJ, Wheeler JS Jr, Nam SI, Nemchausky BA. Source: J Am Paraplegia Soc. 1987 July-October; 10(2): 27-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3450777&dopt=Abstract
•
Zinc, copper and oxalocalcic urolithiasis. Author(s): Grases F, Ruiz J, Costa-Bauza A, Coll R, Conte A. Source: Urologia Internationalis. 1993; 50(4): 205-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8506591&dopt=Abstract
131
CHAPTER 2. NUTRITION AND UROLITHIASIS Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and urolithiasis.
Finding Nutrition Studies on Urolithiasis The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail:
[email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “urolithiasis” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.
7
Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.
132 Urolithiasis
The following is a typical result when searching for recently indexed consumer information on urolithiasis: •
Dietary salt, urinary calcium, and kidney stone risk. Author(s): Washington State University, Spokane, USA. Source: Massey, L K Whiting, S J Nutr-Revolume 1995 May; 53(5): 131-9 0029-6643
•
Revised anti-kidney stone recipe. Source: Anonymous Johns-Hopkins-Med-Lett-Health-After-50. 2002 May; 14(3): 1-3 1042-1882
•
Should dietary calcium and protein be restricted in patients with nephrolithiasis? Author(s): Mineral Bioavailability Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111, USA. Source: Martini, L A Wood, R J Nutr-Revolume 2000 April; 58(4): 111-7 0029-6643
•
Some passing thoughts on kidney stones. Source: Harv-Med-Sch-Health-Lett. Boston : Dept. of Continuing Education, Harvard Medical School. March 1983. volume 8 (5) page 1-2, 5. ill. 0161-7486
The following information is typical of that found when using the “Full IBIDS Database” to search for “urolithiasis” (or a synonym): •
Efficacy of horse gram (Dolichos Biflorus) extract on experimental urolithiasis in goats. Author(s): College of Veterinary and Animal Sciences, Thrissur (India). Department of Animal Nutrition College of Veterinary and Animal Sciences, Mannuthy, Thrissur (India). Department of Pathology Source: SenthilkuMarch, R.P. James, C.S. Gangadevi, P. Kunjamma, C.R.L Cheiron (India). (February & April 2001). volume 30(1 & 2) page 1-5. goats urolithiasis horse gram seeds plant extracts animal feeding feed intake blood composition feed conversion efficiency diet treatment 0379-543 X Summary: caprin urolithiase haricot de kulthi extrait d' origine vegetale alimentation des animaux prise alimentaire animaux composition du sang efficacite alimentaire traitement par regime alimentaire
Additional physician-oriented references include: •
2,8-dihydroxyadenine urolithiasis: report of a case first diagnosed after renal transplant. Author(s): Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467. Source: Glicklich, D Gruber, H E Matas, A J Tellis, V A Karwa, G Finley, K Salem, C Soberman, R Seegmiller, J E Q-J-Med. 1988 October; 68(258): 785-93 0033-5622
•
A family-based study of metabolic phenotypes in calcium urolithiasis. Author(s): Centre de Recherche Guy Bernier, Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada. Source: Tessier, J Petrucci, M Trouve, M L Valiquette, L Guay, G Ouimet, D Bonnardeaux, A Kidney-Int. 2001 September; 60(3): 1141-7 0085-2538
•
Activity of certain fractions of Tribulus terrestris fruits against experimentally induced urolithiasis in rats. Author(s): Division of Pharmacology, Central Drug Research Institute, Lucknow, India.
Nutrition 133
Source: Anand, R Patnaik, G K Kulshreshtha, D K Dhawan, B N Indian-J-Exp-Biol. 1994 August; 32(8): 548-52 0019-5189 •
An outbreak of Streptococcus pyogenes infection associated with calcium oxalate urolithiasis in guineapigs (Cavia porcellus). Source: Okewole, P.A. Odeyemi, P.S. Oladunmade, M.A. Ajagbonna, B.O. Onah, J. Spencer, T. Lab-Anim. London : Royal Society of Medicine Services. April 1991. volume 25 (2) page 184-186. 0023-6772
•
Association between dietary factors and calcium oxalate and magnesium ammonium phosphate urolithiasis in cats. Author(s): Minnesota Urolith Center, Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St Paul 55108, USA. Source: Lekcharoensuk, C Osborne, C A Lulich, J P Pusoonthornthum, R Kirk, C A Ulrich, L K Koehler, L A Carpenter, K A Swanson, L L J-Am-Vet-Med-Assoc. 2001 November 1; 219(9): 1228-37 0003-1488
•
Association of vitamin D receptor gene polymorphism with urolithiasis. Author(s): Department of Urology, University of the Ryukyus, Okinawa, Japan. Source: Nishijima, Saori Sugaya, Kimio Naito, Ayako Morozumi, Makoto Hatano, Tadashi Ogawa, Yoshihide J-Urol. 2002 May; 167(5): 2188-91 0022-5347
•
Biochemical distinction between hyperuricosuric calcium urolithiasis and gouty diathesis. Author(s): Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8885, USA. Source: Pak, C Y Poindexter, J R Peterson, R D Koska, J Sakhaee, K Urology. 2002 November; 60(5): 789-94 1527-9995
•
Biochemical mechanisms and effects of Mimosa pudica (Linn) on experimental urolithiasis in rats. Author(s): Department of Pharmacology, Kasturba Medical College, Manipal, India. Source: Joyamma, V Rao, S G Hrishikeshavan, H J Aroor, A R Kulkarni, D R Indian-JExp-Biol. 1990 March; 28(3): 237-40 0019-5189
•
Bone mineral density loss in patients with urolithiasis: a follow-up study. Author(s): Center for Osteoporosis, Institute for Medical Research and Occupational Health, Ksaverska cesta 2, P.O. Box 291, Zagreb, 10001 Croatia.
[email protected] Source: Cvijetic, S Furedi Milhofer, H Babic Ivancic, V Tucak, A Galic, J Dekanic Ozegovic, D Arch-Med-Res. 2002 Mar-April; 33(2): 152-7 0188-4409
•
Calcium oxalate urolithiasis in cats. Author(s): The Ohio State University Veterinary Hospital, Columbus 43210-1089, USA.
[email protected] Source: Buffington, C A Chew, D J J-Endourol. 1999 November; 13(9): 659-63 0892-7790
•
Calcium oxalate urolithiasis, rat. Source: Khan, S.R. Woodard, J.C. Urinary system / edited by T.C. Jones, U. Mohr, R.D. Hunt. Berlin : Springer-Verlag, c1986. page 355-361. ill. ISBN: 0387165916
•
Canine struvite urolithiasis. Source: Seaman, R. Bartges, J.W. Compend-contin-educ-pract-vet. Trenton, N.J. : Veterinary Learning Systems. May 2001. volume 23 (5) page 407-420. 0193-1903
•
Comparative overview of struvite urolithiasis. Source: Sanderson, S. Compend-contin-educ-pract-vet. Trenton, N.J. : Veterinary Learning Systems. July 1999. volume 21 (7) page 662-663, 667. 0193-1903
134 Urolithiasis
•
Decreased renal expression of the putative calcium oxalate inhibitor Tamm-Horsfall protein in the ethylene glycol rat model of calcium oxalate urolithiasis. Author(s): Jim and Eilleen Dicke Research Laboratory, Department of Urology and Anatomy, School of Medicine, Case Western Reserve University-University Hospitals of Cleveland, Cleveland, Ohio, USA. Source: Marengo, Susan Ruth Chen, Daniel H C Kaung, Hue Lee C Resnick, Martin I Yang, Lizhu J-Urol. 2002 May; 167(5): 2192-7 0022-5347
•
Diet and urolithiasis. Source: National Dairy Council. Dairy-Counc-Dig. Rosemont : National Dairy Council. Sept/October 1983. volume 54 (5) page 25-30. 0011-5568
•
Dietary management of urolithiasis. Author(s): Division of Nephrology and Internal Medicine, Mayo Clinic, Rochester, MN 55905. Source: Smith, L H Curr-Opin-Nephrol-Hypertens. 1994 March; 3(2): 189-94 1062-4821
•
Effect of “Rosa Canina” infusion and magnesium on the urinary risk factors of calcium oxalate urolithiasis. Author(s): Department of Chemistry, University of Balearic Islands, Palma de Mallorca, Spain. Source: Grases, F Masarova, L Costa Bauza, A March, J G Prieto, R Tur, J A Planta-Med. 1992 December; 58(6): 509-12 0032-0943
•
Effect of A. lanata leaf extract and Vediuppu chunnam on the urinary risk factors of calcium oxalate urolithiasis during experimental hyperoxaluria. Author(s): Department of Medical Biochemistry, Dr Alm PG Institute of Basic Medical Sciences, University of Madras, Taramani, Chennai, 600 021, India. Source: Selvam, R Kalaiselvi, P Govindaraj, A Bala Murugan, V Sathish KuMarch, A S Pharmacol-Res. 2001 January; 43(1): 89-93 1043-6618
•
Effect of citrate feeding on free radical induced changes in experimental urolithiasis. Author(s): Department of Medical Biochemistry, Dr. A.L.M. Post-Graduate Institute of Basic Medical Sciences, University of Madras, India. Source: Selvam, R Bijikurien, T Indian-J-Exp-Biol. 1992 August; 30(8): 705-10 0019-5189
•
Effect of combined therapy in patients with urolithiasis of lower urinary pH. Author(s): Department of Urology, Hyogo College of Medicine. Source: Wei, X Y Hinyokika-Kiyo. 1987 November; 33(11): 1778-81 0018-1994
•
Effect of mineral water containing calcium and magnesium on calcium oxalate urolithiasis risk factors. Author(s): Department of Chemistry, University of Cape Town, South Africa.
[email protected] Source: Rodgers, A L Urol-Int. 1997; 58(2): 93-9 0042-1138
•
Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. Author(s): Department of Urology, Faculty of Medicine, University of Ankara, Turkey.
[email protected] Source: Soygur, Tarkan Akbay, Aysegul Kupeli, Sadettin J-Endourol. 2002 April; 16(3): 149-52 0892-7790
•
Effect of unprocessed wheat bran on calciuria and oxaluria in patients with urolithiasis. Author(s): Scott Department of Urology, Baylor College of Medicine, Houston, Texas.
Nutrition 135
Source: Gleeson, M J Thompson, A S Mehta, S Griffith, D P Urology. 1990 March; 35(3): 231-4 0090-4295 •
Effects of sodium citrate, potassium citrate, and citric acid in preventing experimental calcium oxalate urolithiasis in rats. Author(s): Department of Urology, School of Medicine, Juntendo University. Source: Ogawa, Y Tanaka, T Yamaguchi, K Morozumi, M Kitagawa, R Hinyokika-Kiyo. 1987 November; 33(11): 1772-7 0018-1994
•
Epidemiology of urolithiasis. Author(s): Istituto di Urologia, IRCCS Ospedale Maggiore di Milano, Milan. Source: Trinchieri, A Arch-Ital-Urol-Androl. 1996 September; 68(4): 203-49 1124-3562
•
Feline struvite urolithiasis: factors affecting urine pH may be more important than magnesium levels in food. Author(s): Department of Physiology and Anatomy, Massey University, Palmerston North, New Zealand. Source: Tarttelin, M F Vet-Rec. 1987 September 5; 121(10): 227-30 0042-4900
•
Gahat: a Napalese cure for urolithiasis? Author(s): Tripler Army Medical Center, Honolulu, Hawaii, USA. Source: Schwartz, B F Schenkman, N Nguyen, R Stoller, M L Urology. 2000 December 20; 56(6): 912-4 1527-9995
•
Hypercalcemia and calcium oxalate urolithiasis in cats: a report of five cases. Author(s): Department of Small Animal Medicine, Veterinary Teaching Hospital, the University of Georgia, Athens 30602, USA. Source: McClain, H M Barsanti, J A Bartges, J W J-Am-Anim-Hosp-Assoc. 1999 JulAugust; 35(4): 297-301 0587-2871
•
Hyperoxaluria and urolithiasis in young children: an atypical presentation. Author(s): Department of Pediatrics, Mayo Clinic, Rochester, Minnesota 55905, USA. Source: Monico, C G Milliner, D S J-Endourol. 1999 November; 13(9): 633-6 0892-7790
•
Impact of urometabolic evaluation on prevention of urolithiasis: a retrospective study. Author(s): Department of Epidemiology, University Hospital Nijmegen, The Netherlands. Source: van Drongelen, J Kiemeney, L A Debruyne, F M de la Rosette, J J Urology. 1998 September; 52(3): 384-91 0090-4295
•
Influence of dietary mineral imbalance on the incidence of urolithiasis in Egyptian calves. Source: Ahmed, A S Amer, H A Ibrahim, I M Arch-Exp-Veterinarmed. 1989 January; 43(1): 73-7 0003-9055
•
Investigations on dietary treatment of struvite urolithiasis: 3. Effect of an acidifying diet on acid-base- and mineral-balance of cats after acute urethral obstruction. Author(s): Institut fur Tierernahrung, Tierarztlichen Hochschule Hannover. Source: Kienzle, E Meyer Lindenberg, A Schuknecht, A Nolte, I Dtsch-TierarztlWochenschr. 1993 December; 100(12): 473-6 0341-6593
•
Is there a role for uric acid in an animal model of calcium phosphate nephrocalcinosis and calcium phosphate crystallization in urine of patients with idiopathic calcium urolithiasis? An orientational study. Author(s): Department of Surgery, University of Erlangen, Germany. Source: Schwille, P O Schmiedl, A Manoharan, M Wipplinger, J J-Endourol. 1999 November; 13(9): 637-45 0892-7790
136 Urolithiasis
•
Lipids changes in rat tissues in experimental urolithiasis. Source: Rengaraju, M Selvam, R Indian-J-Exp-Biol. 1989 September; 27(9): 795-8 00195189
•
Medical therapy and new approaches to management of urolithiasis. Author(s): Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical School, Dallas, USA. Source: Pak, C Y Resnick, M I Urol-Clin-North-Am. 2000 May; 27(2): 243-53 0094-0143
•
Medical therapy, calcium oxalate urolithiasis. Author(s): Center for Mineral Metabolism and Clinical Research, University of Texas, Southwestern Medical Center, Dallas, USA. Source: Ruml, L A Pearle, M S Pak, C Y Urol-Clin-North-Am. 1997 February; 24(1): 11733 0094-0143
•
Microbial degradation of dietary oxalate in the human gut and urinary oxalate concentrations in patients with calcium oxalate urolithiasis and control persons. Author(s): Universitat Ulm, Urologische Universitatsklinik und Poliklinik. Source: Kleinschmidt, K Mahlmann, A Hautmann, R Investig-Urol-(Berl). 1994; 5222-4
•
Oral potassium citrate treatment for idiopathic hypocitruria in children with calcium urolithiasis. Author(s): Department of Urology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. Source: Tekin, A Tekgul, S Atsu, N Bakkaloglu, M Kendi, S J-Urol. 2002 December; 168(6): 2572-4 0022-5347
•
Oxypurines, protein, glucose and the functional state of blood vasculature are markers of renal calcium stone-forming processes? Observations in men with idiopathic recurrent calcium urolithiasis. Author(s): Mineral Metabolism and Endocrine Research Laboratory, Department of Surgery, University of Erlangen, Germany. Source: Manoharan, M Schwille, P O Clin-Chem-Lab-Med. 2002 March; 40(3): 266-77 1434-6621
•
Pediatric urolithiasis in Kuwait. Author(s): Department of Pediatrics, Faculty of Medicine, Kuwait University, Safat.
[email protected] Source: Al Eisa, A A Al Hunayyan, A Gupta, R Int-Urol-Nephrol. 2002; 33(1): 3-6 03011623
•
Pediatric urolithiasis: developing nation perspectives. Author(s): Sindh Institute of Urology and Transplantation, Dow Medical College, Karachi, Pakistan. Source: Rizvi, S A Naqvi, S A Hussain, Z Hashmi, A Hussain, M Zafar, M N Sultan, S Mehdi, H J-Urol. 2002 October; 168(4 Pt 1): 1522-5 0022-5347
•
Predisposition towards urolithiasis associated with the NQO1 null-allele. Author(s): Institut fur Physiologische Chemie I, Dusseldorf, Germany. Source: Schulz, W A Krummeck, A Rosinger, I Schmitz Drager, B J Sies, H Pharmacogenetics. 1998 October; 8(5): 453-4 0960-314X
•
Promoters and inhibitors of calcium urolithiasis in children. Author(s): Dipartimento di Pediatria, I Facolta, Universita Federico II, Napoli, Italia. Source: Lama, G Carbone, M G Marrone, N Russo, P Spagnuolo, G Child-Nephrol-Urol. 1990; 10(2): 81-4 1012-6694
Nutrition 137
•
Prophylaxis of oxalate urolithiasis with alkaline citrates. Author(s): Department of Urology, Semmelweis University School of Medicine, Budapest. Source: Frang, D Berenyi, M Szebeni, R Ther-Hung. 1990; 38(2): 64-70 0133-3909
•
Protective effect of triterpenes on calcium oxalate crystal-induced peroxidative changes in experimental urolithiasis. Author(s): Department of Biochemistry, Dr. Alm Post-graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai-600 113, India. Source: Malini, M M Lenin, M Varalakshmi, P Pharmacol-Res. 2000 April; 41(4): 413-8 1043-6618
•
Proteoglycan core protein in human urine and its possible role on calcium oxalate urolithiasis. Author(s): Department of Urology, Osaka University Medical School, Suita, Japan.
[email protected] Source: Yoshimura, K Miyake, O Tsujihata, M Yoshioka, T Yamaguchi, S Koide, T Takahara, S Okuyama, A Int-J-Urol. 1999 November; 6(11): 567-71 0919-8172
•
Regulation of osteopontin expression in a rat model of urolithiasis. Author(s): Institute of Urology, First Affiliated Hospital of Peking University, Beijing 100034, China. Source: Chang, L Feng, T Li, J Dou, C Wei, J Guo, Y Chin-Med-J-(Engl). 2001 August; 114(8): 829-32 0366-6999
•
Relation of magnesium to osteoporosis and calcium urolithiasis. Author(s): Medical Education, Catholic Medical Center, Jamaica, N.Y. Source: Wallach, S Magnes-Trace-Elem. 1991-92; 10(2-4): 281-6 1015-3845
•
Renal calcium phosphate and oxalate deposition in prolonged vitamin B6 deficiency: studies on a rat model of urolithiasis. Author(s): Section of Anatomic Pathology, Department of Oncology, University of Bologna, Bologna, Italy. Source: Di Tommaso, L Tolomelli, B Mezzini, R Marchetti, M Cenacchi, G Foschini, M P Mancini, A M BJU-Int. 2002 April; 89(6): 571-5 1464-4096
•
Restoration of antioxidants in liver by methionine feeding in experimental rat urolithiasis. Author(s): Department of Medical Biochemistry, University of Madras. Source: Selvam, R Kurien, T B Indian-J-Biochem-Biophys. 1992 August; 29(4): 364-70 0301-1208
•
Rethinking the role of urinary magnesium in calcium urolithiasis. Author(s): Urology Service, Tripler Army Medical Center, Honolulu, Hawaii, USA. Source: Schwartz, B F Bruce, J Leslie, S Stoller, M L J-Endourol. 2001 April; 15(3): 233-5 0892-7790
•
Risk factors for urolithiasis in children on the ketogenic diet. Author(s): Division of Pediatric Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD 21287-2535, USA.
[email protected] Source: Furth, S L Casey, J C Pyzik, P L Neu, A M Docimo, S G Vining, E P Freeman, J M Fivush, B A Pediatr-Nephrol. 2000 November; 15(1-2): 125-8 0931-041X
•
Role of diet in the therapy of urolithiasis. Author(s): Department of Urology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
138 Urolithiasis
Source: Assimos, D G Holmes, R P Urol-Clin-North-Am. 2000 May; 27(2): 255-68 00940143 •
Role of magnesium in the aetiology of ovine urolithiasis in fattening store lambs and intensively fattened lambs. Author(s): Department of Veterinary Clinical Studies, Royal (Dick) School of Veterinary Studies, Veterinary Field Station, Roslin. Source: Cuddeford, D Vet-Rec. 1987 August 29; 121(9): 194-7 0042-4900
•
Role of the diurnal variation of urinary pH and urinary calcium in urolithiasis: A study in outpatients. Author(s): Department of Urology, Sagamihara National Hospital, Sagamihara, Japan. Source: Murayama, T Sakai, N Yamada, T Takano, T Int-J-Urol. 2001 October; 8(10): 52531 0919-8172
•
Silica urolithiasis without magnesium trisilicate intake. Author(s): Department of Urology, Yamagata University School of Medicine, Yamagata, Japan. Source: Ichiyanagi, O Sasagawa, I Adachi, Y Suzuki, H Kubota, Y Nakada, T Urol-Int. 1998 October; 61(1): 39-42 0042-1138
•
Struvite urolithiasis in a B6C3F1 mouse. Source: Wojcinski, Z.W. Renlund, R.C. Barsoum, N.J. Smith, G.S. Lab-Anim. London : Royal Society of Medicine Services. October 1992. volume 26 (4) page 281-287. 0023-6772
•
Timing effects of uracil-induced urolithiasis on amplification of second-stage promotion in rat bladder carcinogenesis. Author(s): First Department of Pathology, Nagoya City University Medical School. Source: Shibata, M A Hasegawa, R Sano, M Shirai, T Fukushima, S Jpn-J-Cancer-Res. 1991 October; 82(10): 1077-84 0910-5050
•
Two unconventional testimonies of urolithiasis in the 18th century on the 1600th anniversary of St. Liborius' death (397-1997) Author(s): Croatian Academy of Sciences and Arts, Department for the History of Medicine, Zagreb, Croatia. Source: Fatovic Ferencic, S Durrigl, M A Repanic Braun, M Scand-J-Urol-Nephrol. 1998 July; 32(4): 245-9 0036-5599
•
Uric acid urolithiasis and crystallization inhibitors. Author(s): Laboratory of Urolithiasis Research, Faculty of Sciences, University of Illes Balears, Palma de Mallorca, Spain.
[email protected] Source: Grases, F Ramis, M Villacampa, A I Costa Bauza, A Urol-Int. 1999; 62(4): 201-4 0042-1138
•
Urolithiasis in Australian aboriginal children. Author(s): Urology Unit, Women's and Children's Hospital, North Adelaide, Australia. Source: Thambi Dorai, C R Dewan, P A Boucaut, H A Ehrlich, J Aust-N-Z-J-Surg. 1994 February; 64(2): 99-101 0004-8682
•
Urolithiasis in childhood. Source: Polinsky, M S Kaiser, B A Baluarte, H J Pediatr-Clin-North-Am. 1987 June; 34(3): 683-710 0031-3955
•
Urolithiasis in children: current medical management. Author(s): Paediatric Nephrology Unit, Chaim Sheba Medical Centre, Sackler Faculty of Medicine, Tel Aviv University, Israel. Source: Laufer, J Boichis, H Pediatr-Nephrol. 1989 July; 3(3): 317-31 0931-041X
Nutrition 139
•
Urolithiasis in Tunisian children: a study of 120 cases based on stone composition. Author(s): Service de Pediatrie, Hopital Charles Nicolle, Tunis, Tunisia. Source: Kamoun, A Daudon, M Abdelmoula, J Hamzaoui, M Chaouachi, B Houissa, T Zghal, A Ben AmMarch, S Belkahia, C Lakhoua, R Pediatr-Nephrol. 1999 November; 13(9): 920-5; discussion 926 0931-041X
Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •
healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0
•
The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov
•
The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov
•
The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/
•
The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/
•
Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/
•
Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/
•
Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/
Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html
•
Google: http://directory.google.com/Top/Health/Nutrition/
•
Healthnotes: http://www.healthnotes.com/
•
Open Directory Project: http://dmoz.org/Health/Nutrition/
•
Yahoo.com: http://dir.yahoo.com/Health/Nutrition/
•
WebMDHealth: http://my.webmd.com/nutrition
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
140 Urolithiasis
The following is a specific Web list relating to urolithiasis; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
Vitamins Vitamin A Source: Prima Communications, Inc.www.personalhealthzone.com Vitamin A Source: WholeHealthMD.com, LLC. www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10066,00.html Vitamin B Source: WholeHealthMD.com, LLC. www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10067,00.html Vitamin B6 Source: Healthnotes, Inc. www.healthnotes.com Vitamin B6 Source: Prima Communications, Inc.www.personalhealthzone.com Vitamin C Source: Healthnotes, Inc. www.healthnotes.com Vitamin C Source: Prima Communications, Inc.www.personalhealthzone.com Vitamin D Source: Healthnotes, Inc. www.healthnotes.com Vitamin E Source: Healthnotes, Inc. www.healthnotes.com Vitamin K Alternative names: Menadione, Menaphthone, Menaquinone, Phylloquinone Source: Integrative Medicine Communications; www.drkoop.com
•
Minerals Calcium Source: Healthnotes, Inc. www.healthnotes.com Calcium Source: Integrative Medicine Communications; www.drkoop.com Calcium Source: Prima Communications, Inc.www.personalhealthzone.com
Nutrition 141
Calcium Source: WholeHealthMD.com, LLC. www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,884,00.html Calcium: Which Form is Best? Source: Healthnotes, Inc. www.healthnotes.com Magnesium Source: Healthnotes, Inc. www.healthnotes.com Magnesium Source: Integrative Medicine Communications; www.drkoop.com Magnesium Source: Prima Communications, Inc.www.personalhealthzone.com Magnesium Source: WholeHealthMD.com, LLC. www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,890,00.html Potassium Source: Healthnotes, Inc. www.healthnotes.com Potassium Source: WholeHealthMD.com, LLC. www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10086,00.html Stinging Nettle Alternative names: Urtica dioica, Urtica urens, Nettle Source: Integrative Medicine Communications; www.drkoop.com Zinc/copper Source: WholeHealthMD.com, LLC. www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,938,00.html •
Food and Diet Artichoke Source: Healthnotes, Inc. www.healthnotes.com Avocado Source: Healthnotes, Inc. www.healthnotes.com Beets Source: Healthnotes, Inc. www.healthnotes.com
142 Urolithiasis
Burdock Alternative names: Arctium lappa, Arctium minus, Arctium tomentosum Source: Integrative Medicine Communications; www.drkoop.com Chocolate Source: Healthnotes, Inc. www.healthnotes.com Chondroitin Sulfate Source: Healthnotes, Inc. www.healthnotes.com Coffee Source: Healthnotes, Inc. www.healthnotes.com Grapefruit Source: Healthnotes, Inc. www.healthnotes.com Kohlrabi Source: Healthnotes, Inc. www.healthnotes.com Kumquat Source: Healthnotes, Inc. www.healthnotes.com Lemons Source: Healthnotes, Inc. www.healthnotes.com Limes Source: Healthnotes, Inc. www.healthnotes.com Low-Oxalate Diet Source: Healthnotes, Inc. www.healthnotes.com Low-Salt Diet Source: Healthnotes, Inc. www.healthnotes.com Oranges Source: Healthnotes, Inc. www.healthnotes.com Parsnips Source: Healthnotes, Inc. www.healthnotes.com Porcini Mushrooms Source: Healthnotes, Inc. www.healthnotes.com Pumpkin Seeds Source: Healthnotes, Inc. www.healthnotes.com Radishes Source: Healthnotes, Inc. www.healthnotes.com Rhubarb Source: Healthnotes, Inc. www.healthnotes.com
Nutrition 143
Rutabagas Source: Healthnotes, Inc. www.healthnotes.com Tangerines Source: Healthnotes, Inc. www.healthnotes.com Tea Source: Healthnotes, Inc. www.healthnotes.com Ugli Tangelo Fruit Source: Healthnotes, Inc. www.healthnotes.com Water Source: Healthnotes, Inc. www.healthnotes.com Winter Squash Source: Healthnotes, Inc. www.healthnotes.com Yams Source: Healthnotes, Inc. www.healthnotes.com
145
CHAPTER 3. ALTERNATIVE MEDICINE AND UROLITHIASIS Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to urolithiasis. At the conclusion of this chapter, we will provide additional sources.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to urolithiasis and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “urolithiasis” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to urolithiasis: •
A comparison between effects of pyruvate and herb medicines in preventing experimental oxalate urolithiasis in rats. Author(s): Ogawa Y, Morozumi M, Tanaka T, Yamaguchi K. Source: Hinyokika Kiyo. 1986 August; 32(8): 1127-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3788737&dopt=Abstract
•
A complementary approach to urolithiasis prevention. Author(s): Anderson RA. Source: World Journal of Urology. 2002 November; 20(5): 294-301. Epub 2002 October 17. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12522585&dopt=Abstract
•
A few comments on the recipes against kidney stones in the Croatian prayerbook. Author(s): Tiselius HG.
146 Urolithiasis
Source: Scandinavian Journal of Urology and Nephrology. 1998 July; 32(4): 250. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9764449&dopt=Abstract •
A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men. Author(s): Curhan GC, Willett WC, Rimm EB, Stampfer MJ. Source: The Journal of Urology. 1996 June; 155(6): 1847-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8618271&dopt=Abstract
•
Abuse of guaifenesin-containing medications generates an excess of a carboxylate salt of beta-(2-methoxyphenoxy)-lactic acid, a guaifenesin metabolite, and results in urolithiasis. Author(s): Pickens CL, Milliron AR, Fussner AL, Dversdall BC, Langenstroer P, Ferguson S, Fu X, Schmitz FJ, Poole EC. Source: Urology. 1999 July; 54(1): 23-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10414721&dopt=Abstract
•
Activity of certain fractions of Tribulus terrestris fruits against experimentally induced urolithiasis in rats. Author(s): Anand R, Patnaik GK, Kulshreshtha DK, Dhawan BN. Source: Indian J Exp Biol. 1994 August; 32(8): 548-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7959935&dopt=Abstract
•
Acute effects of calcium sodium citrate supplementation of a test meal on mineral homeostasis, oxalate, and calcium oxalate crystallization in the urine of healthy humans--preliminary results in patients with idiopathic calcium urolithiasis. Author(s): Herrmann U, Schwille PO, Schmiedl A, Fan J, Manoharan M. Source: Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 1999 June; 53(5-6): 264-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10424248&dopt=Abstract
•
An oxalate-binding protein with crystal growth promoter activity from human kidney stone matrix. Author(s): Govindaraj A, Selvam R. Source: Bju International. 2002 August; 90(3): 336-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12133075&dopt=Abstract
•
Biochemical mechanisms and effects of Mimosa pudica (Linn) on experimental urolithiasis in rats. Author(s): Joyamma V, Rao SG, Hrishikeshavan HJ, Aroor AR, Kulkarni DR. Source: Indian J Exp Biol. 1990 March; 28(3): 237-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2365419&dopt=Abstract
Alternative Medicine 147
•
Bovine cases of urolithiasis treated with traditional herbal medicine, P-3. Author(s): Sugimoto K, Sakurai N, Shirasawa H, Fujise Y, Shibata K, Shimoda K, Sakata J. Source: The Journal of Veterinary Medical Science / the Japanese Society of Veterinary Science. 1992 June; 54(3): 579-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1643179&dopt=Abstract
•
Control of hyperoxaluria with large doses of pyridoxine in patients with kidney stones. Author(s): Mitwalli A, Ayiomamitis A, Grass L, Oreopoulos DG. Source: International Urology and Nephrology. 1988; 20(4): 353-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3170105&dopt=Abstract
•
Dietary calcium, dietary protein, and kidney stone formation. Author(s): Curhan GC. Source: Mineral and Electrolyte Metabolism. 1997; 23(3-6): 261-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9387129&dopt=Abstract
•
Dietary effects upon calcium oxalate urolithiasis risk. Author(s): Grases F, Prieto R, Tur JA. Source: International Urology and Nephrology. 1992; 24(5): 495-501. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1334059&dopt=Abstract
•
Djenkol bean as a cause of urolithiasis. Author(s): Areekul S, Muangman V, Bohkerd C, Saenghirun C. Source: Southeast Asian J Trop Med Public Health. 1978 September; 9(3): 427-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=34890&dopt=Abstract
•
Effect of “Rosa Canina” infusion and magnesium on the urinary risk factors of calcium oxalate urolithiasis. Author(s): Grases F, Masarova L, Costa-Bauza A, March JG, Prieto R, Tur JA. Source: Planta Medica. 1992 December; 58(6): 509-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1484889&dopt=Abstract
•
Effect of A. lanata leaf extract and Vediuppu chunnam on the urinary risk factors of calcium oxalate urolithiasis during experimental hyperoxaluria. Author(s): Selvam R, Kalaiselvi P, Govindaraj A, Bala Murugan V, Sathish Kumar AS. Source: Pharmacological Research : the Official Journal of the Italian Pharmacological Society. 2001 January; 43(1): 89-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11207071&dopt=Abstract
148 Urolithiasis
•
Effect of blackcurrant-, cranberry- and plum juice consumption on risk factors associated with kidney stone formation. Author(s): Kessler T, Jansen B, Hesse A. Source: European Journal of Clinical Nutrition. 2002 October; 56(10): 1020-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12373623&dopt=Abstract
•
Effect of Crataeva nurvala in experimental urolithiasis. Author(s): Varalakshmi P, Shamila Y, Latha E. Source: Journal of Ethnopharmacology. 1990 March; 28(3): 313-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2335959&dopt=Abstract
•
Effect of herb medicines for urolithiasis on urinary oxalate excretion in rats. Author(s): Ogawa Y, Takahashi S, Kitagawa R. Source: Hinyokika Kiyo. 1983 October; 29(10): 1269-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6681501&dopt=Abstract
•
Effect of Herniaria hirsuta and Agropyron repens on calcium oxalate urolithiasis risk in rats. Author(s): Grases F, Ramis M, Costa-Bauza A, March JG. Source: Journal of Ethnopharmacology. 1995 March; 45(3): 211-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7623486&dopt=Abstract
•
Effect of Trigonella foenum-graecum and Ammi majus on calcium oxalate urolithiasis in rats. Author(s): Ahsan SK, Tariq M, Ageel AM, al-Yahya MA, Shah AH. Source: Journal of Ethnopharmacology. 1989 October; 26(3): 249-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2615405&dopt=Abstract
•
Effects of 5 different diets on urinary risk factors for calcium oxalate kidney stone formation: evidence of different renal handling mechanisms in different race groups. Author(s): Rodgers AL, Lewandowski S. Source: The Journal of Urology. 2002 September; 168(3): 931-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12187193&dopt=Abstract
•
Effects of ascorbate supplements on urinary oxalate and risk of kidney stones. Author(s): Massey LK. Source: Journal of the American Dietetic Association. 2000 May; 100(5): 516. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10841663&dopt=Abstract
•
Gahat: a Napalese cure for urolithiasis? Author(s): Schwartz BF, Schenkman N, Nguyen R, Stoller ML.
Alternative Medicine 149
Source: Urology. 2000 December 20; 56(6): 912-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11113729&dopt=Abstract •
Identification of hemoglobin and two serine proteases in acid extracts of calcium containing kidney stones. Author(s): Petersen TE, Thogersen I, Petersen SE. Source: The Journal of Urology. 1989 July; 142(1): 176-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2733100&dopt=Abstract
•
Intake of vitamins B6 and C and the risk of kidney stones in women. Author(s): Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Source: Journal of the American Society of Nephrology : Jasn. 1999 April; 10(4): 840-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10203369&dopt=Abstract
•
Intracrystalline proteins and the hidden ultrastructure of calcium oxalate urinary crystals: implications for kidney stone formation. Author(s): Lyons Ryall R, Fleming DE, Doyle IR, Evans NA, Dean CJ, Marshall VR. Source: Journal of Structural Biology. 2001 April; 134(1): 5-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11469872&dopt=Abstract
•
Limited risk of kidney stone formation during long-term calcium citrate supplementation in nonstone forming subjects. Author(s): Sakhaee K, Baker S, Zerwekh J, Poindexter J, Garcia-Hernandez PA, Pak CY. Source: The Journal of Urology. 1994 August; 152(2 Pt 1): 324-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8015062&dopt=Abstract
•
Litholytic agents with bacteriostatic properties in conservative treatment of urolithiasis. Author(s): Kallistratos G. Source: European Urology. 1975; 1(6): 261-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=823025&dopt=Abstract
•
Medical management of urolithiasis, what opportunity for phytotherapy? Author(s): Atmani F. Source: Frontiers in Bioscience : a Journal and Virtual Library. 2003 May 1; 8: S507-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12700097&dopt=Abstract
•
Microstructural matrix-crystal interactions in calcium oxalate monohydrate kidney stones. Author(s): Stacholy J, Goldberg EP.
150 Urolithiasis
Source: Scan Electron Microsc. 1985; (Pt 2): 781-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3931207&dopt=Abstract •
Postprandial hyperinsulinaemia, insulin resistance and inappropriately high phosphaturia are features of younger males with idiopathic calcium urolithiasis: attenuation by ascorbic acid supplementation of a test meal. Author(s): Schwille PO, Schmiedl A, Herrmann U, Wipplinger J. Source: Urological Research. 1997; 25(1): 49-58. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9079746&dopt=Abstract
•
Preventing kidney stones: calcium restriction not warranted. Author(s): Hall PM. Source: Cleve Clin J Med. 2002 November; 69(11): 885-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12430973&dopt=Abstract
•
Protective effect of triterpenes on calcium oxalate crystal-induced peroxidative changes in experimental urolithiasis. Author(s): Malini MM, Lenin M, Varalakshmi P. Source: Pharmacological Research : the Official Journal of the Italian Pharmacological Society. 2000 April; 41(4): 413-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10704264&dopt=Abstract
•
Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Author(s): Hiatt RA, Ettinger B, Caan B, Quesenberry CP Jr, Duncan D, Citron JT. Source: American Journal of Epidemiology. 1996 July 1; 144(1): 25-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8659482&dopt=Abstract
•
Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. Author(s): Breslau NA, Brinkley L, Hill KD, Pak CY. Source: The Journal of Clinical Endocrinology and Metabolism. 1988 January; 66(1): 1406. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2826524&dopt=Abstract
•
Renal failure due to 2,8-dihydroxyadenine urolithiasis. Author(s): Greenwood MC, Dillon MJ, Simmonds HA, Barratt TM, Pincott JR, Metreweli C. Source: European Journal of Pediatrics. 1982 July; 138(4): 346-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7128645&dopt=Abstract
Alternative Medicine 151
•
Resolution of proteins in the kidney stone matrix using high-performance liquid chromatography. Author(s): Sugimoto T, Funae Y, Rubben H, Nishio S, Hautmann R, Lutzeyer W. Source: European Urology. 1985; 11(5): 334-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4076273&dopt=Abstract
•
Solubility of inorganic kidney stone components in the presence of acid-base sensitive complexing agents. Author(s): Verplaetse H, Verbeeck RM, Minnaert H, Oosterlinck W. Source: European Urology. 1985; 11(1): 44-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2985396&dopt=Abstract
•
Study of the urinary surface tension and protective colloids in urolithiasis; use of the Revici urotensiometer. Author(s): RAVICH RA, RAVICH A. Source: The Journal of Urology. 1954 December; 72(6): 1050-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=13212921&dopt=Abstract
•
Susceptibility of two commercial single comb White Leghorn strains to calciuminduced urolithiasis: efficacy of dietary supplementation with DL-methionine and ammonium sulphate. Author(s): Lent AJ, Wideman RF. Source: British Poultry Science. 1993 July; 34(3): 577-87. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8358642&dopt=Abstract
•
The effect of ascorbic acid ingestion on the biochemical and physicochemical risk factors associated with calcium oxalate kidney stone formation. Author(s): Auer BL, Auer D, Rodgers AL. Source: Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 1998 March; 36(3): 143-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9589801&dopt=Abstract
•
The effect of takusha, a kampo medicine, on renal stone formation and osteopontin expression in a rat urolithiasis model. Author(s): Yasui T, Fujita K, Sato M, Sugimoto M, Iguchi M, Nomura S, Kohri K. Source: Urological Research. 1999 June; 27(3): 194-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10422821&dopt=Abstract
•
The uric acid-whewellite association in human kidney stones. Author(s): Deganello S, Chou C. Source: Scan Electron Microsc. 1985; (Pt 4): 1545-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3938066&dopt=Abstract
152 Urolithiasis
•
Therapy for urolithiasis by hydroxamic acids. II. Urease inhibitory potency and urinary excretion rate of hippurohydroxamic acid derivatives. Author(s): Kobashi K, Munakata K, Takebe S, Hase J. Source: J Pharmacobiodyn. 1980 September; 3(9): 444-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7007613&dopt=Abstract
•
Therapy for urolithiasis by hydroxamic acids. III. Urease inhibitory potency and urinary excretion rate of N-acylglycinohydroxamic acids. Author(s): Munakata K, Kobashi K, Takebe S, Hase J. Source: J Pharmacobiodyn. 1980 September; 3(9): 451-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7007614&dopt=Abstract
•
Two unconventional testimonies of urolithiasis in the 18th century on the 1600th anniversary of St. Liborius' death (397-1997) Author(s): Fatovic-Ferencic S, Durrigl MA, Repanic-Braun M. Source: Scandinavian Journal of Urology and Nephrology. 1998 July; 32(4): 245-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9764448&dopt=Abstract
•
Urolithiasis and phytotherapy. Author(s): Grases F, Melero G, Costa-Bauza A, Prieto R, March JG. Source: International Urology and Nephrology. 1994; 26(5): 507-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7860196&dopt=Abstract
•
Urolithiasis in animals. Author(s): McIntosh GH. Source: Aust Vet J. 1978 June; 54(6): 267-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=687293&dopt=Abstract
Additional Web Resources A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample: •
Alternative Medicine Foundation, Inc.: http://www.herbmed.org/
•
AOL: http://search.aol.com/cat.adp?id=169&layer=&from=subcats
•
Chinese Medicine: http://www.newcenturynutrition.com/
•
drkoop.com: http://www.drkoop.com/InteractiveMedicine/IndexC.html
•
Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
•
Google: http://directory.google.com/Top/Health/Alternative/
•
Healthnotes: http://www.healthnotes.com/
Alternative Medicine 153
•
MedWebPlus: http://medwebplus.com/subject/Alternative_and_Complementary_Medicine
•
Open Directory Project: http://dmoz.org/Health/Alternative/
•
HealthGate: http://www.tnp.com/
•
WebMDHealth: http://my.webmd.com/drugs_and_herbs
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
•
Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/
The following is a specific Web list relating to urolithiasis; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
General Overview Asthma Source: Prima Communications, Inc.www.personalhealthzone.com Cataracts (Prevention) Source: Prima Communications, Inc.www.personalhealthzone.com Epilepsy Source: Healthnotes, Inc. www.healthnotes.com Gout Source: Integrative Medicine Communications; www.drkoop.com Hyperparathyroidism Source: Integrative Medicine Communications; www.drkoop.com Hypertension Alternative names: High Blood Pressure Source: Prima Communications, Inc.www.personalhealthzone.com Inflammatory Bowel Disease Source: Integrative Medicine Communications; www.drkoop.com Kidney Stones Source: Healthnotes, Inc. www.healthnotes.com Kidney Stones Source: Integrative Medicine Communications; www.drkoop.com Obesity Source: Integrative Medicine Communications; www.drkoop.com Osteoporosis Source: Prima Communications, Inc.www.personalhealthzone.com
154 Urolithiasis
Parathyroid, Overactive Source: Integrative Medicine Communications; www.drkoop.com Sarcoidosis Source: Integrative Medicine Communications; www.drkoop.com Ulcerative Colitis Source: Integrative Medicine Communications; www.drkoop.com •
Alternative Therapy Reflexology Source: WholeHealthMD.com, LLC. www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,730,00.html
•
Chinese Medicine Guangjinqiancoa Alternative names: Snowbellleaf Tickclover Herb; Herba Desmodii Styracifolii Source: Chinese Materia Medica Haijinsha Alternative names: Japanese Climbing Fern Spore; Spora Lygodii Source: Chinese Materia Medica Heizhongcaozi Alternative names: Fennelflower Seed; Semen Nigellae Source: Chinese Materia Medica Huashi Alternative names: Talc; Talcum Source: Chinese Materia Medica Jinqiancao Alternative names: Christina Loosestrife; Herba Lysimachiae Source: Chinese Materia Medica Jixuecao Alternative names: Asiatic Pennywort Herb; Herba Centellae Source: Chinese Materia Medica Lianqiancao Alternative names: Longtube Ground Ivy Herb; Herba Glechomae Source: Chinese Materia Medica Qiancao Alternative names: Longtube Ground Ivy Herb; Lianqiancao; Herba Glechomae Source: Chinese Materia Medica
Alternative Medicine 155
Qumai Alternative names: Lilac Pink Herb; Herba Dianthi Source: Chinese Materia Medica Shiwei Alternative names: Shearer's Pyrrosia Leaf; Folium Pyrrosiae Source: Chinese Materia Medica •
Herbs and Supplements Aloe Alternative names: Aloe vera, Aloe barbadensis, Aloe ferox , Aloe Vera Source: Integrative Medicine Communications; www.drkoop.com Aloe Vera Source: Integrative Medicine Communications; www.drkoop.com Althaea officinalis Source: Integrative Medicine Communications; www.drkoop.com Arctium Alternative names: Burdock, Gobo; Arctium lappa L. Source: Alternative Medicine Foundation, Inc. www.amfoundation.org Arctium lappa Source: Integrative Medicine Communications; www.drkoop.com Arctium minus Source: Integrative Medicine Communications; www.drkoop.com Arctostaphylos Alternative names: Bearberry; Arctostaphylos uva-ursi (L.) Spreng. Source: Alternative Medicine Foundation, Inc. www.amfoundation.org Bilberry Alternative names: Vaccinium myrtillus Source: Healthnotes, Inc. www.healthnotes.com Bilberry Source: WholeHealthMD.com, LLC. www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10007,00.html Butcher's broom Source: WholeHealthMD.com, LLC. www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10010,00.html Cranberry Alternative names: Vaccinium macrocarpon Source: Healthnotes, Inc. www.healthnotes.com
156 Urolithiasis
Cranberry Source: WholeHealthMD.com, LLC. www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10019,00.html Ephedra Alternative names: Ephedra sinica, Ephedra intermedia, Ephedra equisetina Source: Healthnotes, Inc. www.healthnotes.com Ephedra (Ma huang) Source: WholeHealthMD.com, LLC. www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,777,00.html Equisetum Alternative names: Horsetail; Equisetum arvense L. Source: Alternative Medicine Foundation, Inc. www.amfoundation.org Equisetum arvense Source: Integrative Medicine Communications; www.drkoop.com Fiber Source: Healthnotes, Inc. www.healthnotes.com Flurbiprofen Source: Healthnotes, Inc. www.healthnotes.com Glycyrrhiza1 Alternative names: Licorice; Glycyrrhiza glabra L. Source: Alternative Medicine Foundation, Inc. www.amfoundation.org Goldenrod Alternative names: Solidago virgaurea Source: Integrative Medicine Communications; www.drkoop.com Goldenrod Source: Prima Communications, Inc.www.personalhealthzone.com Gravel Root Source: The Canadian Internet Directory for Holistic Help, WellNet, Health and Wellness Network; www.wellnet.ca Horseradish Alternative names: Cochlearia armoracia Source: Healthnotes, Inc. www.healthnotes.com Horsetail Alternative names: Equisetum arvense, Scouring Rush, Shave Grass Source: Integrative Medicine Communications; www.drkoop.com Horsetail Source: WholeHealthMD.com, LLC. www.wholehealthmd.com
Alternative Medicine 157
Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10105,00.html Hydrangea Source: The Canadian Internet Directory for Holistic Help, WellNet, Health and Wellness Network; www.wellnet.ca Marshmallow Alternative names: Althaea officinalis Source: Integrative Medicine Communications; www.drkoop.com Menadione Source: Integrative Medicine Communications; www.drkoop.com Menaphthone Source: Integrative Medicine Communications; www.drkoop.com Menaquinone Source: Integrative Medicine Communications; www.drkoop.com Nettle Source: Integrative Medicine Communications; www.drkoop.com Oak bark Source: WholeHealthMD.com, LLC. www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10108,00.html Phylloquinone Source: Integrative Medicine Communications; www.drkoop.com Pumpkin Alternative names: Cucurbita pepo, Cucurbita maxima Source: Healthnotes, Inc. www.healthnotes.com Scouring Rush Source: Integrative Medicine Communications; www.drkoop.com Shave Grass Source: Integrative Medicine Communications; www.drkoop.com Solidago virgaurea Source: Integrative Medicine Communications; www.drkoop.com Taraxacum Alternative names: Dandelion; Taraxacum officinale (Dhudhal) Source: Alternative Medicine Foundation, Inc. www.amfoundation.org Trigonella Alternative names: Fenugreek; Trigonella foenum graecum L. Source: Alternative Medicine Foundation, Inc. www.amfoundation.org
158 Urolithiasis
Urtica dioica Source: Integrative Medicine Communications; www.drkoop.com Urtica urens Source: Integrative Medicine Communications; www.drkoop.com Wild yam Source: WholeHealthMD.com, LLC. www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10070,00.html
General References A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the MEDLINEplus site at http://www.nlm.nih.gov/medlineplus/alternativemedicine.html. This Web site provides a general overview of various topics and can lead to a number of general sources.
159
CHAPTER 4. PATENTS ON UROLITHIASIS Overview Patents can be physical innovations (e.g. chemicals, pharmaceuticals, medical equipment) or processes (e.g. treatments or diagnostic procedures). The United States Patent and Trademark Office defines a patent as a grant of a property right to the inventor, issued by the Patent and Trademark Office.8 Patents, therefore, are intellectual property. For the United States, the term of a new patent is 20 years from the date when the patent application was filed. If the inventor wishes to receive economic benefits, it is likely that the invention will become commercially available within 20 years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be commercially available. The patent implies only that the inventor has “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States. While this relates to U.S. patents, similar rules govern foreign patents. In this chapter, we show you how to locate information on patents and their inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical patents that use the generic term “urolithiasis” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on urolithiasis, we have not necessarily excluded nonmedical patents in this bibliography.
Patents on Urolithiasis By performing a patent search focusing on urolithiasis, you can obtain information such as the title of the invention, the names of the inventor(s), the assignee(s) or the company that owns or controls the patent, a short abstract that summarizes the patent, and a few excerpts from the description of the patent. The abstract of a patent tends to be more technical in nature, while the description is often written for the public. Full patent descriptions contain much more information than is presented here (e.g. claims, references, figures, diagrams, etc.). We will tell you how to obtain this information later in the chapter. The following is an 8Adapted
from the United States Patent and Trademark Office: http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm.
160 Urolithiasis
example of the type of information that you can expect to obtain from a patent search on urolithiasis: •
Aiming system for kidney stone disintegrator Inventor(s): Shene; William R. (Plattsburgh, NY), Nowacki; Christopher (Arlington Heights, IL), Brisson; Alfred G. (Kildeer, IL), Burdick; Thomas H. (Deerfield, IL), DelaCruz; Exequiel (Arlington Heights, IL) Assignee(s): Northgate Research, Inc. (Arlington Heights, IL) Patent Number: 4,763,652 Date filed: April 16, 1986 Abstract: A kidney stone disintegrating system includes a computer-controlled aiming system. The disintegrating system includes a reflector containing water through which the reflector is coupled to a living body having a kidney stone. The reflector is a portion of an ellipsoid and a spark gap generator is located at one focus of the ellipsoid. An electrical energy source is connected to the spark gap generator for generating a spark which in turn generates a shock wave in the fluid. Three motors are connected to the reflector for moving it in respectively X-axis, Y-axis and Z-axis directions to locate the reflector so that the kidney stone lies at the second focus point thereof. A pair of ultrasound transducers are carried by an articulated support comprising a plurality of pivotally interconnected arms. Precision potentiometers are provided between the arms to indicate the relative positions thereof, and electrical potentials from the potentiometers are connected to a computer. The signals and the computer are connected to a monitor having a screen to display the kidney stone, and particularly the position thereof as determined by the two transducers. The computer is connected to the three motors to position the reflector in accordance with the positions of the transducers to locate the reflector with the second focus point coinciding with the kidney stone. Controls are provided for causing generation of a spark with the resulting shock wave focused on the kidney stone to destroy the kidney stone. Excerpt(s): Kidney stones, and also naturally-occurring stones in the bladder and the ureter can be exquisitely painful, and often require surgical relief. Excision or destruction of stones in the bladder and sometimes in the ureter can be relatively easily accomplished, but removal of stones from the kidney is a major procedure. Removal of stones from the kidney is a very serious and traumatic procedure. A large incision is made in the body. The kidney is essentially removed from the body and cut open. The stone or stones are then removed, whereupon the kidney is sutured and returned to the body, with the body then being sutured. Typical recovery time is on the order of six months. Chemotherapy is available as a non-invasive therapy for uric acid stones. In this therapy the urine is alkalized. The existing stone thus is dissolved over a substantial period of time, and in most cases the patient can be cured before his condition becomes acute. However, the patient's condition is often already acute when the stone is discovered, and immediate surgery is imperative. Attempts at chemical dissolution of other types of stones have not been successful. Web site: http://www.delphion.com/details?pn=US04763652__
Patents 161
•
Drug for relieving pain and promoting the removal of calculi in urolithiasis Inventor(s): Tomiyama; Yoshitaka (Nagano, JP), Akahane; Masuo (Nagano, JP) Assignee(s): Kissei Pharmaceutical Co., Ltd. (JP) Patent Number: 6,410,560 Date filed: November 24, 1999 Abstract: The present invention relates to a novel drug composition for relieving pain and promoting the removal of calculi in urolithiasis which contains an active ingredient having stimulating effects on both.beta.sub.2 - and.beta.sub.3 -adrenoceptors and exerting a potent relaxing effect on human ureteral smooth muscle. Excerpt(s): The present invention relates to drug compositions for relieving pain and promoting the removal of calculi in urolithiasis. The drug compositions of this invention contain active ingredients having stimulating effects on both.beta.sub.2 - and.beta.sub.3 -adrenoceptors. It is known that three subtypes of.beta.-adrenoceptor, which have been classified as.beta.sub.1,.beta.sub.2 and.beta.sub.3 are present in the human body. Each receptor subtype is distributed in specified organs.beta.sub.1 -Adrenoceptor is mainly present in the heart and its stimulation enhances the function of the heart.beta.sub.2 Adrenoceptor is mainly present in the trachea, peripheral blood vessels and the uterus. Smooth muscle of such organs is relaxed by the stimulation of this receptor. In addition, it has recently been reported that.beta.sub.3 -adrenoceptor is present in the digestive tract and adipocytes. The stimulation of.beta.sub.3 -adrenoceptor leads to the relaxation of gastrointestinal smooth muscle, lipolysis and energy expenditure in adipose tissues and so on. Thus, the distribution of.beta.-adrenoceptor subtypes is specified by organs and tissues. Various receptor subtypes including.beta.-adrenoceptor have been actively studied for developing more effective medicinal treatment of some diseases. Consequently, efforts have been paid extensively to develop more effective and highly selective drugs that act upon a specified organ. However,.beta.-adrenoceptor subtypes distributed in human ureter have not yet been elucidated, although the progress of studies to develop drugs that act more effectively on human ureter has been desired. Web site: http://www.delphion.com/details?pn=US06410560__
•
Kidney stone retriever Inventor(s): Duthoy; Everette J. (1472 Cherry Hill Rd., St. Paul, MN 55118) Assignee(s): none reported Patent Number: 4,625,726 Date filed: August 7, 1984 Abstract: The present invention is directed to a kidney stone retrieval device which includes a basket between a ferrule and a tube. Both the tube and the ferrule have aligned passages for receiving a guide wire. In this way, the guide wire may be inserted into a ureter past the stone so that the retrieval device may be pushed along the guide wire until the basket reaches and passes the stone, whereupon the device is maneuvered for dislodging and retrieving the stone with the basket. Excerpt(s): The present invention is directed to the general field of urology and, more particularly, to a device for dislodging and capturing a stone from a person's ureter. Waste body fluids flow from the kidney through the ureter to the bladder. The fluids pass from the bladder through the urethra to exit a person's body. A blockage
162 Urolithiasis
occasionally forms in the ureter of some people. The blockage is usually comprised of a hard stone-like material called calculus. Such a blockage can be painful and dangerous since it restricts the flow of waste fluids through the ureter. Ureteral calculus, more commonly known as a kidney stone, may be removed surgically. It is preferable, however, to try to capture the stone and pull it through the ureter, baldder and urethra. Devices and procedures for such capture and removal are, thus, known. The most common stone retriever device is made from a cable having a wire basket at one end of the cable with a relatively short, somewhat flexible, rod-like end member, called a filiform, at the end of the basket opposite the cable. The basket is usually made of four equally spaced-apart wires which are sufficiently rigid to hold a large V-shape. The filiform of the device is inserted into the ureter and worked past the stone. As the basket is maneuvered alongside the stone, the stone moves into the space surrounded by the wires and is hopefully captured for removal on removal of the cable and basket. The problem with this device is that it is extremely difficult to work the basket around or even with the stone in order to capture the stone. Consequently, the removal procedure may be time consuming and is prone to failure. Web site: http://www.delphion.com/details?pn=US04625726__ •
Kidney stone specimen collection system Inventor(s): Stein; Ronald B. (8810 Weymouth Dr., Houston, TX 77031), Newman; Dennis (3519 Grennoch, Houston, TX 77025) Assignee(s): none reported Patent Number: 5,762,071 Date filed: September 4, 1996 Abstract: A kidney stone specimen collection device having a tubular body with a longitudinal axis, a mesh screen affixed to an interior of the tubular body and extending transverse to a longitudinal axis of the tubular body, a first closure member affixed to one end of the tubular body so as to selectively seal the end of the tubular body, and a second closure member affixed to an opposite end of the tubular body for selectively sealing the opposite end of the tubular body. The tubular body is formed of an impactresistant generally transparent plastic material. A flow indicator is positioned on a surface of the tubular body so as to be indicative of a direction of urine flow through the tubular body. Excerpt(s): The present application is a utility patent application which is based on U.S. Provisional patent application Ser. No. 60/009,260, filed on Dec. 26, 1995, and entitled "KIDNEY STONE SPECIMEN COLLECTION SYSTEM", presently pending. The present invention relates to devices for the collection of kidney stones from a urine stream. More particularly, the present invention relates to containers for the receipt and capture of kidney stones. It is a well known fact, at least to those of the medical profession, that there are hundreds of thousands of people in this country chronically or critically suffering from kidney stone afflictions. The patient is often advised to retrieve the foreign particles for purposes of clinical examination. This presents an obvious problem of inconvenience and perhaps embarrassment, particularly when it is impossible to have ordinary suitable household utensils at hand for the required purpose. Web site: http://www.delphion.com/details?pn=US05762071__
Patents 163
•
Methods of diagnosing complicated urolithiasis and predicting urolithiasis Inventor(s): Makushin; Leonid G. (Moscow, RU), Morozov; Andrei P. (Moscow, RU), Dutov; Valery V. (Moscow, RU), Shatokhina; Svetlana N. (prospekt Mira, 70, kv. 76, Moscow, RU), Shabalin; Vladimir N. (ulitsa B. Galushkina, 3, korpus 1, kv. 21, Moscow, RU), Mitroshnikov; Andrei N. (Moscow, RU), Yakovlev; Sergei A. (Mytischi, RU), Trapeznikova; Margarita F. (Moscow, RU) Assignee(s): Shatokhina; Svetlana N. (Moscow, RU), Shabalin; Vladimir N. (Moscow, RU) Patent Number: 5,366,899 Date filed: September 9, 1993 Abstract: A method of diagnosing complicated urolithiasis consists in testing for and finding the presence of albumen in a urine sample. A portion of said sample is dried and a crystallographic study is performed. On finding a marginal amorphous area, accommodating a central crystalline area, pyelonephritis is diagnosed. On discovering a full crystalline area (i.e. with no marginal amorphous area), calculous pyelonephritis is diagnosed.The method of prognostication involves testing for and finding the absence of albumen in a urine sample. A portion of the urine sample is mixed with a 8-12% protein solution, the mixture is then dried and a crystallographic study is conducted. With a full non-transparent crystallization of the sample (i.e. without the marginal amorphous area), urolithiasis is prognosticated. Excerpt(s): The invention relates to medicine, more specifically, to methods of diagnosing complicated urolithiasis and prognosticating same. At present for purposes of diagnosing said urolithiasis, particularly pyelonephritis, calculous pyelonephritis, use is made of clinical laboratory examination of urea, the X ray and ultrasound analysis of kidneys and urea excretory tracts. A possibility of the onset of urolithiasis is evaluated if risk factors are available such as hereditary predisposition and endemicity. Web site: http://www.delphion.com/details?pn=US05366899__
•
Oral urolithiasis remedy Inventor(s): Stumpf; Werner (Bensberg-Refrath, DE), Madaus; Rolf (Koln-Bruck, DE) Assignee(s): Madaus and Company (Cologne, DE) Patent Number: 4,447,455 Date filed: August 5, 1982 Abstract: The disclosed invention deals with treating urolithiasis with alizarin. Magnesium oxide and phosphate salts may also be added. Excerpt(s): The invention relates to an oral urolithiasis remedy, especially for the treatment and prophylaxis of illnesses due to calcium oxalate calculi and calculi containing calcium oxalate. The chemotherapy of oxalate urolithiasis presents considerable difficulty for which no satisfactory solution was ever found. Magnesiumcontaining mixtures on a citrate basis are known (German Offenlegungsschrift No. 2,252,665), but their effectiveness is disputed, since the citrate content of these preparations is probably metabolized and the effectiveness of the magnesium component in this mixture is unclear with regard to the solubility ratios. Remedies containing succinimide as the active ingredient (German Patent No. 2,030,932) have never become established, and preparations based on cation exchangers provide no
164 Urolithiasis
reliable treatment or prophylaxis. Consideration has been given to the use of complexing agents for calcium, such as glucuronic acid, or of magnesium compounds such as oxides, citrate, adipinate and nicotinate to improve the solubility of calcium oxalate, or also the use of various plant extracts containing ruberythric acid. All of these efforts have failed to produce the desired success. It has now been found surprisingly that alizarin is suitable as a remedy for the treatment of oxalate urolithiasis patients, since it develops a decided inhibitive effect on the formation of stones, and it is also easily tolerated. Web site: http://www.delphion.com/details?pn=US04447455__ •
Phantom kidney stone system Inventor(s): Schafer; Mark E. (Blue Bell, PA) Assignee(s): International Sonic Technologies (Horsham, PA) Patent Number: 5,014,686 Date filed: August 31, 1989 Abstract: The phantom kidney stone system for use with a commercial lithotripsy system includes a phantom kidney stone which simulates a human kidney stone and is suspended into the field of operation of the commerical lithotripsy system. The system also includes a trigger which is connected to receive a shock wave signal from the lithotripter which is representative of a shock wave output from the lithotripter. The trigger generates a trigger signal in response to the signal from the lithotripter. A counter is connected to receive the trigger signal and counts the number of trigger signals which is representative of the number of shock waves output from the lithotripter. A detection circuit is connected to the phantom kidney stone and produces a signal proportional to the detected size of the stone at a given point in time and compares the detected size of the stone to a predetermined reference size indicative of a condition wherein the stone would be crushed. The detection circuit generates an output signal at a time when the detected size of the stone is less than the reference size. A processor is connected to receive the output signal from the detection circuit and is connected tothe counter and outputs the number of trigger signals which were counted by the counter at a time when the detection circuit generates the output signal. A display indicated the number to the user of the lithotripter. Excerpt(s): The present invention relates to a phantom kidney stone system for use with a commercial lithotripsy system. Currently there is no uniformly repeatable test procedure which can be used by manufacturers and/or users of commercial lithotripsy systems for quality control purposes in order to ascertain that the lithotripsy system is functioning properly. Also, there is no uniformly repeatable test procedure which can be used to train operators of commercial lithotripsy systems to improve the accuracy with which the operators perform an actual lithotripsy operation. There is a need for the operators to be trained properly so that when an actual lithotripsy operation is performed, the lowest possible number of shock waves are used to break up the kidney stone. It is necessary to keep the number of shock waves which are input into human tissue as low as possible. Therefore, operators should be trained prior to performing an actual lithotripsy operation on a human patient. At the present time, the operators do not have an opportunity to work with the lithotripsy system until they actually use the equipment on a human patient. Web site: http://www.delphion.com/details?pn=US05014686__
Patents 165
•
Pleated diaphragm for coupling kidney stone disintegrator to human body Inventor(s): Dela-Cruz; Exequiel (Arlington Heights, IL), Nowacki; Christopher (Arlington Heights, IL), Brisson; Alfred G. (Kildeer, IL) Assignee(s): Trutek Research, Inc. (Lake Zurich, IL) Patent Number: 4,745,921 Date filed: December 23, 1986 Abstract: An extracorporeal kidney stone disintegrator comprises an ellipsoidal reflector having an open end. A spark gap is positioned in said reflector at the first focus point thereof. A flexible cap closes the otherwise open end of said reflector, and a body of liquid fills said reflector and said cap. The cap is adapted for disposition against a human body having therein a concretion such as a kidney stone to be disintegrated. The reflector is positioned so that the concretion lies on the second focus point of the reflector. Generation of a spark across said spark gap causes generation of a shock wave focused on the concretion and coupled to the concretion by the body of liquid and the tissues of the body through the cap. The cap has an annular pleat enhancing flexibility of the cap. Excerpt(s): Kidney stones, and also naturally occurring stones in the bladder and the ureter can be exquisitely painful, and often require surgical relief. Excision or destruction of stones in the bladder and sometimes in the ureter can be relatively easily accomplished, but removal of stones from the kidney is a major procedure. Removal of stones from the kidney is a very serious and traumatic surgical procedure. A large incision is made in the body. The kidney is essentially removed from the body and cut open. The stone or stones are then removed, whereupon the kidney is sutured and returned to the body, with the body then being sutured. Various efforts have been made to destroy or disintegrate kidney stones so that they can be excreted with the urine. Chemotherapy is available as a non-invasive therapy for uric acid stones. In this therapy, the urine is alkalyzed, and the stone is dissolved over a substantial period of time. This requires detection of the stone before an acute phase is reached. Web site: http://www.delphion.com/details?pn=US04745921__
•
Shroud for coupling kidney stone disintegrator to human body Inventor(s): Nowacki; Christopher (Arlington Heights, IL), Brisson; Alfred G. (Kildeer, IL) Assignee(s): Trutek Research, Inc. (Lake Zurich, IL) Patent Number: 4,798,196 Date filed: December 16, 1986 Abstract: An extracorporeal kidney stone disintegrator comprises an upwardly open ellipsoidal reflector having an open upper end. A spark gap is provided in said reflector at the first focus point thereof. A flexible waterproof shroud is fixed to the open end of the reflector and secured to the skin of a human body containing a concretion such as a kidney stone to be disintegrated. A body of water fills said reflector and said shroud and is in direct contact with the skin of said human body, the reflector being positioned relative to said body so that the concretion is at the second focus point of the reflector. Generation of a sprak across the spark gap causes generation of a shock wave focused
166 Urolithiasis
on the concretion and coupled to the concretion by the body of water and by the tissues of the human body. Excerpt(s): Kidney stones, and also naturally-occurring stones in the bladder and the ureter can be exquisitely painful, and often require surgical relief. Excision or destruction of stones in the bladder and sometimes in the ureter can be relatively easily accomplished, but removal of stones from the kidney is a major procedure. Removal of stones from the kidney is a very serious and traumatic surgical procedure A large incision is made in the body. The kidney is essentially removed from the body and cut open. The stone or stones are then removed, whereupon the kidney is sutured and returned to the body, with the body then being sutured. Various efforts have been made to destroy or disintegrate kidney stones so that they can be excreted with the urine. Chemotherapy is available as a non-invasive therapy for uric acid stones. In this therapy, the urine is alkalyzed, and the stone is dissolved over a substantial period of time. This requires detection of the stone before an acute phase is reached. Web site: http://www.delphion.com/details?pn=US04798196__
Patent Applications on Urolithiasis As of December 2000, U.S. patent applications are open to public viewing.9 Applications are patent requests which have yet to be granted. (The process to achieve a patent can take several years.) The following patent applications have been filed since December 2000 relating to urolithiasis: •
Compositions for preventing urinary calculus Inventor(s): Yoshida, Yasunori; (Chiba, JP) Correspondence: FITCH EVEN TABIN AND FLANNERY; 120 SOUTH LA SALLE STREET; SUITE 1600; CHICAGO; IL; 60603-3406; US Patent Application Number: 20030186845 Date filed: February 4, 2003 Abstract: Provided is a composition for preventing urinary calculi caused by metal ions liberated from a compound containing a lanthanoid metal or another heavy metal in image diagnosis or therapy using that compound. The composition is a urinary calculus preventing composition containing a multidentate ligand capable of forming a complex with lanthanoid metal ions or other heavy metal ions, or an alkaline earth metal complex of that ligand. The multidentate ligand can be a bifunctional ligand having a polyaminopolycarboxylic acid, polyaminopolyphosphonic acid or the like as its site for forming a complex with a metal and chemically bonded to a physiologically acceptable oligosaccharide or the like, or can also be a polyaminopolycarboxylic or polyaminopolyphosphonic acid per se. Preferably, the polyaminopolycarboxylic acid is EDTA, DTPA, DOTA or TETA, or a derivative thereof. Excerpt(s): The present invention relates to a composition for preventing urinary calculi, more particularly, a composition for preventing urinary calculi that are caused by metal ions liberated from a lanthanoid metal-containing compound or another heavy metalcontaining compound in image diagnosis or therapy using said compound. In recent years, contrast media containing a lanthanoid metal have been generally used in the
9
This has been a common practice outside the United States prior to December 2000.
Patents 167
field of image diagnosis, especially magnetic resonance imaging (MRI). The lanthanoid metal-containing MRI contrast media used as medical products are presently limited to those containing gadolinium such as a complex of diethylenetriaminepentaacetic acid with trivalent gadolinium ion (Gd-DTPA) and a complex of diethylenetriaminepentaacetic acid bismethylamide with trivalent gadolinium ion (GdDTPA-BMA). However, as can be seen in JP10-511934A (corresponding to WO96/16928) for example, there are attempts for applying other lanthanoid metals such as dysprosium. Also, said JP10-511934A (corresponding to W096/16928) directs attention to X-ray absorption characteristics of bismuth- and other heavy metal-containing compounds and lanthanoid metal-containing compounds, and indicates that these compounds may be used as X-ray contrast media instead of iodine-containing X-ray contrast media. Moreover, as can be seen in JP6-55681B (corresponding to EP164843A2) for example, use of heavy metals to radionuclide-based therapeutic agents for internal radiation is also proposed. The lanthanoid metals and other heavy metals in these agents are held in carriers by way of such bonds as coordinate bonds that are chemically weaker than covalent bonds. Therefore, they are likely to be liberated from carriers in vivo due to competition with other ions. It is indicated that, in general, if lanthanoid metal ions are liberated in vivo, especially in blood, they act as heavy metal ions (Cacheris W P, Quay S C and Rocklage R C: Magnetic Resonance Imaging, 8, 467-481, 1990). It can be predicted that heavy metal ions other than lanthanoid metal ions also act similarly. However, behavior of lanthanoid metal-containing pharmaceuticals and of liberated lanthanoid metal ions after their migration from blood into urine, and their effects on living bodies have not been particularly discussed yet. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Kidney stone collection device and method Inventor(s): Phan, Cu Ngoc; (Newport Coast, CA), Tran, Khiem Thanh; (Newport Coast, CA) Correspondence: HAYNES BEFFEL & WOLFELD LLP; P O BOX 366; HALF MOON BAY; CA; 94019; US Patent Application Number: 20030060787 Date filed: August 13, 2002 Abstract: A kidney stone collection device includes entrance and settling chambers coupled at a junction, an inlet opening into the entrance chamber, and an outlet conduit including the device outlet. The outlet conduit also has outlet conduit entrance which opens into the settling chamber. The device includes a base defining the bottom of the settling chamber when the body is in an upright orientation. The outlet conduit entrance is at a higher elevation than at least a portion of the base when the body is in the upright orientation. The body may be made of a pliable and/or transparent material so that the user may see and/or feel kidney stones collected at the base. A shape-maintaining frame element may be used at the inlet to permit the inlet to be maintained in an open configuration. Excerpt(s): This application claims the benefit of provisional patent application No. 60/______ filed on ______ Sep. 2001 and entitled Device/Apparatus and Method to Collect Kidney Stones or Stone Fragments from Urine. The presence of upper urinary tract stones, commonly referred to as kidney stones, is a common medical problem. Fortunately, kidney stones can be effectively treated with extracorporeal shockwave lithotripsy. This is a relatively noninvasive technique during which kidney stones are
168 Urolithiasis
fragmented by shockwaves applied to the skin surface. The stone fragments can then be passed along with urine via urination. Very small stones may be passed spontaneously without lithotripsy. However, it is a very important to collect the kidney stones and stone fragments for analysis and so that the physician can have the composition determined and then prescribe appropriate medication or other treatment to prevent stone recurrence. Stones and stone fragments will usually be referred to collectively as stones. FIGS. 1 and 2 illustrate two different devices 10, 12 currently used to collect stones. Collection device 10 is a conical device typically having a paper or plastic body 14 with a net or mesh 16, or other filtering medium, at the lower end. Device 12 is a telescoping, collapsible-cup type device having a net or mesh 18 at the bottom of the device. The body 20 of device 12 is typically made of plastic. These conventional devices work on the filtration principle. Urine is introduced into the device and the net or mesh, or other filtering medium, is supposed to catch the stones. However these devices have some disadvantages. It is sometimes difficult to determine if there are stones or stone fragments caught by the filtering medium. There are often blood clots in the urine of patients with kidney stones. These blood clots may cover stone fragments. The patient may have to use his or her fingers to squeeze the blood clots to see if there stone fragments inside them, an unpleasant task. Very small stone fragments may pass through the filtering medium. In addition, very small stone fragments are often difficult to remove from the filtering medium. The device may be large and inconvenient to carry around; this may discourage patients from collecting stones when away from home. The device may also be relatively expensive. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Keeping Current In order to stay informed about patents and patent applications dealing with urolithiasis, you can access the U.S. Patent Office archive via the Internet at the following Web address: http://www.uspto.gov/patft/index.html. You will see two broad options: (1) Issued Patent, and (2) Published Applications. To see a list of issued patents, perform the following steps: Under “Issued Patents,” click “Quick Search.” Then, type “urolithiasis” (or synonyms) into the “Term 1” box. After clicking on the search button, scroll down to see the various patents which have been granted to date on urolithiasis. You can also use this procedure to view pending patent applications concerning urolithiasis. Simply go back to http://www.uspto.gov/patft/index.html. Select “Quick Search” under “Published Applications.” Then proceed with the steps listed above.
169
CHAPTER 5. BOOKS ON UROLITHIASIS Overview This chapter provides bibliographic book references relating to urolithiasis. In addition to online booksellers such as www.amazon.com and www.bn.com, excellent sources for book titles on urolithiasis include the Combined Health Information Database and the National Library of Medicine. Your local medical library also may have these titles available for loan.
Book Summaries: Federal Agencies The Combined Health Information Database collects various book abstracts from a variety of healthcare institutions and federal agencies. To access these summaries, go directly to the following hyperlink: http://chid.nih.gov/detail/detail.html. You will need to use the “Detailed Search” option. To find book summaries, use the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer. For the format option, select “Monograph/Book.” Now type “urolithiasis” (or synonyms) into the “For these words:” box. You should check back periodically with this database which is updated every three months. The following is a typical result when searching for books on urolithiasis: •
Smith's General Urology. Fifteenth Edition Source: Columbus, OH: McGraw-Hill, Inc. 2000. 868 p. Contact: Available from McGraw-Hill. Medical Publishing. 1221 P.O. Box 182615, Columbus, OH 43272-5046. (800) 262-4729. PRICE: $54.95;plus shipping and handling. ISBN: 0838586074. Summary: This textbook offers a practical and concise guide to the understanding, diagnosis, and treatment of urologic diseases. The text includes 47 chapters covering the anatomy of the genitourinary tract, embryology of the genitourinary system, symptoms of disorders of the genitourinary tract, physical examination of the genitourinary tract, urologic laboratory examination, radiology of the urinary tract, vascular interventional radiology, percutaneous endourology and ureterorenoscopy, laparoscopic surgery, radionuclide imaging, retrograde instrumentation of the urinary tract, urinary obstruction and stasis, vesicoureteral reflux (return of urine through the ureters to the
170 Urolithiasis
kidney), bacterial infections, specific infections, sexually transmitted diseases, urinary stone (urolithiasis) disease, extracorporeal shock wave lithotripsy (ESWL, used to break up stones), injuries to the genitourinary tract, immunology and immunotherapy of urologic cancers, urothelial carcinoma (cancers of the bladder, ureter, and renal pelvis), renal parenchymal neoplasms (growths in the body of the kidney), neoplasms of the prostate gland, genital tumors, urinary diversion and bladder substitution, urologic laser surgery, chemotherapy of urologic tumors, radiotherapy of urologic tumors, neuropathic (arising from the nervous system) bladder disorders, urodynamic studies, urinary incontinence (involuntary loss of urine), disorders of the adrenal glands, disorders of the kidneys, diagnosis of medical renal diseases, oliguria (acute renal failure, lack of urination), chronic renal failure (CRF) and dialysis, renal transplantation, disorders of the ureter and ureteropelvic junction, disorders of the bladder and prostate (and seminal vesicles), disorders of the penis and male urethra, disorders of the female urethra, disorders of the testis and scrotum (and spermatic cord), skin diseases of the external genitalia, abnormalities of sexual determination and differentiation, renovascular hypertension, male infertility, and male sexual dysfunction. Each chapter concludes with references categorized by subject; the text concludes with an appendix of normal laboratory values and a subject index. The text features over 400 illustrations, including CT scans, radionuclide imaging scans, and x rays. •
Pediatric Urology Practice Source: Philadelphia, PA: Lippincott Williams and Wilkins. 1999. 736 p. Contact: Available from Lippincott Williams and Wilkins. P.O. Box 1600, Hagerstown, MD 21741. (800) 638-3030 or (301) 714-2300. Fax (301) 824-7390. Website: lww.com. PRICE: $150.00 plus shipping and handling. ISBN: 0397513682. Summary: This textbook on pediatric urology practice defines pediatric urology, provides an understanding of the physiology of the maturing urinary tract, considers the psychological impact that reconstruction has on the child and his or her family, and encourages a compassion for and a willingness to undertake and manage the many nonsurgical urologic conditions that are common to pediatric urologic practice (e.g., dysfunctional voiding and urinary infection). The text begins with a thorough chapter on the pediatric physical examination. The remaining 39 chapters cover pediatric anesthesia, the surgical physiology of the neonate, the workup of hematuria and tubular disorders, the management of renal failure in children, prenatal diagnosis and therapy, imaging the urinary tract in children, the molecular basis of pediatric urologic disease, clinical genetics, ureteropelvic junction obstruction, megaureter, posterior urethral valves and other obstructions of the urethra, the effect of obstruction on the detrusor, nonvirilizing adrenal disease, disorders of renal position and parenchymal development, ureteral ectopy, ureteroceles, anatomic abnormalities of the bladder, bladder and cloacal exstrophy, pediatric neurogenic bladder, the surgical and nonsurgical management of the neurogenic bladder, physiology of micturition (urination) and dysfunctional voiding, urinary infection in children, vesicoureteral reflex, hypospadias, cryptorchidism (undescended testicle), adolescent varicocele, anomalies of the penis and scrotum, intersex states, menstrual problems in the adolescent, urolithiasis (urinary stones) in children, pediatric oncology, hydrocele and hernia, imperforate anus and caudal regression syndrome, urogenital sinus and cloaca, the role of urinary diversion in childhood, and indications for laparoscopic procedures in pediatric urology. Each chapter is written by specialists in the field and includes references, black and white photographs, tables, and figures. A subject index concludes the textbook.
Books 171
•
Renal Disease In the Elderly. 2nd ed Source: New York, NY: Marcel Dekker, Inc. 1998. 441 p. Contact: Available from Marcel Dekker, Inc. Cimarron Road, P.O. Box 5005, Monticello, NY 12701-5185. (800) 228-1160 or (914) 796-1919. Fax (914) 796-1772. Website: www.dekker.com. PRICE: $175.00 plus shipping and handling. ISBN: 0824799003. Summary: This textbook offers a comprehensive review of kidney disease in the elderly. Thirteen chapters cover anatomy and physiology; disorders of water and salt metabolism; disorders of potassium metabolism; acid base disorders; disorders of calcium, phosphorus, and magnesium metabolism; primary glomerular disease; renal involvement in systemic diseases; urolithiasis (urinary stones) and obstructive uropathy; urinary infection; acute renal failure; chronic renal failure; hypertension in the elderly; and vascular disease of the kidney. For most of these subjects, the authors summarize the existing information on adults in general and then provide information that is specific to the elderly. Each chapter concludes with a list of references, and a subject index concludes the volume.
•
Clinical Guide to Nutrition Care in End-Stage Renal Disease. 2nd ed Source: Chicago, IL: American Dietetic Association. 1994. 255 p. Contact: Available from American Dietetic Association. 216 West Jackson Boulevard Chicago, IL 60606-6995. (312) 899-0040. PRICE: $24 for members; $28 for non-members; plus shipping and handling. ISBN: 0880911247. Summary: This manual provides guidelines for the clinical nutrition care of patients with end-stage renal disease (ESRD). Designed for renal dietitians, the manual contains 14 chapters and 11 appendices covering topics including normal and diseased kidney anatomy and function; nutrition assessment in chronic renal failure; dietary treatment in the early stages of chronic renal failure; nutrition management of adult hemodialysis and peritoneal dialysis patients; the nutrition management of the adult renal transplant patient; nutrition management of the patient with diabetes and renal disease; nutrition recommendations for infants, children and adolescents with ESRD; enteral nutrition in end-stage renal disease; parenteral nutrition for the patient with renal failure; medications commonly prescribed in chronic renal failure; renal osteodystrophy; attaining nutrition goals for hyperlipidemic and obese renal patients; nutrition management of the patient with urolithiasis; nutrition care of the hospitalized patient with renal failure; helpful hints for common patient problems; the management of anemia in ESRD; pregnancy and dialysis; hyperdietism; forms and documents; disaster diet information for hemodialysis patients; guidelines for estimating renal dietitian staffing levels, and funding for ESRD nutrition services. One of the appendices lists professional organizations for renal dietitians and another provides a medication and manufacturer reference index. The volume concludes with a subject index.
•
Renal Disease in the Aged Source: Boston, MA: Little, Brown and Company. 1991. 407 p. Contact: No longer available from publisher. ISBN: 0316714011. Summary: This book provides a comprehensive review of renal disease in the elderly. For most subject areas, the authors summarize the existing information on adults in general and then provide information that is specific to the elderly. Thirteen chapters discuss anatomy and physiology, disorders of water and salt metabolism, disorders of
172 Urolithiasis
potassium metabolism, acid-base disorders, disorders of calcium, phosphorus and magnesium metabolism, primary glomerular disease, renal involvement in systemic disease, urolithiasis and obstructive uropathy, urinary infections, acute renal failure, chronic renal failure, hypertension, and vascular disease of the kidney. Each chapter includes a lengthy reference list, and a detailed subject index concludes the text. 2201 references.
Book Summaries: Online Booksellers Commercial Internet-based booksellers, such as Amazon.com and Barnes&Noble.com, offer summaries which have been supplied by each title’s publisher. Some summaries also include customer reviews. Your local bookseller may have access to in-house and commercial databases that index all published books (e.g. Books in Print). IMPORTANT NOTE: Online booksellers typically produce search results for medical and non-medical books. When searching for “urolithiasis” at online booksellers’ Web sites, you may discover non-medical books that use the generic term “urolithiasis” (or a synonym) in their titles. The following is indicative of the results you might find when searching for “urolithiasis” (sorted alphabetically by title; follow the hyperlink to view more details at Amazon.com): •
Calcium Urolithiasis: Pathogenesis, Diagnosis, and Management (Topics in Bone and Mineral Disorders) by Charles Y. C. Pak; ISBN: 0306311100; http://www.amazon.com/exec/obidos/ASIN/0306311100/icongroupinterna
•
Distribution of trace elements related to the occurrence of certain cancers, cardiovascular diseases, and urolithiasis : a report of the workshop at South Seas Plantation, Captiva Island, Florida, October 6-11, 1974; ISBN: 0309027950; http://www.amazon.com/exec/obidos/ASIN/0309027950/icongroupinterna
•
New Developments in the Management of Urolithiasis (Topics in Clinical Urology) by James E. Lingeman (Editor), Glenn M. Preminger (Editor); ISBN: 0896402878; http://www.amazon.com/exec/obidos/ASIN/0896402878/icongroupinterna
•
Stones: Clinical Management of Urolithiasis by Robert A. Roth; ISBN: 0683073885; http://www.amazon.com/exec/obidos/ASIN/0683073885/icongroupinterna
•
Symposium on Urolithiasis (Mineral and Electrolyte Metabolism, Vol 13, No 4) by A. Jardin, et al (1987); ISBN: 3805545673; http://www.amazon.com/exec/obidos/ASIN/3805545673/icongroupinterna
•
Treatment of Urolithiasis by Masao Akimoto (Editor), et al; ISBN: 4431703128; http://www.amazon.com/exec/obidos/ASIN/4431703128/icongroupinterna
•
Urolithiasis by Valerie R. Walker, et al (1989); ISBN: 0306432498; http://www.amazon.com/exec/obidos/ASIN/0306432498/icongroupinterna
•
Urolithiasis 2 by Rosemary Rydall, et al; ISBN: 0306447274; http://www.amazon.com/exec/obidos/ASIN/0306447274/icongroupinterna
•
Urolithiasis and Related Clinical Research by Paul O. Schwille (1985); ISBN: 0306419319; http://www.amazon.com/exec/obidos/ASIN/0306419319/icongroupinterna
•
Urolithiasis Research by Ravindra Nath, Swaran K. Thind (1990); ISBN: 8170242444; http://www.amazon.com/exec/obidos/ASIN/8170242444/icongroupinterna
Books 173
•
Urolithiasis research : [proceedings of an International Symposium on Urolithiasis Research held in Davos, Switzerland, March 29-April 1, 1976]; ISBN: 0306309882; http://www.amazon.com/exec/obidos/ASIN/0306309882/icongroupinterna
•
Urolithiasis, clinical and basic research; ISBN: 0306406357; http://www.amazon.com/exec/obidos/ASIN/0306406357/icongroupinterna
•
Urolithiasis: A Medical and Surgical Reference by Martin I. Resnick, et al; ISBN: 0721624391; http://www.amazon.com/exec/obidos/ASIN/0721624391/icongroupinterna
•
Urolithiasis: Etiology, Diagnosis (Handbook of Urology, Vol 17/I) by H.J. Schneider (Editor); ISBN: 0387155821; http://www.amazon.com/exec/obidos/ASIN/0387155821/icongroupinterna
•
Urolithiasis: Therapy - Prevention (Handbook of Urology 17/2) by H.J. Schneider (Editor) (1986); ISBN: 0387157891; http://www.amazon.com/exec/obidos/ASIN/0387157891/icongroupinterna
The National Library of Medicine Book Index The National Library of Medicine at the National Institutes of Health has a massive database of books published on healthcare and biomedicine. Go to the following Internet site, http://locatorplus.gov/, and then select “Search LOCATORplus.” Once you are in the search area, simply type “urolithiasis” (or synonyms) into the search box, and select “books only.” From there, results can be sorted by publication date, author, or relevance. The following was recently catalogued by the National Library of Medicine:10 •
Canine urolithiasis Author: Osborne, Carl A.; Year: 1989; Philadelphia: Saunders, c1986
•
Medical treatment of idiopathic calcium urolithiasis Author: Smith, Lynwood H.,; Year: 1983; New York: National Kidney Foundation, c1983
•
Proceedings of the Symposium on Urolithiasis: a Wellcome Foundation symposium held in Crete, September 24-October 1, 1979 Author: Danielson, Bo G.; Year: 1979; Danderyd, Sweden: Wellcome Foundation, Ltd., Information Dept. in Sweden; Stockholm, Sweden: Distributed by the Almqvist; Wiksell Periodical Co., c1980; ISBN: 9185686069
•
Renal stone disease: proceedings of the 7th European symposium on urolithiasis, [Paris, 1997] Author: Jungers, Paul.; Year: 1983; Paris: Elsevier, 1997
•
Studies on urolithiasis in general practice Author: Laerum, Even.; Year: 1989; Oslo: [s.n.]; Stockholm, Sweden: Distributed by Almqvist; Wiksell Periodical Co., 1983
•
Study Group in Urolithiasis.; Year: 1978; New Delhi, 1971
10
In addition to LOCATORPlus, in collaboration with authors and publishers, the National Center for Biotechnology Information (NCBI) is currently adapting biomedical books for the Web. The books may be accessed in two ways: (1) by searching directly using any search term or phrase (in the same way as the bibliographic database PubMed), or (2) by following the links to PubMed abstracts. Each PubMed abstract has a "Books" button that displays a facsimile of the abstract in which some phrases are hypertext links. These phrases are also found in the books available at NCBI. Click on hyperlinked results in the list of books in which the phrase is found. Currently, the majority of the links are between the books and PubMed. In the future, more links will be created between the books and other types of information, such as gene and protein sequences and macromolecular structures. See http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Books.
174 Urolithiasis
•
Symposium on Biochemical, Nutritional, and Therapeutic Aspects of Idiopathic Urolithiasis: 24, 25 March 1979, Postgraduate Institute of Education and Research, Chandigarh.; Year: 1983; Chandigarh: The Institute, [1979?]
•
Urolithiasis Author: Hautmann, R.; Year: 1983; Berlin; New York: Springer International, 1983
•
Urolithiasis Author: Bichler, K.-H.; Year: 1983; Tubingen: Attempto Verlag, c1996; ISBN: 3893082409
•
Urolithiasis simplified Author: Costandi, Youssef T.; Year: 1976; [Cincinnati?: Y.T. Costandi], c1993
•
Urolithiasis, 1996 Author: Resnick, Martin I.; Year: 1981; Dallas, TX (1000 South Ervay St., Dallas 75201): Millet the Printer, Inc., c1996
•
Urolithiasis, household water and diet Author: Juuti, Markku.; Year: 1980; Kuopio [Finland]: Dept. of Surgery, Dept. of Community Health, University of Kuopio, 1980; ISBN: 9517800967
Chapters on Urolithiasis In order to find chapters that specifically relate to urolithiasis, an excellent source of abstracts is the Combined Health Information Database. You will need to limit your search to book chapters and urolithiasis using the “Detailed Search” option. Go to the following hyperlink: http://chid.nih.gov/detail/detail.html. To find book chapters, use the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Book Chapter.” Type “urolithiasis” (or synonyms) into the “For these words:” box. The following is a typical result when searching for book chapters on urolithiasis: •
Urolithiasis Source: in American Dietetic Association. Manual of Clinical Dietetics, Sixth Edition. Chicago, IL: American Dietetic Association. 2000. p.483-486. Contact: Available from American Dietetic Association. 216 West Jackson Boulevard, Chicago, IL 60606. (800) 877-1600 or (312) 899-0040. Fax (312) 899-4899. PRICE: $59.95 for members, $70.00 for nonmembers. ISBN: 0880911875. Summary: Dietary modifications can be used in conjunction with medical treatment to decrease the predominant components in urine that cause stone formation. Calcium oxalate stones and calcium phosphate stones respond most successfully to dietary management in conjunction with medical treatment. This chapter on urolithiasis (urinary tract stones) is from a comprehensive manual of clinical dietetics designed to help dietitians, physicians, and nurses deliver quality nutrition care. In this chapter, the authors describe how to minimize the supersaturation of components within the urine associated with the formation of renal calculi (kidney stones) and how to inhibit or prevent reformation of kidney stones. The chapter includes the purpose of nutrition care, the indications for use, a description of the diet, a definition of the disease or condition, and a discussion section. The authors note that an emphasis on generous fluid intake has been shown to be more effective than dietary restrictions and promotes greater patient compliance. 3 figures. 16 references.
Books 175
•
Nutrition Management of Urolithiasis Source: in American Dietetic Association. Manual of Clinical Dietetics. Chicago, IL: American Dietetic Association. 1996. p. 569-572. Contact: Available from American Dietetic Association. 216 West Jackson Boulevard, Chicago, IL 60606. (800) 877-1600 or (312) 899-0040. Fax (312) 899-4899. PRICE: $59.95 for members, $70.00 for nonmembers. ISBN: 0880911530. Summary: This section providing guidelines for the nutritional management of urolithiasis (urinary calculi, or stones) is from a manual that serves as a nutrition care guide for dietetics professionals, physicians, nurses, and other health professionals. The manual integrates current knowledge of nutrition, medical science, and food to set forth recommendations for healthy individuals and those for whom medical nutrition therapy (MNT) is indicated. The diet modifications for urolithiasis are designed to minimize the supersaturation of components within the urine associated with the formation of renal calculi. The text notes the purpose, use, modifications, and adequacy of the diet. Dietary modifications should be individualized based on the type and cause of stone formation. Collection of a complete diet history helps to determine the extent of dietary modifications required. Generally, dietary intervention combines the restriction of a specific dietary constituent with generous fluid intake. The section also outlines the related physiology. 2 tables. 20 references. (AA-M).
•
Nutrition Management of the Patient With Urolithiasis Source: in American Dietetic Association. Clinical Guide to Nutrition Care in End-Stage Renal Disease. Chicago, IL: American Dietetic Association. 1994. p. 177-184. Contact: Available from American Dietetic Association. 216 West Jackson Boulevard Chicago, IL 60606-6995. (312) 899-0040. PRICE: $24 for members; $28 for non-members; plus shipping and handling. ISBN: 0880911247. Summary: This chapter, from a manual that provides guidelines for the clinical nutrition care of patients with end-stage renal disease (ESRD), discusses the nutrition management of the patient with urolithiasis (urinary stones). Topics include the causes of urolithiasis; patient evaluation; and nutrition considerations, including fluid, sodium, calcium, oxalate, and protein intake. The author stresses that diet therapy should be instituted only after careful consideration of the individual patient's laboratory tests, including a metabolic evaluation of blood and urine parameters as well as stone analysis data. 2 tables. 34 references.
177
CHAPTER 6. MULTIMEDIA ON UROLITHIASIS Overview In this chapter, we show you how to keep current on multimedia sources of information on urolithiasis. We start with sources that have been summarized by federal agencies, and then show you how to find bibliographic information catalogued by the National Library of Medicine.
Video Recordings An excellent source of multimedia information on urolithiasis is the Combined Health Information Database. You will need to limit your search to “Videorecording” and “urolithiasis” using the “Detailed Search” option. Go directly to the following hyperlink: http://chid.nih.gov/detail/detail.html. To find video productions, use the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Videorecording (videotape, videocassette, etc.).” Type “urolithiasis” (or synonyms) into the “For these words:” box. The following is a typical result when searching for video recordings on urolithiasis: •
Role of Medical Management in the Treatment of Urinary Calculus Disease Source: Marshfield, WI: Marshfield Clinic. 1991. Contact: Available from Marshfield Clinic. Office of Medical Education, 1000 North Oak Avenue, Marshfield, WI 54449-5777. (800) 782-8581, ext. 5127 in WI or (715) 387-5127. PRICE: $60 U-Matic or $45 VHS/Beta (purchase); $35 per tape for 30 days (rental). Order number 89-2576. Summary: In this videotape, Dr. Martin Resnick discusses the evaluation and medical management of the patient with kidney stones. He also talks about the interpretation of laboratory information, patient history, and addresses the issues of treating patients who are trying to prevent recurrent disease. (AA-M).
178 Urolithiasis
Bibliography: Multimedia on Urolithiasis The National Library of Medicine is a rich source of information on healthcare-related multimedia productions including slides, computer software, and databases. To access the multimedia database, go to the following Web site: http://locatorplus.gov/. Select “Search LOCATORplus.” Once in the search area, simply type in urolithiasis (or synonyms). Then, in the option box provided below the search box, select “Audiovisuals and Computer Files.” From there, you can choose to sort results by publication date, author, or relevance. The following multimedia has been indexed on urolithiasis: •
Urolithiasis [sound recording] Source: Rubin H. Flocks, William H. Boyce, Donald Griffith; [produced by R. A. Becker Co., Audiovisual Division]; Year: 1975; Format: Sound recording; New York: Roerig; [for sale by Robert A. Becker Co.], c1975
•
Urolithiasis [videorecording]: advances in diagnosis and treatment Source: the Radiological Society of North America; Year: 1988; Format: Videorecording; Oak Brook, Ill.: The Society, c1988
•
Urolithiasis, percutaneous calculus removal [videorecording] Source: Radiological Society of North America; Year: 1984; Format: Videorecording; [Chicago, Ill.]: RSNA, [1984]
179
CHAPTER 7. PERIODICALS AND NEWS ON UROLITHIASIS Overview In this chapter, we suggest a number of news sources and present various periodicals that cover urolithiasis.
News Services and Press Releases One of the simplest ways of tracking press releases on urolithiasis is to search the news wires. In the following sample of sources, we will briefly describe how to access each service. These services only post recent news intended for public viewing. PR Newswire To access the PR Newswire archive, simply go to http://www.prnewswire.com/. Select your country. Type “urolithiasis” (or synonyms) into the search box. You will automatically receive information on relevant news releases posted within the last 30 days. The search results are shown by order of relevance. Reuters Health The Reuters’ Medical News and Health eLine databases can be very useful in exploring news archives relating to urolithiasis. While some of the listed articles are free to view, others are available for purchase for a nominal fee. To access this archive, go to http://www.reutershealth.com/en/index.html and search by “urolithiasis” (or synonyms). The following was recently listed in this archive for urolithiasis: •
Heating pad relieves symptoms of urolithiasis Source: Reuters Medical News Date: September 01, 2003 http://www.reutershealth.com/archive/2003/09/01/professional/links/20030901clin0 07.html
180 Urolithiasis
•
Underlying metabolic abnormalities cause many HIV-associated kidney stones Source: Reuters Medical News Date: February 07, 2003
•
Gene mutations associated with nephrolithiasis and osteoporosis Source: Reuters Medical News Date: September 25, 2002
•
Differences in renal function may explain racial disparity in urolithiasis in S. Africa Source: Reuters Medical News Date: September 20, 2002
•
CT better than IVP in diagnosing acute urolithiasis Source: Reuters Medical News Date: September 10, 2002
•
Size determines treatment of allograft kidney stones Source: Reuters Medical News Date: April 09, 2002
•
Hematuria is not always present in patients with urolithiasis Source: Reuters Medical News Date: March 15, 2001
•
Absence of hematuria does not rule out urolithiasis in children Source: Reuters Medical News Date: January 10, 2001
•
Indinavir-related renal colic on the rise Source: Reuters Medical News Date: May 17, 1999
•
Urolithiasis Associated With HIV Protease Inhibitor Therapy Source: Reuters Medical News Date: June 16, 1997 The NIH
Within MEDLINEplus, the NIH has made an agreement with the New York Times Syndicate, the AP News Service, and Reuters to deliver news that can be browsed by the public. Search news releases at http://www.nlm.nih.gov/medlineplus/alphanews_a.html. MEDLINEplus allows you to browse across an alphabetical index. Or you can search by date at the following Web page: http://www.nlm.nih.gov/medlineplus/newsbydate.html. Often, news items are indexed by MEDLINEplus within its search engine.
Periodicals and News 181
Business Wire Business Wire is similar to PR Newswire. To access this archive, simply go to http://www.businesswire.com/. You can scan the news by industry category or company name. Market Wire Market Wire is more focused on technology than the other wires. To browse the latest press releases by topic, such as alternative medicine, biotechnology, fitness, healthcare, legal, nutrition, and pharmaceuticals, access Market Wire’s Medical/Health channel at http://www.marketwire.com/mw/release_index?channel=MedicalHealth. Or simply go to Market Wire’s home page at http://www.marketwire.com/mw/home, type “urolithiasis” (or synonyms) into the search box, and click on “Search News.” As this service is technology oriented, you may wish to use it when searching for press releases covering diagnostic procedures or tests. Search Engines Medical news is also available in the news sections of commercial Internet search engines. See the health news page at Yahoo (http://dir.yahoo.com/Health/News_and_Media/), or you can use this Web site’s general news search page at http://news.yahoo.com/. Type in “urolithiasis” (or synonyms). If you know the name of a company that is relevant to urolithiasis, you can go to any stock trading Web site (such as http://www.etrade.com/) and search for the company name there. News items across various news sources are reported on indicated hyperlinks. Google offers a similar service at http://news.google.com/. BBC Covering news from a more European perspective, the British Broadcasting Corporation (BBC) allows the public free access to their news archive located at http://www.bbc.co.uk/. Search by “urolithiasis” (or synonyms).
Newsletter Articles Use the Combined Health Information Database, and limit your search criteria to “newsletter articles.” Again, you will need to use the “Detailed Search” option. Go directly to the following hyperlink: http://chid.nih.gov/detail/detail.html. Go to the bottom of the search page where “You may refine your search by.” Select the dates and language that you prefer. For the format option, select “Newsletter Article.” Type “urolithiasis” (or synonyms) into the “For these words:” box. You should check back periodically with this database as it is updated every three months. The following is a typical result when searching for newsletter articles on urolithiasis: •
Kidney Stones: Often Painful, But Manageable Source: Mayo Clinic Health Letter. 20(4): 6. April 2002.
182 Urolithiasis
Contact: Available from Mayo Clinic Health Letter. Subscription Services, P.O. Box 53889, Boulder, CO 80322-3889. (800) 333-9037 or (303) 604-1465. Summary: This brief newsletter article reviews the problem of kidney stones (nephrolithiasis) and their treatment. The author first reviews the different types of kidney stones, including calcium stones, uric acid stones, struvite stones, and cystine stones. The author cautions that kidney stones often first occur between the ages of 20 and 50 and tend to recur. Small stones may pass with little or no pain. Others can be quite painful as they pass through the narrow tubes that connect each kidney to the bladder (the ureters). Drinking plenty of fluids and staying physically active can help to move a stone through the patient's system. Stones that are too large to pass or that are causing bleeding, kidney damage, or ongoing urinary tract infection (UTI) may require surgical treatment. Stone removal techniques include extracorporeal shock wave lithotripsy (ESWL), percutaneous nephrolithotomy, and ureteroscopic stone removal. One sidebar reviews strategies to prevent future stones.
Academic Periodicals covering Urolithiasis Numerous periodicals are currently indexed within the National Library of Medicine’s PubMed database that are known to publish articles relating to urolithiasis. In addition to these sources, you can search for articles covering urolithiasis that have been published by any of the periodicals listed in previous chapters. To find the latest studies published, go to http://www.ncbi.nlm.nih.gov/pubmed, type the name of the periodical into the search box, and click “Go.” If you want complete details about the historical contents of a journal, you can also visit the following Web site: http://www.ncbi.nlm.nih.gov/entrez/jrbrowser.cgi. Here, type in the name of the journal or its abbreviation, and you will receive an index of published articles. At http://locatorplus.gov/, you can retrieve more indexing information on medical periodicals (e.g. the name of the publisher). Select the button “Search LOCATORplus.” Then type in the name of the journal and select the advanced search option “Journal Title Search.”
183
CHAPTER 9. RESEARCHING MEDICATIONS Overview While a number of hard copy or CD-ROM resources are available for researching medications, a more flexible method is to use Internet-based databases. Broadly speaking, there are two sources of information on approved medications: public sources and private sources. We will emphasize free-to-use public sources.
U.S. Pharmacopeia Because of historical investments by various organizations and the emergence of the Internet, it has become rather simple to learn about the medications recommended for urolithiasis. One such source is the United States Pharmacopeia. In 1820, eleven physicians met in Washington, D.C. to establish the first compendium of standard drugs for the United States. They called this compendium the U.S. Pharmacopeia (USP). Today, the USP is a nonprofit organization consisting of 800 volunteer scientists, eleven elected officials, and 400 representatives of state associations and colleges of medicine and pharmacy. The USP is located in Rockville, Maryland, and its home page is located at http://www.usp.org/. The USP currently provides standards for over 3,700 medications. The resulting USP DI Advice for the Patient can be accessed through the National Library of Medicine of the National Institutes of Health. The database is partially derived from lists of federally approved medications in the Food and Drug Administration’s (FDA) Drug Approvals database, located at http://www.fda.gov/cder/da/da.htm. While the FDA database is rather large and difficult to navigate, the Phamacopeia is both user-friendly and free to use. It covers more than 9,000 prescription and over-the-counter medications. To access this database, simply type the following hyperlink into your Web browser: http://www.nlm.nih.gov/medlineplus/druginformation.html. To view examples of a given medication (brand names, category, description, preparation, proper use, precautions, side effects, etc.), simply follow the hyperlinks indicated within the United States Pharmacopeia (USP). Below, we have compiled a list of medications associated with urolithiasis. If you would like more information on a particular medication, the provided hyperlinks will direct you to ample documentation (e.g. typical dosage, side effects, drug-interaction risks, etc.). The
184 Urolithiasis
following drugs have been mentioned in the Pharmacopeia and other sources as being potentially applicable to urolithiasis: Allopurinol •
Systemic - U.S. Brands: Aloprim; Zyloprim http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202021.html
Antacids •
Oral - U.S. Brands: Advanced Formula Di-Gel; Alamag; Alamag Plus; Alenic Alka; Alenic Alka Extra Strength; Alka-Mints; Alkets; Alkets Extra Strength; Almacone; Almacone II; AlternaGEL; Alu-Cap; Aludrox; Alu-Tab; Amitone; Amphojel; Antacid Gelcaps; Antacid Liquid; Antacid L http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202047.html
Citrates •
Systemic - U.S. Brands: Bicitra; Citrolith; Oracit; Polycitra Syrup; Polycitra-K; Polycitra-K Crystals; Polycitra-LC; Urocit-K http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202144.html
Diuretics, Thiazide •
Systemic - U.S. Brands: Aquatensen; Diucardin; Diulo; Diuril; Enduron; Esidrix; Hydro-chlor; Hydro-D; HydroDIURIL; Hydromox; Hygroton; Metahydrin; Microzide; Mykrox; Naqua; Naturetin; Oretic; Renese; Saluron; Thalitone; Trichlorex 10; Zaroxolyn http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202208.html
Erythromycin and Sulfisoxazole •
Systemic - U.S. Brands: Eryzole; Pediazole http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202224.html
Indinavir •
Systemic - U.S. Brands: Crixivan http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/203523.html
Penicillamine •
Systemic - U.S. Brands: Cuprimine; Depen http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202445.html
Phosphates •
Systemic - U.S. Brands: K-Phos M. F. K-Phos Neutral; K-Phos No. 2; K-Phos Original; Neutra-Phos; Neutra-Phos-K; Uro-KP-Neutral http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202463.html
Probenecid •
Systemic - U.S. Brands: Benemid; Probalan http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202480.html
Researching Medications 185
Probenecid and Colchicine •
Systemic - U.S. Brands: ColBenemid; Col-Probenecid; Proben-C http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202481.html
Pyridoxine (Vitamin B 6 ) •
Systemic - U.S. Brands: Beesix; Doxine; Nestrex; Pyri; Rodex http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202493.html
Sodium Bicarbonate •
Systemic - U.S. Brands: Bell/ans; Citrocarbonate http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202525.html
Sulfadoxine and Pyrimethamine •
Systemic - U.S. Brands: Fansidar http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202534.html
Sulfinpyrazone •
Systemic - U.S. Brands: Anturane http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202538.html
Sulfonamides and Phenazopyridine •
Systemic - U.S. Brands: Azo Gantanol; Azo Gantrisin; Azo-Sulfamethoxazole; Azo-Sulfisoxazole; Azo-Truxazole; Sul-Azo http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202542.html
Urea •
Intra-Amniotic - U.S. Brands: Ureaphil http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202584.html
Commercial Databases In addition to the medications listed in the USP above, a number of commercial sites are available by subscription to physicians and their institutions. Or, you may be able to access these sources from your local medical library.
Mosby’s Drug Consult Mosby’s Drug Consult database (also available on CD-ROM and book format) covers 45,000 drug products including generics and international brands. It provides prescribing information, drug interactions, and patient information. Subscription information is available at the following hyperlink: http://www.mosbysdrugconsult.com/. PDRhealth The PDRhealth database is a free-to-use, drug information search engine that has been written for the public in layman’s terms. It contains FDA-approved drug information adapted from the Physicians’ Desk Reference (PDR) database. PDRhealth can be searched by
186 Urolithiasis
brand name, generic name, or indication. It features multiple drug interactions reports. Search PDRhealth at http://www.pdrhealth.com/drug_info/index.html. Other Web Sites Drugs.com (www.drugs.com) reproduces the information in the Pharmacopeia as well as commercial information. You may also want to consider the Web site of the Medical Letter, Inc. (http://www.medletter.com/) which allows users to download articles on various drugs and therapeutics for a nominal fee.
Researching Orphan Drugs Although the list of orphan drugs is revised on a daily basis, you can quickly research orphan drugs that might be applicable to urolithiasis by using the database managed by the National Organization for Rare Disorders, Inc. (NORD), at http://www.rarediseases.org/. Scroll down the page, and on the left toolbar, click on “Orphan Drug Designation Database.” On this page (http://www.rarediseases.org/search/noddsearch.html), type “urolithiasis” (or synonyms) into the search box, and click “Submit Query.” When you receive your results, note that not all of the drugs may be relevant, as some may have been withdrawn from orphan status. Write down or print out the name of each drug and the relevant contact information. From there, visit the Pharmacopeia Web site and type the name of each orphan drug into the search box at http://www.nlm.nih.gov/medlineplus/druginformation.html. You may need to contact the sponsor or NORD for further information. NORD conducts “early access programs for investigational new drugs (IND) under the Food and Drug Administration’s (FDA’s) approval ‘Treatment INDs’ programs which allow for a limited number of individuals to receive investigational drugs before FDA marketing approval.” If the orphan product about which you are seeking information is approved for marketing, information on side effects can be found on the product’s label. If the product is not approved, you may need to contact the sponsor. The following is a list of orphan drugs currently listed in the NORD Orphan Drug Designation Database for urolithiasis: •
Succimer (trade name: Chemet) http://www.rarediseases.org/nord/search/nodd_full?code=169
•
Tiopronin (trade name: Thiola) http://www.rarediseases.org/nord/search/nodd_full?code=41
•
Potassium citrate (trade name: Urocit-K) http://www.rarediseases.org/nord/search/nodd_full?code=418
If you have any questions about a medical treatment, the FDA may have an office near you. Look for their number in the blue pages of the phone book. You can also contact the FDA through its toll-free number, 1-888-INFO-FDA (1-888-463-6332), or on the World Wide Web at www.fda.gov.
187
APPENDICES
189
APPENDIX A. PHYSICIAN RESOURCES Overview In this chapter, we focus on databases and Internet-based guidelines and information resources created or written for a professional audience.
NIH Guidelines Commonly referred to as “clinical” or “professional” guidelines, the National Institutes of Health publish physician guidelines for the most common diseases. Publications are available at the following by relevant Institute11: •
Office of the Director (OD); guidelines consolidated across agencies available at http://www.nih.gov/health/consumer/conkey.htm
•
National Institute of General Medical Sciences (NIGMS); fact sheets available at http://www.nigms.nih.gov/news/facts/
•
National Library of Medicine (NLM); extensive encyclopedia (A.D.A.M., Inc.) with guidelines: http://www.nlm.nih.gov/medlineplus/healthtopics.html
•
National Cancer Institute (NCI); guidelines available at http://www.cancer.gov/cancerinfo/list.aspx?viewid=5f35036e-5497-4d86-8c2c714a9f7c8d25
•
National Eye Institute (NEI); guidelines available at http://www.nei.nih.gov/order/index.htm
•
National Heart, Lung, and Blood Institute (NHLBI); guidelines available at http://www.nhlbi.nih.gov/guidelines/index.htm
•
National Human Genome Research Institute (NHGRI); research available at http://www.genome.gov/page.cfm?pageID=10000375
•
National Institute on Aging (NIA); guidelines available at http://www.nia.nih.gov/health/
11
These publications are typically written by one or more of the various NIH Institutes.
190 Urolithiasis
•
National Institute on Alcohol Abuse and Alcoholism (NIAAA); guidelines available at http://www.niaaa.nih.gov/publications/publications.htm
•
National Institute of Allergy and Infectious Diseases (NIAID); guidelines available at http://www.niaid.nih.gov/publications/
•
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); fact sheets and guidelines available at http://www.niams.nih.gov/hi/index.htm
•
National Institute of Child Health and Human Development (NICHD); guidelines available at http://www.nichd.nih.gov/publications/pubskey.cfm
•
National Institute on Deafness and Other Communication Disorders (NIDCD); fact sheets and guidelines at http://www.nidcd.nih.gov/health/
•
National Institute of Dental and Craniofacial Research (NIDCR); guidelines available at http://www.nidr.nih.gov/health/
•
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); guidelines available at http://www.niddk.nih.gov/health/health.htm
•
National Institute on Drug Abuse (NIDA); guidelines available at http://www.nida.nih.gov/DrugAbuse.html
•
National Institute of Environmental Health Sciences (NIEHS); environmental health information available at http://www.niehs.nih.gov/external/facts.htm
•
National Institute of Mental Health (NIMH); guidelines available at http://www.nimh.nih.gov/practitioners/index.cfm
•
National Institute of Neurological Disorders and Stroke (NINDS); neurological disorder information pages available at http://www.ninds.nih.gov/health_and_medical/disorder_index.htm
•
National Institute of Nursing Research (NINR); publications on selected illnesses at http://www.nih.gov/ninr/news-info/publications.html
•
National Institute of Biomedical Imaging and Bioengineering; general information at http://grants.nih.gov/grants/becon/becon_info.htm
•
Center for Information Technology (CIT); referrals to other agencies based on keyword searches available at http://kb.nih.gov/www_query_main.asp
•
National Center for Complementary and Alternative Medicine (NCCAM); health information available at http://nccam.nih.gov/health/
•
National Center for Research Resources (NCRR); various information directories available at http://www.ncrr.nih.gov/publications.asp
•
Office of Rare Diseases; various fact sheets available at http://rarediseases.info.nih.gov/html/resources/rep_pubs.html
•
Centers for Disease Control and Prevention; various fact sheets on infectious diseases available at http://www.cdc.gov/publications.htm
Physician Resources 191
NIH Databases In addition to the various Institutes of Health that publish professional guidelines, the NIH has designed a number of databases for professionals.12 Physician-oriented resources provide a wide variety of information related to the biomedical and health sciences, both past and present. The format of these resources varies. Searchable databases, bibliographic citations, full-text articles (when available), archival collections, and images are all available. The following are referenced by the National Library of Medicine:13 •
Bioethics: Access to published literature on the ethical, legal, and public policy issues surrounding healthcare and biomedical research. This information is provided in conjunction with the Kennedy Institute of Ethics located at Georgetown University, Washington, D.C.: http://www.nlm.nih.gov/databases/databases_bioethics.html
•
HIV/AIDS Resources: Describes various links and databases dedicated to HIV/AIDS research: http://www.nlm.nih.gov/pubs/factsheets/aidsinfs.html
•
NLM Online Exhibitions: Describes “Exhibitions in the History of Medicine”: http://www.nlm.nih.gov/exhibition/exhibition.html. Additional resources for historical scholarship in medicine: http://www.nlm.nih.gov/hmd/hmd.html
•
Biotechnology Information: Access to public databases. The National Center for Biotechnology Information conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information for the better understanding of molecular processes affecting human health and disease: http://www.ncbi.nlm.nih.gov/
•
Population Information: The National Library of Medicine provides access to worldwide coverage of population, family planning, and related health issues, including family planning technology and programs, fertility, and population law and policy: http://www.nlm.nih.gov/databases/databases_population.html
•
Cancer Information: Access to cancer-oriented databases: http://www.nlm.nih.gov/databases/databases_cancer.html
•
Profiles in Science: Offering the archival collections of prominent twentieth-century biomedical scientists to the public through modern digital technology: http://www.profiles.nlm.nih.gov/
•
Chemical Information: Provides links to various chemical databases and references: http://sis.nlm.nih.gov/Chem/ChemMain.html
•
Clinical Alerts: Reports the release of findings from the NIH-funded clinical trials where such release could significantly affect morbidity and mortality: http://www.nlm.nih.gov/databases/alerts/clinical_alerts.html
•
Space Life Sciences: Provides links and information to space-based research (including NASA): http://www.nlm.nih.gov/databases/databases_space.html
•
MEDLINE: Bibliographic database covering the fields of medicine, nursing, dentistry, veterinary medicine, the healthcare system, and the pre-clinical sciences: http://www.nlm.nih.gov/databases/databases_medline.html
12
Remember, for the general public, the National Library of Medicine recommends the databases referenced in MEDLINEplus (http://medlineplus.gov/ or http://www.nlm.nih.gov/medlineplus/databases.html). 13 See http://www.nlm.nih.gov/databases/databases.html.
192 Urolithiasis
•
Toxicology and Environmental Health Information (TOXNET): Databases covering toxicology and environmental health: http://sis.nlm.nih.gov/Tox/ToxMain.html
•
Visible Human Interface: Anatomically detailed, three-dimensional representations of normal male and female human bodies: http://www.nlm.nih.gov/research/visible/visible_human.html
The NLM Gateway14 The NLM (National Library of Medicine) Gateway is a Web-based system that lets users search simultaneously in multiple retrieval systems at the U.S. National Library of Medicine (NLM). It allows users of NLM services to initiate searches from one Web interface, providing one-stop searching for many of NLM’s information resources or databases.15 To use the NLM Gateway, simply go to the search site at http://gateway.nlm.nih.gov/gw/Cmd. Type “urolithiasis” (or synonyms) into the search box and click “Search.” The results will be presented in a tabular form, indicating the number of references in each database category. Results Summary Category Journal Articles Books / Periodicals / Audio Visual Consumer Health Meeting Abstracts Other Collections Total
Items Found 21511 224 1 11 0 21747
HSTAT16 HSTAT is a free, Web-based resource that provides access to full-text documents used in healthcare decision-making.17 These documents include clinical practice guidelines, quickreference guides for clinicians, consumer health brochures, evidence reports and technology assessments from the Agency for Healthcare Research and Quality (AHRQ), as well as AHRQ’s Put Prevention Into Practice.18 Simply search by “urolithiasis” (or synonyms) at the following Web site: http://text.nlm.nih.gov.
14
Adapted from NLM: http://gateway.nlm.nih.gov/gw/Cmd?Overview.x.
15
The NLM Gateway is currently being developed by the Lister Hill National Center for Biomedical Communications (LHNCBC) at the National Library of Medicine (NLM) of the National Institutes of Health (NIH). 16 Adapted from HSTAT: http://www.nlm.nih.gov/pubs/factsheets/hstat.html. 17 18
The HSTAT URL is http://hstat.nlm.nih.gov/.
Other important documents in HSTAT include: the National Institutes of Health (NIH) Consensus Conference Reports and Technology Assessment Reports; the HIV/AIDS Treatment Information Service (ATIS) resource documents; the Substance Abuse and Mental Health Services Administration's Center for Substance Abuse Treatment (SAMHSA/CSAT) Treatment Improvement Protocols (TIP) and Center for Substance Abuse Prevention (SAMHSA/CSAP) Prevention Enhancement Protocols System (PEPS); the Public Health Service (PHS) Preventive Services Task Force's Guide to Clinical Preventive Services; the independent, nonfederal Task Force on Community Services’ Guide to Community Preventive Services; and the Health Technology Advisory Committee (HTAC) of the Minnesota Health Care Commission (MHCC) health technology evaluations.
Physician Resources 193
Coffee Break: Tutorials for Biologists19 Coffee Break is a general healthcare site that takes a scientific view of the news and covers recent breakthroughs in biology that may one day assist physicians in developing treatments. Here you will find a collection of short reports on recent biological discoveries. Each report incorporates interactive tutorials that demonstrate how bioinformatics tools are used as a part of the research process. Currently, all Coffee Breaks are written by NCBI staff.20 Each report is about 400 words and is usually based on a discovery reported in one or more articles from recently published, peer-reviewed literature.21 This site has new articles every few weeks, so it can be considered an online magazine of sorts. It is intended for general background information. You can access the Coffee Break Web site at the following hyperlink: http://www.ncbi.nlm.nih.gov/Coffeebreak/.
Other Commercial Databases In addition to resources maintained by official agencies, other databases exist that are commercial ventures addressing medical professionals. Here are some examples that may interest you: •
CliniWeb International: Index and table of contents to selected clinical information on the Internet; see http://www.ohsu.edu/cliniweb/.
•
Medical World Search: Searches full text from thousands of selected medical sites on the Internet; see http://www.mwsearch.com/.
The Genome Project and Urolithiasis In the following section, we will discuss databases and references which relate to the Genome Project and urolithiasis. Online Mendelian Inheritance in Man (OMIM) The Online Mendelian Inheritance in Man (OMIM) database is a catalog of human genes and genetic disorders authored and edited by Dr. Victor A. McKusick and his colleagues at Johns Hopkins and elsewhere. OMIM was developed for the World Wide Web by the National Center for Biotechnology Information (NCBI).22 The database contains textual information, pictures, and reference information. It also contains copious links to NCBI’s Entrez database of MEDLINE articles and sequence information. 19 Adapted 20
from http://www.ncbi.nlm.nih.gov/Coffeebreak/Archive/FAQ.html.
The figure that accompanies each article is frequently supplied by an expert external to NCBI, in which case the source of the figure is cited. The result is an interactive tutorial that tells a biological story. 21 After a brief introduction that sets the work described into a broader context, the report focuses on how a molecular understanding can provide explanations of observed biology and lead to therapies for diseases. Each vignette is accompanied by a figure and hypertext links that lead to a series of pages that interactively show how NCBI tools and resources are used in the research process. 22 Adapted from http://www.ncbi.nlm.nih.gov/. Established in 1988 as a national resource for molecular biology information, NCBI creates public databases, conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information--all for the better understanding of molecular processes affecting human health and disease.
194 Urolithiasis
To search the database, go to http://www.ncbi.nlm.nih.gov/Omim/searchomim.html. Type “urolithiasis” (or synonyms) into the search box, and click “Submit Search.” If too many results appear, you can narrow the search by adding the word “clinical.” Each report will have additional links to related research and databases. In particular, the option “Database Links” will search across technical databases that offer an abundance of information. The following is an example of the results you can obtain from the OMIM for urolithiasis: •
Glycinuria with or without Oxalate Urolithiasis Web site: http://www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmim?138500
•
Uric Acid Urolithiasis Web site: http://www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmim?191700 Genes and Disease (NCBI - Map)
The Genes and Disease database is produced by the National Center for Biotechnology Information of the National Library of Medicine at the National Institutes of Health. This Web site categorizes each disorder by system of the body. Go to http://www.ncbi.nlm.nih.gov/disease/, and browse the system pages to have a full view of important conditions linked to human genes. Since this site is regularly updated, you may wish to revisit it from time to time. The following systems and associated disorders are addressed: •
Cancer: Uncontrolled cell division. Examples: Breast and ovarian cancer, Burkitt lymphoma, chronic myeloid leukemia, colon cancer, lung cancer, malignant melanoma, multiple endocrine neoplasia, neurofibromatosis, p53 tumor suppressor, pancreatic cancer, prostate cancer, Ras oncogene, RB: retinoblastoma, von Hippel-Lindau syndrome. Web site: http://www.ncbi.nlm.nih.gov/disease/Cancer.html
•
Immune System: Fights invaders. Examples: Asthma, autoimmune polyglandular syndrome, Crohn’s disease, DiGeorge syndrome, familial Mediterranean fever, immunodeficiency with Hyper-IgM, severe combined immunodeficiency. Web site: http://www.ncbi.nlm.nih.gov/disease/Immune.html
•
Metabolism: Food and energy. Examples: Adreno-leukodystrophy, atherosclerosis, Best disease, Gaucher disease, glucose galactose malabsorption, gyrate atrophy, juvenile-onset diabetes, obesity, paroxysmal nocturnal hemoglobinuria, phenylketonuria, Refsum disease, Tangier disease, Tay-Sachs disease. Web site: http://www.ncbi.nlm.nih.gov/disease/Metabolism.html
•
Muscle and Bone: Movement and growth. Examples: Duchenne muscular dystrophy, Ellis-van Creveld syndrome, Marfan syndrome, myotonic dystrophy, spinal muscular atrophy. Web site: http://www.ncbi.nlm.nih.gov/disease/Muscle.html
•
Nervous System: Mind and body. Examples: Alzheimer disease, amyotrophic lateral sclerosis, Angelman syndrome, Charcot-Marie-Tooth disease, epilepsy, essential tremor, fragile X syndrome, Friedreich’s ataxia, Huntington disease, Niemann-Pick disease, Parkinson disease,
Physician Resources 195
Prader-Willi syndrome, Rett syndrome, spinocerebellar atrophy, Williams syndrome. Web site: http://www.ncbi.nlm.nih.gov/disease/Brain.html •
Signals: Cellular messages. Examples: Ataxia telangiectasia, Cockayne syndrome, glaucoma, male-patterned baldness, SRY: sex determination, tuberous sclerosis, Waardenburg syndrome, Werner syndrome. Web site: http://www.ncbi.nlm.nih.gov/disease/Signals.html
•
Transporters: Pumps and channels. Examples: Cystic fibrosis, deafness, diastrophic dysplasia, Hemophilia A, long-QT syndrome, Menkes syndrome, Pendred syndrome, polycystic kidney disease, sickle cell anemia, Wilson’s disease, Zellweger syndrome. Web site: http://www.ncbi.nlm.nih.gov/disease/Transporters.html Entrez
Entrez is a search and retrieval system that integrates several linked databases at the National Center for Biotechnology Information (NCBI). These databases include nucleotide sequences, protein sequences, macromolecular structures, whole genomes, and MEDLINE through PubMed. Entrez provides access to the following databases: •
3D Domains: Domains from Entrez Structure, Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=geo
•
Books: Online books, Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=books
•
Genome: Complete genome assemblies, Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Genome
•
NCBI’s Protein Sequence Information Survey Results: Web site: http://www.ncbi.nlm.nih.gov/About/proteinsurvey/
•
Nucleotide Sequence Database (Genbank): Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Nucleotide
•
OMIM: Online Mendelian Inheritance in Man, Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM
•
PopSet: Population study data sets, Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Popset
•
ProbeSet: Gene Expression Omnibus (GEO), Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=geo
•
Protein Sequence Database: Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Protein
•
PubMed: Biomedical literature (PubMed), Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
•
Structure: Three-dimensional macromolecular structures, Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Structure
•
Taxonomy: Organisms in GenBank, Web site: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Taxonomy
196 Urolithiasis
To access the Entrez system at the National Center for Biotechnology Information, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=genome, and then select the database that you would like to search. The databases available are listed in the drop box next to “Search.” Enter “urolithiasis” (or synonyms) into the search box and click “Go.” Jablonski’s Multiple Congenital Anomaly/Mental Retardation (MCA/MR) Syndromes Database23 This online resource has been developed to facilitate the identification and differentiation of syndromic entities. Special attention is given to the type of information that is usually limited or completely omitted in existing reference sources due to space limitations of the printed form. At http://www.nlm.nih.gov/mesh/jablonski/syndrome_toc/toc_a.html, you can search across syndromes using an alphabetical index. Search by keywords at http://www.nlm.nih.gov/mesh/jablonski/syndrome_db.html. The Genome Database24 Established at Johns Hopkins University in Baltimore, Maryland in 1990, the Genome Database (GDB) is the official central repository for genomic mapping data resulting from the Human Genome Initiative. In the spring of 1999, the Bioinformatics Supercomputing Centre (BiSC) at the Hospital for Sick Children in Toronto, Ontario assumed the management of GDB. The Human Genome Initiative is a worldwide research effort focusing on structural analysis of human DNA to determine the location and sequence of the estimated 100,000 human genes. In support of this project, GDB stores and curates data generated by researchers worldwide who are engaged in the mapping effort of the Human Genome Project (HGP). GDB’s mission is to provide scientists with an encyclopedia of the human genome which is continually revised and updated to reflect the current state of scientific knowledge. Although GDB has historically focused on gene mapping, its focus will broaden as the Genome Project moves from mapping to sequence, and finally, to functional analysis. To access the GDB, simply go to the following hyperlink: http://www.gdb.org/. Search “All Biological Data” by “Keyword.” Type “urolithiasis” (or synonyms) into the search box, and review the results. If more than one word is used in the search box, then separate each one with the word “and” or “or” (using “or” might be useful when using synonyms).
23
Adapted from the National Library of Medicine: http://www.nlm.nih.gov/mesh/jablonski/about_syndrome.html. 24 Adapted from the Genome Database: http://gdbwww.gdb.org/gdb/aboutGDB.html - mission.
197
APPENDIX B. PATIENT RESOURCES Overview Official agencies, as well as federally funded institutions supported by national grants, frequently publish a variety of guidelines written with the patient in mind. These are typically called “Fact Sheets” or “Guidelines.” They can take the form of a brochure, information kit, pamphlet, or flyer. Often they are only a few pages in length. Since new guidelines on urolithiasis can appear at any moment and be published by a number of sources, the best approach to finding guidelines is to systematically scan the Internet-based services that post them.
Patient Guideline Sources The remainder of this chapter directs you to sources which either publish or can help you find additional guidelines on topics related to urolithiasis. Due to space limitations, these sources are listed in a concise manner. Do not hesitate to consult the following sources by either using the Internet hyperlink provided, or, in cases where the contact information is provided, contacting the publisher or author directly. The National Institutes of Health The NIH gateway to patients is located at http://health.nih.gov/. From this site, you can search across various sources and institutes, a number of which are summarized below. Topic Pages: MEDLINEplus The National Library of Medicine has created a vast and patient-oriented healthcare information portal called MEDLINEplus. Within this Internet-based system are “health topic pages” which list links to available materials relevant to urolithiasis. To access this system, log on to http://www.nlm.nih.gov/medlineplus/healthtopics.html. From there you can either search using the alphabetical index or browse by broad topic areas. Recently, MEDLINEplus listed the following when searched for “urolithiasis”:
198 Urolithiasis
•
Other guides Anatomy http://www.nlm.nih.gov/medlineplus/anatomy.html Bladder Diseases http://www.nlm.nih.gov/medlineplus/bladderdiseases.html Hepatitis C http://www.nlm.nih.gov/medlineplus/hepatitisc.html Interstitial Cystitis http://www.nlm.nih.gov/medlineplus/interstitialcystitis.html Kidney Cancer http://www.nlm.nih.gov/medlineplus/kidneycancer.html Kidney Diseases http://www.nlm.nih.gov/medlineplus/kidneydiseases.html Kidney Failure and Dialysis http://www.nlm.nih.gov/medlineplus/kidneyfailureanddialysis.html Kidney Stones http://www.nlm.nih.gov/medlineplus/kidneystones.html Kidney Stones http://www.nlm.nih.gov/medlineplus/tutorials/kidneystonesloader.html Kidney Transplantation http://www.nlm.nih.gov/medlineplus/kidneytransplantation.html Pancreas Transplantation http://www.nlm.nih.gov/medlineplus/pancreastransplantation.html Prostate Diseases http://www.nlm.nih.gov/medlineplus/prostatediseases.html Urinary Tract Infections http://www.nlm.nih.gov/medlineplus/urinarytractinfections.html
Within the health topic page dedicated to urolithiasis, the following was listed: •
General/Overviews Kidney Stones http://www.nlm.nih.gov/medlineplus/tutorials/kidneystonesloader.html Kidney Stones Source: Mayo Foundation for Medical Education and Research http://www.mayoclinic.com/invoke.cfm?id=DS00282
•
Diagnosis/Symptoms Abdominal Pain, Acute: Self-Care Flowcharts Source: American Academy of Family Physicians http://familydoctor.org/flowcharts/527.html
Patient Resources 199
Calcium Test Source: American Association for Clinical Chemistry http://www.labtestsonline.org/understanding/analytes/calcium/test.html Lower Back Pain: Self-Care Flowcharts Source: American Academy of Family Physicians http://familydoctor.org/flowcharts/531.html Ultrasound-Abdomen Source: American College of Radiology, Radiological Society of North America http://www.radiologyinfo.org/content/ultrasound-abdomen.htm Uric Acid Test Source: American Association for Clinical Chemistry http://www.labtestsonline.org/understanding/analytes/uric_acid/test.html Urination Problems: Self-Care Flowcharts Source: American Academy of Family Physicians http://familydoctor.org/flowcharts/535.html •
Treatment How Are Kidney Stones Treated? Source: American Foundation for Urologic Disease http://www.afud.org/education/kidney/kidneystones1.asp
•
Nutrition Oxalate Kidney Stones and Diet Source: Mayo Foundation for Medical Education and Research http://www.mayoclinic.com/invoke.cfm?id=AN00261
•
Specific Conditions/Aspects About Primary Hyperoxaluria Source: Oxalosis and Hyperoxaluria Foundation http://www.ohf.org/about_ph.html
•
From the National Institutes of Health What Are Kidney Stones? http://kidney.niddk.nih.gov/kudiseases/pubs/stones_ez/index.htm
•
Men Women Showing Increasing Incidence of Kidney Stones-Diet Changes May be to Blame Source: National Kidney Foundation http://www.kidney.org/meetings/kidneymonth/htdietchange.cfm
200 Urolithiasis
•
Organizations American Foundation for Urologic Disease http://www.afud.org/ National Institute of Diabetes and Digestive and Kidney Diseases http://www.niddk.nih.gov/ National Kidney and Urologic Diseases Information Clearinghouse Source: National Institute of Diabetes and Digestive and Kidney Diseases http://kidney.niddk.nih.gov/ National Kidney Foundation http://www.kidney.org/ Oxalosis and Hyperoxaluria Foundation http://www.ohf.org/
•
Research Studies Show Amount and Choice of Beverages Can Affect Risk for Kidney Stones Source: National Kidney Foundation http://www.kidney.org/meetings/kidneymonth/htbeverages.cfm
•
Statistics Kidney and Urologic Disease Statistics for the United States Source: National Kidney and Urologic Diseases Information Clearinghouse http://kidney.niddk.nih.gov/kudiseases/pubs/kustats/index.htm
•
Women Women Showing Increasing Incidence of Kidney Stones-Diet Changes May be to Blame Source: National Kidney Foundation http://www.kidney.org/meetings/kidneymonth/htdietchange.cfm
You may also choose to use the search utility provided by MEDLINEplus at the following Web address: http://www.nlm.nih.gov/medlineplus/. Simply type a keyword into the search box and click “Search.” This utility is similar to the NIH search utility, with the exception that it only includes materials that are linked within the MEDLINEplus system (mostly patient-oriented information). It also has the disadvantage of generating unstructured results. We recommend, therefore, that you use this method only if you have a very targeted search. The Combined Health Information Database (CHID) CHID Online is a reference tool that maintains a database directory of thousands of journal articles and patient education guidelines on urolithiasis. CHID offers summaries that describe the guidelines available, including contact information and pricing. CHID’s general Web site is http://chid.nih.gov/. To search this database, go to http://chid.nih.gov/detail/detail.html. In particular, you can use the advanced search
Patient Resources 201
options to look up pamphlets, reports, brochures, and information kits. The following was recently posted in this archive: •
Kidney Stones in Adults Source: Bethesda, MD: National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH). 2000. 12 p. Contact: Available from National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC). 3 Information Way, Bethesda, MD 20892-3580. (800) 891-5390 or (301) 654-4415. Fax (301)634-0716. E-mail:
[email protected]. Website: http://www.niddk.nih.gov/health/kidney/nkudic.htm. PRICE: Full-text available online at no charge; single copy free; bulk orders available. Order number: KU-04. Summary: This fact sheet reviews the problem of kidney stones (urolithiasis) in adults. A common problem, occurring in an estimated 10 percent of people in the United States, kidney stones will often pass out of the body without any intervention by a physician. Stones that cause lasting symptoms or other complications may be treated by various techniques, most of which do not involve major surgery. Research advances have led to a better understanding of the many factors that promote stone formation. The fact sheet first reviews the anatomy and physiology of the urinary tract and kidneys, then defines a kidney stone as a hard mass developed from crystals that separate from the urine and build up on the inner surfaces of the kidney. Certain foods may promote stone formation in people who are susceptible, and a person with a family history of kidney stones may be more likely to develop stones. Urinary tract infections, kidney disorders such as cystic kidney diseases, and metabolic disorders such as hyperparathyroidism are also linked to stone formation. The fact sheet reviews the symptoms and diagnosis of kidney stones, then describes treatment options, focusing on prevention for people at risk. Treatment options described include drug therapy, surgery, extracorporeal shockwave lithotripsy (ESWL), percutaneous nephrolithotomy, and ureteroscopic stone removal. The fact sheet concludes with a brief list of current research strategies in this area, a list of suggested readings, and prevention points to remember. The fact sheet lists resource organizations for readers who wish to obtain additional information about kidney stones, hyperparathyroidism, and gout. A brief description of the National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC) is also provided. 6 figures. 5 references. Healthfinder™
Healthfinder™ is sponsored by the U.S. Department of Health and Human Services and offers links to hundreds of other sites that contain healthcare information. This Web site is located at http://www.healthfinder.gov. Again, keyword searches can be used to find guidelines. The following was recently found in this database: •
Kidney Stones Fact Sheet Summary: The information on this site is intended to educate lay persons about kidney stones: what causes kidney stones, who gets them, what kinds of treatments are available, and how kidney stones can be Source: American Foundation for Urologic Disease http://www.healthfinder.gov/scripts/recordpass.asp?RecordType=0&RecordID=3966
202 Urolithiasis
•
Kidney Stones in Adults Summary: Kidney stones are one of the most common disorders of the urinary tract. More than 1 million cases of kidney stones were diagnosed in 1985. Source: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health http://www.healthfinder.gov/scripts/recordpass.asp?RecordType=0&RecordID=830
•
What Are Kidney Stones Summary: This easy-to-read consumer health information document provides basic need-to-know information about kidney stones. Source: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health http://www.healthfinder.gov/scripts/recordpass.asp?RecordType=0&RecordID=3970 The NIH Search Utility
The NIH search utility allows you to search for documents on over 100 selected Web sites that comprise the NIH-WEB-SPACE. Each of these servers is “crawled” and indexed on an ongoing basis. Your search will produce a list of various documents, all of which will relate in some way to urolithiasis. The drawbacks of this approach are that the information is not organized by theme and that the references are often a mix of information for professionals and patients. Nevertheless, a large number of the listed Web sites provide useful background information. We can only recommend this route, therefore, for relatively rare or specific disorders, or when using highly targeted searches. To use the NIH search utility, visit the following Web page: http://search.nih.gov/index.html. Additional Web Sources
A number of Web sites are available to the public that often link to government sites. These can also point you in the direction of essential information. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=168&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/specific.htm
•
Google: http://directory.google.com/Top/Health/Conditions_and_Diseases/
•
Med Help International: http://www.medhelp.org/HealthTopics/A.html
•
Open Directory Project: http://dmoz.org/Health/Conditions_and_Diseases/
•
Yahoo.com: http://dir.yahoo.com/Health/Diseases_and_Conditions/
•
WebMDHealth: http://my.webmd.com/health_topics
Patient Resources 203
Finding Associations There are several Internet directories that provide lists of medical associations with information on or resources relating to urolithiasis. By consulting all of associations listed in this chapter, you will have nearly exhausted all sources for patient associations concerned with urolithiasis. The National Health Information Center (NHIC) The National Health Information Center (NHIC) offers a free referral service to help people find organizations that provide information about urolithiasis. For more information, see the NHIC’s Web site at http://www.health.gov/NHIC/ or contact an information specialist by calling 1-800-336-4797. Directory of Health Organizations The Directory of Health Organizations, provided by the National Library of Medicine Specialized Information Services, is a comprehensive source of information on associations. The Directory of Health Organizations database can be accessed via the Internet at http://www.sis.nlm.nih.gov/Dir/DirMain.html. It is composed of two parts: DIRLINE and Health Hotlines. The DIRLINE database comprises some 10,000 records of organizations, research centers, and government institutes and associations that primarily focus on health and biomedicine. To access DIRLINE directly, go to the following Web site: http://dirline.nlm.nih.gov/. Simply type in “urolithiasis” (or a synonym), and you will receive information on all relevant organizations listed in the database. Health Hotlines directs you to toll-free numbers to over 300 organizations. You can access this database directly at http://www.sis.nlm.nih.gov/hotlines/. On this page, you are given the option to search by keyword or by browsing the subject list. When you have received your search results, click on the name of the organization for its description and contact information. The Combined Health Information Database Another comprehensive source of information on healthcare associations is the Combined Health Information Database. Using the “Detailed Search” option, you will need to limit your search to “Organizations” and “urolithiasis”. Type the following hyperlink into your Web browser: http://chid.nih.gov/detail/detail.html. To find associations, use the drop boxes at the bottom of the search page where “You may refine your search by.” For publication date, select “All Years.” Then, select your preferred language and the format option “Organization Resource Sheet.” Type “urolithiasis” (or synonyms) into the “For these words:” box. You should check back periodically with this database since it is updated every three months.
204 Urolithiasis
The National Organization for Rare Disorders, Inc. The National Organization for Rare Disorders, Inc. has prepared a Web site that provides, at no charge, lists of associations organized by health topic. You can access this database at the following Web site: http://www.rarediseases.org/search/orgsearch.html. Type “urolithiasis” (or a synonym) into the search box, and click “Submit Query.”
205
APPENDIX C. FINDING MEDICAL LIBRARIES Overview In this Appendix, we show you how to quickly find a medical library in your area.
Preparation Your local public library and medical libraries have interlibrary loan programs with the National Library of Medicine (NLM), one of the largest medical collections in the world. According to the NLM, most of the literature in the general and historical collections of the National Library of Medicine is available on interlibrary loan to any library. If you would like to access NLM medical literature, then visit a library in your area that can request the publications for you.25
Finding a Local Medical Library The quickest method to locate medical libraries is to use the Internet-based directory published by the National Network of Libraries of Medicine (NN/LM). This network includes 4626 members and affiliates that provide many services to librarians, health professionals, and the public. To find a library in your area, simply visit http://nnlm.gov/members/adv.html or call 1-800-338-7657.
Medical Libraries in the U.S. and Canada In addition to the NN/LM, the National Library of Medicine (NLM) lists a number of libraries with reference facilities that are open to the public. The following is the NLM’s list and includes hyperlinks to each library’s Web site. These Web pages can provide information on hours of operation and other restrictions. The list below is a small sample of
25
Adapted from the NLM: http://www.nlm.nih.gov/psd/cas/interlibrary.html.
206 Urolithiasis
libraries recommended by the National Library of Medicine (sorted alphabetically by name of the U.S. state or Canadian province where the library is located)26: •
Alabama: Health InfoNet of Jefferson County (Jefferson County Library Cooperative, Lister Hill Library of the Health Sciences), http://www.uab.edu/infonet/
•
Alabama: Richard M. Scrushy Library (American Sports Medicine Institute)
•
Arizona: Samaritan Regional Medical Center: The Learning Center (Samaritan Health System, Phoenix, Arizona), http://www.samaritan.edu/library/bannerlibs.htm
•
California: Kris Kelly Health Information Center (St. Joseph Health System, Humboldt), http://www.humboldt1.com/~kkhic/index.html
•
California: Community Health Library of Los Gatos, http://www.healthlib.org/orgresources.html
•
California: Consumer Health Program and Services (CHIPS) (County of Los Angeles Public Library, Los Angeles County Harbor-UCLA Medical Center Library) - Carson, CA, http://www.colapublib.org/services/chips.html
•
California: Gateway Health Library (Sutter Gould Medical Foundation)
•
California: Health Library (Stanford University Medical Center), http://wwwmed.stanford.edu/healthlibrary/
•
California: Patient Education Resource Center - Health Information and Resources (University of California, San Francisco), http://sfghdean.ucsf.edu/barnett/PERC/default.asp
•
California: Redwood Health Library (Petaluma Health Care District), http://www.phcd.org/rdwdlib.html
•
California: Los Gatos PlaneTree Health Library, http://planetreesanjose.org/
•
California: Sutter Resource Library (Sutter Hospitals Foundation, Sacramento), http://suttermedicalcenter.org/library/
•
California: Health Sciences Libraries (University of California, Davis), http://www.lib.ucdavis.edu/healthsci/
•
California: ValleyCare Health Library & Ryan Comer Cancer Resource Center (ValleyCare Health System, Pleasanton), http://gaelnet.stmarysca.edu/other.libs/gbal/east/vchl.html
•
California: Washington Community Health Resource Library (Fremont), http://www.healthlibrary.org/
•
Colorado: William V. Gervasini Memorial Library (Exempla Healthcare), http://www.saintjosephdenver.org/yourhealth/libraries/
•
Connecticut: Hartford Hospital Health Science Libraries (Hartford Hospital), http://www.harthosp.org/library/
•
Connecticut: Healthnet: Connecticut Consumer Health Information Center (University of Connecticut Health Center, Lyman Maynard Stowe Library), http://library.uchc.edu/departm/hnet/
26
Abstracted from http://www.nlm.nih.gov/medlineplus/libraries.html.
Finding Medical Libraries 207
•
Connecticut: Waterbury Hospital Health Center Library (Waterbury Hospital, Waterbury), http://www.waterburyhospital.com/library/consumer.shtml
•
Delaware: Consumer Health Library (Christiana Care Health System, Eugene du Pont Preventive Medicine & Rehabilitation Institute, Wilmington), http://www.christianacare.org/health_guide/health_guide_pmri_health_info.cfm
•
Delaware: Lewis B. Flinn Library (Delaware Academy of Medicine, Wilmington), http://www.delamed.org/chls.html
•
Georgia: Family Resource Library (Medical College of Georgia, Augusta), http://cmc.mcg.edu/kids_families/fam_resources/fam_res_lib/frl.htm
•
Georgia: Health Resource Center (Medical Center of Central Georgia, Macon), http://www.mccg.org/hrc/hrchome.asp
•
Hawaii: Hawaii Medical Library: Consumer Health Information Service (Hawaii Medical Library, Honolulu), http://hml.org/CHIS/
•
Idaho: DeArmond Consumer Health Library (Kootenai Medical Center, Coeur d’Alene), http://www.nicon.org/DeArmond/index.htm
•
Illinois: Health Learning Center of Northwestern Memorial Hospital (Chicago), http://www.nmh.org/health_info/hlc.html
•
Illinois: Medical Library (OSF Saint Francis Medical Center, Peoria), http://www.osfsaintfrancis.org/general/library/
•
Kentucky: Medical Library - Services for Patients, Families, Students & the Public (Central Baptist Hospital, Lexington), http://www.centralbap.com/education/community/library.cfm
•
Kentucky: University of Kentucky - Health Information Library (Chandler Medical Center, Lexington), http://www.mc.uky.edu/PatientEd/
•
Louisiana: Alton Ochsner Medical Foundation Library (Alton Ochsner Medical Foundation, New Orleans), http://www.ochsner.org/library/
•
Louisiana: Louisiana State University Health Sciences Center Medical LibraryShreveport, http://lib-sh.lsuhsc.edu/
•
Maine: Franklin Memorial Hospital Medical Library (Franklin Memorial Hospital, Farmington), http://www.fchn.org/fmh/lib.htm
•
Maine: Gerrish-True Health Sciences Library (Central Maine Medical Center, Lewiston), http://www.cmmc.org/library/library.html
•
Maine: Hadley Parrot Health Science Library (Eastern Maine Healthcare, Bangor), http://www.emh.org/hll/hpl/guide.htm
•
Maine: Maine Medical Center Library (Maine Medical Center, Portland), http://www.mmc.org/library/
•
Maine: Parkview Hospital (Brunswick), http://www.parkviewhospital.org/
•
Maine: Southern Maine Medical Center Health Sciences Library (Southern Maine Medical Center, Biddeford), http://www.smmc.org/services/service.php3?choice=10
•
Maine: Stephens Memorial Hospital’s Health Information Library (Western Maine Health, Norway), http://www.wmhcc.org/Library/
208 Urolithiasis
•
Manitoba, Canada: Consumer & Patient Health Information Service (University of Manitoba Libraries), http://www.umanitoba.ca/libraries/units/health/reference/chis.html
•
Manitoba, Canada: J.W. Crane Memorial Library (Deer Lodge Centre, Winnipeg), http://www.deerlodge.mb.ca/crane_library/about.asp
•
Maryland: Health Information Center at the Wheaton Regional Library (Montgomery County, Dept. of Public Libraries, Wheaton Regional Library), http://www.mont.lib.md.us/healthinfo/hic.asp
•
Massachusetts: Baystate Medical Center Library (Baystate Health System), http://www.baystatehealth.com/1024/
•
Massachusetts: Boston University Medical Center Alumni Medical Library (Boston University Medical Center), http://med-libwww.bu.edu/library/lib.html
•
Massachusetts: Lowell General Hospital Health Sciences Library (Lowell General Hospital, Lowell), http://www.lowellgeneral.org/library/HomePageLinks/WWW.htm
•
Massachusetts: Paul E. Woodard Health Sciences Library (New England Baptist Hospital, Boston), http://www.nebh.org/health_lib.asp
•
Massachusetts: St. Luke’s Hospital Health Sciences Library (St. Luke’s Hospital, Southcoast Health System, New Bedford), http://www.southcoast.org/library/
•
Massachusetts: Treadwell Library Consumer Health Reference Center (Massachusetts General Hospital), http://www.mgh.harvard.edu/library/chrcindex.html
•
Massachusetts: UMass HealthNet (University of Massachusetts Medical School, Worchester), http://healthnet.umassmed.edu/
•
Michigan: Botsford General Hospital Library - Consumer Health (Botsford General Hospital, Library & Internet Services), http://www.botsfordlibrary.org/consumer.htm
•
Michigan: Helen DeRoy Medical Library (Providence Hospital and Medical Centers), http://www.providence-hospital.org/library/
•
Michigan: Marquette General Hospital - Consumer Health Library (Marquette General Hospital, Health Information Center), http://www.mgh.org/center.html
•
Michigan: Patient Education Resouce Center - University of Michigan Cancer Center (University of Michigan Comprehensive Cancer Center, Ann Arbor), http://www.cancer.med.umich.edu/learn/leares.htm
•
Michigan: Sladen Library & Center for Health Information Resources - Consumer Health Information (Detroit), http://www.henryford.com/body.cfm?id=39330
•
Montana: Center for Health Information (St. Patrick Hospital and Health Sciences Center, Missoula)
•
National: Consumer Health Library Directory (Medical Library Association, Consumer and Patient Health Information Section), http://caphis.mlanet.org/directory/index.html
•
National: National Network of Libraries of Medicine (National Library of Medicine) provides library services for health professionals in the United States who do not have access to a medical library, http://nnlm.gov/
•
National: NN/LM List of Libraries Serving the Public (National Network of Libraries of Medicine), http://nnlm.gov/members/
Finding Medical Libraries 209
•
Nevada: Health Science Library, West Charleston Library (Las Vegas-Clark County Library District, Las Vegas), http://www.lvccld.org/special_collections/medical/index.htm
•
New Hampshire: Dartmouth Biomedical Libraries (Dartmouth College Library, Hanover), http://www.dartmouth.edu/~biomed/resources.htmld/conshealth.htmld/
•
New Jersey: Consumer Health Library (Rahway Hospital, Rahway), http://www.rahwayhospital.com/library.htm
•
New Jersey: Dr. Walter Phillips Health Sciences Library (Englewood Hospital and Medical Center, Englewood), http://www.englewoodhospital.com/links/index.htm
•
New Jersey: Meland Foundation (Englewood Hospital and Medical Center, Englewood), http://www.geocities.com/ResearchTriangle/9360/
•
New York: Choices in Health Information (New York Public Library) - NLM Consumer Pilot Project participant, http://www.nypl.org/branch/health/links.html
•
New York: Health Information Center (Upstate Medical University, State University of New York, Syracuse), http://www.upstate.edu/library/hic/
•
New York: Health Sciences Library (Long Island Jewish Medical Center, New Hyde Park), http://www.lij.edu/library/library.html
•
New York: ViaHealth Medical Library (Rochester General Hospital), http://www.nyam.org/library/
•
Ohio: Consumer Health Library (Akron General Medical Center, Medical & Consumer Health Library), http://www.akrongeneral.org/hwlibrary.htm
•
Oklahoma: The Health Information Center at Saint Francis Hospital (Saint Francis Health System, Tulsa), http://www.sfh-tulsa.com/services/healthinfo.asp
•
Oregon: Planetree Health Resource Center (Mid-Columbia Medical Center, The Dalles), http://www.mcmc.net/phrc/
•
Pennsylvania: Community Health Information Library (Milton S. Hershey Medical Center, Hershey), http://www.hmc.psu.edu/commhealth/
•
Pennsylvania: Community Health Resource Library (Geisinger Medical Center, Danville), http://www.geisinger.edu/education/commlib.shtml
•
Pennsylvania: HealthInfo Library (Moses Taylor Hospital, Scranton), http://www.mth.org/healthwellness.html
•
Pennsylvania: Hopwood Library (University of Pittsburgh, Health Sciences Library System, Pittsburgh), http://www.hsls.pitt.edu/guides/chi/hopwood/index_html
•
Pennsylvania: Koop Community Health Information Center (College of Physicians of Philadelphia), http://www.collphyphil.org/kooppg1.shtml
•
Pennsylvania: Learning Resources Center - Medical Library (Susquehanna Health System, Williamsport), http://www.shscares.org/services/lrc/index.asp
•
Pennsylvania: Medical Library (UPMC Health System, Pittsburgh), http://www.upmc.edu/passavant/library.htm
•
Quebec, Canada: Medical Library (Montreal General Hospital), http://www.mghlib.mcgill.ca/
210 Urolithiasis
•
South Dakota: Rapid City Regional Hospital Medical Library (Rapid City Regional Hospital), http://www.rcrh.org/Services/Library/Default.asp
•
Texas: Houston HealthWays (Houston Academy of Medicine-Texas Medical Center Library), http://hhw.library.tmc.edu/
•
Washington: Community Health Library (Kittitas Valley Community Hospital), http://www.kvch.com/
•
Washington: Southwest Washington Medical Center Library (Southwest Washington Medical Center, Vancouver), http://www.swmedicalcenter.com/body.cfm?id=72
211
ONLINE GLOSSARIES The Internet provides access to a number of free-to-use medical dictionaries. The National Library of Medicine has compiled the following list of online dictionaries: •
ADAM Medical Encyclopedia (A.D.A.M., Inc.), comprehensive medical reference: http://www.nlm.nih.gov/medlineplus/encyclopedia.html
•
MedicineNet.com Medical Dictionary (MedicineNet, Inc.): http://www.medterms.com/Script/Main/hp.asp
•
Merriam-Webster Medical Dictionary (Inteli-Health, Inc.): http://www.intelihealth.com/IH/
•
Multilingual Glossary of Technical and Popular Medical Terms in Eight European Languages (European Commission) - Danish, Dutch, English, French, German, Italian, Portuguese, and Spanish: http://allserv.rug.ac.be/~rvdstich/eugloss/welcome.html
•
On-line Medical Dictionary (CancerWEB): http://cancerweb.ncl.ac.uk/omd/
•
Rare Diseases Terms (Office of Rare Diseases): http://ord.aspensys.com/asp/diseases/diseases.asp
•
Technology Glossary (National Library of Medicine) - Health Care Technology: http://www.nlm.nih.gov/nichsr/ta101/ta10108.htm
Beyond these, MEDLINEplus contains a very patient-friendly encyclopedia covering every aspect of medicine (licensed from A.D.A.M., Inc.). The ADAM Medical Encyclopedia can be accessed at http://www.nlm.nih.gov/medlineplus/encyclopedia.html. ADAM is also available on commercial Web sites such as drkoop.com (http://www.drkoop.com/) and Web MD (http://my.webmd.com/adam/asset/adam_disease_articles/a_to_z/a). The NIH suggests the following Web sites in the ADAM Medical Encyclopedia when searching for information on urolithiasis: •
Basic Guidelines for Urolithiasis Hyperparathyroidism Web site: http://www.nlm.nih.gov/medlineplus/ency/article/001215.htm Nephrolithiasis Web site: http://www.nlm.nih.gov/medlineplus/ency/article/000458.htm
•
Signs & Symptoms for Urolithiasis Abdominal pain Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003120.htm Abnormal urine color Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003139.htm Acute abdomen Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003120.htm
212 Urolithiasis
Back pain Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003108.htm Blood in the urine Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003138.htm Chills Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003091.htm Diaphoresis Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003218.htm Dysuria Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003145.htm Fever Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003090.htm Flank pain Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003113.htm Groin pain Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003111.htm Hematuria Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003138.htm Nausea Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003117.htm Nausea and vomiting Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003117.htm Obesity Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003101.htm Tachycardia Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003077.htm Testicle pain Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003160.htm Urinary frequency/urgency, increased Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003140.htm Urinary hesitancy Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003143.htm Urination, excessive at night Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003141.htm
Online Glossaries 213
Urination, painful Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003145.htm Vomiting Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003117.htm •
Diagnostics and Tests for Urolithiasis Abdominal CT scan Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003789.htm Abdominal X-rays Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003815.htm Abdominal/kidney MRI Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003796.htm ANA Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003535.htm Creatinine Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003475.htm CT Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003330.htm Intravenous pyelogram Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003782.htm IVP Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003782.htm Kidney ultrasound Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003777.htm Red blood cells in urine Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003582.htm Serum calcium Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003477.htm Sonogram Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003336.htm Uric acid Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003476.htm Urinalysis Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003579.htm
214 Urolithiasis
X-ray Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003337.htm •
Background Topics for Urolithiasis Analgesics Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002123.htm Chemotherapy Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002324.htm Chronic Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002312.htm Distal Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002346.htm Incidence Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002387.htm Intravenous Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002383.htm Precipitate Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002275.htm Proximal Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002287.htm Renal Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002289.htm Serum chemistries Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002350.htm
Online Dictionary Directories The following are additional online directories compiled by the National Library of Medicine, including a number of specialized medical dictionaries: •
Medical Dictionaries: Medical & Biological (World Health Organization): http://www.who.int/hlt/virtuallibrary/English/diction.htm#Medical
•
MEL-Michigan Electronic Library List of Online Health and Medical Dictionaries (Michigan Electronic Library): http://mel.lib.mi.us/health/health-dictionaries.html
•
Patient Education: Glossaries (DMOZ Open Directory Project): http://dmoz.org/Health/Education/Patient_Education/Glossaries/
•
Web of Online Dictionaries (Bucknell University): http://www.yourdictionary.com/diction5.html#medicine
215
UROLITHIASIS DICTIONARY The definitions below are derived from official public sources, including the National Institutes of Health [NIH] and the European Union [EU]. Abdomen: That portion of the body that lies between the thorax and the pelvis. [NIH] Abdominal: Having to do with the abdomen, which is the part of the body between the chest and the hips that contains the pancreas, stomach, intestines, liver, gallbladder, and other organs. [NIH] Abdominal Pain: Sensation of discomfort, distress, or agony in the abdominal region. [NIH] Abortion: 1. The premature expulsion from the uterus of the products of conception - of the embryo, or of a nonviable fetus. The four classic symptoms, usually present in each type of abortion, are uterine contractions, uterine haemorrhage, softening and dilatation of the cervix, and presentation or expulsion of all or part of the products of conception. 2. Premature stoppage of a natural or a pathological process. [EU] Acetylcholine: A neurotransmitter. Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. It is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications. [NIH] Acetylcysteine: The N-acetyl derivative of cysteine. It is used as a mucolytic agent to reduce the viscosity of mucous secretions. It has also been shown to have antiviral effects in patients with HIV due to inhibition of viral stimulation by reactive oxygen intermediates. [NIH] Acidity: The quality of being acid or sour; containing acid (hydrogen ions). [EU] Acidosis: A pathologic condition resulting from accumulation of acid or depletion of the alkaline reserve (bicarbonate content) in the blood and body tissues, and characterized by an increase in hydrogen ion concentration. [EU] Acute leukemia: A rapidly progressing cancer of the blood-forming tissue (bone marrow). [NIH]
Acute lymphoblastic leukemia: ALL. A quickly progressing disease in which too many immature white blood cells called lymphoblasts are found in the blood and bone marrow. Also called acute lymphocytic leukemia. [NIH] Acute lymphocytic leukemia: ALL. A quickly progressing disease in which too many immature white blood cells called lymphoblasts are found in the blood and bone marrow. Also called acute lymphoblastic leukemia. [NIH] Acute renal: A condition in which the kidneys suddenly stop working. In most cases, kidneys can recover from almost complete loss of function. [NIH] Adaptability: Ability to develop some form of tolerance to conditions extremely different from those under which a living organism evolved. [NIH] Adenine: A purine base and a fundamental unit of adenine nucleotides. [NIH] Adenine Phosphoribosyltransferase: An enzyme catalyzing the formation of AMP from adenine and phosphoribosylpyrophosphate. It can act as a salvage enzyme for recycling of adenine into nucleic acids. EC 2.4.2.7. [NIH] Adenosine: A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA
216 Urolithiasis
and RNA. Adenosine itself is a neurotransmitter. [NIH] Adipocytes: Fat-storing cells found mostly in the abdominal cavity and subcutaneous tissue. Fat is usually stored in the form of tryglycerides. [NIH] Adipose Tissue: Connective tissue composed of fat cells lodged in the meshes of areolar tissue. [NIH] Adrenal Cortex: The outer layer of the adrenal gland. It secretes mineralocorticoids, androgens, and glucocorticoids. [NIH] Adrenal Glands: Paired glands situated in the retroperitoneal tissues at the superior pole of each kidney. [NIH] Adverse Effect: An unwanted side effect of treatment. [NIH] Aerobic: In biochemistry, reactions that need oxygen to happen or happen when oxygen is present. [NIH] Aetiology: Study of the causes of disease. [EU] Affinity: 1. Inherent likeness or relationship. 2. A special attraction for a specific element, organ, or structure. 3. Chemical affinity; the force that binds atoms in molecules; the tendency of substances to combine by chemical reaction. 4. The strength of noncovalent chemical binding between two substances as measured by the dissociation constant of the complex. 5. In immunology, a thermodynamic expression of the strength of interaction between a single antigen-binding site and a single antigenic determinant (and thus of the stereochemical compatibility between them), most accurately applied to interactions among simple, uniform antigenic determinants such as haptens. Expressed as the association constant (K litres mole -1), which, owing to the heterogeneity of affinities in a population of antibody molecules of a given specificity, actually represents an average value (mean intrinsic association constant). 6. The reciprocal of the dissociation constant. [EU] Agar: A complex sulfated polymer of galactose units, extracted from Gelidium cartilagineum, Gracilaria confervoides, and related red algae. It is used as a gel in the preparation of solid culture media for microorganisms, as a bulk laxative, in making emulsions, and as a supporting medium for immunodiffusion and immunoelectrophoresis. [NIH]
Aldehydes: Organic compounds containing a carbonyl group in the form -CHO. [NIH] Algorithms: A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task. [NIH] Alimentary: Pertaining to food or nutritive material, or to the organs of digestion. [EU] Alkaline: Having the reactions of an alkali. [EU] Alkaptonuria: An inborn error of amino acid metabolism resulting from a defect in the enzyme homogentisate 1,2-dioxygenase and causing an accumulation of homogentisic acid in the urine. The condition is characterized by ochronosis in various tissues and arthritis. [NIH]
Alkylating Agents: Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. [NIH]
Alleles: Mutually exclusive forms of the same gene, occupying the same locus on homologous chromosomes, and governing the same biochemical and developmental process. [NIH] Allograft: An organ or tissue transplant between two humans. [NIH]
Dictionary 217
Allopurinol: A xanthine oxidase inhibitor that decreases uric acid production. [NIH] Alpha Particles: Positively charged particles composed of two protons and two neutrons, i.e., helium nuclei, emitted during disintegration of very heavy isotopes; a beam of alpha particles or an alpha ray has very strong ionizing power, but weak penetrability. [NIH] Alternative medicine: Practices not generally recognized by the medical community as standard or conventional medical approaches and used instead of standard treatments. Alternative medicine includes the taking of dietary supplements, megadose vitamins, and herbal preparations; the drinking of special teas; and practices such as massage therapy, magnet therapy, spiritual healing, and meditation. [NIH] Amenorrhea: Absence of menstruation. [NIH] Amino acid: Any organic compound containing an amino (-NH2 and a carboxyl (- COOH) group. The 20 a-amino acids listed in the accompanying table are the amino acids from which proteins are synthesized by formation of peptide bonds during ribosomal translation of messenger RNA; all except glycine, which is not optically active, have the L configuration. Other amino acids occurring in proteins, such as hydroxyproline in collagen, are formed by posttranslational enzymatic modification of amino acids residues in polypeptide chains. There are also several important amino acids, such as the neurotransmitter y-aminobutyric acid, that have no relation to proteins. Abbreviated AA. [EU] Ammonia: A colorless alkaline gas. It is formed in the body during decomposition of organic materials during a large number of metabolically important reactions. [NIH] Amplification: The production of additional copies of a chromosomal DNA sequence, found as either intrachromosomal or extrachromosomal DNA. [NIH] Ampulla: A sac-like enlargement of a canal or duct. [NIH] Amyloid: A general term for a variety of different proteins that accumulate as extracellular fibrils of 7-10 nm and have common structural features, including a beta-pleated sheet conformation and the ability to bind such dyes as Congo red and thioflavine (Kandel, Schwartz, and Jessel, Principles of Neural Science, 3rd ed). [NIH] Anaerobic: 1. Lacking molecular oxygen. 2. Growing, living, or occurring in the absence of molecular oxygen; pertaining to an anaerobe. [EU] Anaesthesia: Loss of feeling or sensation. Although the term is used for loss of tactile sensibility, or of any of the other senses, it is applied especially to loss of the sensation of pain, as it is induced to permit performance of surgery or other painful procedures. [EU] Anal: Having to do with the anus, which is the posterior opening of the large bowel. [NIH] Analgesics: Compounds capable of relieving pain without the loss of consciousness or without producing anesthesia. [NIH] Analogous: Resembling or similar in some respects, as in function or appearance, but not in origin or development;. [EU] Analytes: A component of a test sample the presence of which has to be demonstrated. The term "analyte" includes where appropriate formed from the analyte during the analyses. [NIH]
Anaplasia: Loss of structural differentiation and useful function of neoplastic cells. [NIH] Anastomosis: A procedure to connect healthy sections of tubular structures in the body after the diseased portion has been surgically removed. [NIH] Anatomical: Pertaining to anatomy, or to the structure of the organism. [EU] Anemia: A reduction in the number of circulating erythrocytes or in the quantity of hemoglobin. [NIH]
218 Urolithiasis
Anesthesia: A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures. [NIH] Animal model: An animal with a disease either the same as or like a disease in humans. Animal models are used to study the development and progression of diseases and to test new treatments before they are given to humans. Animals with transplanted human cancers or other tissues are called xenograft models. [NIH] Anions: Negatively charged atoms, radicals or groups of atoms which travel to the anode or positive pole during electrolysis. [NIH] Anisotropy: A physical property showing different values in relation to the direction in or along which the measurement is made. The physical property may be with regard to thermal or electric conductivity or light refraction. In crystallography, it describes crystals whose index of refraction varies with the direction of the incident light. It is also called acolotropy and colotropy. The opposite of anisotropy is isotropy wherein the same values characterize the object when measured along axes in all directions. [NIH] Anomalies: Birth defects; abnormalities. [NIH] Anorexia: Lack or loss of appetite for food. Appetite is psychologic, dependent on memory and associations. Anorexia can be brought about by unattractive food, surroundings, or company. [NIH] Anorexia Nervosa: The chief symptoms are inability to eat, weight loss, and amenorrhea. [NIH]
Antibacterial: A substance that destroys bacteria or suppresses their growth or reproduction. [EU] Antibiotic: A drug used to treat infections caused by bacteria and other microorganisms. [NIH]
Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the antigen that induced their synthesis in cells of the lymphoid series (especially plasma cells), or with an antigen closely related to it. [NIH] Antibody: A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen. [NIH] Anticoagulant: A drug that helps prevent blood clots from forming. Also called a blood thinner. [NIH] Antigen: Any substance which is capable, under appropriate conditions, of inducing a specific immune response and of reacting with the products of that response, that is, with specific antibody or specifically sensitized T-lymphocytes, or both. Antigens may be soluble substances, such as toxins and foreign proteins, or particulate, such as bacteria and tissue cells; however, only the portion of the protein or polysaccharide molecule known as the antigenic determinant (q.v.) combines with antibody or a specific receptor on a lymphocyte. Abbreviated Ag. [EU] Anti-infective: An agent that so acts. [EU] Anti-inflammatory: Having to do with reducing inflammation. [NIH] Antioxidant: A substance that prevents damage caused by free radicals. Free radicals are highly reactive chemicals that often contain oxygen. They are produced when molecules are split to give products that have unpaired electrons. This process is called oxidation. [NIH]
Dictionary 219
Antiviral: Destroying viruses or suppressing their replication. [EU] Anus: The opening of the rectum to the outside of the body. [NIH] Aqueous: Having to do with water. [NIH] Arachidonic Acid: An unsaturated, essential fatty acid. It is found in animal and human fat as well as in the liver, brain, and glandular organs, and is a constituent of animal phosphatides. It is formed by the synthesis from dietary linoleic acid and is a precursor in the biosynthesis of prostaglandins, thromboxanes, and leukotrienes. [NIH] Arginine: An essential amino acid that is physiologically active in the L-form. [NIH] Arterial: Pertaining to an artery or to the arteries. [EU] Arteries: The vessels carrying blood away from the heart. [NIH] Arterioles: The smallest divisions of the arteries located between the muscular arteries and the capillaries. [NIH] Artery: Vessel-carrying blood from the heart to various parts of the body. [NIH] Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant. [NIH] Assay: Determination of the amount of a particular constituent of a mixture, or of the biological or pharmacological potency of a drug. [EU] Asymptomatic: Having no signs or symptoms of disease. [NIH] Ataxia: Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharnyx, larnyx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or peripheral nerve diseases. Motor ataxia may be associated with cerebellar diseases; cerebral cortex diseases; thalamic diseases; basal ganglia diseases; injury to the red nucleus; and other conditions. [NIH] Atrial: Pertaining to an atrium. [EU] Atrium: A chamber; used in anatomical nomenclature to designate a chamber affording entrance to another structure or organ. Usually used alone to designate an atrium of the heart. [EU] Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes. [NIH] Attenuation: Reduction of transmitted sound energy or its electrical equivalent. [NIH] Atypical: Irregular; not conformable to the type; in microbiology, applied specifically to strains of unusual type. [EU] Autodigestion: Autolysis; a condition found in disease of the stomach: the stomach wall is digested by the gastric juice. [NIH] Autologous: Taken from an individual's own tissues, cells, or DNA. [NIH] Azotemia: An excess of urea or other nitrogenous compounds in the blood. [EU] Bacteria: Unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. [NIH] Bacterial Infections: Infections by bacteria, general or unspecified. [NIH]
220 Urolithiasis
Bacteriophage: A virus whose host is a bacterial cell; A virus that exclusively infects bacteria. It generally has a protein coat surrounding the genome (DNA or RNA). One of the coliphages most extensively studied is the lambda phage, which is also one of the most important. [NIH] Bacteriostatic: 1. Inhibiting the growth or multiplication of bacteria. 2. An agent that inhibits the growth or multiplication of bacteria. [EU] Bacterium: Microscopic organism which may have a spherical, rod-like, or spiral unicellular or non-cellular body. Bacteria usually reproduce through asexual processes. [NIH] Bacteriuria: The presence of bacteria in the urine with or without consequent urinary tract infection. Since bacteriuria is a clinical entity, the term does not preclude the use of urine/microbiology for technical discussions on the isolation and segregation of bacteria in the urine. [NIH] Basal Ganglia: Large subcortical nuclear masses derived from the telencephalon and located in the basal regions of the cerebral hemispheres. [NIH] Basal Ganglia Diseases: Diseases of the basal ganglia including the putamen; globus pallidus; claustrum; amygdala; and caudate nucleus. Dyskinesias (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include cerebrovascular disease; neurodegenerative diseases; and craniocerebral trauma. [NIH] Base: In chemistry, the nonacid part of a salt; a substance that combines with acids to form salts; a substance that dissociates to give hydroxide ions in aqueous solutions; a substance whose molecule or ion can combine with a proton (hydrogen ion); a substance capable of donating a pair of electrons (to an acid) for the formation of a coordinate covalent bond. [EU] Basement Membrane: Ubiquitous supportive tissue adjacent to epithelium and around smooth and striated muscle cells. This tissue contains intrinsic macromolecular components such as collagen, laminin, and sulfated proteoglycans. As seen by light microscopy one of its subdivisions is the basal (basement) lamina. [NIH] Beer: An alcoholic beverage usually made from malted cereal grain (as barley), flavored with hops, and brewed by slow fermentation. [NIH] Benign: Not cancerous; does not invade nearby tissue or spread to other parts of the body. [NIH]
Benzene: Toxic, volatile, flammable liquid hydrocarbon biproduct of coal distillation. It is used as an industrial solvent in paints, varnishes, lacquer thinners, gasoline, etc. Benzene causes central nervous system damage acutely and bone marrow damage chronically and is carcinogenic. It was formerly used as parasiticide. [NIH] Bifida: A defect in development of the vertebral column in which there is a central deficiency of the vertebral lamina. [NIH] Bilateral: Affecting both the right and left side of body. [NIH] Bile: An emulsifying agent produced in the liver and secreted into the duodenum. Its composition includes bile acids and salts, cholesterol, and electrolytes. It aids digestion of fats in the duodenum. [NIH] Bile Acids: Acids made by the liver that work with bile to break down fats. [NIH] Bile Acids and Salts: Steroid acids and salts. The primary bile acids are derived from cholesterol in the liver and usually conjugated with glycine or taurine. The secondary bile acids are further modified by bacteria in the intestine. They play an important role in the digestion and absorption of fat. They have also been used pharmacologically, especially in the treatment of gallstones. [NIH]
Dictionary 221
Bile duct: A tube through which bile passes in and out of the liver. [NIH] Biliary: Having to do with the liver, bile ducts, and/or gallbladder. [NIH] Biliary Tract: The gallbladder and its ducts. [NIH] Binding Sites: The reactive parts of a macromolecule that directly participate in its specific combination with another molecule. [NIH] Bioavailability: The degree to which a drug or other substance becomes available to the target tissue after administration. [EU] Biochemical: Relating to biochemistry; characterized by, produced by, or involving chemical reactions in living organisms. [EU] Bioengineering: The application of engineering principles to the solution of biological problems, for example, remote-handling devices, life-support systems, controls, and displays. [NIH] Biopolymers: Polymers, such as proteins, DNA, RNA, or polysaccharides formed by any living organism. [NIH] Biopsy: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body. [NIH] Biotechnology: Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., genetic engineering) is a central focus; laboratory methods used include transfection and cloning technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction. [NIH] Bismuth: A metallic element that has the atomic symbol Bi, atomic number 83 and atomic weight 208.98. [NIH] Bladder: The organ that stores urine. [NIH] Bladder Calculi: Calculi of the urinary bladder; also known as vesical calculi or bladder stones, and cystoliths. [NIH] Blood Cell Count: A count of the number of leukocytes and erythrocytes per unit volume in a sample of venous blood. A complete blood count (CBC) also includes measurement of the hemoglobin, hematocrit, and erythrocyte indices. [NIH] Blood Coagulation: The process of the interaction of blood coagulation factors that results in an insoluble fibrin clot. [NIH] Blood Coagulation Factors: Endogenous substances, usually proteins, that are involved in the blood coagulation process. [NIH] Blood Glucose: Glucose in blood. [NIH] Blood Groups: The classification systems (or schemes) of the different antigens located on erythrocytes.The antigens are the phenotypic expression of the genetic differences characteristic of specific blood groups. [NIH] Blood pressure: The pressure of blood against the walls of a blood vessel or heart chamber. Unless there is reference to another location, such as the pulmonary artery or one of the heart chambers, it refers to the pressure in the systemic arteries, as measured, for example, in the forearm. [NIH] Blood urea: A waste product in the blood that comes from the breakdown of food protein. The kidneys filter blood to remove urea. As kidney function decreases, the BUN level increases. [NIH]
222 Urolithiasis
Blood vessel: A tube in the body through which blood circulates. Blood vessels include a network of arteries, arterioles, capillaries, venules, and veins. [NIH] Blot: To transfer DNA, RNA, or proteins to an immobilizing matrix such as nitrocellulose. [NIH]
Body Fluids: Liquid components of living organisms. [NIH] Body Regions: Anatomical areas of the body. [NIH] Bone Density: The amount of mineral per square centimeter of bone. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by photon absorptiometry or x-ray computed tomography. [NIH] Bone Development: Gross development of bones from fetus to adult. It includes osteogenesis, which is restricted to formation and development of bone from the undifferentiated cells of the germ layers of the embryo. It does not include osseointegration. [NIH]
Bone Marrow: The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. [NIH] Bone scan: A technique to create images of bones on a computer screen or on film. A small amount of radioactive material is injected into a blood vessel and travels through the bloodstream; it collects in the bones and is detected by a scanner. [NIH] Bowel: The long tube-shaped organ in the abdomen that completes the process of digestion. There is both a small and a large bowel. Also called the intestine. [NIH] Brachytherapy: A collective term for interstitial, intracavity, and surface radiotherapy. It uses small sealed or partly-sealed sources that may be placed on or near the body surface or within a natural body cavity or implanted directly into the tissues. [NIH] Bradykinin: A nonapeptide messenger that is enzymatically produced from kallidin in the blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from mast cells during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter. [NIH] Branch: Most commonly used for branches of nerves, but applied also to other structures. [NIH]
Breakdown: A physical, metal, or nervous collapse. [NIH] Bronchi: The larger air passages of the lungs arising from the terminal bifurcation of the trachea. [NIH] Bypass: A surgical procedure in which the doctor creates a new pathway for the flow of body fluids. [NIH] Calcification: Deposits of calcium in the tissues of the breast. Calcification in the breast can be seen on a mammogram, but cannot be detected by touch. There are two types of breast calcification, macrocalcification and microcalcification. Macrocalcifications are large deposits and are usually not related to cancer. Microcalcifications are specks of calcium that may be found in an area of rapidly dividing cells. Many microcalcifications clustered together may be a sign of cancer. [NIH] Calcitonin: A peptide hor